Top

Richard E. Champlin, M.D.

Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine

About Dr. Richard E. Champlin

I am Professor and Chairman, Department of Stem Cell Transplantation and Cellular Therapy with over 30 years of experience in clinical and translational research involving hematopoietic stem cell transplantation. I am past President of the American Society of Blood and Marrow Transplantation as well as the Center for International Center for Blood and Marrow Transplantation Research. I am a previous Board Member of the National Marrow Donor Program and a current member of the HRSA Advisory Committee for Blood Stem Cell Transplantation. Our Department at the MD Anderson Cancer Center has a major research focus on cord blood transplantation including administration of the Cord Blood Bank and the clinical research program to assess novel approaches to enhance engraftment and hematopoietic/immune recovery and disease free survival. We have been a leading institution in enrollment of patients on clinical research studies of the BMT-CTN and committed to continued enrollment and participation in this important research.

Primary Appointment

Professor of Medicine, Department of Internal Medicine, Division of Cancer Medicine, The University of Texas Health Science Center, Houston, TX

Professor of Medicine, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Hal Jonathan Debesk Distinguished Chair In Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor of Medicine, Department of Internal Medicine, The University of Texas Health Science Center, Houston, TX

Professor of Medicine, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1975	University of Chicago Pritzker School of Medicine, Chicago, Illinois, US, MD
1971	Purdue University, W. Lafayette, Indiana, US, BS in Engineering Sciences

Postgraduate Training

1978-1980	Fellowship, UCLA Center for the Health Sciences, Los Angeles, California
1975-1978	Internship/Residency, UCLA School of Medicine, Los Angeles, California

Licenses & Certifications

1990	Texas Medical Board
1981	American Board of Internal Medicine, Med Oncology
1980	American Board of Internal Medicine, Hematology
1978	American Board of Internal Medicine, Internal Med

Experience & Service

Faculty Academic Appointments

Robert C. Hickey Chair of Clinical Cancer Care, Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 1998 - 2018

Associate Professor, Department of Medicine, UCLA Center for the Health Sciences, Los Angeles, CA, 1985 - 1990

Assistant Professor, Department of Medicine, UCLA Center for the Health Sciences, Los Angeles, CA, 1981 - 1985

Administrative Appointments/Responsibilities

Division Head ad interim, Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - 2015

Associate Division Head ad interim, Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2014

Chair, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, 1998 - 2020

Department Chair ad interim, Department of Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1995 - 1997

Chief, Department of Sections of Blood and Marrow Transplantation & Apheresis, The University of Texas MD Anderson Cancer Center, Houston, TX, 1990 - 1997

Director, Department of Hematology/Oncology Fellowship Program, UCLA - Center for the Health Sciences, Los Angeles, CA, 1984 - 1990

Director, Department of Transplantation Biology Program, UCLA - Jonsson Comprehensive Cancer Center, Los Angeles, CA, 1983 - 1990

Director, Department of Leukemia and Bone Marrow Transplant Service, UCLA Center for the Health Sciences, Los Angeles, CA, 1983 - 1990

Other Professional Positions

Advisor, Genzyme, Cambridge, MA, 2010 - Present

Inspector, Foundation for the Accrededitation of Cellular Therapy (FACT), Omaha, NE, 2009 - Present

Board Member, DKMS Americas, New York, NY, 2009 - Present

Member, Advisory Council on Blood Stem Cell Transplantation of U.S. Health Resources and Services Administration, Washington, DC, 2008 - Present

Co-Chair, Graft Sources Committee, Center for International Blood and Marrow Transplantation Research, Minneapolis, MN, 2008 - Present

Chair, Center for International Blood and Marrow Transplantation Research, Minneapolis, MN, 2006 - 2007

Chair, Autologous Bone Marrow Transplant Registry, Minneapolis, MN, 2003 - 2006

Member, National Cancer Institute Parent Committee D, Bethesda, MD, 2003 - 2006

Member, U.S. Food and Drug Administration, Biologic Response Modifiers Advisory Committee, Silver Spring, MD, 1999 - 2002

Vice President, Foundation for the Accreditation of Cellular Therapy, Omaha, NE, 1996 - 2008

Member, Hematology Board, American Board of Internal Medicine, Philadelphia, PA, 1996 - 2002

President, American Society for Blood and Marrow Transplantation, Arlington Heights, IL, 1992 - 1994

President Council for Donor Collection and Transplant Centers and Board Member, National Donor Marrow Program, Minneapolis, MN, 1990 - 1994

Intramural Institutional Committee Activities

Member, Moon Shots Annual Disease Site Scientific Advisory Board (SAB), The University of Texas MD Anderson Cancer Center, 2022 - Present

Extramural Institutional Committee Activities

Member, DKMS US Board, DKMS, 2018 - Present

Board Member, MD Anderson Physician Network, The University of Texas MD Anderson Cancer Center, 2010 - 2013

Member, MD Anderson Cancer Center Management Committee, The University of Texas MD Anderson Cancer Center, 2006 - 2008

Member, Revenue Cycle Advisory Committee, The University of Texas MD Anderson Cancer Center, 2006 - Present

Member, Division of Cancer Medicine Advisory Committee, The University of Texas MD Anderson Cancer Center, 2003 - Present

Co-Chair, Promotions and Tenure Committee, The University of Texas MD Anderson Cancer Center, 2003 - 2004

Member, Clinical Council, The University of Texas MD Anderson Cancer Center, 2001 - 2006

Member, Promotions and Tenure Committee, The University of Texas MD Anderson Cancer Center, 2001 - 2003

Member, President's Advisory Board, The University of Texas MD Anderson Cancer Center, 2001 - Present

Member, Clinical Faculty Review Committee, The University of Texas MD Anderson Cancer Center, 2000 - 2003

Member, Division of Cancer Medicine Executive Committee, The University of Texas MD Anderson Cancer Center, 1997 - Present

Member, Clinical Research Committee, The University of Texas MD Anderson Cancer Center, 1994 - 1998

Member, Surveillance Committee (IRB), The University of Texas MD Anderson Cancer Center, 1992 - 2000

Editorial Activities

Editorial Board, Clinical Cancer Research, 2007 - Present

Executive Editor, The Oncologist, 2005 - Present

Editorial Board, Bone Marrow Transplantation, 2002 - Present

Editorial Board, Blood, 2002 - Present

Associate Editor, Experimental Hematology, 2002 - Present

Associate Editor, Biology of Blood and Marrow Transplantation, 1999 - Present

Regional Editor, Cytotherapy, 1999 - Present

Honors & Awards

2017	DKMS Mechtild Harf Science Award, DKMS
2017	Mortimer Bortin Lecture, Center for International Blood and Marrow Transplantation Research
2011	2011 ASBMT Lifetime Achievement Award, American Society for Blood and Marrow Transplantation
2010	John Mendelsohn Lifetime Scientific Achievement Award, The University of Texas MD Anderson Cancer Center, Division of Cancer Medicine
2009 - 2010	Best Doctors in America 2009-2010, Best Doctors
2008	Waun Ki Hong Award for Excellence in Team Science, The University of Texas MD Anderson Cancer Center, Division of Cancer Medicine
2004	Thomas Lecture Award, American Society for Blood and Marrow Transplantation
2002	The University of Texas Faculty Achievement Award in Clinical Research, The University of Texas MD Anderson Cancer Center
1998	Robert C. Hickey Chair in Clinical Cancer Care, The University of Texas MD Anderson Cancer Center
1982 - 1984	National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases
1982 - 1984	New Investigator Research Award
1979 - 1981	Giannini Foundation Fellowship
1975	Alpha Omega Alpha, University of Chicago Pritzker School of Medicine
1968	G.A. Ross Scholarship Award

Selected Presentations & Talks

Local Presentations

2014. AML in CR1. Who should get an allogeneic stem cell transplant and should we use an ablative or nonmyeloablative regimen?. Conference. AML in CR1. Who should get an allogeneic stem cell transplant and should we use an ablative or nonmyeloablative regimen?. Houston, TX, US.
2013. Which Patients with AML Should Proceed to Allogeneic Transplantation in First CR?. Conference. Which Patients with AML Should Proceed to Allogeneic Transplantation in First CR?. Houston, TX, US.
2012. Role of Allogeneic SCT in MDS. Conference. Role of Allogeneic SCT in MDS. Houston, TX, US.
2011. MDS. Conference. MDS. Houston, TX, US.
2010. Chronic Myeloid Leukemia. Conference. Chronic Myeloid Leukemia. Houston, TX, US.
2010. BMT. Conference. BMT. Houston, TX, US.

National Presentations

2024. Stem Cell Transplanatation. Invited. Ohio State University BMT Grand Rounds. Columbus, OH, US.
2023. Evolving Role for Allogeneic Hematopoietic Transplantation for AML and MDS. Invited. Stem Cell Transplant & Cellular Therapy Symposium. Scottsdale, AZ, US.
2019. Role of Stem Cell Transplantation in the Era of Targeted Therapies. Invited. University of Miami Miller School of Medicine. Miami, FL, US.
2016. The Karl G. Blume - Gerhard Schmidt Memorial Lecture in Transplantation Biology & Medicine. Conference. The Karl G. Blume - Gerhard Schmidt Memorial Lecture in Transplantation Biology & Medicine. Duarte, CA, US.
2016. Donor Selection: The Great Three-Way Debate session in the BMT Tandem Scientific Meeting. Conference. Donor Selection: The Great Three-Way Debate session in the BMT Tandem Scientific Meeting. Honolulu, HI, US.
2015. Stem Cell Transplantation. Conference. Stem Cell Transplantation. Beijing, US.
2014. Haploidentical Hematopoietic Cell Transplantation. Conference. Haploidentical Hematopoietic Cell Transplantation. San Francisco, CA, US.
2014. Past, Present and Future of HSCT. Conference. Past, Present and Future of HSCT. Grapevine, TX, US.
2013. Comparison of Cord Blood Transplantation with Haploidentical Hematopoietic Transplantation. Conference. Comparison of Cord Blood Transplantation with Haploidentical Hematopoietic Transplantation. San Francisco, CA, US.
2013. Alternative Donor Hematopoietic Transplantation. Conference. Alternative Donor Hematopoietic Transplantation. New York, NY, US.
2013. Reduced-intensity conditioning: are we curing more older patients with AML?. Conference. Reduced-intensity conditioning: are we curing more older patients with AML?. San Francisco, CA, US.
2011. Personalized Therapy Invoking Stem Cell Transplant. Conference. Personalized Therapy Invoking Stem Cell Transplant. Memphis, TN, US.
2011. Newest Modalities in Bone Marrow Transplantation. Conference. Newest Modalities in Bone Marrow Transplantation. Hackensack, NJ, US.
2011. Myelodysplastic Syndrome (MDS). Conference. Myelodysplastic Syndrome (MDS). Honolulu, HI, US.
2010. NK cells. Conference. NK cells. Orlando, FL, US.
2010. Stem Cell Mobilization Lecture. Conference. Stem Cell Mobilization Lecture. Pittsburgh, PA, US.
2010. Overcoming Challenges and Examining Opportunities in Improving Stem Cell Mobilization Outcomes. Conference. Overcoming Challenges and Examining Opportunities in Improving Stem Cell Mobilization Outcomes. Atlanta, GA, US.
2010. Celebration of Life for BMT Program. Conference. Celebration of Life for BMT Program. Phoenix, AZ, US.
2009. Which transplant and when for patients with MDS. Conference. Which transplant and when for patients with MDS. New York, NY, US.
2009. Stem Cell Transplants. Conference. Stem Cell Transplants. New York, NY, US.
2009. Preparative Regimens for Allogeneic Stem Cell Transplantation: Who Needs Myeloablative or Nonmyeloablative Conditioning. Conference. Preparative Regimens for Allogeneic Stem Cell Transplantation: Who Needs Myeloablative or Nonmyeloablative Conditioning. Seoul.
2009. Stem Cell Transplant: The Graft Versus Lymphoma Effect. Conference. Stem Cell Transplant: The Graft Versus Lymphoma Effect. Boston, MA, US.
2008. Why Patients with an Indication for Transplantation Do Not Receive a Transplant. Conference. 6th Annual International Umbilical Cord Blood Transplant Symposium. Los Angeles, CA, US.
2008. Hematopoietic Cell Transplantation for Low- Grade Lymphomma and CLL. Conference. Atlanta BMT Symposium. Atlanta, GA, US.
2007. Stem Cell Transplantation in the Era of Immunodulatory Drugs and Other Novel Therapies. Conference. CIBMTR Tandem Meeting, US.
2007. Transfusion Medicine in Allogeneic Transplantation: A Reducing the Risks of Pathogen ATransmission with Photo-Inactivation Technology. Conference. CIBMTR Tandem Meetings, US.
2006. Stem Cell Transplantation. Conference. ASH - American Society of Hematology. Orlando, FL, US.
2006. Before and After Transplant: Treatment Strategies for Patients with Myelodysplastic Syndrome. Conference. 2006 BMT Tandem Meetings. Honolulu, HI, US.
2005. New Directions in Hematopoietic Stem Cell Transplantation: Overcoming Redundancy of the Immune System. Conference. 2005 BMT Tandem Meetings. Keystone, CO, US.
2005. Non-myeloablative Transplantation – Ready for Prime Time, not Second line?. Conference. 2005 BMT Tandem Meetings. Keystone, CO, US.
2004. AML PO1 Project 4 – Overview Presentation. Conference. American Society of Hematologists. San Diego, CA, US.
2004. Overview of STR in breast cancer metastasis to the bone only. Conference. American Society of Hematologists. San Diego, CA, US.
2004. Practical Aspects of Cord Blood Transplantation. Conference. 2nd Annual International Umbilical Cord Blood Transplantation Symposium, US.
2004. Past, Present and Future of Hematopoietic Transplantation. Conference. Tandem Meetings American Society for Blood and Marrow Transplantation and International Bone Marrow Transplant Registry, US.
2004. Allogeneic stem cell transplantation for CML. Conference. Tandem Meetings American Society for Blood and Marrow Transplantation and International Bone Marrow Transplant Registry, US.
2003. Myeloablative Matched Related Donor Transplantation. Conference. ASH Meeting. San Diego, CA, US.
2003. Graft-vs- Tumor Strategies: Can we separate GvT from GvHD. Conference. Tandem Meetings. Keystone, CO, US.
2002. Title not provided. Conference. ASH. Philadelphia, PA, US.
2002. Title not provided. Conference. Lymphoma Research Foundation. New York, NY, US.
2002. Blood stem cell and bone marrow transplantation. Conference. Current Status and Future Directions, Life Trac Conference. Minneapolis, MN, US.
2002. Title not provided. Conference. Leukemia 2002. Miami, FL, US.
2002. Title not provided. Conference. Stem Cell Biology Symposium. Los Angeles, CA, US.
2002. BMT for Autoimmune Diseases. Conference. BMT for Autoimmune Diseases. Snowbird, UT, US.
2002. Does Dose Intensity matter with Nonablative transplants?. Conference. IBMTR/ABMTR. Orlando, FL, US.
2002. NST – Relevance of Dose. Conference. wNST. Captiva Island, FL, US.
2001. Nonmyeloablative stem cell transplantation for CLL and lymphoma. Conference. American Society of Hematology (ASH). Orlando, FL, US.
2001. Emerging Indications for Chemotherapy Based Nonmyeloablative Allogeneic transplants. Conference. American Society of Hematology (ASH). Orlando, FL, US.
2001. Reduced Intensity regimens/chimerism. Conference. American Society of Hematology (ASH). Orlando, FL, US.
2001. How can we harness the immune system to treat non-Hodgkin’s lymphoma?. Conference. Lymphoma….the next questions. Washington, US.
2001. Aplastic Anemia. Conference. 2001 Aplastic Anemia Foundation of America Annual Patient Conference. St. Louis, MO, US.
2001. Community Respiratory Viral Infections in the BMT Population: Update on Prevention and Management. Conference. International Bone Marrow Transplant Registry/Autologous Blood and Marrow Transplant Registry Tandem meeting. Keystone, CO, US.
2001. Graft versus Host Disease and non-myeloablative transplantation. Conference. International Bone Marrow Transplant Registry/Autologous Blood and Marrow Transplant Registry Tandem meeting. Keystone, CO, US.
2001. Non-myeloablative NST for Hematological Malignancies. Conference. International Bone Marrow Transplant Registry/Autologous Blood and Marrow Transplant Registry Tandem meeting. Keystone, CO, US.
2001. Protocol Development. Conference. 2nd International Workshop on non-myeloablative Stem Cell Transplantation. Caribbean Island.
2000. The Transplanter’s View. Conference. American Society of Hematology. San Francisco, CA, US.
2000. Clinical Update of International Experience in Haploidentical Transplantation. Conference. Workshop on Haploidentical Stem Cell Transplantation. Chicago, IL, US.
2000. BMT for Leukemia. Conference. 13th International Symposium on Treatment of Leukemia and Cancer. New York, NY, US.
2000. New Advances in Mini-allografts. Conference. International Bone Marrow Transplant Registry/Autologous Blood and Marrow Transplant Registry Tandem meeting. Anaheim, CA, US.
2000. Non-myeloablative stem cell transplantation in clinical practice. Conference. International Bone Marrow Transplant Registry/Autologous Blood and Marrow Transplant Registry Tandem meeting. Anaheim, CA, US.
2000. Indolent Non-Hodgkin’s lymphoma. Conference. 13th Annual Midwest Cancer Symposium. Oak Brook, IL, US.
2000. What is a nonmyeloablative regimen in clinical practice?. Conference. International Workshop on non-myeloablative Stem Cell Transplantation. Caribbean Island.
1999. Novel cytokines and Promising strategies: from cancer to autoimmune disease. Conference. American Society of Hematology. New Orleans, LA, US.
1999. Non-myeloablative allogeneic peripheral blood stem cell transplantation for hematologic malignancy. Conference. American Society of Hematology. New Orleans, LA, US.
1999. Transplantation for relapsed indolent lymphoma: When and how?. Conference. Lymphoma….the next questions. Palm Desert, CA, US.
1999. Phase I/II study of Targeted Radiotherapy using Ho-DOTMP with Melphalan and Peripheral Blood Stem Cell Transplant for Multiple Myeloma. Conference. ISEH. Monte Carlo.

International Presentations

2016. Advances with alternative donors: Now everyone can get a transplant. Conference. Advances with alternative donors: Now everyone can get a transplant. Heidelberg, DE.
2015. Microtransplantation. Conference. Microtransplantation. Beijing, CN.
2015. All Patients Should Receive an Allogeneic-SCT for ALL in First CR. Conference. All Patients Should Receive an Allogeneic-SCT for ALL in First CR. Dubrovnik, HR.
2015. Which Strategy for Unmanipulated HSCT. Conference. Which Strategy for Unmanipulated HSCT. Parma, IT.
2014. Novel Therapies for Aplastic Anemia. Conference. Novel Therapies for Aplastic Anemia. Bangkok, TH.
2014. The MD Anderson Experience. Conference. The MD Anderson Experience. Rehovot, IL.
2013. Use of cellular therapy to improve outcomes of allogeneic stem cell transplant: NK cells, CAR T cells. Conference. Use of cellular therapy to improve outcomes of allogeneic stem cell transplant: NK cells, CAR T cells. Hong Kong, HK.
2012. Stem Cell Transplantation in the future. Conference. Stem Cell Transplantation in the future. Antalya, TR.
2012. State of the Art Lecture: Treatment Advanves in High Risk MDS. Conference. State of the Art Lecture: Treatment Advanves in High Risk MDS. Bangkok, TH.
2012. Stem Cell Mobilization Standard of Care for HSCT: Novel Applications. Conference. Stem Cell Mobilization Standard of Care for HSCT: Novel Applications. Hong Kong, HK.
2010. Basics of HLA for the stem cell transplantation physician: What does high resolution typing mean and its implication in related and unrelated transplants?. Conference. Basics of HLA for the stem cell transplantation physician: What does high resolution typing mean and its implication in related and unrelated transplants?. Calcutta, IN.
2010. Advances in Stem Cell Transplantation. Conference. Advances in Stem Cell Transplantation. Heidelberg, DE.
2010. Transplant Options for Mantle Cell Lymphoma. Conference. Transplant Options for Mantle Cell Lymphoma. Shanghai, CN.
2010. Transplantation after non-myeloablative conditioning. Conference. Transplantation after non-myeloablative conditioning. Jerusalem, IL.
2010. Allogeneic Stem Cell Transplantat. Conference. Allogeneic Stem Cell Transplantat. Singapore, SG.
2009. Current status of myeloablative and non-myeloablative allogeneic stem cell transplants for hematologic malignancies. Conference. Current status of myeloablative and non-myeloablative allogeneic stem cell transplants for hematologic malignancies. Quintana Roo, MX.
2009. Update of Allogeneic Stem Cell Transplantation. Conference. Update of Allogeneic Stem Cell Transplantation. Istanbul, TR.
2005. Stem Cell Transplantation. Conference. 2005 International Society of Cellular Therapy. Vancouver, CA.
2004. Haploidentical Transplants in BMT. Conference. 4th International Haploidentical Meeting in Naples. Naples, IT.
2003. GvHD and GvL, balancing immune reactivity post BMT. Conference. iwNST Meeting. Hamilton, BM.
2003. GvHD and GvL, balancing immune reactivity post BMT. Conference. IwNST meeting. Hamilton, BM.
2003. Title not provided. Conference. International Advisory Board for CLL, NHL and BMT. Cancun, MX.
2002. Title not provided. Conference. International Symposium on Haploidentical Transplantation. Orvieto, IT.
2002. Title not provided. Conference. Symposium on Stem Cell Transplantation. Heidelberg, DE.
2002. Reduced Intensity conditioning regimens for allogeneic stem cell transplantation. Conference. Rationale and clinical results. Tsukiji, JP.
2001. Advances in Hematological Malignancies and Supportive Care in Cancer. Conference. 5th Annual Winter Conference. Whistler, CA.
2000. CML. Conference. 3rd International Conference on CML. Bologna, IT.
2000. Using Melphalan and TBI as the control treatment. Conference. 26th Annual Meeting, European Group for Blood and Marrow Transplantation. Innsbruck, AT.
1999. Fludarabine treatment in BMT. Conference. International Fludara Workshop on CLL, NHL and BMT. Nice, FR.
1999. Advances in Allogeneic Hematopoietic Transplantation: Exploitation of the Graft versus Malignancy Effect. Conference. 6th Hong Kong International Cancer Congress. Hong Kong, JP.
1999. Allogeneic Stem Cell Transplantation in Non-Hodgkin’s Lymphoma. Conference. Annual Congress of the German and Austrian Societies of Hematology and Oncology. Jena, DE.

Formal Peers

2013. Alternatives for Alternative Donor Hematopoietic Transplantation. Invited. Boston, MA, US.
2012. Reduced intensity transplants for Lymphoma. Invited. Stanford, CA, US.
2012. Stem Cell Transplantation. Invited. Philadelphia, PA, US.
2012. Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient. Invited. Cleveland, OH, US.
2011. Advisory Council on Blood Stem Cell Transplantation Meeting. Visiting. Bethesda, MD, US.
2011. NCI Special Emphasis Panel Review. Visiting. Rockville, MD, US.
2011. Genzyme Advisory Meeting. Visiting. Chicago, IL, US.
2011. FACT Inspection. Visiting. Oklahoma City, OK, US.
2011. Advisory Council on Blood Stem Cell Transplantation Advisory Meeting. Visiting. Bethesda, MD, US.
2011. Overcoming Challenges and Examining opportunities in Improving Stem Cell Mobilization Outcomes. Invited. New York, NY, US.
2011. DKMS Board Meeting. Visiting. New York, NY, US.
2011. FACT Inspection. Visiting. New York, NY, US.
2010. Advances in Hematopoietic Stem Cell Transplantation. Invited. Miami, FL, US.
2010. NCI Special Emphasis Panel Review. Visiting. Washington, DC, US.
2010. National Marrow Donor Program Meeting. Visiting. Rosemont, IL, US.
2010. Overcoming Challenges and Examining Opportunities in Improving Stem Cell Mobilization Outcomes. Invited. Atlanta, GA, US.
2010. VIP Lymphoma, MDS, BMT Panel. Visiting. Baltimore, MD, US.
2010. View and specialities on the HCMV infection & HBPC transplantation. Visiting. Bonn, DE.
2010. FACT Inspection. Visiting. Birmingham, AL, US.
2009. CIBMTR External Scientific Review Forum. Visiting. Milwaukee, WI, US.
2009. Advisory Council on Blood Stem Cell Transplantation Meeting. Visiting, US.
2006. Topic: GVHD. Invited. Louisville, KY, US.
2006. Advances in Nonmyeloablative Stem Cell Cell Transplantation. Invited. New York, NY, US.
2006. Multiple Myeloma in BMT Patients. Invited. Jupiter, FL, US.
2005. Myelodysplastic Syndrome. Invited. Washington, DC, US.
2005. Early Allogeneic Transplantation is the Treatment of Choice for all Young (<65yo) Patients with CML. Visiting. Naples, FL, US.
2005. High Dose Chemotherapy Stem Cell Support should be Part of Front Line Treatment for Curable Non-Hodgkin’s Lymphoma. Visiting. Naples, FL, US.
2005. Recent Developments in the Treatment of Graft-Versus-Host Disease. Invited. Tucson, AZ, US.
2005. NCI Subcommittee Meeting – William Merritt CDE Meeting. Visiting. Bethesda, MD, US.
2005. Amgen Speakers Group. Visiting. Chicago, IL, US.
2005. FACT Inspection. Visiting. New York, NY, US.
2005. Umbilical Cord Blood Meeting. Visiting. Los Angeles, CA, US.
2005. Allianz Lift Trac. Visiting. Minneapolis, MN, US.
2005. NIH Site Visit. Visiting. Denver, CO, US.
2005. Genzyme Advisory Board Meeting. Visiting. San Francisco, CA, US.
2005. NCI – Subcommittee D. Visiting. Bethesda, MD, US.
2005. NIH Grant Review Meeting – Ullmann. Visiting. Rockville, MD, US.
2005. FACT Inspection. Visiting. Indianapolis, IN, US.
2005. MCL Workshop – Lymphoma Research Foundation. Visiting. New York, NY, US.
2004. BMT Transplantation. Invited. Duarte, CA, US.
2004. BMT Transplantation. Invited. Los Angeles, CA, US.
2004. NCI Subcommittee Meeting. Visiting. Bethesda, MD, US.
2004. Mixed Chimerism Meeting. Visiting. Washington, US.
2004. FACT Inspection. Visiting, NE, US.
2004. Amgen Oncology Academy Meeting. Visiting, CA, US.
2004. NILE Meeting. Visiting, IL, US.
2004. NIH Meeting P01 Cluster Review. Visiting. Washington, US.
2004. FDA Grant Review Meeting. Visiting. Bethesda, MD, US.
2004. Cancer Center Review. Visiting. Charleston, NC, US.
2004. National Cord Blood Stem Cell Program Advisory Board Meeting/Tour. Visiting. Irvine, CA, US.
2004. NILE Presentation Meeting. Visiting. Dallas, TX, US.
2004. FACT Inspection – City of Hope. Visiting. Durante, CA, US.
2004. National Cord Blood Stem Cell Blood Program. Visiting. Woods Hole, ME, US.
2004. Oncointeractive Paliferine Meeting. Visiting. Las Vegas, NV, US.
2004. Photopheresis Meeting. Visiting. New York, NY, US.
2004. CBIMTR. Visiting. Minneapolis, MN, US.
2004. Lymphoma Research Foundation. Visiting. New York, NY, US.
2003. Nonmyelablative Stem Cell Transplantation. Invited. Duarte, CA, US.
2003. Nonmyeloablative Stem Cell Transplantation for Lymphoma and Hodgkin’s Disease. Invited. San Antonio, TX, US.
2003. Follicular Lymphoma. Invited. Edinburgh.
2003. BMT. Invited. San Diego, CA, US.
2003. Nonmyeloablative Stem Cell Transplantation for Lymphoid Malignancies. Invited, US.
2003. Foundation for Accreditation of Cellular Therapies (FACT) Meeting with CBER/FDA. Visiting. Washington, US.
2003. Foundation for Accreditation of Cellular Therapies (FACT) Inspection. Visiting, US.
2003. ECOG Peer Review Meeting. Visiting. Bethesda, MD, US.
2003. Lymphoma Research Foundation Advisory Board. Visiting. New York, NY, US.
2003. Foundation for Accreditation of Cellular Therapies (FACT) Strategic Planning Retreat. Visiting. Omaha, NE, US.
2003. United Resources Meeting. Visiting. Minneapolis, MN, US.
2003. NCI-Subcommittee D Meeting. Visiting. Bethesda, MD, US.
2003. CMV Advisory Panel. Visiting. Philadelphia, PA, US.
2002. IBMTR-NMDP Strategic Development Meeting. Visiting. Minneapolis, MN, US.
2002. Site Visit. Visiting. Boston, MA, US.
2002. NCI Advisory Board Meeting. Visiting. Bethesda, MD, US.
2002. IBMTR External Review. Visiting. Milwaukee, WI, US.
2002. Foundation for Accreditation of Cellular Therapies (FACT) Inspection. Visiting, MN, US.
2002. FDA Site Visit. Visiting. Washington, US.
2001. New Indications for BMT. Invited. Austin, TX, US.
2001. Allogeneic vs. Autologous Transplantation in NHL. Invited. Washington, US.
2001. Reconstitution of Immunity Following Transplantation. Invited. Boston, MA, US.
2001. Allogeneic Stem Cell Transplantation. Invited. San Diego, CA, US.
2001. BMT for Lymphoid Malignancies. Invited. New York, NY, US.
2001. Clinical Advances in Leukemias and Lymphomas. Invited. New York, NY, US.
2000. Non-myeloablative allogeneic hematopoietic transplants: Evolving Indications. Invited. Boston, MA, US.
2000. Non-myeloablative Allogeneic Transplantation. Invited. Los Angeles, CA, US.
2000. Allogeneic Hematopoietic Transplants for Lymphoid Malignancies. Invited. Newport Beach, CA, US.
2000. Chronic Leukemia. Invited. Rochester, MN, US.
2000. Allogeneic vs. Autologous transplants for NHL. Invited. Milwaukee, WI, US.
2000. New Advances in Mini-allografts. Invited. Rochester, MN, US.
2000. Role of Non-myeloablative Allogeneic Transplants for Patients with Malignancy. Invited. Minneapolis, MN, US.
2000. Advances in BMT, Scripps Research Institute. Invited. San Diego, CA, US.
2000. Transplant for Aggressive NHL. Invited. Miami, FL, US.
2000. Hematopoietic and Immune Reconstitution in Elderly Patients. Invited. Ann Arbor, MI, US.
2000. Innovations in Lymphoma research. Invited. New York, NY, US.
2000. Innovations in Lymphoma research. Invited. New York, NY, US.
2000. Non-myeloablative Stem Cell Transplants and Treatment of Malignancies. Visiting. Atlanta, GA, US.
2000. The Treatment of BMT Patients and Antifungal Infections. Visiting. Phoenix, AZ, US.
2000. BMT for Leukemia and Lymphoma. Visiting. New York, NY, US.
2000. Guidelines for preventing transmission of human immunodeficiency virus through transplantation of human tissue and organs. Visiting. Atlanta, GA, US.
2000. Challenging Cases in BMT. Visiting. New York, NY, US.
2000. Allogeneic Stem Cell Transplantation. Visiting. Hilton Head, SC, US.
1999. Research for BMT. Invited. Orlando, FL, US.
1999. Role of Allogeneic Blood and Marrow Transplantation for Lymphoma. Invited. Stanford, CA, US.
1999. Managed Care Roundtable Meeting on Coverage Issues in Oncological Care. Visiting. Phoenix, AZ, US.
1999. Protocol Discussion. Visiting. Medford, ME, US.
1999. Current Therapeutic Options in the Management of B-Cell Malignancies. Visiting. Wilmington, DE, US.

Less

Grant & Contract Support

Date:	2021 - 2026
Title:	A Retrospective Study to Determine the Incidence of, Risk Factors for, and Outcomes of Patients with Transplant-Associated Thrombotic Microangiopathy (TA-TMA)
Funding Source:	Omeros Inc
Role:	PI
ID:	13041498

Date:	2019 - 2024
Title:	Cancer Center Support Grant
Funding Source:	NIH/NCI
Role:	Project Leader
ID:	P30 CA166745

Date:	2019 - 2023
Title:	Optimal Stage and Timing for Leukemia Patients to Receive Stem Cell Transplants
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	PA-18-484

Date:	2019 - 2026
Title:	Anti-viral Central Memory CD8 Veto Cells in Haploidentical HSCT
Funding Source:	Cell Source, Inc
Role:	PI

Date:	2016 - 2022
Title:	Off-the-shelf engineered NK cells for the treatment of AML
Funding Source:	NIH/NCI
Role:	Co-I

Date:	2016 - 2021
Title:	Acute Myeloid Leukemia in the Immunosuppressed Microenvironment - Project 2: Immunotherapy for AML Using Off-the-Shelf and Engineered Cord Blood-Derived Natural Killer Cells
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	RP160693

Date:	2016 - 2020
Title:	A Randomized Study of Once Daily Fludarabine-Clofarabine vs. Fludarabine alone Combined with IV Busulfan Followed by Allogeneic Hemopoietic Stem Cell Transplantation for AML and MDS
Funding Source:	Genzyme/Sanofi
Role:	PI

Date:	2016 - 2019
Title:	Clinical Safety and Efficacy of Third party, fucosylated, cord blood derived regulatory T cells to prevent graft versus host disease
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-PI
ID:	RP160121

Date:	2015 - 2017
Title:	Overcoming Ibrutinib Primary Resistance in Mantle Cell Lymphoma
Funding Source:	NIH/NCI
Role:	Co-I

Date:	2014 - 2019
Title:	Randomized Phase III Study of Clofarabine in Combination with Busulfan and Fludarabine in AML/MDS
Funding Source:	Sanofi
Role:	PI
ID:	13534

Date:	2014 - 2022
Title:	MDS/AML Moonshot Cell Therapy Project
Funding Source:	UTMDACC
Role:	PI

Date:	2014 - 2020
Title:	Research Training in Academic Medical Oncology
Funding Source:	NIH/NCI
Role:	PI
ID:	T32CA009666

Date:	2013 - 2016
Title:	Targeting Complement System as Novel Therapy for GVHD
Funding Source:	Leukemia and Lymphoma Society
Role:	Co-I
ID:	13076330

Date:	2013 - 2015
Title:	Phase 1 Study of Umbilical Cord Blood-Derived T Cells in Malignant B Cells
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01FD004369-01

Date:	2013 - 2023
Title:	Leukemia Specialized Programs of Research Excellence (SPORE) Project 2: Anti-PR1 immune therapy for myeloid leukemia
Funding Source:	NIH/NCI
Role:	Co-Leader-Clinical Research
ID:	P50 CA100632

Date:	2013 - 2018
Title:	The Complement System and Graft-vs-Host Disease
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	GRANT11242218

Date:	2013 - 2018
Title:	Anti-PR1 immune therapy for myeloid leukemia
Funding Source:	NIH/NCI
Role:	Co-I
ID:	GRANT11151663

Date:	2013 - 2018
Title:	DLI of T-cells genetically modified with iCasp9 Suicide Gene
Funding Source:	Bellicum Pharmaceuticals, Inc
Role:	PI

Date:	2012 - 2015
Title:	Difibrotide Pivotal
Funding Source:	Gentium S.p.A
Role:	PI
ID:	G0000468

Date:	2012 - 2015
Title:	CD19-SPECIFIC T-CELL THERAPY AFTER CORD BLOOD TRANSPLANTATION UNDER IND 14739
Funding Source:	Food and Drug Administration (FDA)
Role:	Co-I

Date:	2012 - 2013
Title:	Translational development of novel immunotherapy for multiple myeloma: Core A - Administrative and Biostatistics Core
Funding Source:	Leukemia and Lymphoma Society
Role:	Co-Core Leader
ID:	4199

Date:	2012 - 2017
Title:	Rendering T Cells as Drugs
Funding Source:	NIH/NCI
Role:	Co-I

Date:	2012 - 2017
Title:	Specialized Programs of Research Excellence (SPOREs) in Human Cancer for Years 2010, 2011, 2012 – Project 3: Targeting Tumor Microenvironment in Breast Cancer
Funding Source:	NIH/NCI
Role:	Project 3 - Co-Investigator
ID:	P50CA116199

Date:	2012 - 2014
Title:	A randomized study of once daily Fludarabne-Clofarabine vs Fludarabine alone combined with IV Busulfan followed by allogeneic hemopoietic stem cell transplantation for AML and MDS
Funding Source:	Otsuka Pharmaceutical Development & Commercialization, Inc
Role:	PI
ID:	CS2012-0036506LG 01

Date:	2011 - 2013
Title:	A Phase III Trial Comparing a Combination of IV Bulsulfan with High-Dose Melphalan (Bu-Mel 140) with High-Dose Melphalan (Mel 200) Alone for Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma
Funding Source:	Otsuka Pharmaceuticals, Inc
Role:	Co-I
ID:	CS2010-0032635MA

Date:	2011 - 2012
Title:	High dos Busulfan + Melphalan for Multiple Myeloma
Funding Source:	Otuska
Role:	Co-I
ID:	CS2010-000-32635

Date:	2011 - 2016
Title:	MIRA-Cellular Therapy for Cancer (AC)
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Principal Investigator-MDACC
ID:	RP110553-AC

Date:	2011 - 2016
Title:	MIRA-Cellular Therapy for Cancer (C1)
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Principal Investigator-MDACC
ID:	RP110553-C1

Date:	2011 - 2016
Title:	Adoptive Immunotherapy With NK Cells Expanded Ex Vivo For Treatment of Hematopoietic Malignancies
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	RP110553-P3

Date:	2010 - 2014
Title:	Improving Cord Blood Expanson and Homing for Patients with Cancer
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	RP100469-03

Date:	2010 - 2015
Title:	T-cell Therapy for B-lineage Acute Lymphoblastic Leukemia
Funding Source:	NIH/NCI
Role:	Co-I
ID:	R01 CA141303

Date:	2009 - 2014
Title:	Azacitidine Maintenance Therapy After Allogeneic Stem Cell Transplantation for CML
Funding Source:	Celgene
Role:	PI
ID:	CS2009-00026722LG

Date:	2009 - 2019
Title:	Randomized Controlled study of post-transplant azacitidine for prevention of disease relapse
Funding Source:	Celgene
Role:	PI
ID:	CS2009-00027148LG

Date:	2008 - 2012
Title:	Mechanisms of Symptoms of Multiple Myeloma and Its Therapy (PP-4)
Funding Source:	NIH/NCI
Role:	Project Leader
ID:	P01 CA 124787

Date:	2008 - 2013
Title:	Leukemia SPORE - Adoptive Cellular Therapy for Myeloid Leukemia
Funding Source:	NIH/NCI
Role:	Project 2, Co-Principal Investigator
ID:	2 P50 CA100632

Date:	2008 - 2013
Title:	G-CSF and Plerixafor with Busulfan and Fludarabine for Allogeneic Stem Cell Transplantation for Myeloid Leukemias
Funding Source:	Genzyme
Role:	PI
ID:	CS2008-00024093JW

Date:	2008 - 2013
Title:	Validation of Pre-Clinical Studies to Assess the Product Manufacturing Characteristics and Testing of BP-GMAX-CD1, an Adenoviral Donors
Funding Source:	Bellicum Pharmaceuticals, Inc
Role:	PI
ID:	LS2008-00022235EB

Date:	2007 - 2013
Title:	A randomized study of once daily IV Busulfan with Fludarabine with hemopoietic stem cell transplantation
Funding Source:	PDL Biopharma
Role:	PI
ID:	CS2007-00019150SS 01

Date:	2007 - 2013
Title:	Vaccination of stem cell transplant donors with myeloma-specific antigen
Funding Source:	Leukemia and Lymphoma Society
Role:	Co-Investigator, Project 4 and Core A - Adminstrative Core Co-Director
ID:	7262-08 01

Date:	2006 - 2012
Title:	Busulfan-Fludarabine-Clofarabine with allogeneic stem cell transplantation for advanced refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome and advanced, Gleevec refractory Chronic Myeloid Leukemia. A Randomized Phase II Study
Funding Source:	Genzyme
Role:	PI
ID:	CS2006-00017882LE

Date:	2006 - 2013
Title:	Alloreactive NK Cells with Allogeneic Stem Cell Transplantation for Treatment of AML/MDS
Funding Source:	Commonwealth Foundation for Cancer Research
Role:	PI

Date:	2006 - 2011
Title:	Early Therapeutics Development with Phase II Emphasis (PC-A)
Funding Source:	NCI-DHHS-NIH
Role:	Collaborator
ID:	N01-CM-62202-09

Date:	2005 - 2011
Title:	Alloreactive NK Cells with Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell
Funding Source:	Genzyme
Role:	PI
ID:	CS2006-00015268SP

Date:	2004 - 2007
Title:	Separation of graft-vs.-Lymphoma from graft vs. host disease using anti-third party cytolytic T-cell (CTL) for treatment of mantle cell lymphoma
Funding Source:	Lymphoma Research Foundation
Role:	PI

Date:	2003 - 2008
Title:	Sample Collection processing and Clinical Trials
Funding Source:	NIH/NCI
Role:	Core Leader
ID:	1PO1CA100265-01A1

Date:	2003 - 2010
Title:	Sample Collection, Processing and clinical Trials
Funding Source:	NIH, Core B4
Role:	Core Director
ID:	U19 CA10026

Date:	2003 - 2008
Title:	Leukemia SPORE - Adoptive Cellular Therapy of Myeloid Leukemia
Funding Source:	NIH
Role:	Co-Program Leader
ID:	SPORE 1P50 CA 100632

Date:	2003 - 2004
Title:	Allogeneic BMT in CML
Funding Source:	NIH
Role:	Project Leader
ID:	CA49639-15

Date:	2003 - 2011
Title:	Hematopoietic Progenitor Cells
Funding Source:	NCI-DHHS-NIH
Role:	Collaborator
ID:	R01 CA061508-16

Date:	2002 - 2017
Title:	Improving the Outcomes of Stem Cell Transplantation
Funding Source:	NIH/NHLBI
Role:	Co-I
ID:	U10 HL069334

Date:	1998 - 2023
Title:	Cancer Center Support Grant
Funding Source:	NIH
Role:	Project 19 Leader, Stem Cell Transplantation and Cellular Therapy Program
ID:	P30 CA16672

Date:	1998 - 2003
Title:	Sample Collection
Funding Source:	NIH
Role:	Project Leader
ID:	2PO1 CA55164

Date:	1997 - 2012
Title:	The Therapy of AML
Funding Source:	NIH/NCI
Role:	Project Leader
ID:	P01 CA55164

Date:	1997 - 2016
Title:	The Therapy of CML
Funding Source:	NIH/NCI
Role:	Program Leader
ID:	P01 CA049639

Date:	1997 - 2016
Title:	Therapy in CML (PC-A)
Funding Source:	NIH, Core A
Role:	Project Leader
ID:	P01 CA49639

Date:	1997 - 2016
Title:	The Therapy of CML
Funding Source:	NIH, Project 2
Role:	Project Leader
ID:	PO1 CA49639

Selected Publications

Peer-Reviewed Articles

Pasvolsky, O, Shimony, S, Saliba, RM, Marcoux, C, Ledesma, C, Rondon, G, Tewari, P, Ragoonanan, D, Short, NJ, Jabbour, EJ, Gooptu, M, Ho, VT, Soiffer, RJ, Antin, JH, Koreth, J, Cutler, C, Paolino, JD, Duncan, C, Lehmann, L, DeAngelo, DJ, Jain, N, Champlin, RE, Shpall, E, Luskin, MR, Kebriaei, P. Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults With Acute Lymphoblastic Leukemia—A Retrospective, Dual-Center Study. American journal of hematology 101(1):16-25, 2026. e-Pub 2026. PMID: 41051170.
Shafat, T, Khawaja, F, Jiang, Y, Daher, M, Febres-Aldana, A, Shigle, TL, Rondon, G, Champlin, RE, Bhatti, MM, Spallone, A, Olson, AL, Ariza Heredia, E, Chen, GL, Rezvani, K, Shpall, E, Chemaly, RF. The interplay between Epstein-Barr virus and cytomegalovirus reactivation following allogeneic haematopoietic cell transplantation in the era of primary cytomegalovirus prophylaxis. Clinical Microbiology and Infection 31(12):2063-2072, 2025. e-Pub 2025. PMID: 40865766.
Mehta, RS, Aljawai, YM, Kebriaei, P, Olson, AL, Oran, B, Rondon, G, Rezvani, K, Champlin, RE, Shpall, E. The Impact of Isolated HLA-DQB1 Mismatch and Donor Age in Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide. Transplantation and Cellular Therapy 31(11):920.e1-920.e14, 2025. e-Pub 2025. PMID: 40819683.
Aljawai, YM, Ramdial, JL, Smallbone, PI, Chen, GL, Kebriaei, P, Pasvolsky, O, Popat, UR, Oran, B, Rezvani, K, Champlin, RE, Shpall, E, Mehta, RS. Comparative outcomes of HSCT with posttransplant cyclophosphamide in older adults. Blood Advances 9(20):5201-5206, 2025. e-Pub 2025. PMID: 40795211.
Marcoux, C, Milton, D, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Patel, A, Khan, HN, Ramdial, JL, Nieto, Y, Tang, G, Haider, A, Aljawai, YM, Kebriaei, P, Lee, HC, Ye, JC, Patel, K, Thomas, SK, Orlowski, R, Champlin, RE, Shpall, E, Qazilbash, MH, Pasvolsky, O. Outcomes of Patients With Multiple Myeloma With deletion 1p Following Autologous Stem Cell Transplant. Transplantation and Cellular Therapy 31(10):804.e1-804.e9, 2025. e-Pub 2025. PMID: 40752590.
Aljawai, YM, Ramdial, JL, Rondon, G, Smallbone, PI, Kebriaei, P, Popat, UR, Oran, B, Rezvani, K, Champlin, RE, Shpall, E, Mehta, RS. Outcomes of haploidentical vs mismatched unrelated donor HCT with posttransplant cyclophosphamide prophylaxis. Blood Advances 9(15):4023-4036, 2025. e-Pub 2025. PMID: 40517414.
Smallbone P, Shigle TL, Paslovsky O, Hosing C, Alousi A, Bashir Q, Aljawai Y, Ramdial J, Popat U, Champlin R, Shpall EJ, Oran B. Maintenance therapy with oral decitabine plus cedazuridine after allogeneic stem cell transplantation for myelodysplastic syndrome. Haematologica 110(8):1798-1807, 2025. e-Pub 2025. PMID: 40013380.
Pasvolsky O, Marcoux C, Milton DR, Rafaeli N, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Mohamedi AH, Deen AF, Aljawai Y, Lee HC, Patel KK, Becnel MR, Kebriaei P, Thomas SK, Orlowski RZ, Champlin R, Shpall EJ, Qazilbash MH. Outcomes of Multiple Myeloma Patients With Prior Solid Tumors Undergoing Autologous Transplantation. Transplant Cell Ther 31(8):565.e1-565.e9, 2025. e-Pub 2025. PMID: 40383197.
Oran B, Thall P, Alousi A, Al-Atrash G, Mehta R, Marin D, Kebriaei P, Popat U, Bassett R, Bashir Q, Im J, Olson A, Jewell J, Smallbone P, Shpall E, Champlin R. Guadecitabine improved relapse-free survival in high-risk acute myeloid leukemia and myelodysplastic syndrome patients after transplant: phase II results from a single center. Haematologica, 2025. e-Pub 2025. PMID: 40702903.
Saliba RM, Niemann M, Srour SA, Greenbaum U, Alzahrani KK, Carmazzi Y, Rondon G, Rezvani K, Daher M, Li D, Ma Q, Tanner MR, Cao K, Shpall EJ, Champlin RE, Spierings E, Zou J. Molecular Disparity of HY Antigen Affects Chronic Graft-Versus-Host Disease and Relapse in Female-to-Male Stem Cell Transplants. Transplant Cell Ther 31(11):903-915, 2025. e-Pub 2025. PMID: 40714365.
Brehm V, Wang Z, Rocha L, Jones B, Jenq RR, Chang CC, Cheng GS, Hsu J, Sharifi H, Yanik G, Luna L, Waqar A, Zaveri J, Dickey BF, Bashoura L, Shpall EJ, Zinter M, O'Dwyer D, Champlin RE, Chen G, Alousi A, Paczesny S, Peterson CB, Sheshadri A. Inflammatory Markers and Microbiome Dysbiosis in Hematopoietic Cell Transplant Recipients with Lung Graft-versus-Host Disease. Transplant Cell Ther 31(9):668.e1-668.e12, 2025. e-Pub 2025. PMID: 40543709.
Kawedia JD, Handy VW, Myers AL, Gulbis AM, Mehta R, Champlin RE, Shpall EJ, Nieto Y, Andersson BS, Popat UR. Seizure Prophylaxis and its Impact on Busulfan Pharmacokinetics and Dosing in a Novel Timed Sequential Protocol: MD Anderson Experience. Transplant Cell Ther 31(9):709.e1-709.e10, 2025. e-Pub 2025. PMID: 40514011.
Lontos, K, Saliba, RM, Kanagal Shamanna, R, Ozcan, G, Ramdial, JL, Chen, GL, Kadia, TM, Short, NJ, Daver, N, Kantarjian, HM, Marin, D, Kebriaei, P, Popat, UR, Champlin, RE, Shpall, E, Oran, B. TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS/AML for transplantation. Blood Advances 9(11):2845-2854, 2025. e-Pub 2025. PMID: 39853269.
Liu, WH, Levin, AG, Lask, A, Horn, G, Waks, T, Levi, BN, Krentsis, IM, Shoshan, E, Su, X, Mamonkin, M, Champlin, RE, Reisner, Y, Lustig, EB. Anti-viral CD8 central memory veto cells as a new platform for CAR T cell therapy. Stem Cells Translational Medicine 14(6), 2025. e-Pub 2025. PMID: 40448965.
Pasvolsky, O, Abid, MB, Milton, D, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Jatoi, A, Khan, HN, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Siddiqui, U, Aljawai, YM, Kebriaei, P, Lee, HC, Patel, K, Gaballa, MM, Thomas, SK, Orlowski, R, Champlin, RE, Shpall, E, Qazilbash, MH. Outcomes of patients with multiple myeloma undergoing autologous transplant with suboptimal pretransplant response. British Journal of Haematology 206(6):1730-1736, 2025. e-Pub 2025. PMID: 40159289.
Senapati J, Loghavi S, Garcia-Manero G, Tang G, Kadia T, Short NJ, Abbas HA, Arani N, DiNardo CD, Borthakur G, Pemmaraju N, Oran B, Shpall E, Popat U, Champlin R, Pierce S, Arora S, Issa G, Yilmaz M, Patel K, Takahashi K, Montalban-Bravo G, Hammond D, Haddad FG, Ravandi F, Kantarjian HM, Daver NG. Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms. Haematologica 110(6):1304-1315, 2025. e-Pub 2025. PMID: 39665206.
Senapati, J, Loghavi, S, Marvin-Peek, J, Garcia-Manero, G, Kadia, TM, Borthakur, G, Daver, N, Short, NJ, Jain, N, Issa, GC, Haddad, FG, Hammond, D, Chien, KS, Tang, G, Thakral, B, Montalban Bravo, G, Pemmaraju, N, Bazinet, A, Swaminathan, M, Pierce, S, Abbas, HA, Reville, PK, Popat, UR, Shpall, EJ, Champlin, RE, Jabbour, EJ, Ravandi-Kashani, F, Kantarjian, HM, DiNardo, C. Clinico-Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia. American journal of hematology 100(5):758-769, 2025. e-Pub 2025. PMID: 39921561.
Alkhunaizi, M, Soto-Lanza, F, Leung, CH, Bhan, N, Bashoura, L, Dickey, BF, Sharifi, H, Cheng, GS, Yanik, G, Rondon, G, Saliba, RM, Chen, GL, Al-Atrash, G, Hosing, C, Kebriaei, P, Popat, UR, Shpall, E, Champlin, RE, Li, L, Alousi, AM, Sheshadri, A. Restrictive Ventilatory Defects Following Hematopoietic Stem Cell Transplant Are Associated With Increased Mortality. Transplantation and Cellular Therapy 31(4):255.e1-255.e10, 2025. e-Pub 2025. PMID: 39921208.
Alkhunaizi, M, Soto-Lanza, F, Leung, CH, Bhan, N, Bashoura, L, Dickey, BF, Sharifi, H, Cheng, GS, Yanik, G, Rondon, G, Saliba, RM, Chen, GL, Al-Atrash, G, Hosing, C, Kebriaei, P, Popat, UR, Shpall, E, Champlin, RE, Li, L, Alousi, AM, Sheshadri, A. Restrictive Ventilatory Defects Following Hematopoietic Stem Cell Transplant Are Associated With Increased Mortality. Transplantation and Cellular Therapy 31(4):255.e1-255.e10, 2025. e-Pub 2025. PMID: 39921208.
Nieto, Y, Ramdial, JL, Valdez, B, Thall, PF, Bassett Jr, R, Barnett, M, Srour, S, Hosing, C, Alousi, AM, Qazilbash, MH, Popat, UR, Gulbis, A, Shigle, TL, Ahmed, S, Pacheco, MG, Champlin, RE, Shpall, E, Andersson, BS. Enhancement of High-Dose Chemotherapy and Autologous SCT with the PARP Inhibitor Olaparib for Refractory Lymphoma. Clinical Cancer Research 31(6):975-982, 2025. e-Pub 2025. PMID: 39804167.
Daher, M, Khawaja, F, Spallone, A, Shigle, TL, Bhatti, MM, Vuong, NN, Ariza Heredia, E, Mulanovich, VE, Champlin, RE, Chemaly, RF. Real-World Experience With Maribavir for Treatment of Refractory or Resistant Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients and Hematologic Malignancy Patients. Transplant Infectious Disease 27(2), 2025. e-Pub 2025. PMID: 39826146.
Pasvolsky, O, Marcoux, C, Wang, Z, Milton, D, Pal, B, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Syed, N, Aljawai, YM, Lee, HC, Patel, K, Becnel, M, Ye, JC, Kebriaei, P, Thomas, SK, Orlowski, R, Champlin, RE, Shpall, E, Qazilbash, MH. Outcomes of Standard-Risk Multiple Myeloma Patients Who Undergo Upfront Autologous Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy 31(3):166.e1-166.e9, 2025. e-Pub 2025. PMID: 39746546.
Prasad, R, Rehman, A, Rehman, L, Darbaniyan, F, Blumenberg, V, Schubert, ML, Mor, U, Zamir, E, Schmidt, S, Hayase, T, Chang, C, McDaniel, L, Flores, I, Strati, P, Nair, R, Chihara, D, Fayad, LE, Ahmed, S, Iyer, SP, Wang, ML, Jain, P, Nastoupil, L, Westin, JR, Arora, R, Turner, J, Khawaja, F, Wu, R, Dennison, JB, Menges, M, Hidalgo-Vargas, M, Reid, K, Davila, ML, Dreger, P, Korell, F, Schmitt, A, Tanner, MR, Champlin, RE, Flowers, CR, Shpall, EJ, Hanash, S, Neelapu, SS, Schmitt, M, Subklewe, M, Fahrmann, JF, Thoeringer, C, Elinav, E, Jain, MD, Hayase, E, Jenq, RR, Saini, N. Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy. Blood 145(8):823-839, 2025. e-Pub 2025. PMID: 39441941.
Bashir, Q, Konopleva, M, Abueg, G, Ramdial, JL, Hosing, C, Srour, S, Alousi, AM, Popat, UR, Nieto, Y, Al-Atrash, G, Champlin, RE, Shpall, E, Qazilbash, MH, Pemmaraju, N. Tagraxofusp maintenance post-hematopoietic stem cell transplantation provides long-term survival and manageable safety for a patient with blastic plasmacytoid dendritic cell neoplasm. Leukemia Research Reports 24, 2025. e-Pub 2025. PMID: 40612021.
Marcoux, C, Pasvolsky, O, Milton, D, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Lee, HC, Patel, K, Kebriaei, P, Ahmed, A, Aljawai, YM, Thomas, SK, Orlowski, R, Shpall, EJ, Champlin, RE, Qazilbash, MH. Real-World Outcomes of Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma With Deletion 17p. Transplantation and Cellular Therapy 31(1):12.e1-12.e10, 2025. e-Pub 2025. PMID: 39448031.
Pasvolsky, O, Wang, Z, Milton, D, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Kebriaei, P, Aljawai, YM, Khan, HN, Lee, HC, Ye, JC, Patel, K, Thomas, SK, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH. Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation. Blood cancer journal 14(1), 2024. e-Pub 2024. PMID: 38760362.
Abdel Rahman, Z, Othman, T, Saliba, RM, Vanegas, YM, Mohty, R, Ledesma, C, Rondon, G, Jain, N, Jabbour, EJ, Pullarkat, V, Alkhateeb, HB, Kantarjian, HM, Greipp, PT, Nakamura, R, Kharfan-Dabaja, MA, Champlin, RE, Forman, SJ, Shpall, E, Litzow, M, Foran, J, Aldoss, I, Koller, PB, Kebriaei, P. A Multicenter Analysis of Allogeneic Transplant Outcomes in Adults with Philadelphia-Like B-Cell Acute Lymphoblastic Leukemia in First Complete Remission. Transplantation and Cellular Therapy 30(12):1197-1205, 2024. e-Pub 2024. PMID: 39332807.
Pasvolsky, O, Marcoux, C, Milton, D, Pal, B, Tanner, MR, Bashir, Q, Srour, S, Lee, J, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Aljawai, YM, Kebriaei, P, Becnel, M, Lee, HC, Patel, K, Thomas, SK, Orlowski, R, Shpall, EJ, Champlin, RE, Qazilbash, MH. Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation. Blood cancer journal 14(1), 2024. e-Pub 2024. PMID: 39482325.
Pasvolsky, O, Ghanem, S, Milton, D, Rauf, M, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Aljawai, YM, Khan, HN, Kebriaei, P, Lee, HC, Patel, K, Thomas, SK, Weber, DM, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH. Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant. Blood cancer journal 14(1), 2024. e-Pub 2024. PMID: 38199987.
Yeh J, Pasvolsky O, Saliba RM, Figgins B, Wang C, Fang Z, Ahmed S, Yilmaz M, Daver N, Ravandi F, DiNardo C, Short NJ, Kadia T, Al-Atrash G, Daher M, Costa DM, Popat U, Champlin R, Shpall E, Oran B. Efficacy and Safety of Gilteritinib versus Sorafenib as Post-Transplant Maintenance in Patients With FLT3-ITD Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 24(11):e819-e826, 2024. e-Pub 2024. PMID: 39183099.
Marcoux CM, Alousi AM, Im J, Hill LC, Smallbone P, Popat U, Hosing C, Kebriaei P, Olson A, Mehta R, Chen G, Qazilbash M, Shpall E, Champlin RC, Saliba RM. Gastrointestinal involvement refines prognosis in minnesota standard risk acute graft-vs.-host disease. Bone Marrow Transplant 59(11):1594-1600, 2024. e-Pub 2024. PMID: 39187601.
Pattali S, Hu S, Bashir Q, Champlin RE, Qazilbash MH. The Synchronous Diagnosis of Multiple Myeloma (MM) and Chronic Myeloid Leukemia (CML). Cureus 16(11):e73583, 2024. e-Pub 2024. PMID: 39677110.
Mehta, RS, Ramdial, JL, Kebriaei, P, Champlin, RE, Popat, UR, Rezvani, K, Shpall, EJ. Haploidentical vs HLA-matched sibling donor HCT with PTCy prophylaxis. Blood Advances 8(20):5306-5314, 2024. e-Pub 2024. PMID: 39167765.
Sharifi, H, Bertini, CD, Alkhunaizi, M, Hernandez, M, Musa, Z, Borges, C, Turk, I, Bashoura, L, Dickey, BF, Cheng, GS, Yanik, G, Galban, CJ, Guo, HH, Godoy, M, Reinhardt, JM, Hoffman, E, Castro, M, Rondon, G, Alousi, AM, Champlin, RE, Shpall, E, Lu, Y, Peterson, S, Datta, K, Nicolls, MR, Hsu, JL, Sheshadri, A. CT strain metrics allow for earlier diagnosis of bronchiolitis obliterans syndrome after hematopoietic cell transplant. Blood Advances 8(19):5156-5165, 2024. e-Pub 2024. PMID: 39163616.
Hayase, E, Hayase, T, Mukherjee, A, Stinson, SC, Jamal, M, Ortega, MR, Sanchez, CA, Ahmed, S, Karmouch, J, Chang, C, Flores, I, McDaniel, L, Brown, AN, El-Himri, RK, Chapa, V, Tan, L, Tran, B, Xiao, Y, Fan, C, Pham, D, Halsey, T, Jin, Y, Tsai, W, Prasad, R, Glover, I, Enkhbayar, A, Mohammed, A, Schmiester, M, King, KY, Britton, RA, Reddy, P, Wong, M, Ajami, NJ, Wargo, J, Shelburne, S, Okhuysen, PC, Liu, C, Fowler, S, Conner, ME, Katsamakis, Z, Smith, N, Burgos da Silva, M, Ponce, DM, Peled, JU, van den Brink, MR, Peterson, CB, Rondon, G, Molldrem, JJ, Champlin, RE, Shpall, E, Lorenzi, PL, Mehta, RS, Martens, EC, Alousi, AM, Jenq, RR. Bacteroides ovatus alleviates dysbiotic microbiota-induced graft-versus-host disease. Cell Host and Microbe 32(9):1621-1636.e6, 2024. e-Pub 2024. PMID: 39214085.
Pasvolsky, O, Marcoux, C, Dai, J, Milton, D, Tanner, MR, Syed, N, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Aljawai, YM, Lee, HC, Gaballa, MM, Patel, K, Kebriaei, P, Thomas, SK, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH. Trends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma Over Three Decades. Transplantation and Cellular Therapy 30(8):772.e1-772.e11, 2024. e-Pub 2024. PMID: 38852784.
Saengboon, S, Ciurea, SO, Popat, UR, Ramdial, JL, Bashir, Q, Alousi, AM, Chen, J, Rondon, G, Olson, AL, Im, J, Hosing, C, Shpall, E, Champlin, RE, Srour, S. Long-term outcomes after haploidentical stem cell transplantation for hematologic malignancies. Blood Advances 8(12):3237-3245, 2024. e-Pub 2024. PMID: 38607399.
Febres-Aldana, A, Khawaja, F, Morado-Aramburo, O, Shigle, TL, Rondon, G, Sassine, J, Spallone, A, Srinivasan, K, Ramdial, JL, Alousi, AM, Champlin, RE, Chen, GL, Daher, M, Rezvani, K, Ariza Heredia, E, Shpall, E, Chemaly, RF. Mortality in recipients of allogeneic haematopoietic cell transplantation in the era of cytomegalovirus primary prophylaxis. Clinical Microbiology and Infection 30(6):803-809, 2024. e-Pub 2024. PMID: 38460821.
Khouri, IF, Alzahrani, K, Kantarjian, HM, Milton, D, Gulbis, A, Sasaki, K, Jain, N, Short, NJ, Kadia, TM, Daher, M, Rafei, H, Im, JS, Marin, D, Olson, AL, Popat, UR, Qazilbash, MH, Ramdial, JL, Rondon, G, Srour, S, Kebriaei, P, Shpall, E, Champlin, RE, Jabbour, EJ. Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation. American journal of hematology 99(5):836-843, 2024. e-Pub 2024. PMID: 38400519.
Alzahrani, K, Pasvolsky, O, Wang, Z, Milton, D, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Lee, HC, Patel, K, Manasanch, EE, Kebriaei, P, Thomas, SK, Weber, DM, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH. Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation. British Journal of Haematology 204(5):1944-1952, 2024. e-Pub 2024. PMID: 38448009.
Pasvolsky, O, Saliba, RM, Popat, UR, Alousi, AM, Mehta, RS, Yeh, JC, Al-Atrash, G, Adeel, M, Ramdial, JL, Marin, D, Rondon, G, Kebriaei, P, Champlin, RE, Daver, N, DiNardo, C, Short, NJ, Shpall, E, Oran, B. Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. Clinical Lymphoma, Myeloma and Leukemia 24(5):e196-e204, 2024. e-Pub 2024. PMID: 38403505.
Pasvolsky, O, Pasyar, S, Bassett Jr, R, Khan, HN, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Lee, HC, Patel, K, Kebriaei, P, Thomas, SK, Weber, DM, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH. Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation. Cancer 130(9):1663-1672, 2024. e-Pub 2024. PMID: 38127583.
Ciurea, SO, Kongtim, P, Srour, S, Chen, J, Soebbing, D, Shpall, E, Rezvani, K, Nakkula, RJ, Thakkar, A, Troy, EC, Cash, AA, Behbehani, GK, Cao, K, Schafer, JR, Champlin, RE, Lee, DA. Results of a phase I trial with Haploidentical mbIL-21 ex vivo expanded NK cells for patients with multiply relapsed and refractory AML. American journal of hematology 99(5):890-899, 2024. e-Pub 2024. PMID: 38444268.
Ahmed, S, Bashir, Q, Bassett Jr, R, Ullah, F, Aung, FM, Valdez, B, Alousi, AM, Hosing, C, Kebriaei, P, Khouri, IF, Marin, D, Nieto, Y, Olson, AL, Oran, B, Qazilbash, MH, Rezvani, K, Mehta, RS, Shpall, E, Ciurea, SO, Andersson, BS, Champlin, RE, Popat, UR. Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation. American journal of hematology 99(4):562-569, 2024. e-Pub 2024. PMID: 38314663.
Marcoux, C, Saliba, RM, Wallis, W, Khazal, SJ, Ragoonanan, D, Rondon, G, Tewari, P, Popat, UR, Oran, B, Olson, AL, Bashir, Q, Qazilbash, MH, Alousi, AM, Hosing, C, Nieto, Y, Al-Atrash, G, Marin, D, Rezvani, K, Khouri, IF, Srour, S, Champlin, RE, Shpall, E, Kebriaei, P. Incidence and risk factors of early onset VOD/SOS differ in younger vs older adults after stem cell transplantation. Blood Advances 8(5):1128-1136, 2024. e-Pub 2024. PMID: 38266155.
Marin, D, Li, Y, Basar, R, Rafei, H, Daher, M, Dou, J, Mohanty, V, Dede, M, Nieto, Y, Uprety, N, Acharya, S, Liu, E, Wilson, JM, Banerjee, PP, Macapinlac, HA, Ganesh, C, Thall, PF, Bassett Jr, R, Ammari, M, Rao, SS, Cao, K, Shanley, M, Kaplan, M, Hosing, C, Kebriaei, P, Nastoupil, L, Flowers, CR, Moseley, SM, Lin, P, Ang, O, Popat, UR, Qazilbash, MH, Champlin, RE, Chen, K, Shpall, E, Rezvani, K. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors. Nature medicine 30(3):772-784, 2024. e-Pub 2024. PMID: 38238616.
Nieto, Y, Banerjee, PP, Kaur, I, Kim, KH, Fang, D, Thall, PF, Griffin, L, Barnett, M, Basar, R, Hosing, C, Ramdial, JL, Srour, S, Daher, M, Marin, D, Jiang, X, Chen, K, Champlin, RE, Shpall, E, Rezvani, K. Ex Vivo Expanded Cord Blood Natural Killer Cells Combined with Rituximab and High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B Cell Non-Hodgkin Lymphoma. Transplantation and Cellular Therapy 30(2):203.e1-203.e9, 2024. e-Pub 2024. PMID: 38042257.
Dickey, JS, Dickey, BF, Alousi, AM, Champlin, RE, Sheshadri, A. Early and rapid development of bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation. Respiratory Medicine Case Reports 49, 2024. e-Pub 2024. PMID: 38745870.
Mamlouk O, Strati P, Feng L, Sun R, Ayers A, Steiner RE, Nair R, Flowers C, Ramdial JL, Saini N, Srour SA, Champlin RE, Kebriaei P, Nastoupil LJ, Rodriguez MA, Shpall EJ, Nieto Y, Westin J, Neelapu SS, Mandayam S, Ahmed S. Real-world analysis of safety and efficacy of CAR T-cell therapy in lymphoma patients with decreased kidney function. Br J Haematol 204(1):e11-e16, 2024. e-Pub 2023. PMID: 37822075.
Saliba RM, Kanakry CG, Gadalla S, Kebriaei P, Rezvani K, Champlin RE, Shpall EJ, Weisdorf D, Mehta RS. Effect of donor age in patients with acute myeloid leukemia undergoing haploidentical hematopoietic cell transplantation vary by conditioning intensity and recipient age. Am J Hematol 99(1):38-47, 2024. e-Pub 2023. PMID: 37850688.
Bachar-Lustig BE, Lask A, Eidelstein Y, Or-Geva N, Gidron-Budovsky R, Nathansohn-Levy B, Eyrich M, Liu WH, Dang G, Miranda KC, Ramirez A, Kaur I, Rezvani K, Shpall E, Champlin RE, Nagler A, Shimoni A, Barnees-Kagan S, Reisner Y. Generation of non-alloreactive anti-viral central memory CD8 human veto T cells for cell therapy. Transplant Cell Ther 30(1):71.e1-71.e13, 2024. e-Pub 2023. PMID: 37890590.
Marinos A, Ramdial J, Khawaja F, Saliba RM, Shigle TL, Alousi AM, Rondon G, Chen J, Ledesma C, Champlin RE, Daher M, Chen G, Marin D, Rezvani K, Shpall EJ, Chemaly RF. Hematopoietic cell transplantation can be safely performed after COVID-19. Bone Marrow Transplant 58(12):1410-1412, 2023. e-Pub 2023. PMID: 37726490.
Pasvolsky, O, Bassett Jr, R, Ghanem, S, Cuglievan, B, Tewari, P, Hosing, C, Srour, S, Ramdial, JL, Mahadeo, KM, Khazal, SJ, Petropoulos, D, Popat, UR, Qazilbash, MH, Kebriaei, P, Champlin, RE, Shpall, E, Nieto, Y. Characteristics and outcomes of children, adolescents and young adults with relapsed/refractory non-hodgkin lymphoma undergoing autologous stem cell transplant. BMC cancer 23(1), 2023. e-Pub 2023. PMID: 38124057.
Joseph J, Srour SA, Milton DR, Ramdial JL, Saini NY, Olson AL, Bashir Q, Oran B, Alousi AM, Hosing C, Qazilbash MH, Kebriaei P, Shpall EJ, Champlin RE, Popat UR. Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning. Transplant Cell Ther 29(12):770.e1-770.e6, 2023. e-Pub 2023. PMID: 37742746.
Pasvolsky O, Ghanem S, Milton DR, Masood A, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma. Transplant Cell Ther 29(12):757-762, 2023. e-Pub 2023. PMID: 37673125.
Alkhaldi H, Reinhardt A, Barnett M, Kundu S, Hosing C, Ramdial J, Saini N, Srour S, Alousi A, Kebriaei P, Popat U, Qazilbash M, Champlin R, Shpall EJ, Gulbis A, Shigle TL, Dabaja B, Pinnix C, Ahmed S, Steiner R, Andersson BS, Nieto Y. High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. Transplant Cell Ther 29(11):690-694, 2023. e-Pub 2023. PMID: 37607645.
Kadia TM, Ravandi F, Molica M, Bataller A, Borthakur G, Daver N, Jabbour E, DiNardo CD, Pemmaraju N, Jain N, Ferrajoli A, Ylimaz M, Bose P, Tidwell RS, Marx KR, Rausch CR, Kanagal-Shamanna R, Wang S, Islam R, Champlin R, Shpall E, Konopleva M, Garcia-Manero G, Kantarjian H. Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia. Am J Hematol 98(11):1711-1720, 2023. e-Pub 2023. PMID: 37635400.
Popat UR, Pasvolsky O, Bassett R, Mehta RS, Olson A, Chen J, Alousi AM, Al-Atrash G, Bashir Q, Gulbis AM, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Oran B, Saini N, Shigle TL, Srour SA, Ramdial JL, Rezvani K, Qazilbash MH, Andersson BS, Champlin RE, Shpall EJ. Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities. Blood Adv 7(20):6196-6205, 2023. e-Pub 2023. PMID: 37611156.
Pasvolsky O, Milton DR, Masood A, Sami SS, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Saeed A, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience. Am J Hematol 98(10):1571-1578, 2023. e-Pub 2023. PMID: 37461327.
Mehta RS, Ali H, Dai Y, Yao B, Overman B, Ratanatharathorn V, Gill S, Socié G, Anderson K, Cahn JY, Mujeebuddin A, Champlin R, Shpall E, Holtan SG, Alousi A. A prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement. Bone Marrow Transplant 58(9):1-9, 2023. e-Pub 2023. PMID: 37202544.
Al-Juhaishi T, Wang Y, Milton DR, Xu-Monette ZY, Jabbour E, Daher M, Im JS, Bashir Q, Iyer SP, Marin D, Olson AL, Popat U, Qazilbash M, Rondon G, Gulbis AM, Champlin RE, Young KH, Khouri IF. Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant. Bone Marrow Transplant 58(9):1000-1007, 2023. e-Pub 2023. PMID: 37198234.
Dhakal B, Zhang MJ, Burns LJ, Tang X, Meyer C, Mau LW, Nooka AK, Stadtmauer E, Micallef IN, McGuirk J, Costa L, Juckett MB, Shah N, Champlin RE, Usmani SZ, Farag SS, Nishihori T, Roy V, Bodiford A, Barnes YJ, Drea EJ, Hari P, Hamadani M. Efficacy, safety, and cost of mobilization strategies in multiple myeloma: A prospective observational study. Haematologica 108(8):2249-2254, 2023. e-Pub 2023. PMID: 36601982.
Pasvolsky O, Marcoux C, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Tewari P, Crawford-Suber L, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of young adults (aged?=?40?years) with newly diagnosed multiple myeloma after up-front autologous stem cell transplant. Br J Haematol 202(4):866-873, 2023. e-Pub 2023. PMID: 37376789.
Li L, Mohanty V, Dou J, Huang Y, Banerjee PP, Miao Q, Lohr JG, Vijaykumar T, Frede J, Knoechel B, Muniz-Feliciano L, Laskowski TJ, Liang S, Moyes JS, Nandivada V, Basar R, Kaplan M, Daher M, Liu E, Li Y, Acharya S, Lin P, Shanley M, Rafei H, Marin D, Mielke S, Champlin RE, Shpall EJ, Chen K, Rezvani K. Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering. Sci Adv 9(30):eadd6997, 2023. e-Pub 2023. PMID: 37494448.
Short NJ, Ong F, Ravandi F, Nogueras-Gonzalez G, Kadia TM, Daver N, DiNardo CD, Konopleva M, Borthakur G, Oran B, Al-Atrash G, Mehta R, Jabbour EJ, Yilmaz M, Issa GC, Maiti A, Champlin RE, Kantarjian H, Shpall EJ, Popat U. Impact of Type of Induction Therapy on Outcomes in Older Adults with AML after Allogeneic Stem Cell Transplantation. Blood Adv 7(14):3573-3581, 2023. e-Pub 2023. PMID: 37104058.
Yalniz FF, Greenbaum U, Pasvolsky O, Milton DR, Kanagal-Shamanna R, Ramdial J, Srour S, Mehta R, Alousi A, Popat UR, Nieto Y, Kebriaei P, Al-Atrash G, Oran B, Hosing C, Ahmed S, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. Characteristics and Outcomes of Patients With Multiple Myeloma Who Developed Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autologous Cell Transplantation. Transplant Cell Ther. e-Pub 2023. PMID: 37437764.
Mehta RS, Ramdial J, Marin D, Alousi A, Kanakry CG, Champlin RE, Rezvani K, Shpall EJ, Page K, Gadalla SM, Kebriaei P, Weisdorf D. Impact of Donor Age in Haploidentical-Post-Transplantation Cyclophosphamide versus Matched Unrelated Donor Post-Transplantation Cyclophosphamide Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia. Transplant Cell Ther 29(6):377.e1-377.e7, 2023. e-Pub 2023. PMID: 36990221.
Pasvolsky O, Milton DR, Rauf M, Ghanem S, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Rezvani K, Champlin R, Shpall EJ, Lin P, Qazilbash MH. Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients. Blood Cancer J 13(1):68, 2023. e-Pub 2023. PMID: 37137874.
Marcoux C, Marin D, Ramdial J, AlAtrash G, Alousi AM, Oran B, Kebriaei P, Popat UR, Rezvani K, Champlin RE, Shpall EJ, Mehta RS. Younger haploidentical donor versus older matched unrelated donor for patients with AML/MDS. Am J Hematol 98(5):712-719, 2023. e-Pub 2023. PMID: 36734029.
Pasvolsky O, Saliba RM, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of gender on outcomes of patients with multiple myeloma undergoing autologous Haematopoietic stem cell transplant. Br J Haematol 201(4):e37-e41, 2023. e-Pub 2023. PMID: 36916461.
Mehta RS, Marin D, Alousi A, Kanakry CG, Champlin RE, Rezvani K, Shpall EJ, Page K, Gadalla SM, Weisdorf D, Kebriaei P. Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor type. Blood Adv 7(8):1594-1603, 2023. e-Pub 2023. PMID: 36630564.
Zou J, Kongtim P, Oran B, Srour SA, Greenbaum U, Carmazzi Y, Rondon G, Ciurea SO, Ma Q, Shpall EJ, Champlin RE, Cao K. Molecular disparity of HLA-DPB1 is associated with the development of subsequent solid cancer after allogeneic hematopoietic stem cell transplantation. Cancer 129(8):1205-1216, 2023. e-Pub 2023. PMID: 36738229.
Pasvolsky O, Gaballa MR, Milton DR, Masood A, Sami SS, Tanner MR, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Tang G, Lin P, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience. Transplant Cell Ther 29(4):260.e1-260.e6, 2023. e-Pub 2023. PMID: 36646323.
Afrough A, Alsfeld LC, Milton DR, Delgado R, Popat UR, Nieto Y, Kebriaei P, Oran B, Saini N, Srour S, Hosing C, Cheema FH, Ahmed S, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Weber DM, Orlowski RZ, Pinnix CC, Dabaja BS, Thomas SK, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. Transplant Cell Ther 29(4):264.e1-264.e9, 2023. e-Pub 2023. PMID: 35605883.
Stein-Thoeringer CK, Saini NY, Zamir E, Blumenberg V, Schubert ML, Mor U, Fante MA, Schmidt S, Hayase E, Hayase T, Rohrbach R, Chang CC, McDaniel L, Flores I, Gaiser R, Edinger M, Wolff D, Heidenreich M, Strati P, Nair R, Chihara D, Fayad LE, Ahmed S, Iyer SP, Steiner RE, Jain P, Nastoupil LJ, Westin J, Arora R, Wang ML, Turner J, Menges M, Hidalgo-Vargas M, Reid K, Dreger P, Schmitt A, Müller-Tidow C, Locke FL, Davila ML, Champlin RE, Flowers CR, Shpall EJ, Poeck H, Neelapu SS, Schmitt M, Subklewe M, Jain MD, Jenq RR, Elinav E. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nat Med 29(4):906-916, 2023. e-Pub 2023. PMID: 36914893.
Jabbour EJ, Sasaki K, Haddad FG, Issa GC, Garcia-Manero G, Kadia TM, Jain N, Yilmaz M, DiNardo CD, Patel KP, Kanagal-Shamanna R, Champlin R, Khouri IF, Dellasala S, Pierce SA, Kantarjian H. The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors. Am J Hematol 98(4):658-665, 2023. e-Pub 2023. PMID: 36683287.
Mehta RS, Cao K, Saliba RM, Al-Atrash G, Alousi AM, Lontos K, Marcoux C, Carmazzi Y, Rondon G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Marin D, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial J, Rezvani K, Champlin RE, Shpall EJ. HLA Factors Versus Non-HLA Factors for Haploidentical Donor Selection. Transplant Cell Ther 29(3):189-198, 2023. e-Pub 2023. PMID: 36470579.
Ngo-Huang A, Ombres R, Saliba RM, Szewczyk N, Adekoya L, Soones TN, Ferguson J, Fontillas RC, Gulbis AM, Hosing C, Kebriaei P, Lindsay R, Marin DC, Mehta RS, Alousi AM, Srour S, Oran B, Olson AL, Qazilbash MH, Rivera Z, Champlin RE, Shpall EJ, Popat UR. Enhanced Recovery Stem-Cell Transplantation: Multidisciplinary Efforts to Improve Outcomes in Older Adults Undergoing Hematopoietic Stem-Cell Transplant. JCO Oncol Pract 19(3):e417-e427, 2023. e-Pub 2023. PMID: 36626702.
Alkhunaizi M, Patel B, Bueno L, Bhan N, Ahmed T, Arain MH, Saliba R, Rondon G, Dickey BF, Bashoura L, Ost DE, Li L, Wang S, Shpall E, Champlin RE, Mehta R, Popat UR, Hosing C, Alousi AM, Sheshadri A. Risk factors for bronchiolitis obliterans syndrome after initial detection of pulmonary impairment. Transplant Cell Ther 29(3):204.e1-204.e7, 2023. e-Pub 2023. PMID: 36503180.
Nieto Y, Pasvolsky O, Bassett R, Ghanem S, Cuglievan B, Tewari P, Hosing C, Sr S, Ramdial J, Mahadeo K, Khazal S, Petropoulos D, Popat U, Qazilbash M, Kebriaei P, Champlin R, Shpall E. Characteristics and Outcomes of Children, Adolescents and Young Adults with Relapsed/Refractory Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant. Res Sq, 2023. e-Pub 2023. PMID: 36798261.
Pasvolsky O, Saliba RM, Ledesma C, Popat UR, Alousi A, Olson A, Oran B, Hosing C, Bashir Q, Qazilbash MH, Short NJ, Ravandi F, Champlin R, Shpall EJ, Kebriaei P. Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission. Am J Hematol 98(2):E35-E37, 2023. e-Pub 2023. PMID: 36502492.
Jenq R, Hayase E, Hayase T, Mukherjee A, Stinson S, Jamal M, Ortega M, Sanchez C, Ahmed S, Karmouch J, Chang CC, Flores I, McDaniel L, Brown A, El-Himri R, Chapa V, Tan L, Tran B, Pham D, Halsey T, Jin Y, Tsai WB, Prasad R, Glover I, Ajami N, Wargo J, Shelburne S, Okhuysen P, Liu C, Fowler S, Conner M, Peterson C, Rondon G, Molldrem JJ, Champlin R, Shpall E, Lorenzi P, Mehta R, Martens E, Alousi A. Bacteroides ovatus alleviates dysbiotic microbiota-induced intestinal graft-versus-host disease. Res Sq, 2023. e-Pub 2023. PMID: 36778495.
Damron, EP, Qazilbash, MH, Fang, PQ, Wu, SY, Dabaja, BS, Rondon, G, Hosing, C, Champlin, RE, Bashir, Q, Shpall, E, Knafl, M, Lee, HC, Manasanch, EE, Patel, K, Thomas, SK, Orlowski, R, Weber, DM, Pinnix, CC, Gunther, J. Radiation Therapy Can Be Safely Incorporated into Pretransplantation Treatment Regimens for Patients with Multiple Myeloma. Transplantation and Cellular Therapy 29(1):37.e1-37.e7, 2023. e-Pub 2023. PMID: 37753818.
Ostrin, EJ, Rider, NL, Alousi, AM, Irajizad, E, Li, L, Peng, Q, Kim, ST, Bashoura, L, Arain, MH, Noor, L, Patel, NJ, Mehta, RS, Popat, UR, Hosing, C, Jenq, RR, Rondon, G, Hanash, S, Paczesny, S, Shpall, E, Champlin, RE, Dickey, BF, Sheshadri, A. A Nasal Inflammatory Cytokine Signature Is Associated with Early Graft-versus-Host Disease of the Lung after Allogeneic Hematopoietic Cell Transplantation. ImmunoHorizons 7(6):421-430, 2023. e-Pub 2023. PMID: 37289498.
Cherng HJ, Xu G, Feng L, Steiner R, Fayad L, Strati P, Nair R, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Rodriguez M, Wang M, Hagemeister F, Pinnix CC, Ramdial J, Srour S, Nieto Y, Rezvani K, Champlin R, Kebriaei P, Westin J, Macapinlac HA, Shpall E, Ahmed S. Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant. Br J Haematol 200(1):35-44, 2023. e-Pub 2023. PMID: 36068929.
Ghobadi A, Slade M, Kantarjian H, Alvarenga J, Aldoss I, Mohammed KA, Jabbour E, Faramand R, Shah B, Locke F, Fingrut W, Park JH, Short NJ, Gao F, Uy GL, Westervelt P, DiPersio JF, Champlin RE, Al Malki MM, Ravandi F, Kebriaei P. The Role of Allogeneic Transplant for Adult Ph+ ALL in CR1 with Complete Molecular Remission: A Retrospective Analysis. Blood 140(20):2101-2112, 2022. e-Pub 2022. PMID: 35877996.
Schwabkey ZI, Wiesnoski DH, Chang CC, Tsai WB, Pham D, Ahmed SS, Hayase T, Ortega Turrubiates MR, El-Himri RK, Sanchez CA, Hayase E, Frenk Oquendo AC, Miyama T, Halsey TM, Heckel BE, Brown AN, Jin Y, Raybaud M, Prasad R, Flores I, McDaniel L, Chapa V, Lorenzi PL, Warmoes MO, Tan L, Swennes AG, Fowler S, Conner M, McHugh K, Graf T, Jensen VB, Peterson CB, Do KA, Zhang L, Shi Y, Wang Y, Galloway-Pena JR, Okhuysen PC, Daniel-MacDougall CR, Shono Y, Burgos da Silva M, Peled JU, van den Brink MRM, Ajami N, Wargo JA, Reddy P, Valdivia RH, Davey L, Rondon G, Srour SA, Mehta RS, Alousi AM, Shpall EJ, Champlin RE, Shelburne SA, Molldrem JJ, Jamal MA, Karmouch JL, Jenq RR. Diet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment. Sci Transl Med 14(671):eabo3445, 2022. e-Pub 2022. PMID: 36383683.
Fahrmann JF, Saini NY, Chia-Chi C, Irajizad E, Strati P, Nair R, Fayad LE, Ahmed S, Lee HJ, Iyer S, Steiner R, Vykoukal J, Wu R, Dennison JB, Nastoupil L, Jain P, Wang M, Green M, Westin J, Blumenberg V, Davila M, Champlin R, Shpall EJ, Kebriaei P, Flowers CR, Jain M, Jenq R, Stein-Thoeringer CK, Subklewe M, Neelapu SS, Hanash S. A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma. Cell Rep Med 3(11):100720, 2022. e-Pub 2022. PMID: 36384092.
Pasvolsky O, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour S, Tang G, Saini N, Ramdial J, Masood A, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Lenalidomide-Based Maintenance After Autologous Hematopoietic Stem Cell Transplant for Patients with High-Risk Multiple Myeloma. Transplant Cell Ther 28(11):752.e1-752.e6, 2022. e-Pub 2022. PMID: 35940528.
Popat UR, Andersson BS, Bassett R, Kawedia J, Valdez BC, Alousi AM, Al-Atrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Marin D, Nieto Y, Oran B, Olson A, Qazilbash MH, Srour SA, Shpall EJ, Champlin RE, Mehta RS. Myeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA matched and haploidentical transplantation: results of a phase II study. Haematologica 107(10):2496-2500, 2022. e-Pub 2022. PMID: 35770531.
Pasvolsky, O, Milton, D, Rauf, M, Ghanem, S, Masood, A, Mohamedi, A, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Ramdial, JL, Nieto, Y, Tang, G, Lee, HC, Patel, K, Kebriaei, P, Thomas, SK, Weber, DM, Orlowski, R, Shpall, E, Champlin, RE, Lin, P, Qazilbash, MH. MM-403 Impact of Clonal Plasma Cells in Autografts on the Outcome of High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant. Clinical Lymphoma, Myeloma and Leukemia 22:S421-S422, 2022. e-Pub 2022. PMID: 36164172.
Saengboon, S, Ramdial, JL, Saini, N, Olson, AL, Im, J, Hosing, C, Popat, UR, Shpall, E, Champlin, RE, Srour, S. AML-528 Long-Term Outcomes After Haploidentical Stem Cell Transplantation (Haplo-SCT) for Hematologic Malignancies. Clinical Lymphoma, Myeloma and Leukemia 22:S259-S260, 2022. e-Pub 2022. PMID: 36163857.
Saliba RM, Alousi AM, Pidala J, Arora M, Spellman SR, Hemmer MT, Wang T, Abboud C, Ahmed S, Antin JH, Beitinjaneh A, Buchbinder D, Byrne M, Cahn JY, Choe H, Hanna R, Hematti P, Kamble RT, Kitko CL, Laughlin M, Lekakis L, MacMillan ML, Martino R, Mehta PA, Nishihori T, Patel SS, Perales MA, Rangarajan HG, Ringdén O, Rosenthal J, Savani BN, Schultz KR, Seo S, Teshima T, van der Poel M, Verdonck LF, Weisdorf D, Wirk B, Yared JA, Schriber J, Champlin RE, Ciurea SO. Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis. Transplant Cell Ther 28(10):681-693, 2022. e-Pub 2022. PMID: 35853610.
Li Y, Basar R, Wang G, Liu E, Moyes JS, Li L, Kerbauy LN, Uprety N, Fathi M, Rezvan A, Banerjee PP, Muniz-Feliciano L, Laskowski TJ, Ensley E, Daher M, Shanley M, Mendt M, Acharya S, Liu B, Biederstädt A, Rafei H, Guo X, Melo Garcia L, Lin P, Ang S, Marin D, Chen K, Bover L, Champlin RE, Varadarajan N, Shpall EJ, Rezvani K. KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape. Nat Med 28(10):2133-2144, 2022. e-Pub 2022. PMID: 36175679.
Mehta RS, Saliba RM, Rondon G, Al-Atrash G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial J, Srour SA, Champlin RE, Rezvani K, Shpall EJ, Alousi AM. Post-Transplantation Cyclophosphamide vs Tacrolimus and Methotrexate Graft-versus-Host Disease Prophylaxis For HLA-Matched Donor Transplantation. Transplant Cell Ther 28(10):695.e1-695.e10, 2022. e-Pub 2022. PMID: 35902049.
Hayase E, Hayase T, Jamal MA, Miyama T, Chang CC, Ortega MR, Ahmed SS, Karmouch JL, Sanchez CA, Brown AN, El-Himri RK, Flores II, McDaniel LK, Pham D, Halsey T, Frenk AC, Chapa VA, Heckel BE, Jin Y, Tsai WB, Prasad R, Tan L, Veillon L, Ajami NJ, Wargo JA, Galloway-Peña J, Shelburne S, Chemaly RF, Davey L, Glowacki RWP, Liu C, Rondon G, Alousi AM, Molldrem JJ, Champlin RE, Shpall EJ, Valdivia RH, Martens EC, Lorenzi PL, Jenq RR. Mucus-degrading Bacteroides link carbapenems to aggravated graft-versus-host disease. Cell 185(20):3705-3719.e14, 2022. e-Pub 2022. PMID: 36179667.
Torres HA, Angelidakis G, Jiang Y, Economides M, Mustafayev K, Yibirin M, Orlowski R, Champlin R, Verstovsek S, Raad I. Serologic versus molecular testing for screening for hepatitis C virus infection in patients with hematologic malignancies. Medicine (Baltimore) 101(37):e30608, 2022. e-Pub 2022. PMID: 36123927.
Saini NY, Swoboda DM, Greenbaum U, Ma J, Patel RD, Devashish K, Das K, Tanner MR, Strati P, Nair R, Fayad L, Ahmed S, Lee HJ, Iyer SP, Steiner R, Jain N, Nastoupil L, Loghavi S, Tang G, Bassett RL, Jain P, Wang M, Westin JR, Green MR, Sallman DA, Padron E, Davila ML, Locke FL, Champlin RE, Garcia-Manero G, Shpall EJ, Kebriaei P, Flowers CR, Jain MD, Wang F, Futreal AP, Gillis N, Neelapu SS, Takahashi K. Clonal hematopoiesis is associated with increased risk of severe neurotoxicity in axicabtagene ciloleucel therapy of large B-cell lymphoma. Blood Cancer Discov 3(5):385-393, 2022. e-Pub 2022. PMID: 35533245.
Mehta RS, Saliba RM, Hayase E, Jenq RR, Abraham S, Rashid A, Rondon G, Al-Atrash G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Srour S, Champlin RE, Rezvani K, Shpall EJ, Alousi AM. Mycophenolate Mofetil: A Friend or a Foe with Post-Transplantation Cyclophosphamide and Tacrolimus Prophylaxis in HLA-Matched Donors?. Transplant Cell Ther 28(8):500.e1-500.e10, 2022. e-Pub 2022. PMID: 35662592.
Andersson BS, Thall PF, Ma J, Valdez BC, Bassett R, Chen J, Ahmed S, Alousi A, Bashir Q, Ciurea S, Gulbis A, Cool R, Kawedia J, Hosing C, Kebriaei P, Kornblau S, Myers A, Oran B, Rezvani K, Shah N, Shpall E, Parmar S, Popat UR, Nieto Y, Champlin RE. A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan?±?clofarabine in allogeneic stem cell transplantation. Bone Marrow Transplant 57(8):1295-1303, 2022. e-Pub 2022. PMID: 35610308.
Alatrash G, Saberian C, Bassett R, Thall PF, Ledesma C, Lu Y, Daher M, Valdez BC, Kawedia J, Popat U, Mehta R, Oran B, Nieto Y, Olson A, Anderlini P, Marin D, Hosing C, Alousi AM, Shpall EJ, Rondon G, Chen J, Qazilbash M, Champlin RE, Kebriaei P. Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study Outcomes. Transplant Cell Ther 28(8):501.e1-501.e7, 2022. e-Pub 2022. PMID: 35618218.
Gaballa MR, Ma J, Rauf M, Bassett R, Pasvolsky O, Tanner MR, Bashir Q, Srour SA, Saini N, Ramdial J, Nieto Y, Murphy R, Rezvani K, Tang G, Lin P, Lee HC, Patel KK, Ullah MR, Kaufman GP, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Shpall EJ, Champlin RE, Orlowski RZ, Qazilbash MH. KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma. Bone Marrow Transplant 57(7):1142-1149, 2022. e-Pub 2022. PMID: 35523847.
Mehta RS, Saliba RM, Ghanem S, Alousi AM, Rondon G, Anderlini P, Al-Atrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Saini N, Srour SA, Champlin RE, Rezvani K, Shpall EJ. Haploidentical versus Matched Unrelated versus Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplant Cell Ther 28(7):395.e1-395.e11, 2022. e-Pub 2022. PMID: 35513252.
Kawedia JD, Ramchandran S, Liu X, Gulbis AM, Titus M, Bashir Q, Qazilbash MH, Champlin RE, Ciurea SO. Stability of Captisol-enabled versus propylene glycol-based melphalan at room temperature and after refrigeration. Am J Health Syst Pharm 79(12):1011-1018, 2022. e-Pub 2022. PMID: 35176751.
Li A, Martens KL, Nguyen D, Basom R, Rondon G, Jin S, Young E, Amos CI, Lee SJ, Davis C, Garcia DA, Champlin R, Shpall E, Kebriaei P, Rojas Hernandez C. External validation of the HIGH-2-LOW model: A predictive score for venous thromboembolism after allogeneic transplant. Am J Hematol 97(6):740-748, 2022. e-Pub 2022. PMID: 35266218.
Afrough A, Pasvolsky O, Ma J, Srour S, Bashir Q, Saini N, Hosing C, Popat UR, Kebriaei P, Delgado R, Ullah MR, Murphy R, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation. Transplant Cell Ther 28(6):307.e1-307.e8, 2022. e-Pub 2022. PMID: 35331973.
Akin S, Hosing C, Khouri I, Ahmed S, Alousi A, Fowler N, Joseph J, Truxillo J, Ramdial JL, Maadani F, Rondon G, Daher M, Im JS, Steiner R, Westin J, Iyer SP, Dabaja B, Anderlini P, Popat UR, Qazilbash MH, Flowers CR, Shpall E, Champlin RE, Nieto Y, Srour SA. Autologous Stem Cell Transplantation for Large B-cell Lymphoma with Secondary Central Nervous System Involvement. Blood Adv 6(7):2267-2274, 2022. e-Pub 2022. PMID: 35008100.
Zou J, Kongtim P, Oran B, Kosmoliaptsis V, Carmazzi Y, Ma J, Li L, Rondon G, Srour S, Copley HC, Partlow D, Ciurea SO, Greenbaum U, Ma Q, Shpall EJ, Champlin RE, Cao K. Refined HLA-DPB1 mismatch with molecular algorithms predicts outcomes in hematopoietic stem cell transplantation. Haematologica 107(4):844-856, 2022. e-Pub 2022. PMID: 34435482.
Nieto Y, Gruschkus S, Valdez BC, Jones RB, Anderlini P, Hosing C, Popat U, Qazilbash M, Kebriaei P, Alousi A, Saini N, Srour S, Rezvani K, Ramdial J, Barnett M, Gulbis A, Shigle TL, Ahmed S, Iyer S, Lee H, Nair R, Parmar S, Steiner R, Dabaja B, Pinnix C, Gunther J, Cuglievan B, Mahadeo K, Khazal S, Chuang H, Champlin R, Shpall EJ, Andersson BS. Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis. Haematologica 107(4):899-908, 2022. e-Pub 2022. PMID: 33951890.
Mukherjee A, Milton DR, Jabbour EJ, Gulbis AM, Kadia T, Jain N, Ledesma C, Burger J, Ferrajoli A, Wierda W, Medeiros LJ, Kantarjian H, Champlin R, Khouri IF. Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors. Leuk Lymphoma 63(4):1-9, 2022. e-Pub 2022. PMID: 35225133.
Gaballa MR, Banerjee P, Milton DR, Jiang X, Ganesh C, Khazal S, Nandivada V, Islam S, Kaplan M, Daher M, Basar R, Alousi A, Mehta R, Alatrash G, Khouri I, Oran B, Marin D, Popat U, Olson A, Tewari P, Jain N, Jabbour E, Ravandi F, Kantarjian H, Chen K, Champlin R, Shpall E, Rezvani K, Kebriaei P. Blinatumomab Maintenance After Allogeneic Hematopoietic Cell Transplantation for B-lineage Acute Lymphoblastic Leukemia. Blood 139(12):1908-1919, 2022. e-Pub 2022. PMID: 34914826.
Qazilbash MH, Saini NY, Cha SC, Wang Z, Stadtmauer EA, Baladandayuthapani V, Lin H, Tross B, Honhar M, Rao SS, Kim K, Popescu M, Szymura S, Zhang T, Anderson A, Bashir Q, Shpall EJ, Orlowski RZ, Levine BL, Kerr N, Garfall A, Cohen A, Vogl DT, Dengel K, June CH, Champlin R, Kwak LW. A Randomized Phase II Trial of Idiotype Vaccination and Adoptive Autologous T-Cell Transfer in Multiple Myeloma patients. Blood 139(9):1289-1301, 2022. e-Pub 2022. PMID: 34521108.
Gaballa MR, Ma J, Tanner MR, Al-Juhaishi T, Bashir Q, Srour SA, Saini NY, Ramdial JL, Nieto Y, Murphy R, Rezvani K, Tang G, Lee HC, Patel KK, Kaufman GP, Manasanch EE, Ullah MR, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. Leuk Lymphoma 63(3):1-12, 2022. e-Pub 2022. PMID: 34686083.
Ombres R, des Bordes JKA, Popat UR, Yennu S, Champlin RE, Mohile SG, Kebriaei P, Holmes HM. Serial frailty assessments following allogeneic stem cell transplant in older adults: A pilot study. J Geriatr Oncol 13(2):194-199, 2022. e-Pub 2022. PMID: 34493481.
Zhang X, Zhang R, Ren C, Xu Y, Wu S, Meng C, Pataer A, Song X, Zhang J, Yao Y, He H, Chen H, Ma W, Wang J, Meric-Bernstam F, Champlin RE, Heymach JV, Rooney CM, Swisher SG, Vaporciyan AA, Roth JA, You MJ, Wang M, Fang B. Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo. Blood Adv 6(3):891-901, 2022. e-Pub 2022. PMID: 34861697.
Sheshadri A, Makhnoon S, Alousi AM, Bashoura L, Andrade R, Miller CJ, Stolar KR, Arain MH, Noor L, Balagani A, Jain A, Blanco D, Ortiz A, Taylor MS, Stenzler A, Mehta R, Popat UR, Hosing C, Ost DE, Champlin RE, Dickey BF, Peterson SK. Home-Based Spirometry Telemonitoring After Allogeneic Hematopoietic Cell Transplantation: Mixed Methods Evaluation of Acceptability and Usability. JMIR Form Res 6(2):e29393, 2022. e-Pub 2022. PMID: 35129455.
Short NJ, Venugopal S, Qiao W, Kadia TM, Ravandi F, Macaron W, Dinardo CD, Daver N, Konopleva M, Borthakur G, Shpall EJ, Popat U, Champlin RE, Mehta R, Al-Atrash G, Oran B, Jabbour E, Garcia-Manero G, Issa GC, Montalban-Bravo G, Yilmaz M, Maiti A, Kantarjian H. Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. J Hematol Oncol 15(1):12, 2022. e-Pub 2022. PMID: 35093134.
Bashir Q, Milton DR, Popat UR, Kebriaei P, Hosing C, Khouri IF, Rezvani K, Nieto Y, Oran B, Srour SA, Saini NY, Olson AL, Ahmed S, Al-Atrash G, Rondon G, Konopleva MY, Champlin RE, Shpall EJ, Qazilbash MH, Pemmaraju N. Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Bone Marrow Transplant 57(1):51-56, 2022. e-Pub 2021. PMID: 34629467.
Oran B, Champlin RE, Wang F, Tanaka T, Saliba RM, Al-Atrash G, Garcia-Manero G, Kantarjian H, Cao K, Shpall EJ, Alousi AM, Mehta RS, Popat U, Futreal A, Takahashi K. Correction to: Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia 36(1):298, 2022. e-Pub 2021. PMID: 34876697.
Ciurea SO, Kongtim P, Soebbing D, Trikha P, Behbehani G, Rondon G, Olson A, Bashir Q, Gulbis AM, Indreshpal K, Rezvani K, Shpall EJ, Bassett R, Cao K, Martin AS, Devine S, Horowitz M, Pasquini M, Lee DA, Champlin RE. Decrease post-transplant relapse using donor-derived expanded NK-cells. Leukemia 36(1):155-164, 2022. e-Pub 2021. PMID: 34312462.
Oran B, Champlin RE, Wang F, Tanaka T, Saliba RM, Al-Atrash G, Garcia-Manero G, Kantarjian H, Cao K, Shpall EJ, Alousi AM, Mehta RS, Popat U, Futreal A, Takahashi K. Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia 36(1):257-262, 2022. e-Pub 2021. PMID: 34135465.
Singh H, Srour SA, Milton DR, McCarty J, Dai C, Gaballa MR, Ammari M, Olivares S, Huls H, De Groot E, Marin D, Petropoulos D, Olson AL, Anderlini P, Im JS, Khouri I, Hosing CM, Rezvani K, Champlin RE, Shpall EJ, Cooper LJN, Kebriaei P. Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies. Front Immunol 13:1032397, 2022. e-Pub 2022. PMID: 36439104.
Zou J, Kongtim P, Srour SA, Greenbaum U, Schetelig J, Heidenreich F, Baldauf H, Moore B, Saengboon S, Carmazzi Y, Rondon G, Ma Q, Rezvani K, Shpall EJ, Champlin RE, Ciurea SO, Cao K. Donor selection for KIR alloreactivity is associated with superior survival in haploidentical transplant with PTCy. Front Immunol 13:1033871, 2022. e-Pub 2022. PMID: 36311784.
Saliba RM, Srour SA, Greenbaum U, Ma Q, Carmazzi Y, Moller M, Wood J, Ciurea SO, Kongtim P, Rondon G, Li D, Saengboon S, Alousi AM, Rezvani K, Shpall EJ, Cao K, Champlin RE, Zou J. SIRPα Mismatch Is Associated With Relapse Protection and Chronic Graft-Versus-Host Disease After Related Hematopoietic Stem Cell Transplantation for Lymphoid Malignancies. Front Immunol 13:904718, 2022. e-Pub 2022. PMID: 35874659.
Yeh J, Whited L, Saliba RM, Rondon G, Banchs J, Shpall E, Champlin R, Popat U. Cardiac Toxicity after Matched Allogeneic Hematopoietic Cell Transplantation in the Post-Transplant Cyclophosphamide Era. Blood Adv 5(24):5599-5607, 2021. e-Pub 2021. PMID: 34592759.
Srour SA, Milton DR, Bashir Q, Nieto Y, Saini N, Daher M, Ramdial J, Im J, Hosing C, Delgado R, Manasanch E, Lee HC, Thomas S, Kaufman G, Patel K, Popat U, Weber D, Orlowski R, Shpall E, Champlin RE, Qazilbash MH. Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma. Haematologica 106(12):3211-3214, 2021. e-Pub 2021. PMID: 34407606.
Patel R, Ma J, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Daher M, Mehta R, Srour S, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Shpall ES, Champlin RE, Saini N, Qazilbash MH. Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity-score matched analysis. Am J Hematol 96(12):E455-E457, 2021. e-Pub 2021. PMID: 34559916.
Szewczyk NA, Ngo-Huang A, Soones TN, Adekoya LM, Fontillas RC, Ferguson JK, Gale-Capps HE, Kurse BC, Lindsay RJ, Ombres R, Rivera ZR, Gulbis AM, Neumann JL, Braveman BH, Marin D, Shigle TL, Whited L, Wallis WD, Sullivan H, Cao L, Champlin RE, Shpall E, Popat UR. Feasibility and Implementation of a Multimodal Supportive Care Program to Improve Outcomes in Older Patients Undergoing Allogeneic Stem Cell Transplantation. Transplant Cell Ther 27(12):1008-1014, 2021. e-Pub 2021. PMID: 34537421.
Mehta RS, Saliba RM, Alsfeld LC, Jorgensen JL, Wang SA, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Rondon G, Saini N, Srour SA, Rezvani K, Shpall EJ, Champlin RE, Alousi AM. Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplant Cell Ther 27(12):1003.e1-1003.e13, 2021. e-Pub 2021. PMID: 34537419.
Tanaka T, Morita K, Loghavi S, Wang F, Furudate K, Sasaki Y, Little L, Gumbs C, Matthews J, Daver N, Pemmaraju N, DiNardo CD, Sasaki K, Yilmaz M, Kadia TM, Ravandi F, Konopleva MY, Kantarjian HM, Champlin RE, Al-Atrash G, Garcia-Manero G, Wang SA, Futreal PA, Takahashi K. Clonal Dynamics and clinical implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML). Blood 138(18):1733-1739, 2021. e-Pub 2021. PMID: 34115096.
Khouri IF, Milton DR, Gulbis AM, Jabbour EJ, Nastoupil L, Ledesma C, Anderlini P, Bashir Q, Daher M, Im JS, Iyer SP, Marin D, Mehta RS, Olson AL, Popat UR, Qazilbash M, Saini N, Samaniego F, Rondon G, Medeiros LJ, Champlin RE. Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant. Clin Cancer Res 27(21):5847-5856, 2021. e-Pub 2021. PMID: 34380640.
Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Qazilbash MH, Ramdial J, Saini N, Srour SA, Rezvani K, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. Transplant Cell Ther 27(11):913.e1-913.e12, 2021. e-Pub 2021. PMID: 34329753.
Hare J, DeLeon PG, Pool K, Reioux D, Fontenot M, Champlin RE, Eaton EN, Marin D, Rezvani K, Shpall EJ, Wilson JM, Hosing C. Optimal umbilical cord blood collection, processing and cryopreservation methods for sustained public cord blood banking. Cytotherapy 23(11):1029-1035, 2021. e-Pub 2021. PMID: 34247985.
Ciurea SO, Al Malki MM, Kongtim P, Zou J, Aung FM, Rondon G, Chen J, Taniguchi M, Otoukesh S, Nademanee A, Forman SJ, Champlin R, Gendzekhadze K, Cao K. Treatment of allosensitized patients receiving allogeneic transplantation. Blood Adv 5(20):4031-4043, 2021. e-Pub 2021. PMID: 34474478.
Sassine J, Khawaja F, Shigle TL, Handy V, Foolad F, Aitken SL, Jiang Y, Champlin R, Shpall E, Rezvani K, Ariza-Heredia EJ, Chemaly RF. Refractory and Resistant Cytomegalovirus after Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era. Clin Infect Dis 73(8):1346-1354, 2021. e-Pub 2021. PMID: 33830182.
Saber W, Steinert P, Zhang MJ, Chen M, Pope A, Keating A, Wingard JR, Ballen K, Stiff P, Perales MA, Forman S, Champlin R, Langston A, Rudebeck M, Horowitz M. A Prospective Cohort Study Comparing Long-Term Outcomes with and without Palifermin in Patients Receiving Hematopoietic Cell Transplantation for Hematologic Malignancies. Transplant Cell Ther 27(10):837.e1-837.e10, 2021. e-Pub 2021. PMID: 34224914.
Sasaki K, Kantarjian HM, Morita K, Short NJ, Konopleva M, Jain N, Ravandi F, Garcia-Manero G, Wang S, Khoury JD, Jorgensen JL, Champlin RE, Khouri IF, Kebriaei P, Schroeder HM, Khouri M, Garris R, Takahashi K, O'Brien SM, Jabbour EJ. Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer 127(18):3381-3389, 2021. e-Pub 2021. PMID: 34138471.
Saliba RM, Greenbaum U, Ma Q, Srour SA, Carmazzi Y, Li L, Oran B, Moller M, Wood J, Ciurea SO, Kongtim P, Rondon G, Partlow D, Li D, Rezvani K, Shpall EJ, Cao K, Champlin RE, Zou J. Mismatch in SIRPα, a regulatory protein in innate immunity, is associated with chronic GVHD in hematopoietic stem cell transplantation. Blood Adv 5(17):3407-3417, 2021. e-Pub 2021. PMID: 34495313.
S Mehta R, Torres Cabala CA, DiNardo CD, Daver N, Dabaja B, Rezvani K, Champlin RE, Shpall E, Duvic M. Post-transplantation donor-derived Sezary syndrome in a patient with A91V PRF1 variant hemophagocytic lymphohistiocytosis. Am J Hematol 96(9):E350-E353, 2021. e-Pub 2021. PMID: 34096089.
Olson A, Lin R, Marin D, Rafei H, Bdaiwi MH, Thall PF, Basar R, Abudayyeh A, Banerjee P, Aung FM, Kaur I, Abueg G, Rao S, Chemaly R, Mulanovich V, Al-Atrash G, Alousi AM, Andersson BS, Anderlini P, Bashir Q, Castro KM, Daher M, Galvan IM, Hosing C, Im JS, Jones RB, Kebriaei P, Khouri I, Mehta R, Molldrem J, Nieto Y, Oran B, Popat U, Qazilbash M, Rondon G, Saini N, Spencer B, Srour S, Washington D, Barnett M, Champlin RE, Shpall EJ, Rezvani K. Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol 39(24):2710-2719, 2021. e-Pub 2021. PMID: 33929874.
Sasaki K, Kantarjian HM, Short NJ, Samra B, Khoury JD, Kanagal Shamanna R, Konopleva M, Jain N, DiNardo CD, Khouri R, Garcia-Manero G, Kadia TM, Wierda WG, Khouri IF, Kebriaei P, Mehta RS, Champlin RE, Garris R, Cheung CM, Daver N, Thompson PA, Yilmaz M, Ravandi F, Jabbour E. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer 127(15):2648-2656, 2021. e-Pub 2021. PMID: 33793964.
Yalniz FF, Saliba RM, Greenbaum U, Ramdial J, Popat U, Oran B, Alousi A, Olson A, Alatrash G, Marin D, Rezvani K, Hosing C, Im J, Mehta R, Qazilbash M, Joseph JJ, Rondon G, Kanagal-Shamanna R, Shpall E, Champlin R, Kebriaei P. Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myeloid Leukemia. Transplant Cell Ther 27(8):689-695, 2021. e-Pub 2021. PMID: 34023569.
Kharfan-Dabaja MA, Kumar A, Ayala E, Aljurf M, Nishihori T, Marsh R, Burroughs LM, Majhail N, Al-Homsi AS, Al-Kadhimi ZS, Bar M, Bertaina A, Boelens JJ, Champlin R, Chaudhury S, DeFilipp Z, Dholaria B, El-Jawahri A, Fanning S, Fraint E, Gergis U, Giralt S, Hamilton BK, Hashmi SK, Horn B, Inamoto Y, Jacobsohn DA, Jain T, Johnston L, Kanate AS, Kansagra A, Kassim A, Kean LS, Kitko CL, Knight-Perry J, Kurtzberg J, Liu H, MacMillan ML, Mahmoudjafari Z, Mielcarek M, Mohty M, Nagler A, Nemecek E, Olson TS, Oran B, Perales MA, Prockop SE, Pulsipher MA, Pusic I, Riches ML, Rodriguez C, Romee R, Rondon G, Saad A, Shah N, Shaw PJ, Shenoy S, Sierra J, Talano J, Verneris MR, Veys P, Wagner JE, Savani BN, Hamadani M, Carpenter PA. Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther 27(8):642-649, 2021. e-Pub 2021. PMID: 34304802.
Ramdial JL, Mehta RS, Saliba RM, Alousi AM, Bashir Q, Hosing C, Kebriaei P, Olson AL, Oran B, Qazilbash MH, Srour SA, Andersson BS, Champlin RE, Popat U. Acute graft-versus-host disease is the foremost cause of late nonrelapse mortality. Bone Marrow Transplant 56(8):2005-2012, 2021. e-Pub 2021. PMID: 33846563.
Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, Hosing C, Srour SA, Westin J, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Flowers CR, Tummala S, Ramdial JL, Yalniz FF, Hawkins M, Rezvani K, Champlin RE, Shpall EJ, Neelapu SS, Kebriaei P, Ahmed S. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv 5(14):2799-2806, 2021. e-Pub 2021. PMID: 34264268.
Basar R, Uprety N, Ensley E, Daher M, Klein K, Martinez F, Aung F, Shanley M, Hu B, Gokdemir E, Nunez Cortes AK, Mendt M, Reyes Silva F, Acharya S, Laskowski T, Muniz-Feliciano L, Banerjee PP, Li Y, Li S, Melo Garcia L, Lin P, Shaim H, Yates SG, Marin D, Kaur I, Rao S, Mak D, Lin A, Miao Q, Dou J, Chen K, Champlin RE, Shpall EJ, Rezvani K. Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapy. Cell Rep 36(3):109432, 2021. e-Pub 2021. PMID: 34270918.
Shaim H, Shanley M, Basar R, Daher M, Gumin J, Zamler DB, Uprety N, Wang F, Huang Y, Gabrusiewicz K, Miao Q, Dou J, Alsuliman A, Kerbauy LN, Acharya S, Mohanty V, Mendt M, Li S, Lu J, Wei J, Fowlkes NW, Gokdemir E, Ensley EL, Kaplan M, Kassab C, Li L, Ozcan G, Banerjee PP, Shen Y, Gilbert AL, Jones CM, Bdiwi M, Nunez-Cortes AK, Liu E, Yu J, Imahashi N, Muniz-Feliciano L, Li Y, Hu J, Draetta G, Marin D, Yu D, Mielke S, Eyrich M, Champlin RE, Chen K, Lang FF, Shpall EJ, Heimberger AB, Rezvani K. Targeting the αv integrin/TGF-β axis improves natural killer cell function against glioblastoma stem cells. J Clin Invest 131(14), 2021. e-Pub 2021. PMID: 34138753.
Srour SA, Olson A, Ciurea SO, Desai P, Bashir Q, Oran B, Bose P, Mehta R, Patel KP, Pemmaraju N, Daver N, Verstovsek S, Champlin RE, Popat UR. Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation. Haematologica 106(7):1988-1990, 2021. e-Pub 2021. PMID: 31296578.
Kerbauy LN, Marin ND, Kaplan M, Banerjee PP, Berrien-Elliott MM, Becker-Hapak M, Basar R, Foster M, Garcia Melo L, Neal CC, McClain E, Daher M, Nunez Cortes AK, Desai S, Inng Lim FW, Mendt MC, Schappe T, Li L, Shaim H, Shanley M, Ensley EL, Uprety N, Wong P, Liu E, Ang SO, Cai R, Nandivada V, Mohanty V, Miao Q, Shen Y, Baran N, Fowlkes NW, Chen K, Muniz-Feliciano L, Champlin RE, Nieto YL, Koch J, Treder M, Fischer W, Okamoto OK, Shpall EJ, Fehniger TA, Rezvani K. Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies. Clin Cancer Res 27(13):3744-3756, 2021. e-Pub 2021. PMID: 33986022.
Koller P, Saliba RM, Ledesma C, Rondon G, Popat U, Alousi A, Mehta R, Oran B, Olson A, Hosing C, Qazilbash M, Khouri I, Ciurea S, Shpall E, Jorgensen J, Wang S, Jain N, Jabbour E, Kantarjian H, Champlin R, Konopleva M, Kebriaei P. Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 56(7):1746-1749, 2021. e-Pub 2021. PMID: 33767403.
Shah MV, Saliba RM, Varma A, Ciurea SO, Oran B, Olson A, Bose P, Bashir Q, Masarova L, Alousi AM, Srour S, Mehta RS, Daver N, Pemmaraju N, Verstovsek S, Champlin RE, Popat UR. Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era. Br J Haematol 193(5):1004-1008, 2021. e-Pub 2021. PMID: 33821472.
Mehta RS, Bassett R, Rondon G, Overman BJ, Popat UR, Hosing CM, Rezvani K, Qazilbash MH, Anderlini P, Jones RB, Kebriaei P, Marin D, Khouri IF, Oran B, Ciurea SO, Kondo K, Couriel DR, Shpall EJ, Champlin RE, Alousi AM. Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD. Bone Marrow Transplant 56(6):1316-1324, 2021. e-Pub 2021. PMID: 33398094.
Oran B, Saliba RM, Mehta RS, Alousi AM, Marin D, Valdez BC, Chen J, Bashir Q, Ciurea SO, Olson AL, Hosing C, Kebriaei P, Rezvani K, Shpall EJ, Champlin RE, Andersson BS, Popat UR. Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer 127(10):1598-1605, 2021. e-Pub 2021. PMID: 33471943.
Ragoonanan D, Tambaro FP, Khazal SJ, Tewari P, Petropoulos D, Champlin R, Mahadeo KM. Cytokine release syndrome and complete remission of extra medullary acute lymphoblastic leukemia of the breast with CAR-T and radiation therapy. Pediatr Blood Cancer 68(5):e28839, 2021. e-Pub 2021. PMID: 33258192.
Ahmed S, Bashir Q, Bassett R, Poon MC, Valdez B, Konoplev S, Alousi AM, Andersson BS, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Kim S, Nieto Y, Olson A, Oran B, Parmar S, Qazilbash MH, Rezvani K, Shah N, Shpall EJ, Champlin R, Popat U. Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Transplant Cell Ther 27(5):430.e1-430.e7, 2021. e-Pub 2021. PMID: 33965187.
Joseph J, Ma J, Hennawy F, Abdulrazzaq MN, Saini N, Patel RD, Hosing CM, Alousi AM, Anderlini P, Popat UR, Qazilbash MH, Shpall EJ, Srour S, Kebriaei P, Bashir Q, Nastoupil LJ, Westin JR, Rondon G, Champlin RE, Andersson BS, Nieto Y, Muzzafar T, Ahmed S. Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Transplant Cell Ther 27(5):404.e1-404.e5, 2021. e-Pub 2021. PMID: 33965178.
Greenbaum U, Klein K, Martinez F, Song J, Thall PF, Ramdial JL, Knape C, Aung FM, Scroggins J, Knopfelmacher A, Mulanovich V, Borjan J, Adachi J, Muthu M, Leung C, Medina MC, Champlin R, Olson A, Alousi A, Rezvani K, Shpall EJ. High levels of common cold coronavirus antibodies in convalescent plasma are associated with improved survival in COVID-19 patients. medRxiv, 2021. e-Pub 2021. PMID: 33758890.
Sheshadri A, Saliba R, Patel B, Ahmed T, Bueno LC, Arain MH, Mehta RS, Popat UR, Hosing CM, Rondon G, Bashoura L, Dickey BF, Champlin RE, Alousi AM. Azithromycin may increase hematologic relapse rates in matched unrelated donor hematopoietic cell transplant recipients who receive anti-thymocyte globulin, but not in most other recipients. Bone Marrow Transplant 56(3):745-748, 2021. e-Pub 2021. PMID: 33009515.
Mehta RS, Saliba RM, Jan A, Shigle TL, Wang E, Nieto Y, Ciurea SO, Oran B, Im J, Olson A, Marin D, Qazilbash M, Khouri I, Rondon G, Anderlini P, Rezvani K, Popat U, Kebriaei P, Shpall E, Champlin R, Alousi A. Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease. Transplant Cell Ther 27(3):272.e1-272.e5, 2021. e-Pub 2021. PMID: 33781539.
Srour SA, Saliba RM, Bashir Q, Popat UR, Ahmed S, Mehta RS, Delgado R, Rondon G, Parmar S, Kebriaei P, Hosing C, Manasanch EE, Lee HC, Patel KK, Orlowski RZ, Shpall E, Champlin RE, Qazilbash MH, Nieto Y. Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Transplant Cell Ther 27(3):243.e1-243.e6, 2021. e-Pub 2021. PMID: 33781521.
Daher M, Basar R, Gokdemir E, Baran N, Uprety N, Nunez Cortes AK, Mendt M, Kerbauy LN, Banerjee PP, Shanley M, Imahashi N, Li L, FLWI L, Fathi M, Rezvan A, Mohanty V, Shen Y, Shaim H, Lu J, Ozcan G, Ensley E, Kaplan M, Nandivada V, Bdiwi M, Acharya S, Xi Y, Wan X, Mak D, Liu E, Jiang XR, Ang S, Muniz-Feliciano L, Li Y, Wang J, Kordasti S, Petrov N, Varadarajan N, Marin D, Brunetti L, Skinner RJ, Lyu S, Silva L, Turk R, Schubert MS, Rettig GR, McNeill MS, Kurgan G, Behlke MA, Li H, Fowlkes NW, Chen K, Konopleva M, Champlin RE, Shpall EJ, Rezvani K. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood 137(5):624-636, 2021. e-Pub 2021. PMID: 32902645.
Saberian C, Abdel-Wahab N, Abudayyeh A, Rafei H, Joseph J, Rondon G, Whited L, Gruschkus S, Fa'ak F, Daher M, Knape C, Safa H, Shoukier M, Suarez-Almazor ME, Marcotulli M, Ludford K, Gulbis AM, Konopleva M, Ohanian M, Ravandi F, Garcia-Manero G, Oran B, Popat UR, Mehta R, Alousi AM, Daver N, Champlin R, Diab A, Al-Atrash G. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation. J Immunother Cancer 9(2), 2021. e-Pub 2021. PMID: 33637601.
Saliba RM, Veltri L, Rondon G, Chen J, Al-Atrash G, Alousi A, Martinez C, Augustine L, Hosing CM, Oran B, Rezvani K, Shpall EJ, Kebriaei P, Khouri IF, Popat U, Champlin RE, Ciurea SO. Impact of graft composition on outcomes of haploidentical bone marrow stem cell transplantation. Haematologica 106(1):269-274, 2021. e-Pub 2021. PMID: 32107328.
Ciurea SO, Kongtim P, Srour S, Saini N, Im J, Ramdial J, Khouri I, Anderlini P, Popat U, Hosing C, Champlin RE, Lee HJ, Fayad LE, Hagemeister FB, Bica AM, Lipan L, Craciun O, Jercan CG, Tanase A, Colita A. Can we cure refractory Hodgkin's lymphoma with transplantation?. Bone Marrow Transplant 56(1):278-281, 2021. e-Pub 2021. PMID: 32636464.
Greenbaum U, Klein K, Martinez F, Song J, Thall PF, Ramdial JL, Knape C, Aung FM, Scroggins J, Knopfelmacher A, Mulanovich V, Borjan J, Adachi J, Muthu M, Leung C, Medina MC, Champlin R, Olson A, Alousi A, Rezvani K, Shpall EJ. High Levels of Common Cold Coronavirus Antibodies in Convalescent Plasma Are Associated With Improved Survival in COVID-19 Patients. Front Immunol 12:675679, 2021. e-Pub 2021. PMID: 33995420.
Liu E, Ang SOT, Kerbauy L, Basar R, Kaur I, Kaplan M, Li L, Tong Y, Daher M, Ensley EL, Uprety N, Nunez Cortes AK, Yang RZ, Li Y, Shaim H, Reyes Silva F, Lin P, Mohanty V, Acharya S, Shanley M, Muniz-Feliciano L, Banerjee PP, Chen K, Champlin RE, Shpall EJ, Rezvani K. GMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored Cord Blood CAR-NK Cells. Front Immunol 12:626098, 2021. e-Pub 2021. PMID: 33717142.
Mendt M, Daher M, Basar R, Shanley M, Kumar B, Wei Inng FL, Acharya S, Shaim H, Fowlkes N, Tran JP, Gokdemir E, Uprety N, Nunez-Cortes AK, Ensley E, Mai T, Kerbauy LN, Melo-Garcia L, Lin P, Shen Y, Mohanty V, Lu J, Li S, Nandivada V, Wang J, Banerjee P, Reyes-Silva F, Liu E, Ang S, Gilbert A, Li Y, Wan X, Gu J, Zhao M, Baran N, Muniz-Feliciano L, Wilson J, Kaur I, Gagea M, Konopleva M, Marin D, Tang G, Chen K, Champlin R, Rezvani K, Shpall EJ. Metabolic Reprogramming of GMP Grade Cord Tissue Derived Mesenchymal Stem Cells Enhances Their Suppressive Potential in GVHD. Front Immunol 12:631353, 2021. e-Pub 2021. PMID: 34017325.
Olson AL, Saliba RM, Oran B, Chen J, Alousi A, Ahmed S, Bashir Q, Ciurea SO, Hosing C, Seon Im J, Kebriaei P, Khouri IF, Mehta R, Nieto Y, Parmar S, Rezvani K, Shah N, Shpall E, Srour SA, Qazilbash M, Andersson BS, Champlin R, Popat UR. Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta Haematol 144(1):1-8, 2021. e-Pub 2021. PMID: 32604096.
Puerta-Alcalde P, Champlin RE, Kontoyiannis DP. How I perform hematopoietic stem cell transplantation on patients with a history of invasive fungal disease. Blood 136(24):2741-2753, 2020. e-Pub 2020. PMID: 33301030.
Hu B, Lin X, Lee HC, Huang X, Tidwell RSS, Ahn KW, Hu ZH, Jabbour E, Verstovsek S, Ravandi F, Garcia-Manero G, Kharfan-Dabaja MA, Hossain NM, Marks DI, Kamble RT, Inamoto Y, Kindwall-Keller T, Saad A, Litzow MR, Savani BN, Hale GA, Bacher U, Gerds AT, Liesveld JL, Ustun C, Olsson RF, Daly A, Grunwald MR, Solh M, DeFilipp Z, Aljurf M, Wirk B, Akpek G, Nishihori T, Cerny J, Seo S, Hsu JW, Champlin R, de Lima M, Alyea E, Popat U, Sobecks R, Scott BL, Kantarjian H, Cortes J, Saber W. Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. Leuk Lymphoma 61(12):1-10, 2020. e-Pub 2020. PMID: 32662346.
Major CK, Kantarjian H, Sasaki K, Borthakur G, Kadia T, Pemmaraju N, DiNardo C, Short NJ, Daver N, Jabbour E, Champlin R, Garcia-Manero G, Konopleva M, Andreeff M, Kornblau S, Wierda W, Pierce S, Ravandi F, Cortes J. Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. Leuk Lymphoma 61(13):1-8, 2020. e-Pub 2020. PMID: 32755333.
Oran B, de Lima M, Garcia-Manero G, Thall PF, Lin R, Popat U, Alousi AM, Hosing C, Giralt S, Rondon G, Woodworth G, Champlin RE. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Adv 4(21):5580-5588, 2020. e-Pub 2020. PMID: 33170934.
Abaza Y, Kantarjian H, Alwash Y, Borthakur G, Champlin R, Kadia T, Garcia-Manero G, Daver N, Ravandi F, Verstovsek S, Burger J, Estrov Z, Ohanian M, Lim M, Pemmaraju N, Jabbour E, Cortes J. Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. Am J Hematol 95(11):1288-1295, 2020. e-Pub 2020. PMID: 32681739.
Saini N, Bashir Q, Milton DR, Tang G, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Mehta R, Srour S, Khouri IF, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. Blood Adv 4(19):4834-4837, 2020. e-Pub 2020. PMID: 33027527.
Saini N, Marin D, Ledesma C, Delgado R, Rondon G, Popat UR, Bashir Q, Hosing CM, Nieto Y, Alousi AM, Qazilbash MH, Ciurea S, Shpall E, Khouri I, Kantarjian H, Jabbour E, Ravandi F, Champlin RE, Kebriaei P. Impact of TKI maintenance post-allogeneic transplant in Philadelphia positive acute lymphoblastic leukemia. Blood 136(15):1786-1789, 2020. e-Pub 2020. PMID: 32492706.
Abudayyeh A, Lin H, Abdelrahim M, Rondon G, Andersson BS, Martinez CS, Page VD, Tarrand JJ, Kontoyiannis DP, Marin D, Oran B, Olson A, Jones R, Popat U, Champlin RE, Chemaly RF, Shpall EJ, Rezvani K. Development and validation of a risk assessment tool for BKPyV Replication in allogeneic stem cell transplant recipients. Transpl Infect Dis 22(5):e13395, 2020. e-Pub 2020. PMID: 32602954.
Sheshadri A, Alousi A, Bashoura L, Stolar K, Baghaie S, Arain MH, Noor L, Balagani A, Jain A, Blanco D, Ortiz A, Peterson SK, Langhals R, Taylor M, Stenzler A, Mehta RS, Popat UR, Hosing C, Rondon G, Shen F, Li L, Cheng GS, Ost DE, Champlin RE, Dickey BF. Feasibility and Reliability of Home-based Spirometry Telemonitoring in Allogeneic Hematopoietic Cell Transplant Recipients. Ann Am Thorac Soc 17(10):1329-1333, 2020. e-Pub 2020. PMID: 32614241.
Basar R, Uprety N, Ensley E, Daher M, Klein K, Martinez F, Aung F, Shanley M, Hu B, Gokdemir E, Mendt M, Silva FR, Acharya S, Laskowski T, Muniz-Feliciano L, Banerjee P, Li Y, Li S, Garcia LM, Lin P, Shaim H, Yates SG, Marin D, Kaur I, Rao S, Mak D, Lin A, Miao Q, Dou J, Chen K, Champlin R, Shpall EJ, Rezvani K. Generation of glucocorticoid resistant SARS-CoV-2 T-cells for adoptive cell therapy. bioRxiv, 2020. e-Pub 2020. PMID: 32995792.
Puerta-Alcalde P, Champlin R, Kontoyiannis DP. How I transplant a patient with a history of invasive fungal disease. Blood. e-Pub 2020. PMID: 32845974.
Zou J, Ciurea SO, Kongtim P, Yi M, Carmazzi Y, Rondon G, Srour S, Partlow D, Champlin RE, Cao K. Molecular disparity in human leukocyte antigens is associated with outcomes in haploidentical stem cell transplantation. Blood Adv 4(15):3474-3485, 2020. e-Pub 2020. PMID: 32726398.
Popat U, Mehta RS, Bassett R, Kongtim P, Chen J, Alousi AM, Anderlini P, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Lindsay R, Nieto Y, Olson A, Oran B, Qazilbash MH, Rondon G, Shpall EJ, Verstovsek S, Andersson BS, Champlin RE. Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial. Biol Blood Marrow Transplant 26(8):1439-1445, 2020. e-Pub 2020. PMID: 32438043.
Basar R, Daher M, Uprety N, Gokdemir E, Alsuliman A, Ensley E, Ozcan G, Mendt M, Hernandez Sanabria M, Kerbauy LN, Nunez Cortes AK, Li L, Banerjee PP, Muniz-Feliciano L, Acharya S, Fowlkes NW, Lu J, Li S, Mielke S, Kaplan M, Nandivada V, Bdaiwi M, Kontoyiannis AD, Li Y, Liu E, Ang S, Marin D, Brunetti L, Gundry MC, Turk R, Schubert MS, Rettig GR, McNeill MS, Kurgan G, Behlke MA, Champlin R, Shpall EJ, Rezvani K. Large-scale GMP-compliant CRISPR-Cas9-mediated deletion of the glucocorticoid receptor in multivirus-specific T cells. Blood Adv 4(14):3357-3367, 2020. e-Pub 2020. PMID: 32717029.
Srour SA, Kongtim P, Rondon G, Chen J, Petropoulos D, Ramdial J, Popat U, Kebriaei P, Qazilbash M, Shpall EJ, Champlin RE, Ciurea SO. Haploidentical transplants for patients with relapse after the first allograft. Am J Hematol. e-Pub 2020. PMID: 32619033.
Jabbour E, Richard-Carpentier G, Sasaki Y, Konopleva M, Patel K, Roberts K, Gu Z, Wang F, Huang X, Sasaki K, Short NJ, Jain N, Ravandi F, Daver NG, Kadia TM, Alvarado Y, DiNardo CD, Issa GC, Pemmaraju N, Garcia-Manero G, Verstovsek S, Wang S, Khoury JD, Jorgensen J, Champlin R, Khouri I, Kebriaei P, Schroeder H, Khouri M, Mullighan CG, Takahashi K, O'Brien SM, Kantarjian H. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol 7(7):e523-e533, 2020. e-Pub 2020. PMID: 32589978.
Kanate AS, Majhail NS, Savani BN, Bredeson C, Champlin RE, Crawford S, Giralt SA, LeMaistre CF, Marks DI, Omel JL, Orchard PJ, Palmer J, Saber W, Veys PA, Carpenter PA, Hamadani M. Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant 26(7):1247-1256, 2020. e-Pub 2020. PMID: 32165328.
Kongtim P, Bittencourt M, Srour SA, Ramdial J, Rondon G, Chen J, Khouri I, Betul O, Popat U, Olson A, Bashir Q, Shpall EJ, Kebriaei P, Champlin RE, Ciurea SO. Haploidentical transplants for patients with graft failure after the first allograft. Am J Hematol. e-Pub 2020. PMID: 32602112.
Ohanian M, Kantarjian HM, Shoukier M, Dellasala S, Musaelyan A, Nogueras Gonzalez GM, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Tamamyan G, Champlin R, Pierce S, Ferrajoli A, Kadia T, Cortes JE. The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia. Am J Hematol. e-Pub 2020. PMID: 32557828.
Cordas Dos Santos DM, Saliba RM, Patel R, Bashir Q, Saini N, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Popat U, Ahmed H, Lee HC, Manasanch EE, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 26(6):1077-1083, 2020. e-Pub 2020. PMID: 31786242.
Oran B, Garcia-Manero G, Saliba RM, Alfayez M, Al-Atrash G, Ciurea SO, Jabbour EJ, Mehta RS, Popat UR, Ravandi F, Alousi AM, Kadia TM, Konopleva M, DiNardo CD, Rezvani K, Shpall EJ, Sharma P, Kantarjian HM, Champlin RE, Daver N. Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. Cancer 126(10):2193-2205, 2020. e-Pub 2020. PMID: 32125707.
Ciurea SO, Kongtim P, Hasan O, Ramos Perez JM, Torres J, Rondon G, Champlin RE. Validation of a Hematopoietic Cell Transplant-Composite Risk (HCT-CR) Model for Post-Transplant Survival Prediction in Patients with Hematologic Malignancies. Clin Cancer Res 26(10):2404-2410, 2020. e-Pub 2020. PMID: 32019857.
Yalniz FF, Patel KP, Bashir Q, Marin D, Ahmed S, Alousi AM, Chen J, Ciurea SO, Rezvani K, Popat UR, Shpall EJ, Champlin RE, Oran B. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes. Cancer 126(10):2183-2192, 2020. e-Pub 2020. PMID: 32101640.
Al Malki MM, Yang D, Labopin M, Afanasyev B, Angelucci E, Bashey A, Socié G, Karduss-Urueta A, Helbig G, Bornhauser M, Niittyvuopio R, Ganser A, Ciceri F, Brecht A, Koc Y, Bejanyan N, Ferraro F, Kebriaei P, Mokhtari S, Ghobadi A, Nakamura R, Forman SJ, Champlin R, Mohty M, Ciurea SO, Nagler A. Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation. Blood Adv 4(9):2073-2083, 2020. e-Pub 2020. PMID: 32396617.
Varma A, Rondon G, Srour SA, Chen J, Ledesma C, Champlin RE, Ciurea SO, Saliba RM. Endothelial Activation and Stress Index (EASIX) at Admission Predicts Fluid Overload in Recipients of Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 26(5):1013-1020, 2020. e-Pub 2020. PMID: 32045652.
Varma A, Abraham SC, Mehta RS, Saini NY, Honhar M, Rashid M, Chen J, Srour SA, Bashir Q, Rondon G, Oran B, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Marin D, Khouri IF, Ciurea SO, Qazilbash MH, Rezvani K, Anderlini P, Andersson BS, Shpall EJ, Champlin RE, Popat UR. Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity. Blood Adv 4(7):1296-1306, 2020. e-Pub 2020. PMID: 32236526.
Atallah E, Logan B, Chen M, Cutler C, Deeg J, Jacoby M, Champlin R, Nishihori T, Confer D, Gajewski J, Farnia S, Greenberg P, Warlick E, Weisdorf D, Saber W, Horowitz MM, Rizzo JD. Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study. JAMA Oncol 6(4):486-493, 2020. e-Pub 2020. PMID: 31830234.
Varma A, Sui D, Milton DR, Tang G, Saini N, Hasan O, Mukherjee A, Joseph JJ, Bashir Q, Rondon G, Srour S, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Mehta R, Khouri IF, Ahmed H, Iyer S, Weber DM, Thomas SK, Manasanch E, Lee HC, Patel K, Ciurea SO, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. Biol Blood Marrow Transplant 26(4):665-671, 2020. e-Pub 2020. PMID: 31881283.
Jain P, Zhang S, Kanagal-Shamanna R, Ok CY, Nomie K, Gonzalez GN, Gonzalez-Pagan O, Hill HA, Lee HJ, Fayad L, Westin J, Nastoupil L, Hagemeister F, Chen W, Oriabure O, Badillo M, Jiang C, Yixin Y, Li S, Tang G, Yin CC, Patel KP, Medeiros LJ, Nair R, Ahmed S, Iyer SP, Thirumurthi S, Champlin R, Xu G, Tinsu P, Santos D, Wang R, Han G, Zhang J, Song X, Neelapu S, Romaguera J, Futreal A, Flowers C, Fowler N, Wang L, Wang ML. Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Adv 4(6):1038-1050, 2020. e-Pub 2020. PMID: 32191807.
Edwards BJ, Zhang X, Sun M, Song J, Khalil P, Karuturi MS, Pang L, Geng Y, Dinney CP, Valero V, Champlin RE, Tripathy D. Overall survival in older patients with cancer. BMJ Support Palliat Care 10(1):25-35, 2020. e-Pub 2020. PMID: 30244203.
Ciurea SO, Kongtim P, Varma A, Rondon G, Chen J, Srour S, Bashir Q, Alousi A, Mehta R, Oran B, Popat U, Hosing C, Olson A, Daver N, Konopleva M, Champlin RE. Is There an Optimal Conditioning for Older Patients with AML Receiving Allogeneic Hematopoietic Cell Transplantation?. Blood 135(6):449-452, 2020. e-Pub 2020. PMID: 31826244.
Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med 382(6):545-553, 2020. e-Pub 2020. PMID: 32023374.
Kongtim P, Hasan O, Perez JMR, Varma A, Wang SA, Patel KP, Chen J, Rondon G, Srour S, Bashir Q, Qazilbash M, Mehta R, Shpall EJ, Alousi A, Khouri I, Kebriaei P, Popat U, Champlin RR, Ciurea SO. Novel Disease Risk Model for Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 26(1):197-203, 2020. e-Pub 2020. PMID: 31518645.
El Haddad L, Ghantoji SS, Park AK, Batista MV, Schelfhout J, Hachem J, Lobo Y, Jiang Y, Rondon G, Champlin R, Chemaly RF. Clinical and economic burden of pre-emptive therapy of cytomegalovirus infection in hospitalized allogeneic hematopoietic cell transplant recipients. J Med Virol 92(1):86-95, 2020. e-Pub 2020. PMID: 31448830.
Champlin R. Is unrelated donor or haploidentical hematopoietic transplantation preferred for patients with acute myeloid leukemia in remission?. Haematologica 105(2):252-254, 2020. e-Pub 2020. PMID: 32005652.
Bannon SA, Routbort MJ, Montalban-Bravo G, Mehta RS, Jelloul FZ, Takahashi K, Daver N, Oran B, Pemmaraju N, Borthakur G, Naqvi K, Issa G, Sasaki K, Alvarado Y, Kadia TM, Konopleva M, Shamanna RK, Khoury JD, Ravandi F, Champlin R, Kantarjian HM, Bhalla K, Garcia-Manero G, Patel KP, DiNardo CD. Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. Front Oncol 10:582213, 2020. e-Pub 2020. PMID: 33585199.
Li L, Chen H, Marin D, Xi Y, Miao Q, Lv J, Banerjee PP, Shaim H, Daher M, Basar R, Imahashi N, Jimenez J, Hu B, Mehta RS, Kerbauy LN, Kaplan M, Mendt M, Ozcan G, Gokdemir E, Hernandez Sanabria M, Li Y, Chen K, Wang J, Muniz-Feliciano L, Zhao WL, Champlin RE, Shpall EJ, Rezvani K. A novel immature natural killer cell subpopulation predicts relapse after cord blood transplantation. Blood Adv 3(23):4117-4130, 2019. e-Pub 2019. PMID: 31821460.
Mehta RS, Bassett R, Olson A, Chen J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Molldrem JJ, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Srour SA, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long term results of a prospective phase II clinical trial. Haematologica 104(12):e555-e557, 2019. e-Pub 2019. PMID: 30948491.
Srour SA, Saliba RM, Bittencourt MCB, Perez JMR, Kongtim P, Alousi A, Al-Atrash G, Olson A, Betul O, Mehta R, Popat U, Hosing C, Bashir Q, Khouri I, Kebriaei P, Masarova L, Short N, Jabbour E, Daver N, Konopleva M, Ravandi F, Kantarjian H, Champlin RE, Ciurea SO. Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. Am J Hematol 94(12):1382-1387, 2019. e-Pub 2019. PMID: 31595538.
Saini N, Ma J, Milton DR, Patel R, Varma A, Bashir Q, Delgado R, Mukherjee A, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Tang G, Mehta R, Srour S, Khouri IF, Iyer S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of autologous transplantation in multiple myeloma patients with t(11;14): a propensity-score matched analysis. Clin Cancer Res 25(22):6781-6787, 2019. e-Pub 2019. PMID: 31481508.
Oran B, Champlin RE, Wang F, Jeyakumar N, Garcia-Manero G, Kantarjian HM, Saliba RM, Cao K, Shpall EJ, Alousi AM, Mehta RS, Popat U, Futreal A, Takahashi K. Donor Clonal Hematopoiesis Increases Risk of Acute Graft Versus Host Disease after Matched Related Transplantation in AML and MDS Patients. Blood 134(Supplement_1):47, 2019. e-Pub 2019. PMID: 31723997.
Ciurea SO, Varma A, Kongtim P, Srour S, Bashir Q, Alousi AM, Mehta RS, Oran B, Popat U, Hosing C, Rondon G, Chen J, Olson AL, Konopleva MY, Champlin RE. Optimal Conditioning for Older Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Propensity Score Analysis. Blood 134(Supplement_1):42, 2019. e-Pub 2019. PMID: 31724003.
Tanaka T, Morita K, Wang F, Little L, Gumbs C, Matthews J, DiNardo CD, Kadia TM, Ravandi F, Konopleva MY, Kantarjian HM, Champlin RE, Garcia-Manero G, Futreal PA, Takahashi K. Clonal Dynamics and Clinical Implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML). Blood 134(Supplement_1):17, 2019. e-Pub 2019. PMID: 31724013.
Solomon SR, St Martin A, Shah NN, Fatobene G, Al Malki MM, Ballen KK, Bashey A, Bejanyan N, Bolaños Meade J, Brunstein CG, DeFilipp Z, Champlin RE, Fuchs EJ, Hamadani M, Hematti P, Kanakry CG, McGuirk JP, McNiece IK, Ciurea SO, Pasquini MC, Rocha V, Romee R, Patel SS, Vasu S, Waller EK, Wingard JR, Zhang MJ, Eapen M. Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy. Blood Adv 3(19):2836-2844, 2019. e-Pub 2019. PMID: 31582392.
Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Mukherjee A, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemia. Ann Hematol 98(9):2233-2235, 2019. e-Pub 2019. PMID: 31243571.
Alatrash G, Kidwell KM, Thall PF, Di Stasi A, Chen J, Zope M, Crain AK, Champlin RE, Popat U, Shpall EJ, Jones RB, Andersson BS. Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS. Bone Marrow Transplant 54(8):1245-1253, 2019. e-Pub 2019. PMID: 30532055.
Bashir Q, Chamoun K, Milton DR, Khan M, Ahmed S, Mehta R, Popat UR, Kebriaei P, Nieto Y, Oran B, Ciurea SO, Hosing C, Khouri I, Patel K, Manasanch EE, Lee HC, Orlowski RZ, Champlin RE, Qazilbash MH. Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged =75 years. Leuk Lymphoma:1-8. e-Pub 2019. PMID: 31282244.
Saini NY, Saliba RM, Rondon G, Maadani F, Popat U, Hosing CM, Oran B, Bashir Q, Olson A, Nieto Y, Alousi A, Kebriaei P, Srour S, Mehta R, Anderlini P, Shpall EJ, Qazilbash MH, Khouri IF, Fayad L, Lee H, Fowler N, Parmar S, Westin J, Hagemeister F, Champlin RE, Ciurea SO. Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. Biol Blood Marrow Transplant 25(7):1340-1346, 2019. e-Pub 2019. PMID: 30763728.
Gowda L, Shah M, Badar I, Bashir Q, Shah N, Patel K, Kanagal-Shamanna R, Mehta R, Weber DM, Lee HC, Manasanch EE, Shah A, Thomas SK, Parmar S, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MH. Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs. Bone Marrow Transplant 54(7):1089-1093, 2019. e-Pub 2019. PMID: 30446740.
Chamoun K, Milton DR, Ledesma C, Young KH, Jabbour EJ, Alatrash G, Anderlini P, Bashir Q, Ciurea SO, Marin D, Molldrem JJ, Olson AL, Oran B, Popat UR, Rondon G, Champlin RE, Gulbis AM, Khouri IF. Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results. Biol Blood Marrow Transplant 25(7):1347-1354, 2019. e-Pub 2019. PMID: 30826465.
van Besien K, Artz A, Champlin RE, Guarneri D, Bishop MR, Chen J, Gergis U, Shore T, Liu H, Rondon G, Mayer SA, Srour SA, Stock W, Ciurea SO. Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. Blood Adv 3(12):1858-1867, 2019. e-Pub 2019. PMID: 31217161.
Kongtim P, Parmar S, Milton DR, Perez JMR, Rondon G, Chen J, Chilkulwar AR, Al-Atrash G, Alousi A, Andersson BS, Im JS, Hosing CM, Bashir Q, Khouri I, Kebriaei P, Oran B, Popat U, Champlin R, Ciurea SO. Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant 54(6):839-848, 2019. e-Pub 2019. PMID: 30258129.
Ciurea SO, Hansrivijit P, Ciurea AM, Hymes S, Chen J, Rondon G, Hosing C, Popat U, Champlin RE. Curative potential of hematopoietic stem cell transplantation for advanced psoriasis. Am J Hematol 94(6):E176-E180, 2019. e-Pub 2019. PMID: 30900768.
Zeng Z, Liu W, Benton CB, Konoplev S, Lu H, Wang RY, Chen J, Shpall E, Baggerly KA, Champlin R, Konopleva M. Proteomic Profiling of Signaling Networks Modulated by G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning in Acute Myeloid Leukemia Patients in Remission or with Active Disease prior to Allogeneic Stem Cell Transplantation. Acta Haematol:1-9. e-Pub 2019. PMID: 31112940.
Bashir Q, Thall PF, Milton DR, Fox PS, Kawedia JD, Kebriaei P, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing C, Popat UR, Oran B, Ciurea SO, Lin P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Williams LA, Champlin RE, Qazilbash MH. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematol 6(5):e266-e275, 2019. e-Pub 2019. PMID: 30910541.
Ghobadi A, Milton DR, Gowda L, Rondon G, Chemaly RF, Hamdi A, Alousi A, Afrough A, Oran B, Ciurea S, Kebriaei P, Popat UR, Qazilbash MH, Shpall EJ, Champlin RE, Bashir Q. HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant. Curr Res Transl Med 67(2):51-55, 2019. e-Pub 2019. PMID: 30683577.
Maymani H, Lin P, Saliba RM, Popat U, Bashir Q, Shah N, Patel K, Parmar S, Kebriaei P, Hosing C, Ciurea S, Andersson B, Shpall E, Champlin R, Srour SA, Qazilbash MH. Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. Biol Blood Marrow Transplant 25(5):1039-1044, 2019. e-Pub 2019. PMID: 30639822.
Sheshadri A, Chemaly RF, Alousi AM, Shah PK, Rondon G, Bashoura L, Kmeid J, Azzi J, Blanco DW, Kaous M, Dickey BF, Champlin RE, Shah DP. Pulmonary Impairment after Respiratory Viral Infections Is Associated with High Mortality in Allogeneic Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 25(4):800-809, 2019. e-Pub 2019. PMID: 30521974.
Shah MV, Saliba RM, Rondon G, Chen J, Soebbing D, Rus I, Alousi A, Oran B, Kebriaei P, Qazilbash M, Parmar S, Hosing C, Khouri IF, Popat UR, Champlin RE, Ciurea SO. Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation. Bone Marrow Transplant 54(4):601-606, 2019. e-Pub 2019. PMID: 30337700.
Veltri L, Rezvani K, Oran B, Mehta R, Rondon G, Kebriaei P, Popat U, Nieto Y, Hosing C, Qazilbash M, Khouri I, Shpall E, Champlin R, Marin D. Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia. Biol Blood Marrow Transplant 25(3):505-514, 2019. e-Pub 2019. PMID: 30308325.
Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome. Am J Hematol 94(3):E72-E74, 2019. e-Pub 2019. PMID: 30548467.
Zeng D, Desai A, Yan F, Gong T, Ye H, Ahmed M, Nomie K, Romaguera J, Champlin R, Li S, Wang M. Challenges and Opportunities for High-grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangement (Double-hit Lymphoma). Am J Clin Oncol 42(3):304-316, 2019. e-Pub 2019. PMID: 29419530.
Hu B, Thall P, Milton DR, Sasaki K, Bashir Q, Shah N, Patel K, Popat U, Hosing C, Nieto Y, Lin P, Delgado R, Jorgensen J, Manasanch E, Weber D, Thomas S, Orlowski RZ, Champlin R, Qazilbash MH. High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. Leuk Lymphoma 60(2):442-452, 2019. e-Pub 2019. PMID: 30032678.
Swaminathan M, Bannon SA, Routbort M, Naqvi K, Kadia TM, Takahashi K, Alvarado Y, Ravandi-Kashani F, Patel KP, Champlin R, Kantarjian H, Strong L, DiNardo CD. Hematologic malignancies and Li-Fraumeni syndrome. Cold Spring Harb Mol Case Stud 5(1), 2019. e-Pub 2019. PMID: 30709875.
Saini NY, Patel R, Varma A, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Melphalan-based autologous transplant in octogenarian multiple myeloma patients. Am J Hematol 94(1):E2-E5, 2019. e-Pub 2019. PMID: 30300461.
Shah MV, Patel KP, Luthra R, Kanagal-Shamanna R, Mehrotra M, Bachegowda LS, Champlin RE, Verstovsek S, Popat UR. Sensitive PCR-based monitoring and early detection of relapsed JAK2 V617F myelofibrosis following transplantation. Br J Haematol 183(5):831-835, 2018. e-Pub 2018. PMID: 29265180.
Afrough A, Saliba RM, Hamdi A, Honhar M, Varma A, Cornelison AM, Rondon G, Parmar S, Shah ND, Bashir Q, Hosing C, Popat U, Weber DM, Thomas S, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 24(11):2197-2203, 2018. e-Pub 2018. PMID: 30016656.
Valdez BC, Tang X, Li Y, Murray D, Liu Y, Popat U, Champlin RE, Andersson BS. Epigenetic modification enhances the cytotoxicity of busulfan and4-hydroperoxycyclophosphamide in AML cells. Exp Hematol 67:49-59.e1, 2018. e-Pub 2018. PMID: 30102945.
Jain P, Kanagal-Shamanna R, Zhang S, Ahmed M, Ghorab A, Zhang L, Ok CY, Li S, Hagemeister F, Zeng D, Gong T, Chen W, Badillo M, Nomie K, Fayad L, Medeiros LJ, Neelapu S, Fowler N, Romaguera J, Champlin R, Wang L, Wang ML. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol 183(4):578-587, 2018. e-Pub 2018. PMID: 30175400.
Popat UR, Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Jones R, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Parmar S, Rezvani K, Qazilbash MH, Shah N, Srour SA, Shpall EJ, Champlin RE, Andersson BS. Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. Lancet Haematol 5(11):e532-e542, 2018. e-Pub 2018. PMID: 30389035.
de Lima M, Oran B, Champlin RE, Papadopoulos EB, Giralt SA, Scott BL, William BM, Hetzer J, Laille E, Hubbell B, Skikne BS, Craddock C. CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes. Biol Blood Marrow Transplant 24(10):2017-2024, 2018. e-Pub 2018. PMID: 29933073.
Davies JK, Brennan LL, Wingard JR, Cogle CR, Kapoor N, Shah AJ, Dey BR, Spitzer TR, de Lima M, Cooper LJ, Thall PF, Champlin RE, Nadler LM, Guinan EC. Infusion of Alloanergized Donor Lymphocytes after CD34-selected Haploidentical Myeloablative Hematopoietic Stem Cell Transplantation. Clin Cancer Res 24(17):4098-4109, 2018. e-Pub 2018. PMID: 29769208.
Edwards BJ, Zhang X, Sun M, Holmes HM, Ketonen L, Guha N, Khalil P, Song J, Kesler S, Shah JB, Tripathy D, Valero V, Champlin RE. Neurocognitive deficits in older patients with cancer. J Geriatr Oncol 9(5):482-487, 2018. e-Pub 2018. PMID: 29530493.
Nieto Y, Thall PF, Ma J, Valdez BC, Ahmed S, Anderlini P, Popat U, Jones RB, Shpall EJ, Hosing C, Qazilbash M, Kebriaei P, Alousi A, Timmons M, Gulbis A, Myers A, Oki Y, Fanale M, Dabaja B, Pinnix C, Milgrom S, Champlin R, Andersson BS. Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. Biol Blood Marrow Transplant 24(8):1602-1609, 2018. e-Pub 2018. PMID: 29501779.
Malek E, Gupta V, Creger R, Caimi P, Vatsayan A, Covut F, Bashir Q, Champlin R, Delgado R, Rondon G, Cooper B, de Lima M, Lazarus HM, Qazilbash M. Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma. Leuk Lymphoma 59(8):1-8, 2018. e-Pub 2018. PMID: 29295650.
Shah MV, Jorgensen JL, Saliba RM, Wang SA, Alousi AM, Andersson BS, Bashir Q, Ciurea SO, Kebriaei P, Marin D, Patel KP, Popat UR, Rezvani K, Rondon G, Shpall EJ, Champlin RE, Oran B. Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia. Biol Blood Marrow Transplant 24(7):1514-1520, 2018. e-Pub 2018. PMID: 29448058.
Kantarjian HM, DiNardo CD, Nogueras-Gonzalez GM, Kadia TM, Jabbour E, Bueso-Ramos CE, O'Brien SM, Konopleva M, Jain NB, Daver NG, Shpall EJ, Champlin RE, Simkins A, Garcia-Manero G, Keating MJ, Huang X, Cortes JE, Pierce SA, Ravandi F, Freireich EJ. Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. Cancer 124(12):2534-2540, 2018. e-Pub 2018. PMID: 29645075.
Ciurea SO, Shah MV, Saliba RM, Gaballa S, Kongtim P, Rondon G, Chen J, Wallis W, Cao K, Konopleva M, Daver N, Cortes J, Ravandi F, Alousi A, Ahmed S, Popat U, Parmar S, Bashir Q, Betul O, Hosing C, Shpall EJ, Rezvani K, Khouri IF, Kebriaei P, Champlin RE. Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant 24(6):1232-1236, 2018. e-Pub 2018. PMID: 28918304.
Ariza-Heredia EJ, Chemaly RF, Shahani LR, Jang Y, Champlin RE, Mulanovich VE. Delay of alternative antiviral therapy and poor outcomes of acyclovir-resistant herpes simplex virus infections in recipients of allogeneic stem cell transplant - a retrospective study. Transpl Int 31(6):639-648, 2018. e-Pub 2018. PMID: 29464765.
Ciurea SO, Labopin M, Socie G, Volin L, Passweg J, Chevallier P, Beelen D, Milpied N, Blaise D, Cornelissen JJ, Fegueux N, Polge E, Kongtim P, Rondon G, Esteve J, Mohty M, Savani BN, Champlin RE, Nagler A. Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center. Cancer 124(10):2134-2141, 2018. e-Pub 2018. PMID: 29469961.
Tamari R, Oran B, Hilden P, Maloy M, Kongtim P, Papadopoulos EB, Rondon G, Jakubowski AA, Andersson BS, Devlin SM, Ahmed S, Popat UR, Ponce D, Chen J, Sauter C, Young JW, de Lima M, Perales MA, O'Reilly RJ, Giralt SA, Champlin RE, Castro-Malaspina H. Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected and Unmodified Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 24(5):1079-1087, 2018. e-Pub 2018. PMID: 29325829.
Edwards BJ, Sun M, Zhang X, Holmes HM, Song J, Khalil P, Karuturi M, Shah JB, Dinney CP, Gagel RF, Valero V, Champlin RE, Tripathy D, Murphy WA. Fractures frequently occur in older cancer patients: the MD Anderson Cancer Center experience. Support Care Cancer 26(5):1561-1568, 2018. e-Pub 2018. PMID: 29197959.
Pundole X, Murphy WA, Ebede CC, Karim E, Manocha S, Don-Pedro D, Rondon G, Leung CH, Liu S, Du XL, Champlin RE, Lu H. Fracture risk prediction using FRAX in patients following hematopoietic stem cell transplantation. Arch Osteoporos 13(1):38, 2018. e-Pub 2018. PMID: 29619576.
Shah N, Shi Q, Giralt S, Williams L, Bashir Q, Qazilbash M, Champlin RE, Cleeland CS, Wang XS. Utility of a patient-reported outcome in measuring functional impairment during autologous stem cell transplant in patients with multiple myeloma. Qual Life Res 27(4):979-985, 2018. e-Pub 2018. PMID: 29260444.
Kebriaei P, Anasetti C, Zhang MJ, Wang HL, Aldoss I, de Lima M, Khoury HJ, Sandmaier BM, Horowitz MM, Artz A, Bejanyan N, Ciurea S, Lazarus HM, Gale RP, Litzow M, Bredeson C, Seftel MD, Pulsipher MA, Boelens JJ, Alvarnas J, Champlin R, Forman S, Pullarkat V, Weisdorf D, Marks DI, the CIBMTR ALCO. Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant 24(4):726-733, 2018. e-Pub 2018. PMID: 29197676.
Oran B, Saliba RM, Carmazzi Y, de Lima M, Rondon G, Ahmed S, Alousi A, Andersson BS, Anderlini P, Alvarez M, Bashir Q, Ciurea S, Fernandez-Vina M, Hosing C, Kebriaei P, Korbling M, Cano P, Khouri I, Marin D, Nieto Y, Olson A, Popat U, Rezvani K, Qazilbash M, Shpall EJ, Champlin RE, Cao K. Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion. Blood 131(11):1248-1257, 2018. e-Pub 2018. PMID: 29386198.
Zhang X, Sun M, Liu S, Leung CH, Pang L, Popat UR, Champlin R, Holmes HM, Valero V, Dinney CP, Tripathy D, Edwards BJ. Risk factors for falls in older patients with cancer. BMJ Support Palliat Care 8(1):34-37, 2018. e-Pub 2018. PMID: 28860112.
Ragon BK, Mehta RS, Gulbis AM, Saliba RM, Chen J, Rondon G, Popat UR, Nieto Y, Oran B, Olson AL, Patel K, Hosing CM, Qazilbash MH, Shah N, Kebriaei P, Shpall EJ, Champlin RE, Alousi AM. Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit. Bone Marrow Transplant 53(3):315-325, 2018. e-Pub 2018. PMID: 29269797.
Jabbour E, Ravandi F, Kebriaei P, Huang X, Short NJ, Thomas D, Sasaki K, Rytting M, Jain N, Konopleva M, Garcia-Manero G, Champlin R, Marin D, Kadia T, Cortes J, Estrov Z, Takahashi K, Patel Y, Khouri MR, Jacob J, Garris R, O'Brien S, Kantarjian H. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial. JAMA Oncol 4(2):230-234, 2018. e-Pub 2018. PMID: 28859185.
Hammerstrom AE, Lombardi LR, Pingali SR, Rondon G, Chen J, Milton DR, Chemaly RF, Champlin RE, Gulbis A, Ciurea SO. Prevention of CMV Reactivation in Haploidentical Stem Cell Transplantation. Biol Blood Marrow Transplant 24(2):353-358, 2018. e-Pub 2018. PMID: 28986189.
Mohyuddin GR, Faisal MS, Badar T, Shah N, Bashir Q, Patel KK, Hosing C, Popat UR, Rondon G, Delgado R, Shah JJ, Weber DM, Thomas SK, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH. A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center. Leuk Lymphoma 59(2):515-518, 2018. e-Pub 2018. PMID: 28673185.
Valdez BC, Li Y, Murray D, Liu Y, Nieto Y, Champlin RE, Andersson BS. Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells. Oncotarget 9(3):3908-3921, 2018. e-Pub 2018. PMID: 29423093.
Brammer JE, Chihara D, Poon LM, Caimi P, de Lima M, Ledesma C, Rondon G, Ciurea SO, Nieto Y, Fanale M, Dabaja B, Maziarz RT, Champlin RE, Hosing C, Oki Y. Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes. Clin Lymphoma Myeloma Leuk 18(1):e41-e50, 2018. e-Pub 2018. PMID: 29277360.
Zhang X, Sun M, McKoy JM, Bhulani NNA, Valero V, Barcenas CH, Popat UR, Sri MK, Shah JB, Dinney CP, Hedberg AM, Champlin R, Tripathy D, Holmes HM, Stroehlein JR, Edwards BJ. Malnutrition in older patients with cancer: Appraisal of the Mini Nutritional Assessment, weight loss, and body mass index. J Geriatr Oncol 9(1):81-83, 2018. e-Pub 2018. PMID: 28844850.
Cao K, Marin D, Sekine T, Rondon G, Zhao W, Smith NT, Daher M, Wang Q, Li L, Saliba RM, Pingali R, Popat U, Hosing C, Olson A, Oran B, Basar R, Mehta RS, Champlin R, Shpall EJ, Rezvani K. Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation After Double Cord Blood Transplantation. Front Immunol 9:2444, 2018. e-Pub 2018. PMID: 30405633.
Rondón G, Saliba RM, Chen J, Ledesma C, Alousi AM, Oran B, Hosing CM, Kebriaei P, Khouri IF, Shpall EJ, Popat UR, Champlin RE, Ciurea SO. Impact of Fluid Overload as New Toxicity Category on Hematopoietic Stem Cell Transplantation Outcomes. Biol Blood Marrow Transplant 23(12):2166-2171, 2017. e-Pub 2017. PMID: 28844946.
Boddu P, Garcia-Manero G, Ravandi F, Borthakur G, Jabbour E, DiNardo C, Jain N, Daver N, Pemmaraju N, Anderlini P, Parmar S, Kc D, Akosile M, Pierce SA, Champlin R, Cortes J, Kantarjian H, Kadia T. Clinical outcomes in adult patients with aplastic anemia: A single institution experience. Am J Hematol 92(12):1295-1302, 2017. e-Pub 2017. PMID: 28850699.
Shah N, Cornelison AM, Saliba R, Ahmed S, Nieto YL, Bashir Q, Parmar S, Hosing C, Popat U, Shpall EJ, Champlin RE, Qazilbash M. Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma. Eur J Haematol 99(6):532-535, 2017. e-Pub 2017. PMID: 28895206.
Valdez BC, Li Y, Murray D, Liu Y, Nieto Y, Champlin RE, Andersson BS. The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells. Leuk Lymphoma 58(11):2705-2716, 2017. e-Pub 2017. PMID: 28394191.
Im JS, Abraham SC, Saliba RM, Rondon G, Ross WA, Rashid A, Shpall EJ, Popat U, Qazilbash MH, Hosing C, Oran B, Shah N, Tewari P, Nieto Y, Kebriaei P, Champlin RE, Alousi AM. Histologic Grade 1 Is Associated With Increased Nonrelapsed Mortality in Lower Gastrointestinal Graft Versus Host Disease. Am J Surg Pathol 41(11):1483-1490, 2017. e-Pub 2017. PMID: 28834808.
Ciurea SO, Schafer JR, Bassett R, Denman CJ, Cao K, Willis D, Rondon G, Chen J, Soebbing D, Kaur I, Gulbis A, Ahmed S, Rezvani K, Shpall EJ, Lee DA, Champlin RE. Phase 1 clinical trial using mbIL21 ex-vivo expanded donor-derived NK cells after haploidentical transplantation. Blood 130(16):1857-1868, 2017. e-Pub 2017. PMID: 28835441.
Veltri LW, Milton DR, Delgado R, Shah N, Patel K, Nieto Y, Kebriaei P, Popat UR, Parmar S, Oran B, Ciurea S, Hosing C, Lee HC, Manasanch E, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. Cancer 123(18):3568-3575, 2017. e-Pub 2017. PMID: 28513828.
Srour SA, Li S, Popat UR, Qazilbash MH, Lozano-Cerrada S, Maadani F, Alousi A, Kebriaei P, Anderlini P, Nieto Y, Jones R, Shpall E, Champlin RE, Hosing C. A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results. Br J Haematol 178(4):561-570, 2017. e-Pub 2017. PMID: 28485023.
Mehta RS, Saliba RM, Cao K, Kaur I, Rezvani K, Chen J, Olson A, Parmar S, Shah N, Marin D, Alousi A, Hosing C, Popat U, Kebriaei P, Champlin R, de Lima M, Skerrett D, Burke E, Shpall EJ, Oran B. Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery. Biol Blood Marrow Transplant 23(8):1359-1366, 2017. e-Pub 2017. PMID: 28506845.
Yucel OK, Saliba RM, Rondon G, Ahmed S, Alousi A, Bashir Q, Ciurea SO, Popat U, Khouri I, Marin D, Rezvani K, Kebriaei P, Shpall EJ, Champlin RE, Oran B. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning. Cancer 123(14):2661-2670, 2017. e-Pub 2017. PMID: 28324640.
Pingali SR, Saliba RM, Anderlini P, Hosing C, Khouri I, Alousi AM, Nieto Y, Qazilbash MH, Champlin R, Popat UR. Age over Fifty-Five Years at Diagnosis Increases Risk of Second Malignancies after Autologous Transplantation for Patients with Hodgkin Lymphoma. Biol Blood Marrow Transplant 23(7):1059-1063, 2017. e-Pub 2017. PMID: 28389254.
Huang XJ, Liu K, Ritchie D, Andersson B, Lu J, Hou J, Burguera AF, Wang J, Yeoh A, Yan C, Zhou D, Tan D, Kim DW, Wu D, Shpall E, Kornblau S, Neelapu S, Hongeng S, Li J, Hu J, Zhang LS, Wang M, Malhotra P, Jiang Q, Qin Y, Wong R, Champlin R, Hagemeister F, Westin J, Iyer S, Mathews V, Wang Y, Hu Y, Xiao Z, Shao Z, Orlowski RZ, Chim CS, Mulligan S, Sanz M, Ozawa K, Parmar S, Issaragrisil S. Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China. Oncotarget 8(25):41620-41630, 2017. e-Pub 2017. PMID: 28404929.
Bachegowda LS, Saliba RM, Ramlal R, Kongtim P, Chen J, Rondon G, Wallis W, Alousi A, Ahmed S, Hosing CM, Parmar S, Qazilbash M, Khouri IF, Bashir Q, Oran B, Popat U, Shpall EJ, Marin D, Rezvani K, Kebriaei P, Champlin RE, Ciurea SO. Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation. Blood 129(22):3031-3033, 2017. e-Pub 2017. PMID: 28351938.
Weisdorf DJ, Millard HR, Horowitz MM, Hyare PS, Champlin R, Ho V, Mielcarek M, Rezvani A, Stockerl-Goldstein K, Khoury HJ, De Lima M, Saber W, Sandmaier B, Zhang MJ, Eapen M. Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission. Cancer 123(11):2025-2034, 2017. e-Pub 2017. PMID: 28117884.
Bayraktar UD, Milton DR, Shpall EJ, Rondon G, Price KJ, Champlin RE, Nates JL. Prognostic Index for Critically Ill Allogeneic Transplantation Patients. Biol Blood Marrow Transplant 23(6):991-996, 2017. e-Pub 2017. PMID: 28263919.
Nieto Y, Valdez BC, Pingali SR, Bassett R, Delgado R, Nguyen J, Shah N, Popat U, Jones RB, Andersson BS, Gulbis A, Ahmed S, Bashir Q, Parmar S, Patel K, Myers A, Rondon G, Orlowski RZ, Champlin R, Qazilbash M. High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. Lancet Haematol 4(6):e283-e292, 2017. e-Pub 2017. PMID: 28522110.
Thompson PA, Stingo F, Keating MJ, Wierda WG, O'Brien SM, Estrov Z, Ledesma C, Rezvani K, Qazilbash M, Shah N, Parmar S, Popat U, Anderlini P, Yago N, Ciurea SO, Kebriaei P, Champlin R, Shpall EJ, Hosing CM. Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival. Br J Haematol 177(4):567-577, 2017. e-Pub 2017. PMID: 28295181.
Maher OM, Silva JG, Wu J, Liu D, Cooper LJ, Tarek N, Worth L, Lee DA, Petropoulos D, Franklin AR, Zweidler-Mckay P, Wells RJ, Rondon G, Champlin RE, Tewari P. Outcomes of children, adolescents, and young adults following allogeneic stem cell transplantation for secondary acute myeloid leukemia and myelodysplastic syndromes-The MD Anderson Cancer Center experience. Pediatr Transplant 21(3), 2017. e-Pub 2017. PMID: 28160352.
Shah N, Li L, McCarty J, Kaur I, Yvon E, Shaim H, Muftuoglu M, Liu E, Orlowski RZ, Cooper L, Lee D, Parmar S, Cao K, Sobieiski C, Saliba R, Hosing C, Ahmed S, Nieto Y, Bashir Q, Patel K, Bollard C, Qazilbash M, Champlin R, Rezvani K, Shpall EJ. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br J Haematol 177(3):457-466, 2017. e-Pub 2017. PMID: 28295190.
Andersson BS, Thall PF, Valdez BC, Milton DR, Al-Atrash G, Chen J, Gulbis A, Chu D, Martinez C, Parmar S, Popat U, Nieto Y, Kebriaei P, Alousi A, de Lima M, Rondon G, Meng QH, Myers A, Kawedia J, Worth LL, Fernandez-Vina M, Madden T, Shpall EJ, Jones RB, Champlin RE. Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients. Bone Marrow Transplant 52(4):580-587, 2017. e-Pub 2017. PMID: 27991894.
Gaballa S, Saliba R, Oran B, Brammer JE, Chen J, Rondon G, Alousi AM, Kebriaei P, Marin D, Popat UR, Andersson BS, Shpall EJ, Jabbour E, Daver N, Andreeff M, Ravandi F, Cortes J, Patel K, Champlin RE, Ciurea SO. Relapse Risk and Survival in Patients with FLT3 Acute Myeloid Leukemia Undergoing Stem Cell Transplantation. Am J Hematol 92(4):331-337, 2017. e-Pub 2017. PMID: 28052408.
Varma A, Biritxinaga L, Saliba RM, Stich M, Jauch SF, Afrough A, Honhar M, Popat UR, Shafi MA, Shah N, Bashir Q, Dinh Y, Hosing C, Champlin RE, Qazilbash MH. Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant 23(4):581-587, 2017. e-Pub 2017. PMID: 28063964.
Ge I, Saliba RM, Maadani F, Popat UR, Qazilbash MH, Ravi Pingali S, Shah N, Ahmed S, Bashir Q, Nieto Y, Champlin RE, Hosing C. Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphoma. Transfusion 57(4):1052-1057, 2017. e-Pub 2017. PMID: 28185276.
de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, Mufti GJ, Fenaux P, Sanz G, Martino R, Alessandrino EP, Onida F, Symeonidis A, Passweg J, Kobbe G, Ganser A, Platzbecker U, Finke J, van Gelder M, van de Loosdrecht AA, Ljungman P, Stauder R, Volin L, Deeg HJ, Cutler C, Saber W, Champlin R, Giralt S, Anasetti C, Kröger N. Use of hematopoietic cell transplantation for patients with myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 129(13):1753-1762, 2017. e-Pub 2017. PMID: 28096091.
El Boghdadly Z, Oran B, Jiang Y, Rondon G, Champlin R, Kontoyiannis DP. Pretransplant chest computed tomography screening in asymptomatic patients with leukemia and myelodysplastic syndrome. Bone Marrow Transplant 52(3):476-479, 2017. e-Pub 2017. PMID: 27941772.
Badar T, Srour S, Bashir Q, Shah N, Al-Atrash G, Hosing C, Popat U, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MH. Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma. Eur J Haematol 98(3):263-268, 2017. e-Pub 2017. PMID: 27862330.
Qazilbash MH, Wieder E, Thall PF, Wang X, Rios R, Lu S, Kanodia S, Ruisaard KE, Giralt SA, Estey EH, Cortes J, Komanduri KV, Clise-Dwyer K, Alatrash G, Ma Q, Champlin RE, Molldrem JJ. PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia 31(3):697-704, 2017. e-Pub 2017. PMID: 27654852.
Alsuliman A, Muftuoglu M, Khoder A, Ahn YO, Basar R, Verneris MR, Muranski P, Barrett AJ, Liu E, Li L, Stringaris K, Armstrong-James D, Shaim H, Kondo K, Imahashi N, Andersson B, Marin D, Champlin RE, Shpall EJ, Rezvani K. A subset of virus-specific CD161+ T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML. Blood 129(6):740-758, 2017. e-Pub 2017. PMID: 27821506.
Issa GC, Kantarjian HM, Yin CC, Qiao W, Ravandi F, Thomas D, Short NJ, Sasaki K, Garcia-Manero G, Kadia TM, Cortes JE, Daver N, Borthakur G, Jain N, Konopleva M, Khouri I, Kebriaei P, Champlin RE, Pierce S, O'Brien SM, Jabbour E. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer 123(3):459-467, 2017. e-Pub 2017. PMID: 27696391.
Brammer JE, Khouri I, Marin D, Ledesma C, Rondon G, Ciurea SO, Nieto Y, Champlin RE, Hosing C, Kebriaei P. Stem cell transplantation outcomes in lymphoblastic lymphoma. Leuk Lymphoma 58(2):1-6, 2017. e-Pub 2017. PMID: 27348707.
Srour SA, Milton DR, Bashey A, Karduss-Urueta A, Al Malki MM, Romee R, Solomon S, Nademanee A, Brown S, Slade M, Perez R, Rondon G, Forman SJ, Champlin RE, Kebriaei P, Ciurea SO. Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant 23(2):318-324, 2017. e-Pub 2017. PMID: 27856368.
Abudayyeh A, Hamdi A, Abdelrahim M, Lin H, Page VD, Rondon G, Andersson BS, Afrough A, Martinez CS, Tarrand JJ, Kontoyiannis DP, Marin D, Gaber AO, Oran B, Chemaly RF, Ahmed S, Abudayyeh I, Olson A, Jones R, Popat U, Champlin RE, Shpall EJ, Rezvani K. Poor immune reconstitution is associated with symptomatic BK polyomavirus viruria in allogeneic stem cell transplant recipients. Transpl Infect Dis 19(1), 2017. e-Pub 2017. PMID: 27862740.
Kebriaei P, Bassett R, Lyons G, Valdez B, Ledesma C, Rondon G, Oran B, Ciurea S, Alousi A, Popat U, Patel K, Ahmed S, Olson A, Bashir Q, Shah N, Jones R, Marin D, Rezvani K, Nieto Y, Khouri I, Qazilbash M, Hosing C, Shpall E, Champlin RE, Andersson BS. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. Biol Blood Marrow Transplant 23(2):285-292, 2017. e-Pub 2017. PMID: 27816651.
Jabbour E, Short NJ, Jorgensen JL, Yilmaz M, Ravandi F, Wang SA, Thomas DA, Khoury J, Champlin RE, Khouri I, Kebriaei P, O'Brien SM, Garcia-Manero G, Cortes JE, Sasaki K, Dinardo CD, Kadia TM, Jain N, Konopleva M, Garris R, Kantarjian HM. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer 123(2):294-302, 2017. e-Pub 2017. PMID: 27602508.
Oran B, Jorgensen JL, Marin D, Wang S, Ahmed S, Alousi AM, Andersson BS, Bashir Q, Bassett R, Lyons G, Chen J, Rezvani K, Popat U, Kebriaei P, Patel K, Rondon G, Shpall EJ, Champlin RE. Pretransplantion minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia. Haematologica 102(1):110-117, 2017. e-Pub 2017. PMID: 27540139.
Brammer JE, Saliba RM, Jorgensen JL, Ledesma C, Gaballa S, Poon M, Maziarz RT, Champlin RE, Hosing C, Kebriaei P. Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes. Bone Marrow Transplant 52(1):20-27, 2017. e-Pub 2017. PMID: 27618682.
Khoder A, Alsuliman A, Basar R, Sobieski C, Kondo K, Alousi AM, Szydlo R, Muftuoglu M, Shaim H, Apperley JF, Gokdemir E, Cooper N, Mehta RS, Marin D, Champlin R, Shpall E, Rezvani K. Evidence for B Cell Exhaustion in Chronic Graft-versus-Host Disease. Front Immunol 8:1937, 2017. e-Pub 2017. PMID: 29375566.
Mian I, Milton DR, Shah N, Nieto Y, Popat UR, Kebriaei P, Parmar S, Oran B, Shah JJ, Manasanch EE, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. Cancer 122(24):3831-3837, 2016. e-Pub 2016. PMID: 27680710.
Stringaris K, Marin D, Barrett AJ, Hills R, Sobieski C, Cao K, Saltarrelli JG, Daher M, Shaim H, Smith N, Linch D, Gale R, Allen C, Sekine T, Mehta R, Champlin R, Shpall EJ, Kantarjian H, Garcia-Manero G, Rezvani K. KIR gene haplotype: an independent predictor of clinical outcome in MDS patients. Blood 128(24):2819-2823, 2016. e-Pub 2016. PMID: 27760759.
Short NJ, Kantarjian HM, Sasaki K, Cortes JE, Ravandi F, Thomas DA, Garcia-Manero G, Khouri I, Kebriaei P, Champlin RE, Pierce S, Issa GC, Konopleva M, Kadia TM, Bueso-Ramos C, Khoury JD, Jain N, O'Brien SM, Jabbour E. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer 122(24):3812-3820, 2016. e-Pub 2016. PMID: 27508525.
Najjar AM, Manuri PR, Olivares S, Flores L, Mi T, Huls H, Shpall EJ, Champlin RE, Turkman N, Paolillo V, Roszik J, Rabinovich B, Lee DA, Alauddin M, Gelovani J, Cooper LJ. Imaging of Sleeping Beauty-Modified CD19-Specific T Cells Expressing HSV1-Thymidine Kinase by Positron Emission Tomography. Mol Imaging Biol 18(6):838-848, 2016. e-Pub 2016. PMID: 27246312.
Bock F, Lu G, Srour SA, Gaballa S, Lin HY, Baladandayuthapani V, Honhar M, Stich M, Shah ND, Bashir Q, Patel K, Popat U, Hosing C, Korbling M, Delgado R, Rondon G, Shah JJ, Thomas SK, Manasanch EE, Isermann B, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 22(12):2159-2164, 2016. e-Pub 2016. PMID: 27638366.
Hurton LV, Singh H, Najjar AM, Switzer KC, Mi T, Maiti S, Olivares S, Rabinovich B, Huls H, Forget MA, Datar V, Kebriaei P, Lee DA, Champlin RE, Cooper LJ. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc Natl Acad Sci U S A 113(48):E7788-E7797, 2016. e-Pub 2016. PMID: 27849617.
Gaballa S, Ge I, El Fakih R, Brammer JE, Kongtim P, Tomuleasa C, Wang SA, Lee D, Petropoulos D, Cao K, Rondon G, Chen J, Hammerstrom A, Lombardi L, Alatrash G, Korbling M, Oran B, Kebriaei P, Ahmed S, Shah N, Rezvani K, Marin D, Bashir Q, Alousi A, Nieto Y, Qazilbash M, Hosing C, Popat U, Shpall EJ, Khouri I, Champlin RE, Ciurea SO. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer 122(21):3316-3326, 2016. e-Pub 2016. PMID: 27404668.
Teo EC, Valdez BC, Ji J, Li Y, Liu Y, Brammer JE, Hosing C, Nieto Y, Champlin RE, Andersson BS. Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells. Leuk Lymphoma 57(11):1-9, 2016. e-Pub 2016. PMID: 26980288.
Gaballa S, Saliba RM, Srour S, Lu G, Brammer JE, Shah N, Bashir Q, Patel K, Bock F, Parmar S, Hosing C, Popat U, Delgado R, Rondon G, Shah JJ, Manasanch EE, Orlowski RZ, Champlin R, Qazilbash MH. Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. Am J Hematol 91(10):E442-7, 2016. e-Pub 2016. PMID: 27420405.
Badar T, Cornelison AM, Shah ND, Bashir Q, Parmar S, Patel K, Hosing C, Popat U, Weber DM, Thomas SK, Shah JJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients with Systemic Light chain (AL) Amyloidosis with Concurrent Renal and Cardiac Involvement. Eur J Haematol 97(4):342-7, 2016. e-Pub 2016. PMID: 26773409.
Alatrash G, Thall PF, Valdez BC, Fox PS, Ning J, Garber HR, Janbey S, Worth LL, Popat U, Hosing C, Alousi AM, Kebriaei P, Shpall EJ, Jones RB, de Lima M, Rondon G, Chen J, Champlin RE, Andersson BS. Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once Daily IV Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and MDS. Biol Blood Marrow Transplant 22(10):1792-800, 2016. e-Pub 2016. PMID: 27377901.
Sarvaria A, Basar R, Mehta RS, Shaim H, Muftuoglu M, Khoder A, Sekine T, Gokdemir E, Kondo K, Marin D, Daher M, Alousi AM, Alsuliman A, Liu E, Oran B, Olson A, Jones RB, Popat U, Hosing C, Champlin R, Shpall EJ, Rezvani K. IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation. Blood 128(10):1346-61, 2016. e-Pub 2016. PMID: 27439912.
Nieto Y, Valdez BC, Thall PF, Jones RB, Wei W, Myers A, Hosing C, Ahmed S, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Shah N, Bashir Q, Alousi A, Oki Y, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. Cancer 122(17):2680-8, 2016. e-Pub 2016. PMID: 27203405.
Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R, Olivares S, Jena B, Dawson MJ, Kumaresan PR, Su S, Maiti S, Dai J, Moriarity B, Forget MA, Senyukov V, Orozco A, Liu T, McCarty J, Jackson RN, Moyes JS, Rondon G, Qazilbash M, Ciurea S, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Kantarjian H, Keating M, Wierda W, Do KA, Largaespada DA, Lee DA, Hackett PB, Champlin RE, Cooper LJ. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest 126(9):3363-76, 2016. e-Pub 2016. PMID: 27482888.
Valdez BC, Li Y, Murray D, Brammer JE, Liu Y, Hosing C, Nieto Y, Champlin RE, Andersson BS. Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy. Oncotarget. e-Pub 2016. PMID: 27564097.
Valdez BC, Brammer JE, Li Y, Murray D, Teo EC, Liu Y, Hosing C, Nieto Y, Champlin RE, Andersson BS. Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells. Leuk Res 47:100-108, 2016. e-Pub 2016. PMID: 27294334.
Sekine T, Marin D, Cao K, Li L, Mehta P, Shaim H, Sobieski C, Jones R, Oran B, Hosing C, Rondon G, Alsuliman A, Paust S, Andersson B, Popat U, Kebriaei P, Muftuoglu M, Basar R, Kondo K, Nieto Y, Shah N, Olson A, Alousi A, Liu E, Sarvaria A, Parmar S, Armstrong-James D, Imahashi N, Molldrem J, Champlin R, Shpall EJ, Rezvani K. Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood 128(2):297-312, 2016. e-Pub 2016. PMID: 27247137.
Rezvani K, Champlin RE. Epstein-Barr Virus and B Cells in the Pathogenesis of Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol 34(19):2201-2, 2016. e-Pub 2016. PMID: 27091710.
Oran B, Cortes J, Beitinjaneh A, Chen HC, de Lima M, Patel K, Ravandi F, Wang X, Brandt M, Andersson BS, Ciurea S, Santos FP, de Padua Silva L, Shpall EJ, Champlin RE, Kantarjian H, Borthakur G. Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia. Biol Blood Marrow Transplant 22(7):1218-26, 2016. e-Pub 2016. PMID: 27058617.
Anderlini P, Saliba RM, Ledesma C, Plair T, Alousi AM, Hosing CM, Khouri IF, Nieto Y, Popat UR, Shpall EJ, Fanale MA, Hagemeister FB, Oki Y, Neelapu S, Romaguera JE, Younes A, Champlin RE. Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma. Biol Blood Marrow Transplant 22(7):1333-7, 2016. e-Pub 2016. PMID: 27064056.
Lu J, Hou J, Liu KY, Parmar S, De La Fuente A, Andersson B, Yan C, Zhou D, Tan D, Ritchie D, Wu D, Shpall E, Laport GG, Li J, Hu J, Zhang LS, Wang M, Malhotra P, Jiang Q, Qin Y, Wong R, Champlin R, Issaragrisil S, Iyer S, Mathews V, Wang Y, Hu Y, Xiao Z, Shao Z, Rosengarten R, Steuernagle J, Xiao JH, Orlowski R, Chim CS. Asia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th International Hematologic Malignancies Conference: Bridging the Gap 2015, Beijing, China. Leuk Lymphoma 57(7):1-5, 2016. e-Pub 2016. PMID: 26887657.
Lee DA, Denman CJ, Rondon G, Woodworth G, Chen J, Fisher T, Kaur I, Fernandez-Vina M, Cao K, Ciurea S, Shpall EJ, Champlin RE. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial. Biol Blood Marrow Transplant 22(7):1290-8, 2016. e-Pub 2016. PMID: 27090958.
Thompson PA, Perera T, Marin D, Oran B, Popat U, Qazilbash M, Shah N, Parmar S, Rezvani K, Olson A, Kebriaei P, Anderlini P, Rondon G, Alousi A, Ciurea S, Champlin RE, Bajel A, Szer J, Shpall EJ, Ritchie D, Hosing CM. Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma. Leuk Lymphoma 57(7):1-9, 2016. e-Pub 2016. PMID: 26472485.
Caruso HG, Torikai H, Zhang L, Maiti S, Dai J, Do KA, Singh H, Huls H, Lee DA, Champlin RE, Heimberger AB, Cooper LJ. Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor. J Immunother 39(5):205-17, 2016. e-Pub 2016. PMID: 27163741.
Ji J, Valdez BC, Li Y, Liu Y, Teo EC, Nieto Y, Champlin RE, Andersson BS. Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: A preclinical study. Exp Hematol 44(6):458-65, 2016. e-Pub 2016. PMID: 26976752.
Mehta RS, Saliba RM, Chen J, Rondon G, Hammerstrom AE, Alousi A, Qazilbash M, Bashir Q, Ahmed S, Popat U, Hosing C, Khouri I, Shpall EJ, Champlin RE, Ciurea SO. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. Br J Haematol 173(3):444-55, 2016. e-Pub 2016. PMID: 26947769.
Aung FM, Lichtiger B, Rondon G, Yin CC, Alousi A, Ahmed S, Andersson BS, Bashir Q, Ciurea SO, Hosing C, Jones R, Kebriaei P, Khouri I, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Shpall EJ, Champlin RE, Popat U. Pure Red Cell Aplasia in Major ABO Mismatched Allogeneic Hematopoietic Stem Cell Transplantation is Associated with Severe Pancytopenia. Biol Blood Marrow Transplant 22(5):961-5, 2016. e-Pub 2016. PMID: 26921820.
Kyvernitakis A, Mahale P, Popat UR, Jiang Y, Hosry J, Champlin RE, Torres HA. Hepatitis C virus infection in patients undergoing hematopoietic cell transplantation in the era of direct-acting antiviral agents. Biol Blood Marrow Transplant 22(4):717-22, 2016. e-Pub 2016. PMID: 26712592.
Al Malki MM, Horowitz M, Handgretinger R, Leung W, Roy DC, Huang XJ, Fuchs E, Locatelli F, Blaise D, Mineishi S, Martelli M, Miller J, June C, Ai HS, Luznik L, Mavilio D, Lugli E, van den Brink MR, Champlin RE, Ciurea SO. Proceedings from the Second Haploidentical Stem Cell Transplantation Symposium-Haplo2014, San Francisco, California, December 4, 2014. Biol Blood Marrow Transplant 22(4):594-604, 2016. e-Pub 2016. PMID: 26806585.
Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, Arai S, Grupp SA, Guinan EC, Martin PL, Steinbach G, Krishnan A, Nemecek ER, Giralt S, Rodriguez T, Duerst R, Doyle J, Antin JH, Smith A, Lehmann L, Champlin R, Gillio A, Bajwa R, D'Agostino RB, Massaro J, Warren D, Miloslavsky M, Hume RL, Iacobelli M, Nejadnik B, Hannah AL, Soiffer RJ. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood 127(13):1656-65, 2016. e-Pub 2016. PMID: 26825712.
Shanavas M, Popat U, Michaelis LC, Fauble V, McLornan D, Klisovic R, Mascarenhas J, Tamari R, Arcasoy MO, Davies J, Gergis U, Ukaegbu OC, Kamble RT, Storring JM, Majhail NS, Romee R, Verstovsek S, Pagliuca A, Vasu S, Ernst B, Atenafu EG, Hanif A, Champlin R, Hari P, Gupta V. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. Biol Blood Marrow Transplant 22(3):432-40, 2016. e-Pub 2016. PMID: 26493563.
Bayraktar UD, Milton DR, Guindani M, Rondon G, Chen J, Al-Atrash G, Rezvani K, Champlin R, Ciurea SO. Optimal Threshold and Time of Absolute Lymphocyte Count Assessment for Outcome Prediction after Bone Marrow Transplantation. Biol Blood Marrow Transplant 22(3):505-13, 2016. e-Pub 2016. PMID: 26524730.
Brammer JE, Khouri I, Gaballa S, Anderlini P, Tomuleasa C, Ahmed S, Ledesma C, Hosing C, Champlin RE, Ciurea SO. Outcomes of Haploidentical Stem Cell Transplantation for Lymphoma with Melphalan-Based Conditioning. Biol Blood Marrow Transplant 22(3):493-8, 2016. e-Pub 2016. PMID: 26497906.
Wang Y, Yang F, Shen Y, Zhang W, Wang J, Chang VT, Andersson BS, Qazilbash MH, Champlin RE, Berenson JR, Guan X, Wang ML. Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review. J Natl Cancer Inst 108(3), 2016. e-Pub 2016. PMID: 26582244.
Ravandi F, Jorgensen JL, O'Brien SM, Jabbour E, Thomas DA, Borthakur G, Garris R, Huang X, Garcia-Manero G, Burger JA, Ferrajoli A, Wierda W, Kadia T, Jain N, Wang SA, Konoplev S, Kebriaei P, Champlin RE, McCue D, Estrov Z, Cortes JE, Kantarjian HM. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol 172(3):392-400, 2016. e-Pub 2016. PMID: 26492205.
Shah N, Shi Q, Williams LA, Mendoza TR, Wang XS, Reuben JM, Dougherty PM, Bashir Q, Qazilbash MH, Champlin RE, Cleeland CS, Giralt SA. Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis. Biol Blood Marrow Transplant 22(2):226-31, 2016. e-Pub 2016. PMID: 26253006.
Kollman C, Spellman SR, Zhang MJ, Hassebroek A, Anasetti C, Antin JH, Champlin RE, Confer DL, DiPersio JF, Fernandez-Viña M, Hartzman RJ, Horowitz MM, Hurley CK, Karanes C, Maiers M, Mueller CR, Perales MA, Setterholm M, Woolfrey AE, Yu N, Eapen M. The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy. Blood 127(2):260-7, 2016. e-Pub 2016. PMID: 26527675.
Kongtim P, Popat U, Jimenez A, Gaballa S, El Fakih R, Rondon G, Chen J, Bueso-Ramos C, Borthakur G, Pemmaraju N, Garcia-Manero G, Kantarjian H, Alousi A, Hosing C, Anderlini P, Khouri IF, Kebriaei P, Andersson BS, Oran B, Rezvani K, Marin D, Shpall EJ, Champlin RE, Ciurea SO. Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia. Biol Blood Marrow Transplant 22(1):47-53, 2016. e-Pub 2016. PMID: 26343946.
Wang ML, Lee H, Chuang H, Wagner-Bartak N, Hagemeister F, Westin J, Fayad L, Samaniego F, Turturro F, Oki Y, Chen W, Badillo M, Nomie K, Rosa MD, Zhao D, Lam L, Addison A, Zhang H, Young KH, Li S, Santos D, Medeiros LJ, Champlin R, Romaguera J, Zhang L. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol 17(1):48-56, 2016. e-Pub 2016. PMID: 26640039.
Jacobs RW, Saliba RM, Sasaki K, Farhan S, Armas A, Shah ND, Bashir Q, Qureshi S, Rondon G, Hosing C, Popat U, Parmar S, Shah JJ, Wang M, Weber DM, Thomas SK, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk 16(1):36-42, 2016. e-Pub 2016. PMID: 26702475.
Thokala R, Olivares S, Mi T, Maiti S, Deniger D, Huls H, Torikai H, Singh H, Champlin RE, Laskowski T, McNamara G, Cooper LJ. Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors. PLoS One 11(8):e0159477, 2016. e-Pub 2016. PMID: 27548616.
Torikai H, Mi T, Gragert L, Maiers M, Najjar A, Ang S, Maiti S, Dai J, Switzer KC, Huls H, Dulay GP, Reik A, Rebar EJ, Holmes MC, Gregory PD, Champlin RE, Shpall EJ, Cooper LJ. Genetic editing of HLA expression in hematopoietic stem cells to broaden their human application. Sci Rep 6:21757, 2016. e-Pub 2016. PMID: 26902653.
Devine SM, Owzar K, Blum W, Mulkey F, Stone RM, Hsu JW, Champlin RE, Chen YB, Vij R, Slack J, Soiffer RJ, Larson RA, Shea TC, Hars V, Sibley AB, Giralt S, Carter S, Horowitz MM, Linker C, Alyea EP. Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. J Clin Oncol 33(35):4167-75, 2015. e-Pub 2015. PMID: 26527780.
Ravandi F, O'Brien SM, Cortes JE, Thomas DM, Garris R, Faderl S, Burger JA, Rytting ME, Ferrajoli A, Wierda WG, Verstovsek S, Champlin R, Kebriaei P, McCue DA, Huang X, Jabbour E, Garcia-Manero G, Estrov Z, Kantarjian HM. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 121(23):4158-64, 2015. e-Pub 2015. PMID: 26308885.
Abudayyeh A, Hamdi A, Lin H, Abdelrahim M, Rondon G, Andersson BS, Afrough A, Martinez CS, Tarrand JJ, Kontoyiannis DP, Marin D, Osama Gaber A, Salahudeen A, Oran B, Chemaly RF, Olson A, Jones R, Popat U, Champlin RE, Shpall EJ, Winkelmayer WC, Rezvani K. Symptomatic BK Virus Infection Is Associated with Kidney Function Decline and Poor Overall Survival in Allogeneic Hematopoietic Stem Cell Recipients. Am J Transplant. e-Pub 2015. PMID: 26608093.
Nieto Y, Valdez BC, Thall PF, Ahmed S, Jones RB, Hosing C, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Alousi A, Shah N, Bashir Q, Liu Y, Oki Y, Hagemeister F, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Vorinostat Combined with High-Dose Gemcitabine, Busulfan and Melphalan with Autologous Stem-Cell Transplantation in Patients with Refractory Lymphomas. Biol Blood Marrow Transplant 21(11):1914-20, 2015. e-Pub 2015. PMID: 26071868.
Badar T, Kantarjian HM, Nogueras-Gonzalez GM, Borthakur G, Garcia Manero G, Andreeff M, Konopleva M, Kadia TM, Daver N, Wierda WG, Luthra R, Patel K, Oran B, Champlin R, Ravandi F, Cortes JE. Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. Am J Hematol 90(11):1065-70, 2015. e-Pub 2015. PMID: 26299958.
Lee HC, Saliba RM, Rondon G, Chen J, Charafeddine Y, Medeiros LJ, Alatrash G, Andersson BS, Popat U, Kebriaei P, Ciurea S, Oran B, Shpall E, Champlin R. Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes. Biol Blood Marrow Transplant 21(11):1948-54, 2015. e-Pub 2015. PMID: 26183077.
Kazmi SM, Nusrat M, Gunaydin H, Cornelison AM, Shah N, Kebriaei P, Nieto Y, Parmar S, Popat UR, Oran B, Shah JJ, Orlowski RZ, Champlin RE, Qazilbash MH, Bashir Q. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation. Clin Lymphoma Myeloma Leuk 15(11):687-93, 2015. e-Pub 2015. PMID: 26361647.
Majhail NS, Farnia SH, Carpenter PA, Champlin RE, Crawford S, Marks DI, Omel JL, Orchard PJ, Palmer J, Saber W, Savani BN, Veys PA, Bredeson CN, Giralt SA, LeMaistre CF. Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 21(11):1863-9, 2015. e-Pub 2015. PMID: 26256941.
Carter BZ, Mak PY, Mak DH, Ruvolo VR, Schober W, McQueen T, Cortes J, Kantarjian HM, Champlin RE, Konopleva M, Andreeff M. Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells. Oncotarget 6(31):30487-99, 2015. e-Pub 2015. PMID: 26431162.
Oran B, Cao K, Saliba RM, Rezvani K, de Lima M, Ahmed S, Hosing CM, Popat UR, Carmazzi Y, Kebriaei P, Nieto Y, Rondon G, Willis D, Shah N, Parmar S, Olson A, Moore B, Marin D, Mehta R, Fernández-Viña M, Champlin RE, Shpall EJ. Better allele-level matching improves transplant-related mortality after double cord blood transplantation. Haematologica 100(10):1361-70, 2015. e-Pub 2015. PMID: 26250579.
Caruso HG, Hurton LV, Najjar A, Rushworth D, Ang S, Olivares S, Mi T, Switzer K, Singh H, Huls H, Lee DA, Heimberger AB, Champlin RE, Cooper LJ. Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. Cancer Res 75(17):3505-18, 2015. e-Pub 2015. PMID: 26330164.
Ciurea SO, Zhang MJ, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS, Armand P, Antin JH, Chen J, Devine SM, Fowler DH, Luznik L, Nakamura R, O'Donnell PV, Perales MA, Pingali SR, Porter DL, Riches MR, Ringdén OT, Rocha V, Vij R, Weisdorf DJ, Champlin RE, Horowitz MM, Fuchs EJ, Eapen M. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood 126(8):1033-40, 2015. e-Pub 2015. PMID: 26130705.
Afable M, Caimi PF, Hosing C, de Lima M, Khouri I, William BM, Nieto Y, Cooper BW, Anderlini P, Gerson SL, Lazarus HM, Champlin R, Popat U. Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30(+) Lymphoma Patients Who Received Multiple Prior Lines of Treatment. Biol Blood Marrow Transplant 21(8):1529-31, 2015. e-Pub 2015. PMID: 25937397.
Oran B, Jimenez AM, De Lima M, Popat UR, Bassett R, Andersson BS, Borthakur G, Bashir Q, Chen J, Ciurea SO, Jabbour E, Cortes J, Kebriaei P, Khouri IF, Qazilbash MH, Ravandi F, Rondon G, Lu X, Shpall EJ, Champlin RE. Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 21(8):1405-12, 2015. e-Pub 2015. PMID: 25840338.
El Fakih R, Fox P, Popat U, Nieto Y, Shah N, Parmar S, Oran B, Ciurea S, Kebriaei P, Hosing C, Ahmed S, Shah J, Orlowski R, Champlin R, Qazilbash M, Bashir Q. Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients. Clin Lymphoma Myeloma Leuk 15(8):472-6, 2015. e-Pub 2015. PMID: 25963284.
Ciurea SO, Thall PF, Milton DR, Barnes TH, Kongtim P, Carmazzi Y, López AA, Yap DY, Popat U, Rondon G, Lichtiger B, Aung F, Afshar-Kharghan V, Ma Q, Fernández-Viña M, Champlin RE, Cao K. Complement-Binding Donor-Specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 21(8):1392-8, 2015. e-Pub 2015. PMID: 25985919.
Afrough A, Saliba RM, Hamdi A, El Fakih R, Varma A, Dinh YT, Rondon G, Cornelison AM, Shah ND, Bashir Q, Shah JJ, Hosing C, Popat U, Orlowski RZ, Champlin RE, Parmar S, Qazilbash MH. Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 21(8):1413-7, 2015. e-Pub 2015. PMID: 25842049.
Valdez BC, Li Y, Murray D, Ji J, Liu Y, Popat U, Champlin RE, Andersson BS. Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators. Exp Hematol 43(6):448-461.e2, 2015. e-Pub 2015. PMID: 25704054.
Rozovski U, Benjamini O, Jain P, Thompson PA, Wierda WG, O'Brien S, Burger JA, Ferrajoli A, Faderl S, Shpall E, Hosing C, Khouri IF, Champlin R, Keating MJ, Estrov Z. Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure. J Clin Oncol 33(14):1557-63, 2015. e-Pub 2015. PMID: 25847930.
Popat U, Mehta RS, Rezvani K, Fox P, Kondo K, Marin D, McNiece I, Oran B, Hosing C, Olson A, Parmar S, Shah N, Andreeff M, Kebriaei P, Kaur I, Yvon E, de Lima M, Cooper LJ, Tewari P, Champlin RE, Nieto Y, Andersson BS, Alousi A, Jones RB, Qazilbash MH, Bashir Q, Ciurea S, Ahmed S, Anderlini P, Bosque D, Bollard C, Molldrem JJ, Chen J, Rondon G, Thomas M, Miller L, Wolpe S, Simmons P, Robinson S, Zweidler-McKay PA, Shpall EJ. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood 125(19):2885-92, 2015. e-Pub 2015. PMID: 25778529.
Alousi AM, Brammer JE, Saliba RM, Andersson B, Popat U, Hosing C, Jones R, Shpall EJ, Khouri I, Qazilbash M, Nieto Y, Shah N, Ahmed S, Oran B, Al Atrash G, Ciurea S, Kebriaei P, Chen J, Rondon G, Champlin RE. Phase Ii Trial Of Gvhd Prophylaxis with Post-Transplantation Cyclophosphamide Following Reduced-Intensity Busulfan/Fludarabine (Bu/Flu) Conditioning for Hematological Malignancies. Biol Blood Marrow Transplant 21(5):906-12, 2015. e-Pub 2015. PMID: 25667989.
Pundole XN, Barbo AG, Lin H, Champlin RE, Lu H. Increased incidence of fractures in recipients of hematopoietic stem-cell transplantation. J Clin Oncol 33(12):1364-70, 2015. e-Pub 2015. PMID: 25779562.
Kongtim P, Di Stasi A, Rondon G, Chen J, Adekola K, Popat U, Oran B, Kebriaei P, Andersson BS, Champlin RE, Ciurea SO. Can a Female Donor for a Male Recipient Decrease the Relapse Rate for Patients With Acute Myeloid Leukemia Treated With Allogeneic Hematopoietic Stem Cell Transplantation?. Biol Blood Marrow Transplant 21(4):713-9, 2015. e-Pub 2015. PMID: 25540936.
Poon ML, Fox PS, Samuels BI, O'Brien S, Jabbour E, Hsu Y, Gulbis A, Korbling M, Champlin R, Abruzzo LV, Bassett RL, Khouri IF. Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis. Leuk Lymphoma 56(3):1-5, 2015. e-Pub 2015. PMID: 24913509.
Glitza IC, Lu G, Shah R, Bashir Q, Shah N, Champlin RE, Shah J, Orlowski RZ, Qazilbash MH. Chromosome 8q24.1/c-MYC Abnormality: A Marker for High-Risk Myeloma. Leuk Lymphoma 56(3):1-18, 2015. e-Pub 2015. PMID: 24844357.
Wang Y, Zhang LL, Champlin RE, Wang ML. Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies. Clin Pharmacol Ther. e-Pub 2015. PMID: 25669675.
Eapen M, Logan BR, Horowitz MM, Zhong X, Perales MA, Lee SJ, Rocha V, Soiffer RJ, Champlin RE. Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation. J Clin Oncol 33(4):364-9, 2015. e-Pub 2015. PMID: 25534391.
Gul Z, Bashir Q, Cremer M, Yusuf SW, Gunaydin H, Arora S, Slone S, Nieto Y, Sherwani N, Parmar S, Shah N, Dinh YT, Hosing CM, Popat UR, Kebriaei P, Shpall EJ, Giralt SA, Champlin RE, Qazilbash MH. Short-term Cardiac Toxicity of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Leuk Lymphoma 56(2):1-8, 2015. e-Pub 2015. PMID: 24882259.
Pemmaraju N, Shah D, Kantarjian H, Orlowski RZ, Nogueras González GM, Baladandayuthapani V, Jain N, Wagner V, Garcia-Manero G, Shah J, Ravandi F, Pierce S, Takahashi K, Daver N, Nazha A, Verstovsek S, Jabbour E, De Lima M, Champlin R, Cortes J, Qazilbash MH. Characteristics and Outcomes of Patients With Multiple Myeloma Who Develop Therapy-Related Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 15(2):110-4, 2015. e-Pub 2015. PMID: 25107338.
Eapen M, Logan BR, Appelbaum FR, Antin JH, Anasetti C, Couriel DR, Chen J, Maziarz RT, McCarthy PL, Nakamura R, Ratanatharathorn V, Vij R, Champlin RE. Long-Term Survival after Transplantation of Unrelated Donor Peripheral Blood or Bone Marrow Hematopoietic Cells for Hematologic Malignancy. Biol Blood Marrow Transplant 21(1):55-9, 2015. e-Pub 2015. PMID: 25255165.
Kumaresan P, Figliola M, Moyes JS, Huls MH, Tewari P, Shpall EJ, Champlin R, Cooper LJ. Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System. J Vis Exp(104), 2015. e-Pub 2015. PMID: 26484782.
Deniger DC, Yu J, Huls MH, Figliola MJ, Mi T, Maiti SN, Widhopf GF, Hurton LV, Thokala R, Singh H, Olivares S, Champlin RE, Wierda WG, Kipps TJ, Cooper LJ. Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations. PLoS One 10(6):e0128151, 2015. e-Pub 2015. PMID: 26030772.
Di Stasi A, Milton DR, Poon LM, Hamdi A, Rondon G, Chen J, Pingali SR, Konopleva M, Kongtim P, Alousi A, Qazilbash MH, Ahmed S, Bashir Q, Al-atrash G, Oran B, Hosing CM, Kebriaei P, Popat U, Shpall EJ, Lee DA, de Lima M, Rezvani K, Khouri IF, Champlin RE, Ciurea SO. Similar Transplantation Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Haploidentical versus 10/10 Human Leukocyte Antigen-Matched Unrelated and Related Donors. Biol Blood Marrow Transplant 20(12):1975-81, 2014. e-Pub 2014. PMID: 25263628.
Deniger DC, Maiti SN, Mi T, Switzer KC, Ramachandran V, Hurton LV, Ang S, Olivares S, Rabinovich BA, Huls MH, Lee DA, Bast RC, Champlin RE, Cooper LJ. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies. Clin Cancer Res 20(22):5708-19, 2014. e-Pub 2014. PMID: 24833662.
Kanakry CG, O'Donnell PV, Furlong T, de Lima MJ, Wei W, Medeot M, Mielcarek M, Champlin RE, Jones RJ, Thall PF, Andersson BS, Luznik L. Multi-Institutional Study of Post-Transplantation Cyclophosphamide As Single-Agent Graft-Versus-Host Disease Prophylaxis After Allogeneic Bone Marrow Transplantation Using Myeloablative Busulfan and Fludarabine Conditioning. J Clin Oncol 32(31):3497-505, 2014. e-Pub 2014. PMID: 25267759.
Hamdi A, Mawad R, Bassett R, di Stasi A, Ferro R, Afrough A, Ram R, Dabaja B, Rondon G, Champlin R, Sandmaier BM, Doney K, Bar M, Kebriaei P. Central Nervous System Relapse in Adults with Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 20(11):1767-71, 2014. e-Pub 2014. PMID: 25017763.
Song G, Valdez BC, Li Y, Liu Y, Champlin RE, Andersson BS. Synergistic Cytotoxicity of Sorafenib with Busulfan and Nucleoside Analogs in Human FMS-like Tyrosine Kinase 3 Internal Tandem Duplications-Positive Acute Myeloid Leukemia Cells. Biol Blood Marrow Transplant 20(11):1687-95, 2014. e-Pub 2014. PMID: 25111583.
Oran B, Kongtim P, Popat U, de Lima M, Jabbour E, Lu X, Chen J, Rondon G, Kebriaei P, Ahmed S, Andersson B, Alousi A, Ciurea S, Shpall E, Champlin RE. Cytogenetics, Donor Type, and Use of Hypomethylating Agents in Myelodysplastic Syndrome with Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 20(10):1618-25, 2014. e-Pub 2014. PMID: 24953017.
Khoder A, Sarvaria A, Alsuliman A, Chew C, Sekine T, Cooper N, Mielke S, de Lavallade H, Muftuoglu M, Fernandez Curbelo I, Liu E, Muraro PA, Alousi A, Stringaris K, Parmar S, Shah N, Shaim H, Yvon E, Molldrem J, Rouce R, Champlin R, McNiece I, Mauri C, Shpall EJ, Rezvani K. Regulatory B-Cells Are Enriched Within the IgM Memory and Transitional Subsets in Healthy Donors but Deficient In Chronic Graft-Versus-Host Disease. Blood 124(13):2034-45, 2014. e-Pub 2014. PMID: 25051962.
Chemaly RF, Ghantoji SS, Shah DP, Shah JN, El Taoum KK, Champlin RE, Nunez CA, Mulanovich V, Ariza-Heredia E. Respiratory syncytial virus infections in children with cancer. J Pediatr Hematol Oncol 36(6):e376-81, 2014. e-Pub 2014. PMID: 24327130.
Zhou Y, Slack R, Jorgensen JL, Wang SA, Rondon G, de Lima M, Shpall E, Popat U, Ciurea S, Alousi A, Qazilbash M, Hosing C, O'Brien S, Thomas D, Kantarjian H, Medeiros LJ, Champlin RE, Kebriaei P. The Effect of Peritransplant Minimal Residual Disease in Adults With Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk 14(4):319-26, 2014. e-Pub 2014. PMID: 24548609.
Tang X, Alatrash G, Ning J, Jakher H, Stafford P, Zope M, Shpall EJ, Jones RB, Champlin RE, Thall PF, Andersson BS. Increasing Chimerism Following Allogeneic Stem Cell Transplantation is Associated with Longer Survival Time. Biol Blood Marrow Transplant 20(8):1139-44, 2014. e-Pub 2014. PMID: 24727332.
Kumaresan PR, Manuri PR, Albert ND, Maiti S, Singh H, Mi T, Roszik J, Rabinovich B, Olivares S, Krishnamurthy J, Zhang L, Najjar AM, Huls MH, Lee DA, Champlin RE, Kontoyiannis DP, Cooper LJ. Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. Proc Natl Acad Sci U S A 111(29):10660-5, 2014. e-Pub 2014. PMID: 25002471.
Champlin R. Acute graft-versus-host disease: more than just alloreactivity. Blood 124(2):163-4, 2014. e-Pub 2014. PMID: 25013162.
Song G, Valdez BC, Li Y, Dominguez JR, Corn P, Champlin RE, Andersson BS. The histone deacetylase inhibitor SAHA sensitizes AML cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan. Leuk Lymphoma 55(7):1625-34, 2014. e-Pub 2014. PMID: 24144307.
Shah DP, Ghantoji SS, Ariza-Heredia EJ, Shah JN, El Taoum KK, Shah PK, Nesher L, Hosing C, Rondon G, Champlin RE, Chemaly RF. An Immunodeficiency Scoring Index to predict poor outcomes in hematopoietic cell transplant recipients with respiratory syncytial virus infections. Blood 123(21):3263-8, 2014. e-Pub 2014. PMID: 24700783.
Holmes HM, Des Bordes JK, Kebriaei P, Yennu S, Champlin RE, Giralt S, Mohile SG. Optimal screening for geriatric assessment in older allogeneic hematopoietic cell transplantation candidates. J Geriatr Oncol. e-Pub 2014. PMID: 24835889.
Chemaly RF, Ullmann AJ, Stoelben S, Richard MP, Bornhäuser M, Groth C, Einsele H, Silverman M, Mullane KM, Brown J, Nowak H, Kölling K, Stobernack HP, Lischka P, Zimmermann H, Rübsamen-Schaeff H, Champlin RE, Ehninger G, Team AIC. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med 370(19):1781-9, 2014. e-Pub 2014. PMID: 24806159.
Ohanian M, Kantarjian HM, Quintas-Cardama A, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Champlin R, Pierce S, Alattar ML, Trinh LX, Luthra R, Ferrajoli A, Kadia T, O'Brien S, Cortes JE. Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. Clin Lymphoma Myeloma Leuk 14(2):155-162.e1, 2014. e-Pub 2014. PMID: 24332214.
Cai Q, Westin J, Fu K, Desai M, Zhang L, Huang H, Jiang W, Liang R, Qian Z, Champlin RE, Wang M. Accelerated therapeutic progress in diffuse large B cell lymphoma. Ann Hematol 93(4):541-56, 2014. e-Pub 2014. PMID: 24375125.
Jabbour E, Daver N, Champlin R, Mathisen M, Oran B, Ciurea S, Khouri I, Cornelison AM, Ghanem H, Cardenas-Turanzas M, Popat U, Ravandi F, Giralt S, Garcia-Manero G, Cortes J, Kantarjian H, de Lima M. Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy. Am J Hematol 89(4):395-8, 2014. e-Pub 2014. PMID: 24375514.
Mehta RS, Di Stasi A, Andersson BS, Nieto Y, Jones R, de Lima M, Hosing C, Popat U, Kebriaei P, Oran B, Alousi A, Rezvani K, Qazilbash M, Bashir Q, Bollard C, Cooper L, Worth L, Tewari P, McNiece I, Willhelm K, Champlin R, Shpall EJ. The Development of a Myeloablative, Reduced-Toxicity, Conditioning Regimen for Cord Blood Transplantation. Clin Lymphoma Myeloma Leuk 14(1):e1-5, 2014. e-Pub 2014. PMID: 24169268.
Eckrich MJ, Ahn KW, Champlin RE, Coccia P, Godder K, Horan J, Margolis D, Deeg HJ, Eapen M. Effect of race on outcomes after allogeneic hematopoietic cell transplantation for severe aplastic anemia. Am J Hematol 89(2):125-9, 2014. e-Pub 2014. PMID: 24122901.
Robinson SN, Thomas MW, Simmons PJ, Lu J, Yang H, Parmar S, Liu X, Shah N, Martín-Antonio B, Bollard C, Dotti G, Savoldo B, Cooper LJ, Najjar A, Rezvani K, Kaur I, McNiece IK, Champlin RE, Miller LP, Zweidler-McKay PA, Shpall EJ. Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment. Cytotherapy 16(1):84-9, 2014. e-Pub 2014. PMID: 24094497.
Bayraktar UD, Shpall EJ, Liu P, Ciurea SO, Rondon G, de Lima M, Cardenas-Turanzas M, Price KJ, Champlin RE, Nates JL. Hematopoietic Cell Transplantation-Specific Comorbidity Index Predicts Inpatient Mortality and Survival in Patients Who Received Allogeneic Transplantation Admitted to the Intensive Care Unit. J Clin Oncol 31(33):4207-14, 2013. e-Pub 2013. PMID: 24127454.
Mascarenhas JO, Orazi A, Bhalla KN, Champlin RE, Harrison C, Hoffman R. Advances in myelofibrosis: a clinical case approach. Haematologica 98(10):1499-509, 2013. e-Pub 2013. PMID: 24091929.
Bashir Q, Khan H, Thall PF, Liu P, Shah N, Kebriaei P, Parmar S, Oran B, Ciurea S, Nieto Y, Jones R, Hosing CM, Popat UR, Dinh YT, Rondon G, Orlowski RZ, Shah JJ, De Lima M, Shpall E, Champlin R, Giralt S, Qazilbash MH. A Randomized Phase II Trial of Fludarabine/Melphalan 100 versus Fludarabine/Melphalan 140 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma. Biol Blood Marrow Transplant 19(10):1453-8, 2013. e-Pub 2013. PMID: 23872222.
Chakhachiro ZI, Saliba RM, Okoroji GJ, Korbling M, Alousi AM, Betul O, Anderlini P, Ciurea SO, Popat U, Champlin R, Samuels BI, Medeiros LJ, Bueso-Ramos C, Khouri IF. Cytarabine, Ki-67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell transplantation during first remission. Cancer 119(18):3318-25, 2013. e-Pub 2013. PMID: 23775587.
Champlin R. Reduced intensity allogeneic hematopoietic transplantation is an established standard of care for treatment of older patients with acute myeloid leukemia. Best Pract Res Clin Haematol 26(3):297-300, 2013. e-Pub 2013. PMID: 24309534.
Smith VR, Popat U, Ciurea S, Nieto Y, Anderlini P, Rondon G, Alousi A, Qazilbash M, Kebriaei P, Khouri I, de Lima M, Champlin R, Hosing C. Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization. Am J Hematol 88(9):754-7, 2013. e-Pub 2013. PMID: 23749720.
Torikai H, Reik A, Soldner F, Warren EH, Yuen C, Zhou Y, Crossland DL, Huls H, Littman N, Zhang Z, Tykodi SS, Kebriaei P, Lee DA, Miller JC, Rebar EJ, Holmes MC, Jaenisch R, Champlin RE, Gregory PD, Cooper LJ. Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood 122(8):1341-9, 2013. e-Pub 2013. PMID: 23741009.
Ravandi F, Jorgensen JL, Thomas DA, O'Brien S, Garris R, Faderl S, Huang X, Wen S, Burger JA, Ferrajoli A, Kebriaei P, Champlin RE, Estrov Z, Challagundla P, Wang SA, Luthra R, Cortes JE, Kantarjian HM. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood 122(7):1214-21, 2013. e-Pub 2013. PMID: 23836561.
Kantarjian H, Thomas D, Jorgensen J, Kebriaei P, Jabbour E, Rytting M, York S, Ravandi F, Garris R, Kwari M, Faderl S, Cortes J, Champlin R, O'Brien S. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer 119(15):2728-36, 2013. e-Pub 2013. PMID: 23633004.
Shah DP, Ghantoji SS, Shah JN, El Taoum KK, Jiang Y, Popat U, Hosing C, Rondon G, Tarrand JJ, Champlin RE, Chemaly RF. Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. J Antimicrob Chemother 68(8):1872-80, 2013. e-Pub 2013. PMID: 23572228.
Pemmaraju N, Tanaka MF, Ravandi F, Lin H, Baladandayuthapani V, Rondon G, Giralt SA, Chen J, Pierce S, Cortes J, Kantarjian H, Champlin RE, De Lima M, Qazilbash MH. Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk 13(4):485-92, 2013. e-Pub 2013. PMID: 23769669.
Sasaki K, Lu G, Saliba RM, Bashir Q, Hosing C, Popat U, Shah N, Parmar S, Dinh Y, Ahmed S, Shpall EJ, Kebriaei P, Shah JJ, Orlowski RZ, Champlin R, Qazilbash MH. Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant 19(8):1227-32, 2013. e-Pub 2013. PMID: 23733001.
Valdez BC, Wang G, Murray D, Nieto Y, Li Y, Shah J, Turturro F, Wang M, Weber DM, Champlin RE, Qazilbash MH, Andersson BS. Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma; relevance of p53 and its clinical implications. Exp Hematol 41(8):719-30, 2013. e-Pub 2013. PMID: 23648290.
Poon LM, Hamdi A, Saliba R, Rondon G, Ledesma C, Kendrick M, Qazilbash M, Hosing C, Jones RB, Popat UR, Nieto Y, Alousi A, Ciurea S, Shpall EJ, Champlin RE, Kebriaei P. Outcomes of adults with acute lymphoblastic leukemia (ALL) following relapse post allogeneic hematopoietic stem cell transplantation (HSCT). Biol Blood Marrow Transplant 19(7):1059-64, 2013. e-Pub 2013. PMID: 23644077.
Kebriaei P, Wilhelm K, Ravandi F, Brandt M, de Lima M, Ciurea S, Worth L, O'Brien S, Thomas D, Champlin RE, Kantarjian H. Feasibility of Allografting in Patients with Advanced Acute Lymphoblastic Leukemia After Salvage Therapy With Inotuzumab Ozogamicin. Clin Lymphoma Myeloma Leuk 13(3):296-301, 2013. e-Pub 2013. PMID: 23313065.
Bayraktar UD, de Lima M, Saliba RM, Maloy M, Castro-Malaspina HR, Chen J, Rondon G, Chiattone A, Jakubowski AA, Boulad F, Kernan NA, O'Reilly RJ, Champlin RE, Giralt S, Andersson BS, Papadopoulos EB. Ex Vivo T Cell Depleted versus Unmodified Allografts in Patients with Acute Myeloid Leukemia in First Complete Remission. Biol Blood Marrow Transplant 19(6):898-903, 2013. e-Pub 2013. PMID: 23467126.
Karuturi M, Hosing C, Fanale M, Medeiros LJ, Alousi AM, de Lima MJ, Qazilbash MH, Kebriaei P, Younes A, Khouri I, Andersson BS, Champlin R, Anderlini P, Popat U. High-dose Chemotherapy and Autologous Stem Cell Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma. Biol Blood Marrow Transplant 19(6):991-4, 2013. e-Pub 2013. PMID: 23507470.
Fernández-Viña MA, Klein JP, Haagenson M, Spellman SR, Anasetti C, Noreen H, Baxter-Lowe LA, Cano P, Flomenberg N, Confer DL, Horowitz MM, Oudshoorn M, Petersdorf EW, Setterholm M, Champlin R, Lee SJ, de Lima M. Multiple mismatches at the low expression HLA loci DP, DQ, DRB3/4/5 associate with adverse outcomes in hematopoietic stem cell transplantation. Blood 121(22):4603-10, 2013. e-Pub 2013. PMID: 23596045.
Hammerstrom AE, Howell J, Gulbis A, Rondon G, Champlin RE, Popat U. Tacrolimus-associated posterior reversible encephalopathy syndrome in hematopoietic allogeneic stem cell transplantation. Am J Hematol 88(4):301-5, 2013. e-Pub 2013. PMID: 23460378.
Alousi AM, Le-Rademacher J, Saliba RM, Appelbaum FR, Artz A, Benjamin J, Devine SM, Kan F, Laughlin MJ, Lazarus HM, Liesveld J, Perales MA, Maziarz RT, Sabloff M, Waller EK, Eapen M, Champlin RE. Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?. Blood 121(13):2567-73, 2013. e-Pub 2013. PMID: 23361908.
Deniger DC, Switzer K, Mi T, Maiti S, Hurton L, Singh H, Huls H, Olivares S, Lee DA, Champlin RE, Cooper LJ. Bispecific T-cells Expressing Polyclonal Repertoire of Endogenous γδ T-cell Receptors and Introduced CD19-specific Chimeric Antigen Receptor. Mol Ther 21(3):638-47, 2013. e-Pub 2013. PMID: 23295945.
Jabbour E, Mathisen MS, Garcia-Manero G, Champlin R, Popat U, Khouri I, Giralt S, Kadia T, Chen J, Pierce S, Koca E, Daver N, Tanaka M, Rondon G, Oran B, Parmar S, Kantarjian H, de Lima M. Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study. Am J Hematol 88(3):198-200, 2013. e-Pub 2013. PMID: 23345254.
Nieto Y, Popat U, Anderlini P, Valdez B, Andersson B, Liu P, Hosing C, Shpall EJ, Alousi A, Kebriaei P, Qazilbash M, Parmar S, Bashir Q, Shah N, Khouri I, Rondon G, Champlin R, Jones RB. Autologous Stem-Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome. Biol Blood Marrow Transplant 19(3):410-7, 2013. e-Pub 2013. PMID: 23128322.
Bayraktar UD, Bashir Q, Qazilbash M, Champlin RE, Ciurea SO. Fifty Years of Melphalan Use in Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 19(3):344-56, 2013. e-Pub 2013. PMID: 22922522.
Parmar S, Rondon G, de Lima M, Thall P, Bassett R, Anderlini P, Kebriaei P, Khouri I, Ganesan P, Champlin R, Giralt S. Dose Intensification of Busulfan in the Preparative Regimen is Associated with Improved Survival: A Phase I/II Controlled, Randomized Study. Biol Blood Marrow Transplant 19(3):474-80, 2013. e-Pub 2013. PMID: 23220013.
Aung FM, Lichtiger B, Bassett R, Liu P, Alousi A, Bashier Q, Ciurea SO, de Lima MJ, Hosing C, Kebriaei P, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Khouri I, Champlin RE, Popat U. Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation. Br J Haematol 160(6):798-805, 2013. e-Pub 2013. PMID: 23330820.
Ciurea SO, Champlin RE. Donor Selection in T Cell-Replete Haploidentical Hematopoietic Stem Cell Transplantation: Knowns, Unknowns, and Controversies. Biol Blood Marrow Transplant 19(2):180-4, 2013. e-Pub 2013. PMID: 22892554.
Keating A, Dasilva G, Pérez WS, Gupta V, Cutler CS, Ballen KK, Cairo MS, Camitta BM, Champlin RE, Gajewski JL, Lazarus HM, Lill M, Marks DI, Nabhan C, Schiller GJ, Socie G, Szer J, Tallman MS, Weisdorf DJ. Autologous blood cell transplantation versus HLA-identical siblingtransplantation for acute myeloid leukemia in first complete remission:a registry study from the Center for International Blood and MarrowTransplantation Research. Haematologica 98(2):185-92, 2013. e-Pub 2013. PMID: 22983587.
Oran B, Popat U, Rondon G, Ravandi F, Garcia-Manero G, Abruzzo L, Andersson BS, Bashir Q, Chen J, Kebriaei P, Khouri IF, Koca E, Qazilbash MH, Champlin R, de Lima M. Significance of Persistent Cytogenetic Abnormalities at Myeloablative Allogeneic Stem Cell Transplantation in First Complete Remission. Biol Blood Marrow Transplant 19(2):214-20, 2013. e-Pub 2013. PMID: 22982533.
Maiti SN, Huls H, Singh H, Dawson M, Figliola M, Olivares S, Rao P, Zhao YJ, Multani A, Yang G, Zhang L, Crossland D, Ang S, Torikai H, Rabinovich B, Lee DA, Kebriaei P, Hackett P, Champlin RE, Cooper LJ. Sleeping Beauty System to Redirect T-cell Specificity for Human Applications. J Immunother. e-Pub 2013. PMID: 23377665.
Denzen EM, Majhail NS, Stickney Ferguson S, Anasetti C, Bracey A, Burns L, Champlin R, Chell J, Leather H, Lill M, Maziarz RT, Medoff E, Neumann J, Schmit-Pokorny K, Snyder EL, Wiggins L, Yolin Raley DS, Murphy EA. Hematopoietic Cell Transplantation in 2020: Summary of Year II Recommendations of the National Marrow Donor Program's System Capacity Initiative. Biol Blood Marrow Transplant 19(1):4-11, 2013. e-Pub 2013. PMID: 23078785.
Singh H, Figliola MJ, Dawson MJ, Olivares S, Zhang L, Yang G, Maiti S, Manuri P, Senyukov V, Jena B, Kebriaei P, Champlin RE, Huls H, Cooper LJ. Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells. PLoS One 8(5):e64138, 2013. e-Pub 2013. PMID: 23741305.
Jones D, Vichaya EG, Wang XS, Williams LA, Shah ND, Thomas SK, Johnson VE, Champlin RE, Cleeland CS, Mendoza TR. Validation of the M. D. Anderson Symptom Inventory multiple myeloma module. J Hematol Oncol 6:13, 2013. e-Pub 2013. PMID: 23384030.
Jena B, Maiti S, Huls H, Singh H, Lee DA, Champlin RE, Cooper LJ. Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials. PLoS One 8(3):e57838, 2013. e-Pub 2013. PMID: 23469246.
Shah N, Martin-Antonio B, Yang H, Ku S, Lee DA, Cooper LJ, Decker WK, Li S, Robinson SN, Sekine T, Parmar S, Gribben J, Wang M, Rezvani K, Yvon E, Najjar A, Burks J, Kaur I, Champlin RE, Bollard CM, Shpall EJ. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One 8(10):e76781, 2013. e-Pub 2013. PMID: 24204673.
Poon LM, Stasi AD, Popat U, Champlin RE, Ciurea SO. Romiplostim for delayed platelet recovery and secondary thrombocytopenia following allogeneic stem cell transplantation. Am J Blood Res 3(3):260-4, 2013. e-Pub 2013. PMID: 23997988.
de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, Alousi A, Saliba R, McMannis JD, Kaur I, Kebriaei P, Parmar S, Popat U, Hosing C, Champlin R, Bollard C, Molldrem JJ, Jones RB, Nieto Y, Andersson BS, Shah N, Oran B, Cooper LJ, Worth L, Qazilbash MH, Korbling M, Rondon G, Ciurea S, Bosque D, Maewal I, Simmons PJ, Shpall EJ. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 367(24):2305-15, 2012. e-Pub 2012. PMID: 23234514.
Ciurea SO, Mulanovich V, Saliba RM, Bayraktar UD, Jiang Y, Bassett R, Wang SA, Konopleva M, Fernandez-Vina M, Montes N, Bosque D, Chen J, Rondon G, Alatrash G, Alousi A, Bashir Q, Korbling M, Qazilbash M, Parmar S, Shpall E, Nieto Y, Hosing C, Kebriaei P, Khouri I, Popat U, de Lima M, Champlin RE. Improved Early Outcomes Using a T-cell Replete Graft Compared with T-cell Depleted Haploidentical Hematopoietic Stem-Cell Transplantation. Biol Blood Marrow Transplant 18(12):1835-44, 2012. e-Pub 2012. PMID: 22796535.
Chemaly RF, Torres HA, Munsell MF, Shah DP, Rathod DB, Bodey GP, Hosing C, Saifan C, Raad II, Champlin RE. An Adaptive Randomized Trial of an Intermittent Dosing Schedule of Aerosolized Ribavirin in Patients With Cancer and Respiratory Syncytial Virus Infection. J Infect Dis 206(9):1367-71, 2012. e-Pub 2012. PMID: 22927454.
Nieto Y, Thall P, Valdez B, Andersson B, Popat U, Anderlini P, Shpall EJ, Bassett R, Alousi A, Hosing C, Kebriaei P, Qazilbash M, Frazier E, Gulbis A, Chancoco C, Bashir Q, Ciurea S, Khouri I, Parmar S, Shah N, Worth L, Rondon G, Champlin R, Jones RB. High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. Biol Blood Marrow Transplant 18(11):1677-86, 2012. e-Pub 2012. PMID: 22643322.
Valdez BC, Nieto Y, Murray D, Li Y, Wang G, Champlin RE, Andersson BS. Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines. Exp Hematol 40(10):800-10, 2012. e-Pub 2012. PMID: 22687754.
Zhang M, Maiti S, Bernatchez C, Huls H, Rabinovich B, Champlin RE, Vence LM, Hwu P, Radvanyi L, Cooper LJ. A new approach to simultaneously quantify both TCR α- and β-chain diversity after adoptive immunotherapy. Clin Cancer Res 18(17):4733-42, 2012. e-Pub 2012. PMID: 22761473.
Khouri IF, Champlin RE. Nonmyeloablative allogeneic stem cell transplantation for non-hodgkin lymphoma. Cancer J 18(5):457-62, 2012. e-Pub 2012. PMID: 23006952.
Beitinjaneh AM, Saliba R, Bashir Q, Shah N, Parmar S, Hosing C, Popat U, Anderlini P, Dinh Y, Qureshi S, Rondon G, Champlin RE, Giralt SA, Qazilbash MH. Durable Responses after Donor Lymphocyte Infusion for Patients with Residual Multiple Myeloma following Non-myeloablative Allogeneic Stem Cell Transplantation. Leuk Lymphoma 53(8):1525-9, 2012. e-Pub 2012. PMID: 22242817.
Ma Q, Li D, Nurieva R, Patenia R, Bassett R, Cao W, Alekseev AM, He H, Molldrem JJ, Kroll MH, Champlin RE, Sale GE, Afshar-Kharghan V. Reduced Graft-versus-Host Disease in C3-Deficient Mice Is Associated with Decreased Donor Th1/Th17 Differentiation. Biol Blood Marrow Transplant 18(8):1174-81, 2012. e-Pub 2012. PMID: 22664751.
Robinson S, Simmons PJ, Thomas MW, Brouard N, Javni JA, Trilok S, Shim JS, Yang H, Steiner D, Decker WK, Xing D, Shultz LD, Savoldo B, Dotti G, Bollard CM, Miller L, Champlin RE, Shpall EJ, Zweidler-McKay PA. In reply. Exp Hematol 40(7):519-20, 2012. e-Pub 2012. PMID: 22507641.
Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, Samaniego F, McLaughlin P, Fanale M, Younes A, Cabanillas F, Fowler N, Newberry KJ, Sun L, Young KH, Champlin R, Kwak L, Feng L, Badillo M, Bejarano M, Hartig K, Chen W, Chen Y, Byrne C, Bell N, Zeldis J, Romaguera J. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 13(7):716-23, 2012. e-Pub 2012. PMID: 22677155.
Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ, Valverde R, Alousi AM, Anderlini P, Bashir Q, Ciurea S, Gulbis AM, de Lima M, Hosing C, Kebriaei P, Popat UR, Fowler N, Neelapu SS, Samaniego F, Champlin RE, Macapinlac HA. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood 119(26):6373-8, 2012. e-Pub 2012. PMID: 22586182.
Torikai H, Reik A, Liu PQ, Zhou Y, Zhang L, Maiti S, Huls H, Miller JC, Kebriaei P, Rabinovitch B, Lee DA, Champlin RE, Bonini C, Naldini L, Rebar EJ, Gregory PD, Holmes MC, Cooper LJ. A foundation for "universal" T-cell based immunotherapy: T-cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood 119(24):5697-705, 2012. e-Pub 2012. PMID: 22535661.
Brunstein CG, Eapen M, Ahn KW, Appelbaum FR, Ballen KK, Champlin RE, Cutler C, Kan F, Laughlin MJ, Soiffer RJ, Weisdorf DJ, Woolfrey A, Wagner JE. Reduced intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. Blood 119(23):5591-8, 2012. e-Pub 2012. PMID: 22496153.
Robinson SN, Simmons PJ, Thomas MW, Brouard N, Javni JA, Trilok S, Shim JS, Yang H, Steiner D, Decker WK, Xing D, Shultz LD, Savoldo B, Dotti G, Bollard CM, Miller L, Champlin RE, Shpall EJ, Zweidler-McKay PA. Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2Rγ(null) mice. Exp Hematol 40(6):445-56, 2012. e-Pub 2012. PMID: 22306295.
Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Ledesma C, Andersson BS, Jones R, Popat UR, Hosing CM, Nieto Y, Qazilbash MH, Ueno NT, Giralt SA, de Lima MJ, Champlin RE. Donor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. Anderson Cancer Center. Leuk Lymphoma 53(6):1239-41, 2012. e-Pub 2012. PMID: 22132837.
Sharma M, Khan H, Thall PF, Orlowski RZ, Bassett RL, Shah N, Bashir Q, Parmar S, Wang M, Shah JJ, Hosing CM, Popat UR, Giralt SA, Champlin RE, Qazilbash MH. A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer 118(9):2507-15, 2012. e-Pub 2012. PMID: 21887685.
Bashir Q, Munsell MF, Giralt S, de Padua Silva L, Sharma M, Couriel D, Chiattone A, Popat U, Qazilbash MH, Fernandez-Vina M, Champlin RE, de Lima MJ. Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplantation. Leuk Lymphoma 53(5):915-9, 2012. e-Pub 2012. PMID: 22023525.
Valdez BC, Murray D, Nieto Y, Li Y, Wang G, Champlin RE, Andersson BS. Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and SAHA in lymphoma cell lines. Leuk Lymphoma 53(5):973-81, 2012. e-Pub 2012. PMID: 22023523.
Ciurea SO, Saliba RM, Hamerschlak N, Karduss Aurueta AJ, Bassett R, Fernandez-Vina M, Petropoulos D, Worth LL, Chan KW, Couriel DR, Rondon G, Sharma M, Qazilbash M, Jones RB, Kebriaei P, McMannis J, Hosing CM, Nieto Y, Champlin RE, Shpall EJ, de Lima M. Fludarabine, Melphalan, Thiotepa and ATG Conditioning for Unrelated Cord Blood Transplantation. Leuk Lymphoma 53(5):901-6, 2012. e-Pub 2012. PMID: 21988645.
Kebriaei P, Saliba R, Rondon G, Chiattone A, Luthra R, Anderlini P, Andersson B, Shpall E, Popat U, Jones R, Worth L, Ravandi F, Thomas D, O'Brien S, Kantarjian H, de Lima M, Giralt S, Champlin R. Long-Term Follow-up of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact of Tyrosine Kinase Inhibitors on Treatment Outcomes. Biol Blood Marrow Transplant 18(4):584-92, 2012. e-Pub 2012. PMID: 21867666.
Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M, York S, Ravandi F, Kwari M, Faderl S, Rios MB, Cortes J, Fayad L, Tarnai R, Wang SA, Champlin R, Advani A, O'Brien S. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol 13(4):403-11, 2012. e-Pub 2012. PMID: 22357140.
Chemaly RF, Hanmod SS, Rathod DB, Ghantoji SS, Jiang Y, Doshi A, Vigil K, Adachi JA, Khoury AM, Tarrand J, Hosing C, Champlin R. The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation. Blood 119(12):2738-45, 2012. e-Pub 2012. PMID: 22246027.
Kantarjian H, O'Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, Rios MB, Ravandi F, Faderl S, Kadia T, Borthakur G, Huang X, Champlin R, Talpaz M, Cortes J. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 119(9):1981-7, 2012. e-Pub 2012. PMID: 22228624.
Bashir Q, Khan H, Orlowski RZ, Amjad AI, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Thomas SK, Shah JJ, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol 87(3):272-6, 2012. e-Pub 2012. PMID: 22231283.
Farhan S, Lee DA, Champlin RE, Ciurea SO. NK cell therapy: targeting disease relapse after hematopoietic stem cell transplantation. Immunotherapy 4(3):305-13, 2012. e-Pub 2012. PMID: 22329587.
Anderlini P, Saliba RM, Ledesma C, Chancoco C, Alousi AM, Shpall EJ, Popat UR, Hosing CM, Khouri IF, Nieto Y, Ciurea S, Younes A, Fanale MA, Acholonu S, Valverde R, Champlin RE. Gemcitabine, fludarabine and melphalan (G-FM) as a reduced-intensity conditioning regimen for allogeneic stem cell transplantation in relapsed and refractory hodgkin lymphoma: preliminary results. Leuk Lymphoma 53(3):499-502, 2012. e-Pub 2012. PMID: 21859247.
Bayraktar UD, Champlin RE, Ciurea SO. Progress in Haploidentical Stem Cell Transplantation. Biol Blood Marrow Transplant 18(3):372-80, 2012. e-Pub 2012. PMID: 21835146.
Majhail NS, Murphy EA, Denzen EM, Ferguson SS, Anasetti C, Bracey A, Burns L, Champlin R, Hubbard N, Markowitz M, Maziarz RT, Medoff E, Neumann J, Schmit-Pokorny K, Weisdorf DJ, Yolin Raley DS, Chell J, Snyder EL. The National Marrow Donor Program's Symposium on Hematopoietic Cell Transplantation in 2020: A Health Care Resource and Infrastructure Assessment. Biol Blood Marrow Transplant 18(2):172-82, 2012. e-Pub 2012. PMID: 22178961.
Kebriaei P, Huls H, Jena B, Munsell M, Jackson R, Lee DA, Hackett PB, Rondon G, Shpall E, Champlin RE, Cooper LJ. Infusing CD19-Directed T Cells to Augment Disease Control in Patients Undergoing Autologous Hematopoietic Stem-Cell Transplantation for Advanced B-Lymphoid Malignancies. Hum Gene Ther. e-Pub 2012. PMID: 22107246.
Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Orlowski RZ, Thomas SK, Shah J, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Feasibility of autologous hematopoietic stem cell transplantation in patients aged =70 years with multiple myeloma. Leuk Lymphoma 53(1):118-22, 2012. e-Pub 2012. PMID: 21780997.
Kebriaei P, Kelly SS, Manuri P, Jena B, Jackson R, Shpall E, Champlin R, Cooper LJ. Chimeric antibody receptors (CARs): Driving T-cell specificity to enhance anti-tumor immunity. Front Biosci (Schol Ed) 4:520-31, 2012. e-Pub 2012. PMID: 22202074.
O'Connor CM, Sheppard S, Hartline CA, Huls H, Johnson M, Palla SL, Maiti S, Ma W, Davis RE, Craig S, Lee DA, Champlin R, Wilson H, Cooper LJ. Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy. Sci Rep 2:249, 2012. e-Pub 2012. PMID: 22355761.
Cheng YC, Takagi M, Milbourne A, Champlin RE, Ueno NT. Phase II study of gonadotropin-releasing hormone analog for ovarian function preservation in hematopoietic stem cell transplantation patients. Oncologist 17(2):233-8, 2012. e-Pub 2012. PMID: 22282904.
Denman CJ, Senyukov VV, Somanchi SS, Phatarpekar PV, Kopp LM, Johnson JL, Singh H, Hurton L, Maiti SN, Huls MH, Champlin RE, Cooper LJ, Lee DA. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One 7(1):e30264, 2012. e-Pub 2012. PMID: 22279576.
Alatrash G, Pelosini M, Saliba RM, Koca E, Rondon G, Andersson BS, Chiattone A, Zhang W, Giralt SA, Cernosek AM, Kebriaei P, Alousi AM, Popat UR, Hosing C, Khouri IF, Champlin RE, de Lima MJ. Platelet Recovery Before Allogeneic Stem Cell Transplantation Predicts Posttransplantation Outcomes in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant 17(12):1841-5, 2011. e-Pub 2011. PMID: 21684343.
Eapen M, Klein JP, Sanz GF, Spellman S, Ruggeri A, Anasetti C, Brown M, Champlin RE, Garcia-Lopez J, Hattersely G, Koegler G, Laughlin MJ, Michel G, Nabhan SK, Smith FO, Horowitz MM, Gluckman E, Rocha V, for Blood EG, Transplantation M, Netcord, International Blood CF, Research MT. Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. Lancet Oncol 12(13):1214-21, 2011. e-Pub 2011. PMID: 21982422.
Passweg JR, Zhang MJ, Rocha V, Kan F, Champlin RE, Isola LM, Gee AP, Gibson J, Laughlin MJ, Lazarus HM, Loren A, Marks DI, Gratwohl A, Eapen M. Donor characteristics affecting graft failure, graft vs. Host disease and survival after unrelated donor transplantation with reduced intensity conditioning for hematologic malignancies. Biol Blood Marrow Transplant 17(12):1869-73, 2011. e-Pub 2011. PMID: 21771571.
Sharma M, Ravandi F, Bayraktar UD, Chiattone A, Bashir Q, Giralt S, Chen J, Qazilbash M, Kebriaei P, Konopleva M, Andreeff M, Cortes J, McCue D, Kantarjian H, Champlin RE, de Lima M. Treatment of FLT3-ITD Positive Acute Myeloid Leukemia Relapsing After Allogeneic Stem Cell Transplantation with Sorafenib. Biol Blood Marrow Transplant 17(12):1874-7, 2011. e-Pub 2011. PMID: 21767516.
Ciurea SO, Thall PF, Wang X, Wang SA, Hu Y, Cano P, Aung F, Rondon G, Molldrem JJ, Korbling M, Shpall EJ, de Lima M, Champlin RE, Fernandez-Vina M. Donor-specific anti-HLA antibodies and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood 118(22):5957-64, 2011. e-Pub 2011. PMID: 21967975.
Shah N, Ahmed F, Bashir Q, Qureshi S, Dinh Y, Rondon G, Wen S, Thall P, Khan H, Giralt S, Champlin R, Qazilbash MH. Durable remission with salvage second autotransplants in patients with multiple myeloma. Cancer. e-Pub 2011. PMID: 22086552.
Joseph RW, Alousi A, Konda B, Komanduri K, Neumann J, Trevino C, Stolar K, Qazilbash M, Hosing C, Kebriaei P, Couriel DR, Champlin RE, Saliba R, Popat U. High incidence of vitamin D deficiency in patients undergoing allogeneic stem cell transplantation. Am J Hematol 86(11):954-6, 2011. e-Pub 2011. PMID: 21948087.
Howell JE, Gulbis AM, Champlin RE, Qazilbash MH. Retrospective analysis of weekly intravenous immunoglobulin prophylaxis versus intravenous immunoglobulin by IgG level monitoring in hematopoietic stem cell transplant recipients. Am J Hematol. e-Pub 2011. PMID: 22081487.
Parmar S, de Lima M, Deeg HJ, Champlin R. Hematopoietic stem cell transplantation for myelodysplastic syndrome: a review. Semin Oncol 38(5):693-704, 2011. e-Pub 2011. PMID: 21943676.
Alatrash G, de Lima M, Hamerschlak N, Pelosini M, Wang X, Xiao L, Kerbauy F, Chiattone A, Rondon G, Qazilbash MH, Giralt SA, de Padua Silva L, Hosing C, Kebriaei P, Zhang W, Nieto Y, Saliba RM, Champlin RE, Andersson BS. Myeloablative Reduced-Toxicity i.v. Busulfan-Fludarabine and Allogeneic Hematopoietic Stem Cell Transplant for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome in the Sixth through Eighth Decades of Life. Biol Blood Marrow Transplant 17(10):1490-6, 2011. e-Pub 2011. PMID: 21338705.
Khan H, Oberoi S, Mahvash A, Sharma M, Rondon G, Alousi A, Shpall EJ, Kontoyiannis DP, Champlin RE, Ciurea SO. Reversible Ureteral Obstruction due to Polyomavirus Infection after Percutaneous Nephrostomy Catheter Placement. Biol Blood Marrow Transplant 17(10):1551-5, 2011. e-Pub 2011. PMID: 21396475.
Eapen M, Le Rademacher J, Antin JH, Champlin RE, Carreras J, Fay J, Passweg JR, Tolar J, Horowitz MM, Marsh JC, Deeg HJ. Effect of stem cell source on outcomes after adult unrelated donor transplantation in severe aplastic anemia. Blood 118(9):2618-21, 2011. e-Pub 2011. PMID: 21677312.
Ciurea SO, Champlin RE. Outcomes of patients treated and one human leukocyte antigen-mismatched related compared with matched unrelated donors. Biol Blood Marrow Transplant 17(8):1261, 2011. e-Pub 2011. PMID: 21699878.
Ciurea SO, Mulanovich V, Jiang Y, Bassett R, Rondon G, McMannis J, de Lima M, Shpall EJ, Champlin RE. Lymphocyte Recovery Predicts Outcomes in Cord Blood and T Cell-Depleted Haploidentical Stem Cell Transplantation. Biol Blood Marrow Transplant 17(8):1169-75, 2011. e-Pub 2011. PMID: 21126598.
Yang H, Robinson SN, Nieto Y, Jones RJ, Gocke CD, Lu J, Giralt SA, Jones RB, Decker WK, Xing D, Steiner D, Champlin RE, McMannis JD, Ng J, Thomas MW, Shah N, Andersson BS, Parmar S, Shpall EJ. Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma. Cancer Res 71(14):5040-9, 2011. e-Pub 2011. PMID: 21646477.
Bashir Q, Andersson BS, Fernandez-Vina M, de Padua Silva L, Giralt S, Chiattone A, Wei W, Sharma M, Anderlini P, Shpall EJ, Popat U, Rodrigues M, Champlin RE, de Lima M. Unrelated donor transplantation for acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant 17(7):1067-71, 2011. e-Pub 2011. PMID: 21087679.
Hosing C, Champlin RE. Stem-cell transplantation in T-cell non-Hodgkin's lymphomas. Ann Oncol 22(7):1471-7, 2011. e-Pub 2011. PMID: 21551006.
Soiffer RJ, Lerademacher J, Ho V, Kan F, Artz A, Champlin RE, Devine S, Isola L, Lazarus HM, Marks DI, Porter DL, Waller EK, Horowitz MM, Eapen M. Impact of immune modulation with anti-T cell antibodies on outcomes of reduced intensity allogeneic hematopoietic cell transplantation for hematologic malignancies. Blood 117(25):6963-70, 2011. e-Pub 2011. PMID: 21464372.
Hosing C, Smith V, Rhodes B, Walters K, Thompson R, Qazilbash M, Khouri I, de Lima M, Balzer RJ, McMannis J, Champlin R, Giralt S, Popat U. Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantation. Transfusion 51(6):1300-13, 2011. e-Pub 2011. PMID: 21575005.
Champlin R, Jabbour E, Kebriaei P, Anderlini P, Andersson B, de Lima M. Allogeneic stem cell transplantation for chronic myeloid leukemia resistant to tyrosine kinase inhibitors. Clin Lymphoma Myeloma Leuk 11 Suppl 1:S96-100, 2011. e-Pub 2011. PMID: 22035758.
Ciurea SO, Saliba RM, Rondon G, Patah PA, Aung F, Cano P, Andersson BS, Kebriaei P, Popat U, Fernandez-Vina M, Champlin RE, de Lima M. Outcomes of patients with myeloid malignancies treated with allogeneic hematopoietic stem cell transplantation from matched unrelated donors compared with one human leukocyte antigen mismatched related donors using HLA typing at 10 loci. Biol Blood Marrow Transplant 17(6):923-9, 2011. e-Pub 2011. PMID: 20969970.
Andersson BS, Valdez BC, de Lima M, Wang X, Thall PF, Worth LL, Popat U, Madden T, Hosing C, Alousi A, Rondon G, Kebriaei P, Shpall EJ, Jones RB, Champlin RE. Clofarabine±Fludarabine with Once Daily IV Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and MDS. Biol Blood Marrow Transplant 17(6):893-900, 2011. e-Pub 2011. PMID: 20946966.
Singh H, Figliola MJ, Dawson MJ, Huls H, Olivares S, Switzer K, Mi T, Maiti S, Kebriaei P, Lee DA, Champlin RE, Cooper LJ. Reprogramming CD19-Specific T Cells with IL-21 Signaling Can Improve Adoptive Immunotherapy of B-Lineage Malignancies. Cancer Res 71(10):3516-27, 2011. e-Pub 2011. PMID: 21558388.
Kazmi SM, Saliba RM, Donato M, Wang M, Hosing C, Qureshi S, Anderlini P, Popat U, Champlin RE, Giralt SA, Qazilbash MH. Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma. Bone Marrow Transplant 46(4):510-5, 2011. e-Pub 2011. PMID: 20581887.
Samuelson S, Sandmaier BM, Heslop HE, Popat U, Carrum G, Champlin RE, Storb R, Prchal JT, Gooley TA, Deeg HJ. Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age. Br J Haematol 153(1):76-82, 2011. e-Pub 2011. PMID: 21323890.
Jin Z, Maiti S, Huls H, Singh H, Olivares S, Mátés L, Izsvák Z, Ivics Z, Lee DA, Champlin RE, Cooper LJ. The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor. Gene Ther. e-Pub 2011. PMID: 21451576.
Khouri IF, Bassett R, Poindexter N, O'Brien S, Bueso-Ramos CE, Hsu Y, Ferrajoli A, Keating MJ, Champlin R, Fernandez-Vina M. Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: Long-Term Follow-Up, Prognostic Factors, and Effect of Human Leukocyte Histocompatibility Antigen Subtype on Outcome. Cancer. e-Pub 2011. PMID: 21455998.
Jabbour E, Cortes J, Santos FP, Jones D, O'Brien S, Rondon G, Popat U, Giralt S, Kebriaei P, Jones RB, Kantarjian H, Champlin R, de Lima M. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood 117(13):3641-7, 2011. e-Pub 2011. PMID: 21156844.
Popat U, de Lima MJ, Saliba RM, Anderlini P, Andersson BS, Alousi AM, Hosing C, Nieto Y, Parmar S, Khouri IF, Kebriaei P, Qazilbash M, Champlin RE, Giralt SA. Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR. Bone Marrow Transplant. e-Pub 2011. PMID: 21423123.
Saliba RM, Couriel DR, Giralt S, Rondon G, Okoroji GJ, Rashid A, Champlin RE, Alousi AM. Prognostic value of response after upfront therapy for acute GVHD. Bone Marrow Transplant. e-Pub 2011. PMID: 21383686.
Kebriaei P, Madden T, Kazerooni R, Wang X, Thall PF, Ledesma C, Nieto Y, Shpall EJ, Hosing C, Qazilbash M, Popat U, Khouri I, Champlin RE, Jones RB, Andersson BS. Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Advanced Lymphoid Malignancies. Biol Blood Marrow Transplant 17(3):412-20, 2011. e-Pub 2011. PMID: 20674757.
Bashir Q, Langford LA, Parmar S, Champlin RE, Qazilbash MH. Primary systemic amyloid light chain amyloidosis decompensating after filgrastim-induced mobilization and stem-cell collection. J Clin Oncol 29(4):e79-80, 2011. e-Pub 2011. PMID: 21060030.
Parmar S, Andersson BS, Couriel D, Munsell MF, Fernandez-Vina M, Jones RB, Shpall EJ, Popat U, Anderlini P, Giralt S, Alousi A, Cano P, Bosque D, Hosing C, Silva Lde P, Westmoreland M, Wathen JK, Berry D, Champlin RE, de Lima MJ. Prophylaxis of Graft-Versus-Host Disease in Unrelated Donor Transplantation with Pentostatin, Tacrolimus, and "Mini"-Methotrexate: A Phase I/II Controlled, Adaptively Randomized Study. J Clin Oncol 29(3):294-302, 2011. e-Pub 2011. PMID: 21149654.
Valdez BC, Li Y, Murray D, Champlin RE, Andersson BS. The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling. Biochem Pharmacol 81(2):222-32, 2011. e-Pub 2011. PMID: 20933509.
Champlin R. Hematopoietic stem cell transplantation for treatment of myleodysplastic syndromes. Biol Blood Marrow Transplant 17(1 Suppl):S6-8, 2011. e-Pub 2011. PMID: 21195312.
Anderlini P, Acholonu SA, Okoroji GJ, Bassett RE, Shpall EJ, Qazilbash MH, Popat UR, Worth LL, Giralt SA, Champlin RE. Fludarabine, cyclophosphamide, and antithymocyte globulin for matched related and unrelated allogeneic stem cell transplant in severe aplastic anemia. Leuk Lymphoma 52(1):137-41, 2011. e-Pub 2011. PMID: 20939697.
Mulanovich VE, Jiang Y, de Lima M, Shpall EJ, Champlin RE, Ciurea SO. Infectious complications in cord blood and T-cell depleted haploidentical stem cell transplantation. Am J Blood Res 1(1):98-105, 2011. e-Pub 2011. PMID: 22432070.
Westin JR, Saliba RM, De Lima M, Alousi A, Hosing C, Qazilbash MH, Khouri IF, Shpall EJ, Anderlini P, Rondon G, Andersson BS, Champlin R, Couriel DR. Steroid-Refractory Acute GVHD: Predictors and Outcomes. Adv Hematol 2011:601953, 2011. e-Pub 2011. PMID: 22110505.
de Lima M, Giralt S, Thall PF, de Padua Silva L, Jones RB, Komanduri K, Braun TM, Nguyen HQ, Champlin R, Garcia-Manero G. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 116(23):5420-31, 2010. e-Pub 2010. PMID: 20672358.
Li D, Li Y, Hernandez JA, Patenia R, Kim TK, Khalili J, Dougherty MC, Hanley PJ, Bollard CM, Komanduri KV, Hwu P, Champlin RE, Radvanyi LG, Molldrem JJ, Ma Q. Lovastatin Inhibits T-cell Proliferation While Preserving the Cytolytic Function of EBV, CMV, and MART-1-specific CTLs. J Immunother 33(9):975-82, 2010. e-Pub 2010. PMID: 20948439.
Ma W, Wang M, Wang ZQ, Sun L, Graber D, Matthews J, Champlin R, Yi Q, Orlowski RZ, Kwak LW, Weber DM, Thomas SK, Shah J, Kornblau S, Davis RE. Effect of Long-Term Storage in TRIzol on Microarray-Based Gene Expression Profiling. Cancer Epidemiol Biomarkers Prev 19(10):2445-52, 2010. e-Pub 2010. PMID: 20805315.
Choi Y, Yuen C, Maiti SN, Olivares S, Gibbons H, Huls H, Raphael R, Killian TC, Stark DJ, Lee DA, Torikai H, Monticello D, Kelly SS, Kebriaei P, Champlin RE, Biswal SL, Cooper LJ. A high throughput microelectroporation device to introduce a chimeric antigen receptor to redirect the specificity of human T cells. Biomed Microdevices 12(5):855-63, 2010. e-Pub 2010. PMID: 20574820.
Ravandi F, O'Brien S, Thomas D, Faderl S, Jones D, Garris R, Dara S, Jorgensen J, Kebriaei P, Champlin R, Borthakur G, Burger J, Ferrajoli A, Garcia-Manero G, Wierda W, Cortes J, Kantarjian H. First report of phase II study of dasatinib with hyperCVAD for the frontline treatment of patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia. Blood 116(12):2070-7, 2010. e-Pub 2010. PMID: 20466853.
Xing D, Ramsay AG, Gribben JG, Decker WK, Burks JK, Munsell M, Li S, Robinson SN, Yang H, Steiner D, Shah N, McMannis JD, Champlin RE, Hosing C, Zweidler-McKay PA, Shpall EJ, Bollard CM. Cord Blood Natural Killer Cells Exhibit Impaired Lytic Immunological Synapse Formation That Is Reversed With IL-2 Exvivo Expansion. J Immunother 33(7):684-96, 2010. e-Pub 2010. PMID: 20664358.
Kassis C, Champlin RE, Hachem RY, Hosing C, Tarrand JJ, Perego CA, Neumann JL, Raad II, Chemaly RF. Detection and Control of a Nosocomial Respiratory Syncytial Virus Outbreak in a Stem Cell Transplantation Unit: The Role of Palivizumab. Biol Blood Marrow Transplant 16(9):1265-71, 2010. e-Pub 2010. PMID: 20304082.
Velev N, Cortes J, Champlin R, Jones D, Rondon G, Giralt S, Borthakur G, Kantarjian HM, De Lima M. Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. Cancer 116(15):3631-7, 2010. e-Pub 2010. PMID: 20564073.
Efebera YA, Qureshi SR, Cole SM, Saliba R, Pelosini M, Patel RM, Koca E, Mendoza FL, Wang M, Shah J, Alousi A, Hosing C, Popat U, Kebriaei P, Anderlini P, Khouri IF, Champlin R, Giralt S, Qazilbash MH. Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma. Biol Blood Marrow Transplant 16(8):1122-1129, 2010. e-Pub 2010. PMID: 20178853.
Bashir Q, De Lima MJ, McMannis JD, Garcia-Manero G, Shpall E, Kantarjian H, Cortes JE, O'Brien SM, Jones D, Qazilbash M, Wei W, Giralt SA, Champlin RE, Hosing C. Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy. Leuk Lymphoma 51(8):1478-84, 2010. e-Pub 2010. PMID: 20658954.
Sharma M, Qureshi SR, Champlin RE, Popat U, Giralt S, Qazilbash MH. The outcome of IgD myeloma after autologous hematopoietic stem cell transplantation is similar to other Ig subtypes. Am J Hematol 85(7):502-4, 2010. e-Pub 2010. PMID: 20575022.
Silva Lde P, Patah PA, Saliba RM, Szewczyk NA, Gilman L, Neumann J, Han XY, Tarrand J, Ribeiro R, Gulbis A, Shpall EJ, Jones R, Popat U, Walker JA, Petropoulos D, Chiattone A, Stewart J, El-Zimaity M, Anderlini P, Giralt S, Champlin RE, de Lima M. Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type. Haematologica 95(7):1183-90, 2010. e-Pub 2010. PMID: 20410183.
Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang MJ, Arcese W, Sirvent A, Champlin RE, Chao N, Gee AP, Isola L, Laughlin MJ, Marks DI, Nabhan S, Ruggeri A, Soiffer R, Horowitz MM, Gluckman E, Wagner JE, International Blood CF, Research MT, Marrow Transplantation) ALWPE(EGFB, Blood Center NCBPOTNY. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol 11(7):653-60, 2010. e-Pub 2010. PMID: 20558104.
Yang H, Robinson SN, Lu J, Decker WK, Xing D, Steiner D, Parmar S, Shah N, Champlin RE, Munsell M, Leen A, Bollard C, Simmons PJ, Shpall EJ. CD3(+) and/or CD14(+) depletion from cord blood mononuclear cells before ex vivo expansion culture improves total nucleated cell and CD34(+) cell yields. Bone Marrow Transplant 45(6):1000-7, 2010. e-Pub 2010. PMID: 19838220.
Davies JK, Singh H, Huls H, Yuk D, Lee DA, Kebriaei P, Champlin RE, Nadler LM, Guinan EC, Cooper LJ. Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies. Cancer Res 70(10):3915-24, 2010. e-Pub 2010. PMID: 20424114.
Duvic M, Donato M, Dabaja B, Richmond H, Singh L, Wei W, Acholonu S, Khouri I, Champlin R, Hosing C. Total Skin Electron Beam and Non-Myeloablative Allogeneic Hematopoietic Stem-Cell Transplantation in Advanced Mycosis Fungoides and Sezary Syndrome. J Clin Oncol 28(14):2365-72, 2010. e-Pub 2010. PMID: 20351328.
Hurton LV, Siddik RI, Singh H, Olivares S, Rabinovich BA, Tian R, Mojsilovic D, Hildebrand W, Lee DA, Kelly SS, Champlin R, Shpall EJ, Fernandez-Viña M, Cooper LJ. Identifying candidate allogeneic NK-cell donors for hematopoietic stem-cell transplantation based on functional phenotype. Leukemia 24(5):1059-62, 2010. e-Pub 2010. PMID: 20164852.
Ramos CA, Saliba RM, de Pádua Silva L, Khorshid O, Shpall EJ, Giralt S, Patah PA, Hosing CM, Popat UR, Rondon G, Nieto Y, Champlin RE, de Lima M. Resolved hepatitis B virus infection is not associated with worse outcomes after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 16(5):686-94, 2010. e-Pub 2010. PMID: 20056165.
Ciurea SO, de Lima M, Giralt S, Saliba R, Bueso-Ramos C, Andersson BS, Hosing CM, Verstovsek S, Champlin RE, Popat U. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation. Biol Blood Marrow Transplant 16(4):555-9, 2010. e-Pub 2010. PMID: 20005966.
Shannon VR, Andersson BS, Lei X, Champlin RE, Kontoyiannis DP. Utility of early versus late fiberoptic bronchoscopy in the evaluation of new pulmonary infiltrates following hematopoietic stem cell transplantation. Bone Marrow Transplant 45(4):647-55, 2010. e-Pub 2010. PMID: 19684637.
Manuri PV, Wilson MH, Maiti SN, Mi T, Singh H, Olivares S, Dawson MJ, Huls H, Lee DA, Rao PH, Kaminski JM, Nakazawa Y, Gottschalk S, Kebriaei P, Shpall EJ, Champlin RE, Cooper LJ. piggyBac Transposon/Transposase System to Generate CD19-Specific T Cells for the Treatment of B-Lineage Malignancies. Hum Gene Ther 21(4):427-37, 2010. e-Pub 2010. PMID: 19905893.
Valdez BC, Li Y, Murray D, Corn P, Champlin RE, Andersson BS. 5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis. Leuk Res 34(3):364-72, 2010. e-Pub 2010. PMID: 19732952.
Ciurea SO, Saliba R, Rondon G, Pesoa S, Cano P, Fernandez-Vina M, Qureshi S, Worth LL, McMannis J, Kebriaei P, Jones RB, Korbling M, Qazilbash M, Shpall EJ, Giralt S, de Lima M, Champlin RE, Gajewski J. Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. Bone Marrow Transplant 45(3):429-36, 2010. e-Pub 2010. PMID: 19668237.
Safdar A, Rodriguez GH, Mihu CN, Mora-Ramos L, Mulanovich V, Chemaly RF, Champlin RE, Khouri I. Infections in non-myeloablative hematopoietic stem cell transplantation patients with lymphoid malignancies: spectrum of infections, predictors of outcome and proposed guidelines for fungal infection prevention. Bone Marrow Transplant 45(2):339-47, 2010. e-Pub 2010. PMID: 19561648.
Collins NH, Gee AP, Durett AG, Kan F, Zhang MJ, Champlin RE, Confer D, Eapen M, Howard A, King R, Laughlin MJ, Plante RJ, Setterholm M, Spellman S, Keever-Taylor C, Wagner JE, Weisdorf DJ. The Effect of the Composition of Unrelated Donor Bone Marrow and Peripheral Blood Progenitor Cell Grafts on Transplantation Outcomes. Biol Blood Marrow Transplant 16(2):253-62, 2010. e-Pub 2010. PMID: 19822219.
Couriel DR, Saliba R, de Lima M, Giralt S, Andersson B, Khouri I, Hosing C, Ippoliti C, Shpall EJ, Champlin R, Alousi A. A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 15(12):1555-1562, 2009. e-Pub 2009. PMID: 19896079.
Murphy WJ, Artz AS, Champlin RE, Koreth J, Longo DL. Blood stem cell transplantation in older patients. Biol Blood Marrow Transplant 15(12):1638-9, 2009. e-Pub 2009. PMID: 19911448.
Cheng YC, Rondón G, Sanchez LF, McMannis JD, Couriel DR, de Lima MJ, Hosing C, Khouri IF, Giralt SA, Champlin RE, Ueno NT. Interleukin-2 and granulocyte-macrophage-colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Int J Hematol 90(5):627-34, 2009. e-Pub 2009. PMID: 19998065.
Wang Y, Li D, Jones D, Bassett R, Sale GE, Khalili J, Komanduri KV, Couriel DR, Champlin RE, Molldrem JJ, Ma Q. Blocking LFA-1 activation with lovastatin prevents graft-versus-host disease in mouse bone marrow transplantation. Biol Blood Marrow Transplant 15(12):1513-22, 2009. e-Pub 2009. PMID: 19896074.
Armistead PM, de Lima M, Pierce S, Qiao W, Wang X, Thall PF, Giralt S, Ravandi F, Kantarjian H, Champlin R, Estey E. Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia. Biol Blood Marrow Transplant 15(11):1431-8, 2009. e-Pub 2009. PMID: 19822303.
Fenske TS, Hari PN, Carreras J, Zhang MJ, Kamble RT, Bolwell BJ, Cairo MS, Champlin RE, Chen YB, Freytes CO, Gale RP, Hale GA, Ilhan O, Khoury HJ, Lister J, Maharaj D, Marks DI, Munker R, Pecora AL, Rowlings PA, Shea TC, Stiff P, Wiernik PH, Winter JN, Rizzo JD, van Besien K, Lazarus HM, Vose JM. Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma. Biol Blood Marrow Transplant 15(11):1455-64, 2009. e-Pub 2009. PMID: 19822306.
Nakayama K, Liu P, Detry M, Schover LR, Milbourne A, Neumann J, Rondon G, Thewes B, Champlin RE, Ueno NT. Receiving information on fertility- and menopause-related treatment effects among women who undergo hematopoietic stem cell transplantation: changes in perceived importance over time. Biol Blood Marrow Transplant 15(11):1465-74, 2009. e-Pub 2009. PMID: 19822307.
Ciurea SO, de Lima M, Cano P, Korbling M, Giralt S, Shpall EJ, Wang X, Thall PF, Champlin RE, Fernandez-Vina M. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation 88(8):1019-24, 2009. e-Pub 2009. PMID: 19855248.
Parmar S, de Lima M, Zou Y, Patah P, Liu P, Cano P, Rondon G, Pesoa S, de Padua Silva L, Qazilbash MH, Hosing C, Popat U, Kebriaei P, Shpall EJ, Giralt S, Champlin RE, Stastny P, Fernandez-Vina M. Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease. Blood 114(14):2884-7, 2009. e-Pub 2009. PMID: 19654407.
Qazilbash MH, Amjad AI, Qureshi S, Qureshi SR, Saliba RM, Khan ZU, Hosing C, Giralt SA, De Lima MJ, Popat UR, Yusuf SW, Champlin RE. Outcome of allogeneic hematopoietic stem cell transplantation in patients with low left ventricular ejection fraction. Biol Blood Marrow Transplant 15(10):1265-70, 2009. e-Pub 2009. PMID: 19747634.
Souza D, JA, Saliba, RM, Patah, P, Rondon, G, Ribeiro, R, Silva DP, L, Qazilbash, MH, Hosing, C, Popat, U, Efebera, Y, Champlin, RE, Lima AD, M. Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 15(9):1094-9, 2009. e-Pub 2009. PMID: 19660722.
Ueno NT, de Souza JA, Booser D, Nakayama K, Madewell J, Wendt Iii RE, Hortobagyi GN, Podoloff D, Champlin RE. Pilot study of targeted skeletal radiation therapy for bone-only metastatic breast cancer. Clin Breast Cancer 9(3):173-7, 2009. e-Pub 2009. PMID: 19661041.
de Souza JA, Davis ML, Rondon G, Cheng YC, Jones RB, Champlin RE, Ueno NT. Prolonged disease control by nonmyeloablative allogeneic transplantation for metastatic breast cancer. Bone Marrow Transplant 44(2):81-7, 2009. e-Pub 2009. PMID: 19448681.
Parikh GC, Amjad AI, Saliba RM, Kazmi SM, Khan ZU, Lahoti A, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Popat U, Alousi AM, Champlin RE, Giralt SA, Qazilbash MH. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant 15(7):812-6, 2009. e-Pub 2009. PMID: 19539212.
Falchook GS, Vega F, Dang NH, Samaniego F, Rodriguez MA, Champlin RE, Hosing C, Verstovsek S, Pro B. Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. Ann Oncol 20(6):1080-5, 2009. e-Pub 2009. PMID: 19237479.
Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, Shpall E, McMannis J, Körbling M, Alousi A, Andersson B, Nieto Y, Kebriaei P, Khouri I, de Lima M, Weber D, Thomas S, Wang M, Jones R, Champlin R, Giralt S. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 15(6):718-23, 2009. e-Pub 2009. PMID: 19450756.
Hosing C, Saliba RM, Ahlawat S, Körbling M, Kebriaei P, Alousi A, De Lima M, Okoroji JG, McMannis J, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I, Popat U. Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol 84(6):335-7, 2009. e-Pub 2009. PMID: 19384931.
De Padua Silva L, de Lima M, Kantarjian H, Faderl S, Kebriaei P, Giralt S, Davisson J, Garcia-Manero G, Champlin R, Issa JP, Ravandi F. Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant 43(11):839-43, 2009. e-Pub 2009. PMID: 19151791.
Jabbour E, Giralt S, Kantarjian H, Garcia-Manero G, Jagasia M, Kebriaei P, de Padua L, Shpall EJ, Champlin R, de Lima M. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 115(9):1899-905, 2009. e-Pub 2009. PMID: 19235255.
Lazarus HM, Kan F, Tarima S, Champlin RE, Confer DL, Frey N, Gee AP, Wagner JE, Horowitz MM, Eapen M. Rapid transport and infusion of hematopoietic cells is associated with improved outcome after myeloablative therapy and unrelated donor transplant. Biol Blood Marrow Transplant 15(5):589-96, 2009. e-Pub 2009. PMID: 19361751.
van Besien K, Carreras J, Bierman PJ, Logan BR, Molina A, King R, Nelson G, Fay JW, Champlin RE, Lazarus HM, Vose JM, Hari PN. Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes. Biol Blood Marrow Transplant 15(5):554-63, 2009. e-Pub 2009. PMID: 19361747.
Saliba RM, Komanduri KV, Giralt S, de Souza J, Patah P, Oran B, Couriel D, Rondon G, Champlin RE, de Lima M. Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML. Bone Marrow Transplant 43(9):685-92, 2009. e-Pub 2009. PMID: 19011667.
Tam CS, Bassett R, Ledesma C, Korbling M, Alousi A, Hosing C, Kebraei P, Harrell R, Rondon G, Giralt SA, Anderlini P, Popat U, Pro B, Samuels B, Hagemeister F, Medeiros LJ, Champlin RE, Khouri IF. Mature results of the MD Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 113(18):4144-52, 2009. e-Pub 2009. PMID: 19168784.
Singh H, Najjar AM, Olivares S, Nishii R, Mukhopadhyay U, Alauddin M, Manuri PR, Huls H, Lee DA, Dotti G, Bollard C, Simmons PJ, Shpall EJ, Champlin RE, Gelovani JG, Cooper LJ. PET imaging of T cells derived from umbilical cord blood. Leukemia 23(3):620-2, 2009. e-Pub 2009. PMID: 18830258.
Ramos CA, Saliba RM, de Pádua L, Khorshid O, Shpall EJ, Giralt S, Patah PA, Hosing CM, Popat UR, Rondon G, Khouri IF, Nieto YL, Champlin RE, de Lima M. Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Haematologica 94(2):249-57, 2009. e-Pub 2009. PMID: 19144658.
Qazilbash MH, Saliba RM, Nieto Y, Parikh G, Pelosini M, Khan FB, Jones RB, Hosing C, Mendoza F, Weber DM, Wang M, Popat U, Alousi A, Anderlini P, Champlin RE, Giralt S. Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant 14(12):1401-7, 2008. e-Pub 2008. PMID: 19041063.
Lee SJ, Astigarraga CC, Eapen M, Artz AS, Davies SM, Champlin R, Jagasia M, Kernan NA, Loberiza FR, Bevans M, Soiffer RJ, Joffe S. Variation in supportive care practices in hematopoietic cell transplantation. Biol Blood Marrow Transplant 14(11):1231-8, 2008. e-Pub 2008. PMID: 18940677.
Valdez BC, Murray D, Ramdas L, de Lima M, Jones R, Kornblau S, Betancourt D, Li Y, Champlin RE, Andersson BS. Altered gene expression in busulfan-resistant human myeloid leukemia. Leuk Res 32(11):1684-97, 2008. e-Pub 2008. PMID: 18339423.
Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M, Woolfrey AE, Cervantes F, Champlin RE, Gale RP, Halter J, Keating A, Marks DI, McCarthy PL, Olavarria E, Stadtmauer EA, Abecasis M, Gupta V, Khoury HJ, George B, Hale GA, Liesveld JL, Rizzieri DA, Antin JH, Bolwell BJ, Carabasi MH, Copelan E, Ilhan O, Litzow MR, Schouten HC, Zander AR, Horowitz MM, Maziarz RT. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood 112(8):3500-7, 2008. e-Pub 2008. PMID: 18664621.
Tam CS, Nussenzveig RM, Popat U, Bueso-Ramos CE, Thomas DA, Cortes JA, Champlin RE, Ciurea SE, Manshouri T, Pierce SM, Kantarjian HM, Verstovsek S. The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. Blood 112(5):1628-37, 2008. e-Pub 2008. PMID: 18566326.
Rondón G, Saliba RM, Khouri I, Giralt S, Chan K, Jabbour E, McMannis J, Champlin R, Shpall E. Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis. Biol Blood Marrow Transplant 14(8):859-66, 2008. e-Pub 2008. PMID: 18640568.
Lee HJ, Gulbis A, De Padua Silva L, Hosing C, Khouri I, de Lima M, Champlin RE, Ciurea SO. Rituximab for passenger lymphocyte syndrome associated with allogeneic SCT. Bone Marrow Transplant 42(1):67-9, 2008. e-Pub 2008. PMID: 18347568.
Alousi AM, Saliba RM, Okoroji GJ, Macapinlac HA, Hosing C, Korbling M, Samuels BI, Popat U, Kebriaei P, Anderlini P, Qazilbash MH, de Lima M, Giralt SA, Champlin RE, Khouri IF. Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation. Br J Haematol 142(5):786-92, 2008. e-Pub 2008. PMID: 18564354.
Andersson BS, de Lima M, Thall PF, Wang X, Couriel D, Korbling M, Roberson S, Giralt S, Pierre B, Russell JA, Shpall EJ, Jones RB, Champlin RE. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant 14(6):672-84, 2008. e-Pub 2008. PMID: 18489993.
Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, Medeiros LJ, Fayad L, Samaniego F, Alousi A, Anderlini P, Couriel D, de Lima M, Giralt S, Neelapu SS, Ueno NT, Samuels BI, Hagemeister F, Kwak LW, Champlin RE. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 111(12):5530-6, 2008. e-Pub 2008. PMID: 18411419.
Hosing C, Saliba RM, Okoroji GJ, Popat U, Couriel D, Ali T, De Padua Silva L, Kebriaei P, Alousi A, De Lima M, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I. High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age. Ann Oncol 19(6):1166-71, 2008. e-Pub 2008. PMID: 18272911.
de Lima M, McMannis J, Gee A, Komanduri K, Couriel D, Andersson BS, Hosing C, Khouri I, Jones R, Champlin R, Karandish S, Sadeghi T, Peled T, Grynspan F, Daniely Y, Nagler A, Shpall EJ. Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. Bone Marrow Transplant 41(9):771-8, 2008. e-Pub 2008. PMID: 18209724.
Lee SJ, Joffe S, Artz AS, Champlin RE, Davies SM, Jagasia M, Kernan NA, Loberiza FR, Soiffer RJ, Eapen M. Individual physician practice variation in hematopoietic cell transplantation. J Clin Oncol 26(13):2162-70, 2008. e-Pub 2008. PMID: 18378566.
Anderlini P, Swanston N, Rashid A, Bueso-Ramos C, Macapinlac HA, Champlin RE. Evidence of a graft-versus-Hodgkin lymphoma effect in the setting of extensive bone marrow involvement. Biol Blood Marrow Transplant 14(4):478-80, 2008. e-Pub 2008. PMID: 18342791.
Singh H, Manuri PR, Olivares S, Dara N, Dawson MJ, Huls H, Hackett PB, Kohn DB, Shpall EJ, Champlin RE, Cooper LJ. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res 68(8):2961-71, 2008. e-Pub 2008. PMID: 18413766.
Ueno NT, Rizzo JD, Demirer T, Cheng YC, Hegenbart U, Zhang MJ, Bregni M, Carella A, Blaise D, Bashey A, Bitran JD, Bolwell BJ, Elfenbein GJ, Fields KK, Freytes CO, Gale RP, Lazarus HM, Champlin RE, Stiff PJ, Niederwieser D. Allogeneic hematopoietic cell transplantation for metastatic breast cancer. Bone Marrow Transplant 41(6):537-45, 2008. e-Pub 2008. PMID: 18084340.
de Lima M, Champlin RE, Thall PF, Wang X, Martin TG, Cook JD, McCormick G, Qazilbash M, Kebriaei P, Couriel D, Shpall EJ, Khouri I, Anderlini P, Hosing C, Chan KW, Andersson BS, Patah PA, Caldera Z, Jabbour E, Giralt S. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia 22(2):258-64, 2008. e-Pub 2008. PMID: 17989720.
Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno NT, Hosing C, Khouri IF, Couriel D, de Lima M, Qazilbash MH, Pro B, Romaguera J, Fayad L, Hagemeister F, Younes A, Munsell MF, Champlin RE. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 93(2):257-64, 2008. e-Pub 2008. PMID: 18223284.
Chou LS, Lewis RE, Ippoliti C, Champlin RE, Kontoyiannis DP. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients. Pharmacotherapy 27(12):1644-50, 2007. e-Pub 2007. PMID: 18041885.
Safdar A, Rodriguez GH, De Lima MJ, Petropoulos D, Chemaly RF, Worth LL, Shpall EJ, Rolston KV, Raad II, Chan KW, Champlin RE. Infections in 100 cord blood transplantations: spectrum of early and late posttransplant infections in adult and pediatric patients 1996-2005. Medicine (Baltimore) 86(6):324-33, 2007. e-Pub 2007. PMID: 18004177.
Sims CR, Thompson K, Chemaly RF, Shpall EJ, Champlin RE, Safdar A. Oral topical cidofovir: novel route of drug delivery in a severely immunosuppressed patient with refractory multidrug-resistant herpes simplex virus infection. Transpl Infect Dis 9(3):256-9, 2007. e-Pub 2007. PMID: 17605730.
Lin EH, Hassan M, Li Y, Zhao H, Nooka A, Sorenson E, Xie K, Champlin R, Wu X, Li D. Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence. Cancer 110(3):534-42, 2007. e-Pub 2007. PMID: 17594720.
Nakayama K, Tannir NM, Liu P, Wathen JK, Cheng YC, Champlin RE, Ueno NT. Natural history of metastatic renal cell carcinoma in patients who underwent consultation for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 13(8):975-85, 2007. e-Pub 2007. PMID: 17640602.
Jabbour E, Cortes J, Kantarjian H, Giralt S, Andersson BS, Giles F, Shpall E, Kebriaei P, Champlin R, de Lima M. Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. Cancer 110(2):340-4, 2007. e-Pub 2007. PMID: 17559140.
Ozdemir E, Saliba RM, Champlin RE, Couriel DR, Giralt SA, de Lima M, Khouri IF, Hosing C, Kornblau SM, Anderlini P, Shpall EJ, Qazilbash MH, Molldrem JJ, Chemaly RF, Komanduri KV. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant 40(2):125-36, 2007. e-Pub 2007. PMID: 17530009.
Champlin RE, Perez WS, Passweg JR, Klein JP, Camitta BM, Gluckman E, Bredeson CN, Eapen M, Horowitz MM. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood 109(10):4582-5, 2007. e-Pub 2007. PMID: 17272503.
Khouri IF, Saliba RM, Admirand J, O'Brien S, Lee MS, Korbling M, Samuels BI, Giralt S, Lima de M, Keating MJ, Champlin RE, Bueso-Ramos C. Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol 137(4):355-63, 2007. e-Pub 2007. PMID: 17456058.
Saliba RM, de Lima M, Giralt S, Andersson B, Khouri I, Hosing C, Ghosh S, Neumann J, Jsu Y, De Jesus J, Qazilbash M, Champlin R, Couriel DR. Hyper-acute GVHD: risk factors, outcomes and clinical implications. Blood 109(7):2751-8, 2007. e-Pub 2007.
Oran B, Donato M, Aleman A, Hosing C, Korbling M, Detry MA, Wei C, Anderlini P, Popat U, Shpall E, Giralt S, Champlin RE. Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment. Biol Blood Marrow Transplant 13(4):469-77, 2007. e-Pub 2007. PMID: 17382253.
Qazilbash MH, Saliba RM, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Flosser T, Couriel DR, De Lima M, Kebriaei P, Popat U, Alousi AM, Champlin RE, Giralt SA. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant 39(5):279-83, 2007. e-Pub 2007. PMID: 17262062.
Estey E, de Lima M, Tibes R, Pierce S, Kantarjian H, Champlin R, Giralt S. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 109:1395-400, 2007. e-Pub 2007. PMID: 17038533.
Safdar A, Rodriguez G, Rolston KV, O'Brien S, Khouri IF, Shpall EJ, Keating MJ, Kantarjian HM, Champlin RE, Raad II, Kontoyiannis DP. High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopietic stem cell transplantation. Bone Marrow Transplant 39:157-164, 2007. e-Pub 2007.
Madden T, de Lima M, Thapar N, Ngyuen J, Roberson S, Couriel D, Pierre B, Shpall EJ, Jones RB, Champlin RE, Andersson BA. Pharmacokinetics of a once-daily busulfun as part of pretransplantation preparative regimen: a comparison with an every 6-hour schedule. Biol Blood Marrow Transplant 13:56-64, 2007. e-Pub 2007.
Körbling M, Reuben JM, Gao H, Lee BN, Harris DM, Cogdell D, Giralt SA, Khouri IF, Saliba RM, Champlin RE, Zhang W, Estrov Z. Recombinant human granulocyte-colony-stimulating factor-mobilized and apheresis-collected endothelial progenitor cells: a novel blood cell component for therapeutic vasculogenesis. Transfusion 46(10):1795-802, 2006. e-Pub 2006. PMID: 17002637.
Johnson MR, Del Carpio-Jayo D, Lin P, Giralt S, Anderlini P, Champlin RE, Khouri IF, Vadhan-Raj S, Medeiros LJ, Bueso-Ramos CE. Primary plasma cell leukemia: morphologic, immunophenotypic, and cytogenetic features of 4 cases treated with chemotherapy and stem cell transplantation. Ann Diagn Pathol 10:263-8, 2006. e-Pub 2006. PMID: 16979517.
Lekakis L, Giralt S, Couriel D, Shpall EJ, Hosing C, Khouri IF, Anderlini P, Korbling M, Martin T, Champlin RE, de Lima M. Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. Bone Marrow Transplant 38:421-6, 2006. e-Pub 2006. PMID: 16892072.
Chemaly RF, Ghosh S, Bodey GP, Rohatgi N, Safdar A, Keating MJ, Champlin RE, Aguilera EA, Tarrand JJ, Raad, II. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore) 85:278-87, 2006. e-Pub 2006. PMID: 16974212.
Kebriaei P, Saliba RM, Ma C, Ippoliti C, Couriel DR, de Lima M, Giralt S, Qazilbash MH, Gajewski JL, Ha CS, Champlin RE, Khouri IF. Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia. Bone Marrow Transplant 38:203-9, 2006. e-Pub 2006. PMID: 16799614.
Jabbour E, Cortes J, Kantarjian HM, Giralt S, Jones D, Jones R, Giles F, Andersson BS, Champlin R, de Lima M. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood 108(4):1421-3, 2006. e-Pub 2006. PMID: 16601247.
Hosing C, Saliba RM, Korbling M, Acholonu S, McMannis J, Anderlini P, Giralt S, De Lima M, Okoroji GJ, Couriel DR, Champlin R, Khouri IF, Donato ML. High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma 47:1290-4, 2006. e-Pub 2006. PMID: 16923559.
Qazilbash MH, Saliba RM, Aleman A, Lei X, Weber D, Carrasco A, Champlin RE, Giralt SA. Risk factors for relapse after complete remission with high-dose therapy for multiple myeloma. Leuk Lymphoma 47:1360-4, 2006. e-Pub 2006. PMID: 16923569.
Anderlini P, Champlin RE. Reduced intensity conditioning for allogeneic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: where do we stand?. Biol Blood Marrow Transplant 12:599-602, 2006. e-Pub 2006. PMID: 16737932.
Safdar A, Rodriguez GH, Lichtiger B, Dickey BF, Kontoyiannis DP, Freireich EJ, Shpall EJ, Raad II, Kantarjian HM, Champlin RE. Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. Cancer 106(12):2664-71, 2006. e-Pub 2006. PMID: 16691620.
Hanrahan EO, Broglio K, Frye D, Buzdar AU, Theriault RL, Valero V, Booser DJ, Singletary SE, Strom EA, Gajewski JL, Champlin RE, Hortobagyi GN. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years. Cancer 106(11):2327-36, 2006. e-Pub 2006. PMID: 16639731.
Hosing C, Qazilbash MH, Kebriaei P, Giralt S, Davis MS, Popat U, Anderlini P, Shpall EJ, McMannis J, Körbling M, Champlin RE. Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma. Br J Haematol 133(5):533-7, 2006. e-Pub 2006. PMID: 16681642.
Tsimberidou AM, O'Brien S, Khouri I, Giles FJ, Kantarjian HM, Champlin R, Wen S, Do KA, Smith SC, Lerner S, Freireich EJ, Keating MJ. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol 24:2343-51, 2006. e-Pub 2006. PMID: 16710033.
Ueno NT, Konoplev S, Buchholz TA, Smith T, Rondón G, Anderlini P, Giralt SA, Gajewski JL, Donato ML, Cristofanilli M, Champlin RE. High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to neoadjuvant chemotherapy. Bone Marrow Transplant 37(10):929-35, 2006. e-Pub 2006. PMID: 16565737.
Couriel DR, Hosing C, Saliba R, Shpall EJ, Anderlini P, Rhodes B, Smith V, Khouri I, Giralt S, de Lima M, Hsu Y, Ghosh S, Neumann J, Andersson B, Qazilbash M, Hymes S, Kim S, Champlin R, Donato M. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood 107(8):3074-80, 2006. e-Pub 2006. PMID: 16368882.
Decker WK, Xing D, Li S, Robinson SN, Yang H, Yao X, Segall H, McMannis JD, Komanduri KV, Champlin RE, Shpall EJ. Double loading of dendritic cell MHC class I and MHC class II with an AML antigen repertoire enhances correlates of T-cell immunity in vitro via amplification of T-cell help. Vaccine 24(16):3203-16, 2006. e-Pub 2006. PMID: 16480795.
Yang H, Eaves C, de Lima M, Lee MS, Champlin RE, McMannis JD, Robinson SN, Niu T, Decker WK, Xing D, Ng J, Li S, Yao X, Eaves AC, Jones R, Andersson BS, Shpall EJ. A novel triple purge strategy for eliminating chronic myelogenous leukemia (CML) cells from autografts. Bone Marrow Transplant 37:575-82, 2006. e-Pub 2006. PMID: 16435011.
Qazilbash MH, Saliba R, De Lima M, Hosing C, Couriel D, Aleman A, Roden L, Champlin R, Giralt SA. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer 106:1084-9, 2006. e-Pub 2006. PMID: 16456814.
Robinson SN, Ng J, Niu T, Yang H, McMannis JD, Karandish S, Kaur I, Fu P, Del Angel M, Messinger R, Flagge F, de Lima M, Decker W, Xing D, Champlin R, Shpall EJ. Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells. Bone Marrow Transplant 37:359-66, 2006. e-Pub 2006. PMID: 16400333.
Couriel D, Hosing C, Saliba R, Shpall EJ, Andelini P, Popat U, Donato M, Champlin R. Extracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work?. Biol Blood Marrow Transplant 12:37-40, 2006. e-Pub 2006. PMID: 16399600.
Qazilbash MH, Ueno NT, Hosing C, de Lima M, Cortes J, Massaro A, Rivera Z, Deavers M, Adachi JA, Champlin RE. Strongyloidiasis after unrelated nonmyeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 38(5):393-394, 2006. e-Pub 2006.
Xing D, Decker WK, Li S, Robinson SN, Yang H, Segal H, O'Connor S, Yao X, Komanduri KV, McMannis JD, Jones RB, de Lima M, Champlin RE, Shpall EJ. AML-loaded DC generate Th1-type cellular immune responses in vitro. Cytotherapy 8:95-104, 2006. e-Pub 2006. PMID: 16698683.
Hosing C, Qazilbash MH, Kebriaei P, giralt S, Davis MS, Popat U, Anderlini P, Shpall EJ, McMannis J, Korbling M, Champlin RE. Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell transplantation in relapsed and refractory Hodgkin Lymphoma: where do we stand?. BR J Haematol 133(5):533-537, 2006. e-Pub 2006.
Schmitz N, Eapen M, horowitz MM, Zhang MJ, Klein JP, Rizzo JD, Loberiza FR, Gratwohl A, Champlin RE. Long term outcome of patients transplanted with mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood 108(13):4288-90, 2006. e-Pub 2006.
Robinson SN, Ng J, Niu T, Yang H, McMannis JD, Karandish S, Kaur I, Fu P, Del Angel M, Messinger R, Flagge F, de Lima M, Decker W, Xing D, Champlin R, Shpall EJ. Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells. Bone Marrow Transplant 37:359-366, 2006. e-Pub 2006.
Johnson MR, del Carpio-Jayo D, Lin P, giralt S, Anderlini P, Champlin RE, Khouri IF, Vadhan-Raj S, Medeiros LJ, Bueso-Ramos CE. Primary plasma cell leukemia: morphlogic, immunophenotypic, and cytogenetic features of 4 cases treated with chemotherapy and stem cell transplantation. Ann Dign Pathol 10:263-268, 2006. e-Pub 2006.
Loren AW, Bunin GR, Boudreau C, Champlin RE, Cnaan A, Horowitz MM, loberiza FR, Porter DL. Impact of donor and receipient sex and parity on outcomes of HLA-identical sibling allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 12:758-769, 2006. e-Pub 2006.
Champlin RE. Steroid myopathy in patients with acute graft-versus-host disease treated with high-dose steroid therapy. Bone Marrow Transplant 38:203-209, 2006. e-Pub 2006.
Parmar S, Robinson SN, Komanduri K, St John L, Decker W, Xing D, Yang H, McMannis J, Champlin R, de Lima M, Molldrem J, Rieber A, Bonyhadi M, Berenson R, Shpall EJ. Ex vivo expanded umbilical cord blood T cells maintain naive phenotype and TCR diversity. Cytotherapy 8:149-57, 2006. e-Pub 2006. PMID: 16698688.
Petropoulos D Worth LL, Mullen CA, Madden R, Mahajan A, Choroszy M, Ha CS, Champlin RE, Chan KW. Total body irradiation, fludarabine, melphalan, and allogeneic hematopoietic stem cell transplantation for advanced pediatric hematologic malignancies. Bone Marrow Transplantation 37:463-467, 2006. e-Pub 2006.
Couriel D, Hosing C, Saliba R, Shpall EJ, Anderlini P, Rhosed B, Smith V, Khouri I, Giralt S, de Lima M, Hsu Y, Ghosh S, Neumann J, Andersson B, Qazilbash M, Hymes S, Kim S, Champlin R, Donato M. Extracorporeal photopheresis for acute and chronic graft-versus-host diseas: does it work?. Biol Blood Marrow Transplant 12:37-40, 2006. e-Pub 2006.
Lee SA, Diwan AH, Cohn M, Champlin R, Safdar A. Cutaneous toxoplasmosis: a case of confounding diagnosis. Bone Marrow Transplant 36(5):465-6, 2005. e-Pub 2005. PMID: 16007107.
Couriel DR, Saliba R, Escalon MP, Hsu Y, Ghosh S, Ippoliti C, Hicks K, Donato M, Giralt S, Khouri IF, Hosing C, de Lima MJ, Andersson B, Neumann J, Champlin R. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol 130(3):409-17, 2005. e-Pub 2005. PMID: 16042691.
Hosing C, Saliba RM, Shahjahan M, Estey EH, Couriel D, Giralt S, Andersson B, Champlin RE, De Lima M. Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia. Bone Marrow Transplant 36(2):157-62, 2005. e-Pub 2005. PMID: 15937511.
Aviner S, Yao X, Krauthgamer R, Gan Y, Goren-Arbel R, Klein T, Tabilio A, McMannis JD, Champlin R, Martelli MF, Bachar-Lustig E, Reisner Y. Large-scale preparation of human anti-third-party veto cytotoxic T lymphocytes depleted of graft-versus-host reactivity: a new source for graft facilitating cells in bone marrow transplantation. Hum Immunol 66(6):644-52, 2005. e-Pub 2005. PMID: 15993710.
Kantarjian H, Talpaz M, O'Brien S, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Shan J, Rios MB, Champlin R, de Lima M, Cortes J. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience. Cancer 103(10):2099-108, 2005. e-Pub 2005. PMID: 15830345.
Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Donato M, Giralt S, Andersson B, Ueno NT, Khouri I, De Lima M, Hosing C, Cohen A, Ippoliti C, Romaguera J, Rodriguez MA, Pro B, Fayad L, Goy A, Younes A, Champlin RE. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 35(10):943-51, 2005. e-Pub 2005. PMID: 15806128.
Khouri IF, Saliba RM, Hosing C, Okoroji GJ, Acholonu S, Anderlini P, Couriel D, De Lima M, Donato ML, Fayad L, Giralt S, Jones R, Korbling M, Maadani F, Manning JT, Pro B, Shpall E, Younes A, McLaughlin P, Champlin RE. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol 23(10):2240-7, 2005. e-Pub 2005. PMID: 15800314.
Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C, Safdar A, Kantarjian H, Champlin R, Walsh TJ, Raad, II. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 191(8):1350-60, 2005. e-Pub 2005. PMID: 15776383.
Safdar A, Rodriguez G, Ohmagari N, Kontoyiannis DP, Rolston KV, Raad II, Champlin RE. The safety of interferon-gamma-1b therapy for invasive fungal infections after hematopoietic stem cell transplantation. Cancer 103(4):731-9, 2005. e-Pub 2005. PMID: 15641032.
Wong R, Shahjahan M, Wang X, Thall PF, De Lima M, Khouri I, Gajewski J, Alamo J, Couriel D, Andersson BS, Donato M, Hosing C, Komanduri K, Anderlini P, Molldrem J, Ueno NT, Estey E, Ippoliti C, Champlin R, Giralt S. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant 11(2):108-14, 2005. e-Pub 2005. PMID: 15682071.
Donato ML, Feasel AM, Weber DM, Prieto VG, Giralt SA, Champlin RE, Duvic M. Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation. Blood 107(2):463-6, 2005. e-Pub 2005. PMID: 16179379.
Korbling M, Robinson S, Estrov Z, Champlin RE, Shpall E. Umbilical cord blood-derived cells for tissue repair. Cytotherapy 7(3):258-261, 2005. e-Pub 2005.
Laughlin, MJ, Eapen M, Rubinstein P, Wagner JE, Zhang MJ, Champlin RE, Stevens C, Barker JN, Gale RP, Lazarus HM, Marks DI, van Rood JJ, Scaradavou A, Horowitz MM. Outcomes After Transplantation of Cord Blood or Bone Marrow From Unrelated Donors in Adults With Leukemia. Obstet Gynecol Surv 60((5)):295-296, 2005. e-Pub 2005.
Qazilbash M, Qu Z, Hosing C, Donato M, Giralt S, Champlin R. Superior ex-vivo expansion of umbilical cord blood. Cytotherapy 80(1):43-45, 2005. e-Pub 2005.
Eapen M, Horowitz MM, Klein JP, Champlin RE, Loberiza FR, Jr, Ringden O, Wagner JE. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol 22(24):4872-80, 2004. e-Pub 2004. PMID: 15520055.
Khorshid O, Hosing C, Bibawi S, Ueno N, Reveille J, Mayes MD, Champlin RE. Nonmyeloablative stem cell transplant in a patient with advanced systemic sclerosis and systemic lupus erythematosus. J Rheumatol 31(12):2513-6, 2004. e-Pub 2004. PMID: 15570660.
Martins SL, St John LS, Champlin RE, Wieder ED, McMannis J, Molldrem JJ, Komanduri KV. Functional assessment and specific depletion of alloreactive human T cells using flow cytometry. Blood 104(12):3429-36, 2004. e-Pub 2004. PMID: 15284108.
Cheng YC, Rondon G, Yang Y, Smith TL, Gajewski JL, Donato ML, Shpall EJ, Jones R, Hortobagyi GN, Champlin RE, Ueno NT. The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy. Biol Blood Marrow Transplant 10(11):794-804, 2004. e-Pub 2004. PMID: 15505610.
Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang MJ, Champlin RE, Stevens C, Barker JN, Gale RP, Lazarus HM, Marks DI, van Rood JJ, Scaradavou A, Horowitz MM. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 351(22):2265-75, 2004. e-Pub 2004. PMID: 15564543.
Anderlini P, Acholonu SA, Okoroji GJ, Andersson BS, Couriel DR, De Lima MJ, Donato ML, Khouri IF, Giralt SA, Ueno NT, Champlin RE. Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response. Bone Marrow Transplant 34(6):511-4, 2004. e-Pub 2004. PMID: 15273710.
Alexanian R, Weber D, Delasalle K, Handy B, Champlin R, Giralt S. Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma. Bone Marrow Transplant 34(3):229-34, 2004. e-Pub 2004. PMID: 15170166.
de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C, Andersson BS, Gajewski J, Couriel D, Cortes J, Donato M, Neumann J, Champlin R, Giralt S. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 104(3):865-72, 2004. e-Pub 2004. PMID: 15090449.
Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C, Khouri I, Andersson B, Gajewski J, Donato M, Anderlini P, Kontoyiannis DP, Cohen A, Martin T, Giralt S, Champlin R. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 104(3):649-54, 2004. e-Pub 2004. PMID: 15069017.
de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R, Shpall EJ, Shahjahan M, Pierre B, Giralt S, Korbling M, Russell JA, Champlin RE, Andersson BS. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 104(3):857-64, 2004. e-Pub 2004. PMID: 15073038.
Patel SR, Papadopolous N, Raymond AK, Donato M, Seong CM, Yasko AW, Lewis VO, Lin PP, Champlin R, Benjamin RS. A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis. Cancer 101(1):156-63, 2004. e-Pub 2004. PMID: 15222001.
Alyea EP, Canning C, Neuberg D, Daley H, Houde H, Giralt S, Champlin R, Atkinson K, Soiffer RJ. CD8+ cell depletion of donor lymphocyte infusions using cd8 monoclonal antibody-coated high-density microparticles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: a pilot study. Bone Marrow Transplant 34(2):123-8, 2004. e-Pub 2004. PMID: 15133487.
El-Zimaity M, Saliba R, Chan K, Shahjahan M, Carrasco A, Khorshid O, Caldera H, Couriel D, Giralt S, Khouri I, Ippoliti C, Champlin R, de Lima M. Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: donor type matters. Blood 103(12):4674-80, 2004. e-Pub 2004. PMID: 14726405.
Donato ML, Aleman A, Champlin RE, Saliba RM, Wharton JT, Burke TW, Bodurka DC, Bevers MW, Levenback CF, Wolf JK, Bast RC, Freedman RS, Ippoliti C, Brewer M, Gajewski JL, Gershenson DM. Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant 33(12):1219-24, 2004. e-Pub 2004. PMID: 15122311.
Van Besien K, Mehra R, Wadehra N, Stock W, Khouri I, Giralt S, Devine S, Wickrema A, Peace D, Sosman J, Gajewski J, Champlin R. Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed or refractory non-Hodgkin lymphoma. Biol Blood Marrow Transplant 10(6):386-94, 2004. e-Pub 2004. PMID: 15148492.
Thall PF, Champlin RE, Andersson BS. Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment and center effects. Bone Marrow Transplant 33(12):1191-9, 2004. e-Pub 2004. PMID: 15122310.
Escalon MP, Champlin RE, Saliba RM, Acholonu SA, Hosing C, Fayad L, Giralt S, Ueno NT, Maadani F, Pro B, Donato M, McLaughlin P, Khouri IF. Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 22(12):2419-23, 2004. e-Pub 2004. PMID: 15197204.
Thomas DA, Faderl S, Cortes J, O'Brien S, Giles FJ, Kornblau SM, Garcia-Manero G, Keating MJ, Andreeff M, Jeha S, Beran M, Verstovsek S, Pierce S, Letvak L, Salvado A, Champlin R, Talpaz M, Kantarjian H. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103(12):4396-407, 2004. e-Pub 2004. PMID: 14551133.
Popat U, Hosing C, Saliba RM, Anderlini P, van Besien K, Przepiorka D, Khouri IF, Gajewski J, Claxton D, Giralt S, Rodriguez M, Romaguera J, Hagemeister F, Ha C, Cox J, Cabanillas F, Andersson BS, Champlin RE. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Bone Marrow Transplant 33(10):1015-23, 2004. e-Pub 2004. PMID: 15048145.
Mittal P, Saliba RM, Giralt SA, Shahjahan M, Cohen AI, Karandish S, Onida F, Beran M, Champlin RE, de Lima M. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia. Bone Marrow Transplant 33(10):1005-9, 2004. e-Pub 2004. PMID: 15048141.
Donato ML, Aleman A, Champlin RE, Weber D, Alexanian R, Ippoliti CM, de Lima M, Anagnostopoulos A, Giralt S. High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma. Leuk Lymphoma 45(4):755-9, 2004. e-Pub 2004. PMID: 15160952.
Anagnostopoulos A, Aleman A, Yang Y, Donato M, Weber D, Champlin R, Smith T, Alexanian R, Giralt S. Outcomes of autologous stem cell transplantation in patients with multiple myeloma who received dexamethasone-based nonmyelosuppressive induction therapy. Bone Marrow Transplant 33(6):623-8, 2004. e-Pub 2004. PMID: 14730336.
Couriel DR, Saliba RM, Giralt S, Khouri I, Andersson B, de Lima M, Hosing C, Anderlini P, Donato M, Cleary K, Gajewski J, Neumann J, Ippoliti C, Rondon G, Cohen A, Champlin R. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 10(3):178-85, 2004. e-Pub 2004. PMID: 14993883.
Stanzani M, Martins SL, Saliba RM, St John LS, Bryan S, Couriel D, McMannis J, Champlin RE, Molldrem JJ, Komanduri KV. CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk for graft-versus-host disease after HLA-identical stem cell transplantation in humans. Blood 103(3):1140-6, 2004. e-Pub 2004. PMID: 12907445.
Studeny, M, Marini FC, Dembinski JK, Zompetta C, Cabreira-Hansen M, Champlin RE, Andreeff M. Bone marrow derived mesenchymal stem cells as precursors for tumor stroma and targeted delivery vehicles of anti-cancer agents. JNCI 96(21):1593-1603, 2004. e-Pub 2004.
Niu, T, Najjar A, Robinson S, Yanhg H, Decker W, McMannis J, NgJ, Thomas M, Xing D, Champlin RE, Gelovani J, Shpall EJ. High Efficiency Transduction of Human Mesenchymal Stem Cells Using Retroviral Gene Transfer with Triple Reporter Genes. Blood 104:150b(4258), 2004. e-Pub 2004.
Khouri IF, Lee MS, Saliba RM, Andersson B, Anderlini P, Couriel D, Hosing C, Giralt S, Korbling M, McMannis J, Keating MJ, Champlin RE. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol 32(1):28-35, 2004. e-Pub 2004. PMID: 14725898.
Donato ML, Levenback C, Gershenson DM, McMeekin S, Champlin RE. Matched unrelated donor bone marrow transplantation for the treatment of platinum refractory ovarian carcinoma: a case report. Gynecol Oncol 92(1):365-7, 2004. e-Pub 2004. PMID: 14751187.
Khouri, I, Albitar M, Saliba R, Ippliti C, Ma YC, Keating MJ, Champlin RE. Low-Dose Alemtuzumab (CampathÒ) In Vivo With High-Dose Chemoradiotherapy and Allogeneic Stem Cell Transplantation (ASCT): Graft-versus-leukemia with no Acute Graft-Versus-Host-Disease (GVHD. Bone Marrow Transplantation 33:833-837, 2004. e-Pub 2004.
Pentz RD, Chan KW, Neumann JL, Champlin RE, Korbling M. Designing an ethical policy for bone marrow donation by minors and others lacking capacity. Camb Q Healthc Ethics 13(2):149-55, 2004. e-Pub 2004. PMID: 15124402.
Shreyaskumar, P, Papadopolous N, Raymond AK, Donato M, C-M S, Yasko A, Lewis V, Lin P, Champlin R, Benjamin R. A Phase II Study of Cisplatin, Doxorubincin, and ifosfamide with Peripheral Blood Stem Cell support in Patients with Skeletal Osteosarcoma and Variant Bone Tumors with a Poor Prognosis. Cancer 101:156-153, 2004. e-Pub 2004.
Anderlini, P, Sheth S, Hicks K, Ippoliti C, Giralt S, Champlin RE. Re: imatinib Mesylate Administration in the First 100 days after Stem cell transplantation. Bio. Blood & Marrow Trans 12:883-884, 2004. e-Pub 2004.
Anagnostopoulos A, Aleman A, Ayers G, Donato M, Champlin R, Weber D, Alexanian R, Giralt S. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan and cyclophosphamide for patietns with multiple myeloma. Cancer 100(12):2607-2612, 2004. e-Pub 2004.
Eapen M, Giralt SA, Horowitz MM, Klein JP, Wagner JE, Zhang MJ, Tallman MS, Marks DI, Camitta BM, Champlin RE, Ringden O, Bredson CN, Martino R, Gale RP. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant 34:721-727, 2004. e-Pub 2004.
Anderlini P, Valbuena JR, Champlin RE, Bueso-Ramos CE. Epstein-Barr virus associated, CD-20 - polyclonal lymphoproliferative disorder after matched unrelated donor marrow transplantation. Bone Marrow Transplant 34(10):919-921, 2004. e-Pub 2004.
Khouri IF, Lee MS, Saliba RM, Jun G, Fayad L, Younes A, Pro B, Acholonu S, McLaughlin P, Katz RL, Champlin RE. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 21(23):4407-12, 2003. e-Pub 2003. PMID: 14645431.
Khorshid O, de Meis E, Martin T, Jones RB, Shpall EJ, Nieto Y, Khouri I, Shahjahan M, Gajewski J, Giralt S, Champlin R, de Lima M. Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant. Leukemia 17(12):2538-40, 2003. e-Pub 2003. PMID: 14523458.
Chatzinikolaou I, Hanna H, Graviss L, Chaiban G, Perego C, Arbuckle R, Champlin R, Darouiche R, Samonis G, Raad I. Clinical experience with minocycline and rifampin-impregnated central venous catheters in bone marrow transplantation recipients: efficacy and low risk of developing staphylococcal resistance. Infect Control Hosp Epidemiol 24(12):961-3, 2003. e-Pub 2003. PMID: 14700414.
Khouri IF, Saliba RM, Okoroji GJ, Acholonu SA, Champlin RE. Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score. Cancer 98(12):2630-5, 2003. e-Pub 2003. PMID: 14669282.
Wu HH, Talpaz M, Champlin RE, Pilat SR, Kurzrock R. Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses. Cancer 98(11):2410-9, 2003. e-Pub 2003. PMID: 14635076.
Ueno NT, Cheng YC, Rondon G, Tannir NM, Gajewski JL, Couriel DR, Hosing C, de Lima MJ, Anderlini P, Khouri IF, Booser DJ, Hortobagyi GN, Pagliaro LC, Jonasch E, Giralt SA, Champlin RE. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 102(10):3829-36, 2003. e-Pub 2003. PMID: 12881308.
Wong R, Giralt SA, Martin T, Couriel DR, Anagnostopoulos A, Hosing C, Andersson BS, Cano P, Shahjahan M, Ippoliti C, Estey EH, McMannis J, Gajewski JL, Champlin RE, de Lima M. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood 102(8):3052-9, 2003. e-Pub 2003. PMID: 12842990.
Wong R, Beguelin GZ, de Lima M, Giralt SA, Hosing C, Ippoliti C, Forman AD, Kumar AJ, Champlin R, Couriel D. Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation. Br J Haematol 122(1):128-34, 2003. e-Pub 2003. PMID: 12823354.
Kontoyiannis DP, Hachem R, Lewis RE, Rivero GA, Torres HA, Thornby J, Champlin R, Kantarjian H, Bodey GP, Raad, II. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 98(2):292-9, 2003. e-Pub 2003. PMID: 12872348.
Wong R, Rondon G, Saliba RM, Shannon VR, Giralt SA, Champlin RE, Ueno NT. Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancer. Bone Marrow Transplant 31(12):1157-63, 2003. e-Pub 2003. PMID: 12796796.
Wong R, de Lima M, Couriel D, Giralt S, Hosing C, Shahjahan M, Cheng YC, Bruton J, Champlin R, Khouri I. Treatment of relapsing refractory diffuse large cell lymphoma after matched unrelated donor bone marrow transplant with immunosuppression withdrawal and rituximab. Leuk Lymphoma 44(5):829-32, 2003. e-Pub 2003. PMID: 12802922.
Montemurro F, Rondón G, Munsell M, Smith TL, Donato ML, Gajewski JL, Rahman ZU, Buzdar AU, Champlin RE, Ueno NT. Predicting outcome based on Swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection. Biol Blood Marrow Transplant 9(5):330-40, 2003. e-Pub 2003. PMID: 12766883.
Hosing C, Saliba RM, McLaughlin P, Andersson B, Rodriguez MA, Fayad L, Cabanillas F, Champlin RE, Khouri IF. Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma. Ann Oncol 14(5):737-44, 2003. e-Pub 2003. PMID: 12702528.
Levine JE, Harris RE, Loberiza FR, Armitage JO, Vose JM, Van Besien K, Lazarus HM, Horowitz MM, Bashey A, Bolwell BJ, Burns LJ, Cairo MS, Champlin RE, Freytes CO, Gibson J, Goldstein SC, Laughlin MJ, Lister J, Marks DI, Maziarz RT, Miller AM, Milone GA, Pavlovsky S, Pecora AL, Rizzo JD, Schiller G, Schouten HC, Zhang MJ, Writing Committee LS, Transplant Registry IBM, Blood A, Registry MT. A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood 101(7):2476-82, 2003. e-Pub 2003. PMID: 12456505.
Herne KL, Talpur R, Breuer-McHam J, Champlin R, Duvic M. Cytomegalovirus seropositivity is significantly associated with mycosis fungoides and Sezary syndrome. Blood 101(6):2132-6, 2003. e-Pub 2003. PMID: 12446446.
Thall PF, Wathen JK, Bekele BN, Champlin RE, Baker LH, Benjamin RS. Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes. Stat Med 22(5):763-80, 2003. e-Pub 2003. PMID: 12587104.
de Lima M, Ravandi F, Shahjahan M, Andersson B, Couriel D, Donato M, Khouri I, Gajewski J, van Besien K, Champlin R, Giralt S, Kantarjian H. Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer 97(5):1242-7, 2003. e-Pub 2003. PMID: 12599231.
Apisarnthanarax N, Donato M, Korbling M, Couriel D, Gajewski J, Giralt S, Khouri I, Hosing C, Champlin R, Duvic M, Anderlini P. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results. Bone Marrow Transplant 31(6):459-65, 2003. e-Pub 2003. PMID: 12665841.
Giralt, S, Bensinger W, Goodman M, Podoloff D, Eary J, Wendt R, Alexanian R, Weber D, Maloney D, Holmberg L, Rajandran J, Breitz H, Ghalie R, Champlin R. 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials. Blood 102:2684 – 2691, 2003. e-Pub 2003.
De Lima M, St John LS, Wieder ED, Lee MS, McMannis J, Karandish S, Giralt S, Beran M, Couriel D, Korbling M, Bibawi S, Champlin R, Komanduri KV. Double-chimaerism after transplantation of two human leucocyte antigen mismatched, unrelated cord blood units. Br J Haematol 119(3):773-6, 2002. e-Pub 2002. PMID: 12437658.
Guo JQ, Lin H, Kantarjian H, Talpaz M, Champlin R, Andreeff M, Glassman A, Arlinghaus RB. Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients. Leukemia 16(12):2447-53, 2002. e-Pub 2002. PMID: 12454751.
Gajewski JL, Ippoliti C, Ma Y, Champlin R. Discontinuation of immunosuppression for prevention of kidney graft rejection after receiving a bone marrow transplant from the same HLA identical sibling donor. Am J Hematol 71(4):311-3, 2002. e-Pub 2002. PMID: 12447962.
Ozdemir E, St John LS, Gillespie G, Rowland-Jones S, Champlin RE, Molldrem JJ, Komanduri KV. Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells. Blood 100(10):3690-7, 2002. e-Pub 2002. PMID: 12393402.
Anderlini P, Chan FA, Champlin RE, Korbling M, Strom SS. Long-term follow-up of normal peripheral blood progenitor cell donors treated with filgrastim: no evidence of increased risk of leukemia development. Bone Marrow Transplant 30(10):661-3, 2002. e-Pub 2002. PMID: 12420204.
Sierra J, Pérez WS, Rozman C, Carreras E, Klein JP, Rizzo JD, Davies SM, Lazarus HM, Bredeson CN, Marks DI, Canals C, Boogaerts MA, Goldman J, Champlin RE, Keating A, Weisdorf DJ, de Witte TM, Horowitz MM. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 100(6):1997-2004, 2002. e-Pub 2002. PMID: 12200358.
Kantarjian HM, O'Brien S, Cortes JE, Giralt SA, Rios MB, Shan J, Giles FJ, Thomas DA, Faderl S, De Lima M, Garcia-Manero G, Champlin R, Arlinghaus R, Talpaz M. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 100(5):1590-5, 2002. e-Pub 2002. PMID: 12176876.
Giralt S, Aleman A, Anagnostopoulos A, Weber D, Khouri I, Anderlini P, Molldrem J, Ueno NT, Donato M, Korbling M, Gajewski J, Alexanian R, Champlin R. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 30(6):367-73, 2002. e-Pub 2002. PMID: 12235521.
Konopleva M, Zhao S, Hu W, Jiang S, Snell V, Weidner D, Jackson CE, Zhang X, Champlin R, Estey E, Reed JC, Andreeff M. The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells. Br J Haematol 118(2):521-34, 2002. e-Pub 2002. PMID: 12139741.
Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 62(13):3603-8, 2002. e-Pub 2002. PMID: 12097260.
Shaikh ZH, Torres HA, Walsh GL, Champlin RE, Kontoyiannis DP. Open lung biopsy in bone marrow transplant recipients has a poor diagnostic yield for a specific diagnosis. Transpl Infect Dis 4(2):80-4, 2002. e-Pub 2002. PMID: 12220244.
Montemurro F, Rondon G, Ueno NT, Munsell M, Gajewski JL, Champlin RE. Factors affecting progression-free survival in hormone-dependent metastatic breast cancer patients receiving high-dose chemotherapy and hematopoietic progenitor cell transplantation: role of maintenance endocrine therapy. Bone Marrow Transplant 29(10):861-6, 2002. e-Pub 2002. PMID: 12058236.
Körbling M, Katz RL, Khanna A, Ruifrok AC, Rondon G, Albitar M, Champlin RE, Estrov Z. Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells. N Engl J Med 346(10):738-46, 2002. e-Pub 2002. PMID: 11882729.
van Rood JJ, Loberiza FR, Zhang MJ, Oudshoorn M, Claas F, Cairo MS, Champlin RE, Gale RP, Ringdén O, Hows JM, Horowitz MH. Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling. Blood 99(5):1572-7, 2002. e-Pub 2002. PMID: 11861270.
Hosing C, Munsell M, Yazji S, Andersson B, Couriel D, de Lima M, Donato M, Gajewski J, Giralt S, Korbling M, Martin T, Ueno NT, Champlin RE, Khouri IF. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. Ann Oncol 13(3):450-9, 2002. e-Pub 2002. PMID: 11996478.
Champlin RE. Non-myeloablative hematopoietic transplantation for treatment of malignant diseases. Current Opinion in Organ Transplantation 7:275-278, 2002. e-Pub 2002.
Gajewski JL, Rondon G, Donato ML, Anderlini P, Korbling M, Ippoliti C, Benyunes M, Miller LL, LaTemple D, Jones D, Ashby M, Hellmann S, Durett A, Lauppe J, Geisler D, Khouri IF, Giralt SA, Andersson B, Ueno NT, Champlin R. Use of thrombopoietin in combination with chemotherapy and granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization. Biol Blood Marrow Transplant 8(10):550-6, 2002. e-Pub 2002. PMID: 12434950.
McMannis JD, Champlin RE. Role of the GMP facility for adoptive immunotherapy. Cytotherapy 4(4):329-31, 2002. e-Pub 2002. PMID: 12396832.
Wong, R, Champlin RE, Anderlini P. Bases biologicas e indicaciones de los trasplantes no mieloablativos. Hematologia 5:182-192, 2002. e-Pub 2002.
Khouri IF, Keating MJ, Saliba RM, Champlin RE. Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation. Cytotherapy 4(3):217-21, 2002. e-Pub 2002. PMID: 12194718.
Kashyap A, Wingard J, Cagnoni P, Roy J, Tarantolo S, Hu W, Blume K, Niland J, Palmer JM, Vaughan W, Fernandez H, Champlin R, Forman S, Andersson BS. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant 8(9):493-500, 2002. e-Pub 2002. PMID: 12374454.
Andersson BS, Kashyap A, Gian V, Wingard JR, Fernandez H, Cagnoni PJ, Jones RB, Tarantolo S, Hu WW, Blume KG, Forman SJ, Champlin RE. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant 8(3):145-54, 2002. e-Pub 2002. PMID: 11939604.
Andersson BS, Thall PF, Madden T, Couriel D, Wang X, Tran HT, Anderlini P, de Lima M, Gajewski J, Champlin RE. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 8(9):477-85, 2002. e-Pub 2002. PMID: 12374452.
Hosing C, Champlin RE. The choice of allogeneic or autologous hematopoietic transplantation for NHL. Cytotherapy 4(3):259-69, 2002. e-Pub 2002. PMID: 12194722.
Kantarijan H, O, Brien S, Cortes JE, Giralt S, Rios MB, Shan J, Giles FJ, Thomas DA, Faderl S, de Lima M, Garcia-Manero G, Champlin R, Arlinghaus R, Talpaz M. Imatinib mesylate theraypy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 100:1590-1595, 2002. e-Pub 2002.
Kim YS, Konoplev SN, Montemurro F, Hoy E, Smith TL, Rondon G, Champlin RE, Sahin AA, Ueno NT. HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation. Clin Cancer Res 7(12):4008-12, 2001. e-Pub 2001. PMID: 11751494.
Khouri IF, Saliba RM, Giralt SA, Lee MS, Okoroji GJ, Hagemeister FB, Korbling M, Younes A, Ippoliti C, Gajewski JL, McLaughlin P, Anderlini P, Donato ML, Cabanillas FF, Champlin RE. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 98(13):3595-9, 2001. e-Pub 2001. PMID: 11739162.
Gopal R, Ha CS, Tucker SL, Khouri IF, Giralt SA, Gajewski JL, Andersson BS, Cox JD, Champlin RE. Comparison of two total body irradiation fractionation regimens with respect to acute and late pulmonary toxicity. Cancer 92(7):1949-58, 2001. e-Pub 2001. PMID: 11745270.
Rodriguez J, Munsell M, Yazji S, Hagemeister FB, Younes A, Andersson B, Giralt S, Gajewski J, de Lima M, Couriel D, Romaguera J, Cabanillas FF, Champlin RE, Khouri IF. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 19(17):3766-70, 2001. e-Pub 2001. PMID: 11533100.
Przepiorka D, Anderlini P, Saliba R, Cleary K, Mehra R, Khouri I, Huh YO, Giralt S, Braunschweig I, van Besien K, Champlin R. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 98(6):1695-700, 2001. e-Pub 2001. PMID: 11535499.
Donato ML, Gershenson DM, Wharton JT, Ippoliti CM, Aleman AS, Bodurka-Bevers D, Bevers MW, Burke TW, Levenback CF, Wolf JK, Freedman RS, Bast RC, Jr, Gajewski JL, Champlin RE. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer. Gynecol Oncol 82(3):420-6, 2001. e-Pub 2001. PMID: 11520135.
Bibawi S, Abi-Said D, Fayad L, Anderlini P, Ueno NT, Mehra R, Khouri I, Giralt S, Gajewski J, Donato M, Claxton D, Braunschweig I, van Besien K, Andreeff M, Andersson BS, Estey EH, Champlin R, Przepiorka D. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. Am J Hematol 67(4):227-33, 2001. e-Pub 2001. PMID: 11443634.
Przepiorka D, Smith TL, Folloder J, Anderlini P, Chan KW, Korbling M, Lichtiger B, Norfleet F, Champlin R. Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors. Blood 97(11):3405-10, 2001. e-Pub 2001. PMID: 11369630.
Ravandi F, Kantarjian H, Cohen A, Davis M, O'Brien S, Anderlini P, Andersson B, Claxton D, Donato M, Gajewski J, Khouri I, Korbling M, Ueno N, deVos D, Champlin R, Giralt S. Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study. Bone Marrow Transplant 27(12):1221-5, 2001. e-Pub 2001. PMID: 11548839.
Alexanian R, Weber D, Giralt S, Dimopoulos M, Delasalle K, Smith T, Champlin R. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 27(10):1037-43, 2001. e-Pub 2001. PMID: 11438818.
Anagnostopoulos A, Dimopoulos MA, Aleman A, Weber D, Alexanian R, Champlin R, Giralt S. High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom's macroglobulinemia. Bone Marrow Transplant 27(10):1027-9, 2001. e-Pub 2001. PMID: 11438816.
Kornblau SM, Stiouf I, Snell V, Przepiorka D, Stephens LC, Champlin R, Marini FC, rd. Preemptive control of graft-versus-host disease in a murine allogeneic transplant model using retrovirally transduced murine suicidal lymphocytes. Cancer Res 61(8):3355-60, 2001. e-Pub 2001. PMID: 11309292.
Anderlini P, Rizzo JD, Nugent ML, Schmitz N, Champlin RE, Horowitz MM. Peripheral blood stem cell donation: an analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases. Bone Marrow Transplant 27(7):689-92, 2001. e-Pub 2001. PMID: 11360107.
Shimoni A, Smith TL, Aleman A, Weber D, Dimopoulos M, Anderlini P, Andersson B, Claxton D, Ueno NT, Khouri I, Donato M, Korbling M, Alexanian R, Champlin R, Giralt S. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma. Bone Marrow Transplant 27(8):821-8, 2001. e-Pub 2001. PMID: 11477439.
Konoplev S, Champlin RE, Giralt S, Ueno NT, Khouri I, Raad I, Rolston K, Jacobson K, Tarrand J, Luna M, Nguyen Q, Whimbey E. Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients. Bone Marrow Transplant 27(8):877-81, 2001. e-Pub 2001. PMID: 11477447.
La Rosa AM, Champlin RE, Mirza N, Gajewski J, Giralt S, Rolston KV, Raad I, Jacobson K, Kontoyiannis D, Elting L, Whimbey E. Adenovirus infections in adult recipients of blood and marrow transplants. Clin Infect Dis 32(6):871-6, 2001. e-Pub 2001. PMID: 11247710.
Esmaeli B, Medeiros LJ, Myers J, Champlin R, Singh S, Ginsberg L. Orbital mass secondary to precursor T-cell acute lymphoblastic leukemia: a rare presentation. Arch Ophthalmol 119(3):443-6, 2001. e-Pub 2001. PMID: 11231781.
van Besien K, Rodriguez A, Tomany S, Younes A, Donato M, Sarris A, Giralt S, Mehra R, Andersson B, Gajewski J, Champlin R, Cabanillas F. Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival. Bone Marrow Transplant 27(4):397-404, 2001. e-Pub 2001. PMID: 11313669.
Champlin RE. Introduction: Community Respiratory virus infections in the bone marrow transplant population. Biology of Blood and Marrow Transplantation 7:1S, 2001. e-Pub 2001.
Shimoni A, Gajewski JA, Donato M, Martin T, O'Brien S, Talpaz M, Cohen A, Korbling M, Champlin R, Giralt S. Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant 7(10):568-75, 2001. e-Pub 2001. PMID: 11760089.
Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C, Claxton D, Donato M, Bruton J, Cohen A, Davis M, Andersson BS, Anderlini P, Gajewski J, Kornblau S, Andreeff M, Przepiorka D, Ueno NT, Molldrem J, Champlin R. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 97:631-7, 2001. e-Pub 2001. PMID: 11157478.
Wang Y, Liu J, Wu Y, Luo W, Lin SH, Lin H, Hawk N, Sun T, Guo JQ, Estrov Z, Talpaz M, Champlin R, Arlinghaus RB. Expression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth and induces cell death. Cancer Res 61(1):138-44, 2001. e-Pub 2001. PMID: 11196151.
Korbling M, Giralt S, Khouri I, Mirza N, Donato M, Anderlini P, Fischer H, Andreeff M, McMannis J, Champlin R. Donor lymphocyte apheresis for adoptive immunotherapy compared with blood stem cell apheresis. J Clin Apher 16(2):82-7, 2001. e-Pub 2001. PMID: 11746533.
Andersson, B, Tran H, Madden T, Esfandiary N, Gajewski J, Couriel D, Giralt S, Donato M, Anderlini P, Körbling M, Khouri I, Kantarjian H, Champlin R. Acute graft vs host disease (aGvHD) and toxicity correlate with busulfan systemic exposure (buse) after the IV BuCy2 regimen and stem cell transplantation (HSCT) for CML. Blood 96((11)):393a, 2000. e-Pub 2000.
Andersson BS, Madden T, Tran HT, Hu WW, Blume KG, Chow DS, Champlin RE, Vaughan WP. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant 6(5A):548-54, 2000. e-Pub 2000. PMID: 11071260.
Rodriguez J, Keating MJ, O'Brien S, Champlin RE, Khouri IF. Allogeneic haematopoietic transplantation for Richter's syndrome. Br J Haematol 110:897-9, 2000. e-Pub 2000. PMID: 11054078.
Hanna H, Raad I, Gonzalez V, Umphrey J, Tarrand J, Neumann J, Champlin R. Control of nosocomial Clostridium difficile transmission in bone marrow transplant patients. Infect Control Hosp Epidemiol 21:226-8, 2000. e-Pub 2000. PMID: 10738997.
Przepiorka D, Kernan NA, Ippoliti C, Papadopoulos EB, Giralt S, Khouri I, Lu JG, Gajewski J, Durett A, Cleary K, Champlin R, Andersson BS, Light S. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 95(1):83-9, 2000. e-Pub 2000. PMID: 10607689.
Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE, Davis MM. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 6:1018-23, 2000. e-Pub 2000. PMID: 10973322.
Abbott B, Ippoliti C, Hecth D, Bruton J, Whaley B, Champlin R. Granisetron (Kytril) plus dexamethasone for antiemetic control in bone marrow transplant patients receiving highly emetogenic chemotherapy with or without total body irradiation. Bone Marrow Transplant 25:1279-83, 2000. e-Pub 2000. PMID: 10871733.
Braunschweig I, Mirza NQ, Rondon G, Lauppe J, Mehra R, Gajewski J, Korbling M, Huh YO, Geisler D, Gee AP, Champlin R, Przepiorka D. High CD34 cell doses do not worsen regimen-related toxicity or early mortality after autologous blood stem cell transplantation for breast cancer. Cytotherapy 2(2):105-10, 2000. e-Pub 2000. PMID: 12042047.
de Lima M, van Besien K, Gajewski J, Khouri I, Andersson B, Korbling M, Champlin R, Giralt S. High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant. Bone Marrow Transplant 26:333-8, 2000. e-Pub 2000. PMID: 10967575.
Buchholz TA, Tucker SL, Moore RA, McNeese MD, Strom EA, Jhingrin A, Hortobagyi GN, Singletary SE, Champlin RE. Importance of radiation therapy for breast cancer patients treated with high-dose chemotherapy and stem cell transplant. Int J Radiat Oncol Biol Phys 46:337-43, 2000. e-Pub 2000. PMID: 10661340.
Huaringa AJ, Leyva FJ, Giralt SA, Blanco J, Signes-Costa J, Velarde H, Champlin RE. Outcome of bone marrow transplantation patients requiring mechanical ventilation. Crit Care Med 28:1014-7, 2000. e-Pub 2000. PMID: 10809275.
Nash RA, Kurzrock R, DiPersio J, Vose J, Linker C, Maharaj D, Nademanee AP, Negrin R, Nimer S, Shulman H, Ashby M, Jones D, Appelbaum FR, Champlin R. A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 6(1):25-34, 2000. e-Pub 2000. PMID: 10707996.
Hortobagyi GN, Buzdar AU, Theriault RL, Valero V, Frye D, Booser DJ, Holmes FA, Giralt S, Khouri I, Andersson B, Gajewski JL, Rondon G, Smith TL, Singletary SE, Ames FC, Sneige N, Strom EA, McNeese MD, Deisseroth AB, Champlin RE. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst 92:225-33, 2000. e-Pub 2000. PMID: 10655439.
Ghosh S, Champlin RE, Englund J, Giralt SA, Rolston K, Raad I, Jacobson K, Neumann J, Ippoliti C, Mallik S, Whimbey E. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin. Bone Marrow Transplant 25:751-5, 2000. e-Pub 2000. PMID: 10745261.
Champlin RE, Passweg JR, Zhang MJ, Rowlings PA, Pelz CJ, Atkinson KA, Barrett AJ, Cahn JY, Drobyski WR, Gale RP, Goldman JM, Gratwohl A, Gordon-Smith EC, Henslee-Downey PJ, Herzig RH, Klein JP, Marmont AM, O'Reilly RJ, Ringden O, Slavin S, Sobocinski KA, Speck B, Weiner RS, Horowitz MM. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood 95:3996-4003, 2000. e-Pub 2000. PMID: 10845940.
McGlave PB, Shu XO, Wen W, Anasetti C, Nademanee A, Champlin R, Antin JH, Kernan NA, King R, Weisdorf DJ. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. Blood 95:2219-25, 2000. e-Pub 2000. PMID: 10733488.
Donato, ML, Gershenson D, Ippoliti C, Wharton JT, Bast RC, Aleman A, Anderlini P, Gajewski JG, Giralt S, Molldrem J, Ueno N, Lauppe J, Körbling J, Boyer J, Bodurka-Bevers D, Bevers M, Burke T, Freedman R, Wolf J, Champlin RE. Intensive-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer. Bone Marrow Transplantation 25:1137-1140, 2000. e-Pub 2000.
Donato ML, Champlin RE, Wharton JT, Bodurka-Bevers D, Gershenson D. Intensive-dose ifosfamide and etoposide with filgrastim for cytoreduction before peripheral blood stem cell collection in patients with advanced ovarian cancer. Eur J Gynaecol Oncol 21(3):241-4, 2000. e-Pub 2000. PMID: 10949384.
Seong CM, Giralt S, Kantarjian H, Xu J, Swantkowski J, Hayes K, Glassman AB, Khouri I, Korbling M, Thall P, Siciliano MJ, Champlin RE. Early detection of relapse by hypermetaphase fluorescence in situ hybridization after allogeneic bone marrow transplantation for chronic myeloid leukemia. J Clin Oncol 18:1831-6, 2000. e-Pub 2000. PMID: 10784623.
Besien V, K, Khouri I, Champlin R, McCarthy P. Allogeneic transplantation for low-grade lymphoma: Long-term follow-up. Journal of Clinical Oncology 18((3)):702-703, 2000. e-Pub 2000.
Anderlini P, Giralt S, Andersson B, Ueno NT, Khouri I, Acholonu S, Cohen A, Korbling MJ, Manning J, Romaguera J, Sarris A, Rodriguez, Hagemeister F, McLaughlin P, Cabanillas F, Champlin RE. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease. Bone Marrow Transplant 26:615-20, 2000. e-Pub 2000. PMID: 11041566.
Przepiorka D, Saliba R, Cleary K, Fischer H, Tonai R, Fritsche H, Khouri IF, Folloder J, Ueno NT, Mehra R, Ippoliti C, Giralt S, Gajewski J, Donato M, Claxton D, Braunschweig I, van Besien K, Anderlini P, Andersson BS, Champlin R. Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1. Biol Blood Marrow Transplant 6(2A):190-7, 2000. e-Pub 2000. PMID: 10816027.
Shimoni A, Korbling M, Champlin R, Molldrem J. Cryofibrinogenemia and skin necrosis in a patient with diffuse large cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant 26:1343-5, 2000. e-Pub 2000. PMID: 11223976.
Champlin RE, Schmitz N, Horowitz MM, Chapuis B, Chopra R, Cornelissen JJ, Gale RP, Goldman JM, Loberiza FR, Jr, Hertenstein B, Klein JP, Montserrat E, Zhang MJ, Ringden O, Tomany SC, Rowlings PA, Van Hoef ME, Gratwohl A. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 95:3702-9, 2000. e-Pub 2000. PMID: 10845900.
Huaringa AJ, Leyva FJ, Signes-Costa J, Morice RC, Raad I, Darwish AA, Champlin RE. Bronchoalveolar lavage in the diagnosis of pulmonary complications of bone marrow transplant patients. Bone Marrow Transplant 25:975-9, 2000. e-Pub 2000. PMID: 10800066.
Anderlini P, Donato M, Lauppe MJ, Huh YO, Martin TG, Chan KW, Champlin RE, Korbling M. A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors. Br J Haematol 109:770-2, 2000. e-Pub 2000. PMID: 10929027.
Prezpiorka D, Khouri I, Ippoliti C, Ueno NT, Mehra R, Korbling M, Giralt S, Gajewski J, Fischer H, Donato M, Cleary K, Claxton D, K-W C, Braunschweig I, van Besien K, Andersson B, Anderlini P, Champlin RE. Tacrolimus and mini-dose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. Bone Marrow Transplant 24:763-768, 2000. e-Pub 2000.
Molldrem JJ, Lee PP, Wang C, Champlin RE, Davis MM. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res 59:2675-81, 1999. e-Pub 1999. PMID: 10363991.
Anderlini P, Donato M, Chan KW, Huh YO, Gee AP, Lauppe MJ, Champlin RE, Korbling M. Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience. Transfusion 39:555-60, 1999. e-Pub 1999. PMID: 10378833.
Abbott B, Ippoliti C, Bruton J, Neumann J, Whaley R, Champlin R. Antiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation. Bone Marrow Transplant 23:265-9, 1999. e-Pub 1999. PMID: 10084258.
Przepiorka D, van Besien K, Khouri I, Hagemeister F, Samuels B, Folloder J, Ueno NT, Molldrem J, Mehra R, Korbling M, Giralt S, Gajewski J, Donato M, Cleary K, Claxton D, Braunschweig I, Andersson B, Anderlini P, Champlin R. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol 10:527-32, 1999. e-Pub 1999. PMID: 10416001.
Maltezou H, Whimbey E, Abi-Said D, Przepiorka D, Champlin R, Goodrich J. Cytomegalovirus disease in adult marrow transplant recipients receiving ganciclovir prophylaxis: a retrospective study. Bone Marrow Transplant 24:665-9, 1999. e-Pub 1999. PMID: 10490734.
Przepiorka, D, Lu J, Anderlini P, Körbling M, Donato M, Champlin RE, Gee A, van Vlasselaer P. Debulking blood stem cell collections by density gradient centrifugation in a closed vessel system. Cytotherapy 1:111-118, 1999. e-Pub 1999.
Choudhury BA, Liang JC, Thomas EK, Flores-Romo L, Xie QS, Agusala K, Sutaria S, Sinha I, Champlin RE, Claxton DF. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood 93:780-6, 1999. e-Pub 1999. PMID: 9920826.
Garderet L, Snell V, Przepiorka D, Schenk T, Lu JG, Marini F, Gluckman E, Andreeff M, Champlin RE. Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations. Transplantation 67:124-30, 1999. e-Pub 1999. PMID: 9921808.
Andreeff M, Jiang S, Zhang X, Konopleva M, Estrov Z, Snell VE, Xie Z, Okcu MF, Sanchez-Williams G, Dong J, Estey EH, Champlin RC, Kornblau SM, Reed JC, Zhao S. Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia 13:1881-92, 1999. e-Pub 1999. PMID: 10557066.
Margolin KA, Van Besien K, Wright C, Niland J, Champlin R, Fung HC, Kashyap A, Molina A, Nademanee AP, O'Donnell MR, Parker P, Smith E, Spielberger R, Somlo G, Snyder D, Stein A, Woo D, Thomas M, Sniecinski I, Forman SJ. Interleukin-2-activated autologous bone marrow and peripheral blood stem cells in the treatment of acute leukemia and lymphoma. Biol Blood Marrow Transplant 5(1):36-45, 1999. e-Pub 1999. PMID: 10232739.
Nguyen Q, Champlin R, Giralt S, Rolston K, Raad I, Jacobson K, Ippoliti C, Hecht D, Tarrand J, Luna M, Whimbey E. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. Clin Infect Dis 28:618-23, 1999. e-Pub 1999. PMID: 10194088.
Gajewski, JL, Nimer S, Saliba RM, Thomas M, Przepiorka D, Giralt S, van Besien K, Mehra R, Andersson B, Chan KW, Ippoliti C, Warkentin D, Feig S, Territo M, Schiller G, Lebkowski J, Moseley AM, Lloyd K, von Hoeff M, Okarma T, Champlin R. Long Term Outcome of Partial T-cell Depletion By Panning CD-5/CD8 (+) T-cells in One Antigen Mismatched Related Donor and matched Unrelated Donor. Cytotherapy 1:401-407, 1999. e-Pub 1999.
Deeg HJ, Seidel K, Casper J, Anasetti C, Davies S, Gajeweski JL, Territo M, Ramsay N, Harris RE, Catro-Malaspina H, Collins R, Champlin R, Schoch G, King R, Howe C. Marrow transplantation from unrelated donors for patients with severe aplastic anemia who have failed immunosuppressive therapy. Biol Blood Marrow Transplant 5(4):243-52, 1999. e-Pub 1999. PMID: 10465104.
Donato, ML, Gershenson D, Wharton JT, Aleman A, Ippoliti C, Bodurka D, Levenback C, Bevers M, Wolf J, Freedman R, Gajewski J, Bast R, Champlin RE. Phase I study of High-dose Topotecan and alkylating agents for Advanced Ovarian cancer. J Clin Onc 18:44a, 1999. e-Pub 1999.
Ghosh S, Champlin R, Couch R, Englund J, Raad I, Malik S, Luna M, Whimbey E. Rhinovirus infections in myelosuppressed adult blood and marrow transplant recipients. Clin Infect Dis 29:528-32, 1999. e-Pub 1999. PMID: 10530441.
Przepiorka D, Smith TL, Folloder J, Khouri I, Ueno NT, Mehra R, Korbling M, Huh YO, Giralt S, Gajewski J, Donato M, Cleary K, Claxton D, Braunschweig I, van Besien K, Andersson BS, Anderlini P, Champlin R. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 94:1465-70, 1999. e-Pub 1999. PMID: 10438735.
Rahman, Z, Kavanagh JJ, Champlin RE, Giles RE, Cote R, Hortobagyi G, Deisseroth A. Safety and efficacy of chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer. Clinical Cancer Res 4:2717-2721, 1999. e-Pub 1999.
Anderlini P, Riggs SA, Korbling M, Champlin R. Syngeneic blood stem cell transplantation for infectious mononucleosis-related aplastic anaemia. Br J Haematol 106:159-61, 1999. e-Pub 1999. PMID: 10444179.
Przepiorka D, Khouri I, Thall P, Mehra R, Lee MS, Ippoliti C, Giralt S, Gajewski J, van Besien K, Andersson B, Korbling M, Deisseroth AB, Champlin R. Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia. Bone Marrow Transplant 23:977-81, 1999. e-Pub 1999. PMID: 10373061.
Warkentin D, Ippoliti C, Bruton J, Van Besien K, Champlin R. Toxicity of single daily dose gentamicin in stem cell transplantation. Bone Marrow Transplant 24:57-61, 1999. e-Pub 1999. PMID: 10435736.
Marini FC, Snell V, Yu Q, Zhang X, Singletary SE, Champlin R, Andreeff M. Purging of contaminating breast cancer cells from hematopoietic stem cell grafts by adenoviral GAL-TEK gene therapy and magnetic antibody cell separation. Clin Cancer Res 5:1557-68, 1999. e-Pub 1999. PMID: 10389945.
Donato ML, Champlin RE, Van Besien KW, Korbling M, Cabanillas F, Anderlini P, Gajewski JG, Lauppe J, Durett A, Andersson B, Giralt S, Khouri I, Hagemeister F, Romaguera JE, Sarris A, McLaughlin P, Younes A, Ippoliti C, Blamble DA, Hester J, Gee A, Rodriguez MA. Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma. Leuk Lymphoma 35:317-24, 1999. e-Pub 1999. PMID: 10706456.
Bachier CR, Giles RE, Ellerson D, Hanania EG, Garcia-Sanchez F, Andreeff M, Cabanillas F, Champlin R, Choudhury R, Berenson R, Heimfeld S, Deisseroth AB. Hematopoietic retroviral gene marking in patients with follicular non-Hodgkin's lymphoma. Leuk Lymphoma 32(3-4):279-88, 1999. e-Pub 1999. PMID: 10037025.
Khouri IF, Lee MS, Romaguera J, Mirza N, Kantarjian H, Korbling M, Albitar M, Giralt S, Samuels B, Anderlini P, Rodriguez J, von Wolff B, Gajewski J, Cabanillas F, Champlin R. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy. Ann Oncol 10:1293-9, 1999. e-Pub 1999. PMID: 10631455.
Khouri IF, Keating M, Körbling M, Przepiorka D, Anderlini P, O'Brien S, Giralt S, Ippoliti C, von Wolff B, Gajewski J, Donato M, Claxton D, Ueno N, Andersson B, Gee A, Champlin R. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 16(8):2817-24, 1998. e-Pub 1998. PMID: 9704734.
Khouri IF, Romaguera J, Kantarjian H, Palmer JL, Pugh WC, Korbling M, Hagemeister F, Samuels B, Rodriguez A, Giralt S, Younes A, Przepiorka D, Claxton D, Cabanillas F, Champlin R. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 16:3803-9, 1998. e-Pub 1998. PMID: 9850025.
Bojko P, Hester J, Durett A, Maadani F, Körbling M, Champlin RE. Identification of megakaryocyte precursors in peripheral blood stem cell collections from normal donors. Journal of Clinical Apheresis 13:7-15, 1998. e-Pub 1998.
Narvios AB, Przepiorka D, Tarrand J, Chan KW, Champlin R, Lichtiger B. Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients. Bone Marrow Transplant 22:575-7, 1998. e-Pub 1998. PMID: 9758346.
Randhawa GS, Cui H, Barletta JA, Strichman-Almashanu LZ, Talpaz M, Kantarjian H, Deisseroth AB, Champlin RC, Feinberg AP. Loss of imprinting in disease progression in chronic myelogenous leukemia. Blood 91:3144-7, 1998. e-Pub 1998. PMID: 9558368.
Bernstein SH, Nademanee AP, Vose JM, Tricot G, Fay JW, Negrin RS, DiPersio J, Rondon G, Champlin R, Barnett MJ, Cornetta K, Herzig GP, Vaughan W, Geils G, Jr, Keating A, Messner H, Wolff SN, Miller KB, Linker C, Cairo M, Hellmann S, Ashby M, Stryker S, Nash RA. A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. Blood 91:3509-17, 1998. e-Pub 1998. PMID: 9558412.
Seong C, Delasalle K, Hayes K, Weber D, Dimopoulos M, Swantkowski J, Huh Y, Glassman A, Champlin R, Alexanian R. Prognostic value of cytogenetics in multiple myeloma. Br J Haematol 101:189-94, 1998. e-Pub 1998. PMID: 9576200.
Wang MW, Consoli U, Lane CM, Durett A, Lauppe MJ, Champlin R, Andreeff M, Deisseroth AB. Rescue from apoptosis in early (CD34-selected) versus late (non-CD34-selected) human hematopoietic cells by very late antigen 4- and vascular cell adhesion molecule (VCAM) 1-dependent adhesion to bone marrow stromal cells. Cell Growth Differ 9:105-12, 1998. e-Pub 1998. PMID: 9486846.
Englund JA, Champlin RE, Wyde PR, Kantarjian H, Atmar RL, Tarrand J, Yousuf H, Regnery H, Klimov AI, Cox NJ, Whimbey E. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis 26:1418-24, 1998. e-Pub 1998. PMID: 9636873.
Popat U, Przepiork D, Champlin R, Pugh W, Amin K, Mehra R, Rodriguez J, Giralt S, Romaguera J, Rodriguez A, Preti A, Andersson B, Khouri I, Claxton D, de Lima M, Donato M, Anderlini P, Gajewski J, Cabanillas F, van Besien K. High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome. J Clin Oncol 16(1):63-9, 1998. e-Pub 1998. PMID: 9440724.
Ueno NT, Rondon G, Mirza NQ, Geisler DK, Anderlini P, Giralt SA, Andersson BS, Claxton DF, Gajewski JL, Khouri IF, Korbling M, Mehra RC, Przepiorka D, Rahman Z, Samuels BI, van Besien K, Hortobagyi GN, Champlin RE. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 16:986-93, 1998. e-Pub 1998. PMID: 9508181.
Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P, O'Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran M, Przepiorka D, Koller C, Kornblau S, Korbling M, Keating M, Kantarjian H, Champlin R. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89:4531-6, 1997. e-Pub 1997. PMID: 9192777.
Khouri IF, Przepiorka D, van Besien K, O'Brien S, Palmer JL, Lerner S, Mehra RC, Vriesendorp HM, Andersson BS, Giralt S, Korbling M, Keating MJ, Champlin RE. Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. Br J Haematol 97:466-73, 1997. e-Pub 1997. PMID: 9163617.
Przepiorka D, Anderlini P, Ippoliti C, Khouri I, Fietz T, Thall P, Mehra R, Giralt S, Gajewski J, Deisseroth AB, Cleary K, Champlin R, van Besien K, Andersson B, Korbling M. Allogeneic blood stem cell transplantation in advanced hematologic cancers. Bone Marrow Transplant 19:455-60, 1997. e-Pub 1997. PMID: 9052911.
Anderlini P, Korbling M, Dale D, Gratwohl A, Schmitz N, Stroncek D, Howe C, Leitman S, Horowitz M, Gluckman E, Rowley S, Przepiorka D, Champlin R. Allogeneic blood stem cell transplantation: considerations for donors. Blood 90:903-8, 1997. e-Pub 1997. PMID: 9242518.
van Besien K, Thall P, Korbling M, Pugh WC, Khouri I, Mehra R, Giralt S, Anderlini P, Amin K, Mirza N, Seong D, Gajewski J, Hester J, Andersson B, Cabanillas F, Champlin R, Przepiorka D. Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients. Biol Blood Marrow Transplant 3:150-6, 1997. e-Pub 1997. PMID: 9310192.
Rondon G, Giralt S, Pereira M, Van Besien K, Mehra R, Champlin R, Andreeff M. Analysis of chimerism following allogeneic bone marrow transplantation by fluorescent-in-situ hybridization. Leuk Lymphoma 25:463-7, 1997. e-Pub 1997. PMID: 9250816.
Kim SW, Rice L, Champlin R, Udden MM. Aplastic anemia in eosinophilic fasciitis: responses to immunosuppression and marrow transplantation. Haematologia (Budap) 28(3):131-7, 1997. e-Pub 1997. PMID: 9283913.
de Lima M, van Besien KW, Giralt SA, Khouri IF, Mehra R, Andersson BS, Przepiorka D, Gajewski JL, Korbling M, Champlin RE. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant 19(2):121-7, 1997. e-Pub 1997. PMID: 9116608.
Passweg JR, Socie G, Hinterberger W, Bacigalupo A, Biggs JC, Camitta BM, Champlin RE, Gale RP, Gluckman E, Gordon-Smith EC, Hows JM, Klein JP, Nugent ML, Pasquini R, Rowlings PA, Speck B, Tichelli A, Zhang MJ, Horowitz MM, Bortin MM. Bone marrow transplantation for severe aplastic anemia: has outcome improved?. Blood 90:858-64, 1997. e-Pub 1997. PMID: 9226187.
Anderlini P, Przepiorka D, Lauppe J, Seong D, Giralt S, Champlin R, Korbling M. Collection of peripheral blood stem cells from normal donors 60 years of age or older. Br J Haematol 97:485-7, 1997. e-Pub 1997. PMID: 9163620.
Nicholson VA, Whimbey E, Champlin R, Abi-Said D, Przepiorka D, Tarrand J, Chan K, Bodey GP, Goodrich JM. Comparison of cytomegalovirus antigenemia and shell vial culture in allogeneic marrow transplantation recipients receiving ganciclovir prophylaxis. Bone Marrow Transplant 19(1):37-41, 1997. e-Pub 1997. PMID: 9012929.
van Besien K, Verschraegen C, Mehra R, Giralt S, Kudelka AP, Edwards CL, Piamsonboom S, Termrungruanglert W, Champlin R, Kavanagh JJ. Complete remission of refractory gestational trophoblastic disease with brain metastases treated with multicycle ifosfamide, carboplatin, and etoposide (ICE) and stem cell rescue. Gynecol Oncol 65:366-9, 1997. e-Pub 1997. PMID: 9159354.
Collins RH, Jr, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, Goodman SA, Wolff SN, Hu W, Verfaillie C, List A, Dalton W, Ognoskie N, Chetrit A, Antin JH, Nemunaitis J. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15:433-44, 1997. e-Pub 1997. PMID: 9053463.
Anderlini P, Przepiorka D, Seong C, Smith TL, Huh YO, Lauppe J, Champlin R, Korbling M. Factors affecting mobilization of CD34+ cells in normal donors treated with filgrastim. Transfusion 37:507-12, 1997. e-Pub 1997. PMID: 9149776.
Ippoliti C, Morgan A, Warkentin D, van Besien K, Mehra R, Khouri I, Giralt S, Gajewski J, Champlin R, Andersson B, Przepiorka D. Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir. Bone Marrow Transplant 20:491-5, 1997. e-Pub 1997. PMID: 9313883.
Woo MH, Ippoliti C, Bruton J, Mehra R, Champlin R, Przepiorka D. Headache, circumoral paresthesia, and facial flushing associated with high-dose carmustine infusion. Bone Marrow Transplant 19:845-7, 1997. e-Pub 1997. PMID: 9134180.
Gajewski, J, Gjertson D, Cecka M, Tonai R, Przepiorka D, Giralt SChan KW, Feig S, Territo M, Andersson B, van Besien K, Khouri I, Fischer H, Babbitt L, Hunt L, Schiller G, Petz L, Terasaki P, Champlin RE. Impact of molecular subtype of HLA b1 and DQb alleles on acute graft-vs.-host disease and relapse free survival in HLA serologically identical unrelated donor bone marrow transplants: effect of T-cell depletion. Biol Blood Marrow Transplant 3:76-82, 1997. e-Pub 1997.
Rahman ZU, Frye DK, Buzdar AU, Smith TL, Asmar L, Champlin RE, Hortobagyi GN. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol 15:3171-7, 1997. e-Pub 1997. PMID: 9336352.
van Besien KW, de Lima M, Giralt SA, Moore DF, Jr, Khouri IF, Rondon G, Mehra R, Andersson BS, Dyer C, Cleary K, Przepiorka D, Gajewski JL, Champlin RE. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant 19:977-82, 1997. e-Pub 1997. PMID: 9169641.
Seong C, Durett A, Mirza N, Huh Y, Anderlini P, Champlin R. Mobilization kinetics of CD34+/Thy-1dim progenitor cells during recombinant human granulocyte-colony-stimulating factor administration in normal donors. Transfusion 37:406-10, 1997. e-Pub 1997. PMID: 9111278.
Garcia R, Raad I, Abi-Said D, Bodey G, Champlin R, Tarrand J, Hill LA, Umphrey J, Neumann J, Englund J, Whimbey E. Nosocomial respiratory syncytial virus infections: prevention and control in bone marrow transplant patients. Infect Control Hosp Epidemiol 18:412-6, 1997. e-Pub 1997. PMID: 9181397.
Anderlini P, Lauppe J, Przepiorka D, Seong D, Champlin R, Korbling M. Peripheral blood stem cell apheresis in normal donors: feasibility and yield of second collections. Br J Haematol 96:415-7, 1997. e-Pub 1997. PMID: 9029035.
Johansen MJ, Madden T, Mehra RC, Wood JG, Rondon G, Browne V, Newman RA, Champlin RE. Phase I pharmacokinetic study of multicycle high-dose carboplatin followed by peripheral-blood stem-cell infusion in patients with cancer. J Clin Oncol 15:1481-91, 1997. e-Pub 1997. PMID: 9193344.
Giralt S, Weber D, Colome M, Dimopoulos M, Mehra R, Van Besien K, Gajewski J, Andersson B, Khouri I, Przepiorka D, von Wolff B, Delasalle K, Korbling M, Seong D, Alexanian R, Champlin R. Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue. J Clin Oncol 15:667-73, 1997. e-Pub 1997. PMID: 9053492.
Shpall EJ, LeMaistre CF, Holland K, Ball E, Jones RB, Saral R, Jacobs C, Heimfeld S, Berenson R, Champlin R. A prospective randomized trial of buffy coat versus CD34-selected autologous bone marrow support in high-risk breast cancer patients receiving high-dose chemotherapy. Blood 90:4313-20, 1997. e-Pub 1997. PMID: 9373242.
Chen CS, Seidel K, Armitage JO, Fay JW, Appelbaum FR, Horowitz MM, Shpall EJ, Weiden PL, Antman KS, Champlin RE, Kersey JH, Sullivan KM. Safeguarding the administration of high-dose chemotherapy: a national practice survey by the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 3:331-40, 1997. e-Pub 1997. PMID: 9502301.
Zhang MJ, Baccarani M, Gale RP, McGlave PB, Atkinson K, Champlin RE, Dicke KA, Giralt S, Gluckman E, Goldman JM, Klein JP, Herzig RH, Masaoka T, O'Reilly RJ, Rozman C, Rowlings PA, Sobocinski KA, Speck B, Zwaan FE, Horowitz MM. Survival of patients with chronic myelogenous leukaemia relapsing after bone marrow transplantation: comparison with patients receiving conventional chemotherapy. Br J Haematol 99:23-9, 1997. e-Pub 1997. PMID: 9359497.
Choudhury A, Gajewski JL, Liang JC, Popat U, Claxton DF, Kliche KO, Andreeff M, Champlin RE. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 89:1133-42, 1997. e-Pub 1997. PMID: 9028934.
Ippoliti C, Champlin R, Bugazia N, Przepiorka D, Neumann J, Giralt S, Khouri I, Gajewski J. Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies. J Clin Oncol 15:3350-4, 1997. e-Pub 1997. PMID: 9363865.
Seong D, Giralt S, Fischer H, Hayes K, Glassman A, Arlinghaus R, Xu J, Kantarjian H, Siciliano M, Champlin R. Usefulness of detection of minimal residual disease by 'hypermetaphase' fluorescent in situ hybridization after allogeneic BMT for chronic myelogenous leukemia. Bone Marrow Transplant 19:565-70, 1997. e-Pub 1997. PMID: 9085736.
Rozman C, Carreras E, Qian C, Gale RP, Bortin MM, Rowlings PA, Ash RC, Champlin RE, Henslee-Downey PJ, Herzig RH, Hinterberger W, Klein JP, Prentice HG, Reiffers J, Zwaan FE, Horowitz MM. Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia. Bone Marrow Transplant 17(1):75-80, 1996. e-Pub 1996. PMID: 8673059.
Khouri IF, Kantarjian HM, Talpaz M, Giralt S, Rios MO, Hester JP, Champlin RE, Deisseroth AB. Results with high-dose chemotherapy and unpurged autologous stem cell transplantation in 73 patients with chronic myelogenous leukemia: the MD Anderson experience. Bone Marrow Transplant 17:775-9, 1996. e-Pub 1996. PMID: 8733697.
Chan KW, Gajewski JL, Supkis D, Jr, Pentz R, Champlin R, Bleyer WA. Use of minors as bone marrow donors: current attitude and management. A survey of 56 pediatric transplantation centers. J Pediatr 128:644-8, 1996. e-Pub 1996. PMID: 8627436.
Deisseroth AB, Holmes F, Hortobagyi G, Champlin R. Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of breast cancer: a pilot trial. Hum Gene Ther 7:401-16, 1996. e-Pub 1996. PMID: 8835224.
Hanania, EG, Giles RE, Kavanagh J, Ellerson D, Zu Z, Wang T, Su Y, Kudlka A, Rahman Z, Holmes F, Hortobagyi G, Claxton D, Bachier C, Hester J, Körbling M, Seong D, Cote R, Holzmayer T, Mechetner E, Heimfeld S, Berenson R, Burtness B, Edwards C, Bast R, Andreeff M, Champlin RE, Deisseroth AB. Results of mdr-1 modification trial indicate that CFU-GM do not contribute to post transplant hematopoietic recovery following intensive systemic therapy. . Proc Natl Acad Sci U S A 93:346-351, 1996. e-Pub 1996.
Lewis VA, Champlin R, Englund J, Couch R, Goodrich JM, Rolston K, Przepiorka D, Mirza NQ, Yousuf HM, Luna M, Bodey GP, Whimbey E. Respiratory disease due to parainfluenza virus in adult bone marrow transplant recipients. Clin Infect Dis 23:1033-7, 1996. e-Pub 1996. PMID: 8922798.
Rondon G, Giralt S, Huh Y, Khouri I, Andersson B, Andreeff M, Champlin R. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 18:669-72, 1996. e-Pub 1996. PMID: 8879640.
Seong D, Bruner JM, Lee KH, Mirza N, Kwon BD, Lee JH, Lee YY, Ro J, Talpaz M, Champlin R, Deisseroth AB. Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation in a patient with chronic myelogenous leukemia. Clin Infect Dis 23:402-3, 1996. e-Pub 1996. PMID: 8842290.
Greenberg P, Advani R, Keating A, Gulati SC, Nimer S, Champlin R, Karanes C, Gorin NC, Powles RL, Smith A, Lamborn K, Cuffie C. GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 18:1057-64, 1996. e-Pub 1996. PMID: 8971373.
Przepiorka D, Ippoliti C, Khouri I, Anderlini P, Mehra R, Giralt S, Gajewski J, Fritsche H, Deisseroth AB, Cleary K, Champlin R, van Besien K, Andersson B, Korbling M. Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus. Transplantation 62:1806-10, 1996. e-Pub 1996. PMID: 8990368.
van Besien KW, Mehra RC, Giralt SA, Kantarjian HM, Pugh WC, Khouri IF, Moon Y, Williams P, Andersson BS, Przepiorka D, McCarthy PL, Gajewski JL, Deisseroth AB, Cabanillas FF, Champlin R. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology. Am J Med 100:299-307, 1996. e-Pub 1996. PMID: 8629675.
Przepiorka D, Van Vlasselaer P, Huynh L, Durett A, Agbor P, Lauppe J, Valone F, Champlin R, Korbling M. Rapid debulking and CD34 enrichment of filgrastim-mobilized peripheral blood stem cells by semiautomated density gradient centrifugation in a closed system. J Hematother 5:497-502, 1996. e-Pub 1996. PMID: 8938521.
Anderlini P, Przepiorka D, Seong D, Miller P, Sundberg J, Lichtiger B, Norfleet F, Chan KW, Champlin R, Korbling M. Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures. Transfusion 36:590-5, 1996. e-Pub 1996. PMID: 8701453.
McCarthy PL, Jr, Williams L, Harris-Bacile M, Yen J, Przepiorka D, Ippoliti C, Champlin R, Fay J, Blosch C, Jacobs C, Anasetti C. A clinical phase I/II study of recombinant human interleukin-1 receptor in glucocorticoid-resistant graft-versus-host disease. Transplantation 62:626-31, 1996. e-Pub 1996. PMID: 8830827.
Whimbey E, Champlin RE, Couch RB, Englund JA, Goodrich JM, Raad I, Przepiorka D, Lewis VA, Mirza N, Yousuf H, Tarrand JJ, Bodey GP. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis 22:778-82, 1996. e-Pub 1996. PMID: 8722930.
Przepiorka D, Ippoliti C, Khouri I, Woo M, Mehra R, Le Bherz D, Giralt S, Gajewski J, Fischer H, Fritsche H, Deisseroth AB, Cleary K, Champlin R, Besien K, Andersson B, Maher R, Fitzsimmons W. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood 88:4383-9, 1996. e-Pub 1996. PMID: 8943876.
Anderlini P, Przepiorka D, Seong D, Champlin R, Korbling M. Transient neutropenia in normal donors after G-CSF mobilization and stem cell apheresis. Br J Haematol 94:155-8, 1996. e-Pub 1996. PMID: 8757527.
Khouri IF, Ippoliti C, Gajewski J, Przepiorka D, Champlin RE. Neutropenias following allogeneic bone marrow transplantation: response to therapy with high-dose intravenous immunoglobulin. Am J Hematol 52:313-5, 1996. e-Pub 1996. PMID: 8701951.
van Besien K, Przepiorka D, Mehra R, Giralt S, Khouri I, Gajewski J, Andersson B, Champlin R. Impact of preexisting CNS involvement on the outcome of bone marrow transplantation in adult hematologic malignancies. J Clin Oncol 14:3036-42, 1996. e-Pub 1996. PMID: 8918502.
Gale RP, Horowitz MM, Rees JK, Gray RG, Oken MM, Estey EH, Kim KM, Zhang MJ, Ash RC, Atkinson K, Champlin RE, Dicke KA, Gajewski JL, Goldman JM, Helbig W, Henslee-Downey PS, Hinterberger W, Jacobsen N, Keating A, Klein JP, Marmont AM, Prentice HG, Reiffers J, Rimm AA, Bortin MM, et al. Chemotherapy versus transplants for acute myelogenous leukemia in second remission. Leukemia 10(1):13-9, 1996. e-Pub 1996. PMID: 8558917.
Korbling M, Chan KW, Anderlini P, Seong D, Durett A, Langlinais A, Przepiorka D, Gajewski J, Miller P, Sundberg J, Alilaen P, Bojko P, Mirza N, Claxton D, van Besien K, Khouri I, Andersson B, Mehra R, Champlin R. Allogeneic peripheral blood stem cell transplantation using normal patient-related pediatric donors. Bone Marrow Transplant 18:885-90, 1996. e-Pub 1996. PMID: 8932841.
Khouri, I, Champlin R. Allogeneic bone marrow transplantation in chronic lymphocytic leukemia. Ann Intern Med 125:780, 1996. e-Pub 1996.
Gale RP, Buchner T, Zhang MJ, Heinecke A, Champlin RE, Dicke KA, Gluckman E, Good RA, Gratwohl A, Herzig RH, Keating A, Klein JP, Marmont AM, Prentice HG, Rowlings PA, Sobocinski KA, Speck B, Weiner RS, Horowitz MM. HLA-identical sibling bone marrow transplants vs chemotherapy for acute myelogenous leukemia in first remission. Leukemia 10:1687-91, 1996. e-Pub 1996. PMID: 8892667.
Gajewski JL, Phillips GL, Sobocinski KA, Armitage JO, Gale RP, Champlin RE, Herzig RH, Hurd DD, Jagannath S, Klein JP, Lazarus HM, McCarthy PL, Jr, Pavlovsky S, Peterson FB, Rowlings PA, Russell JA, Silver SM, Vose JM, Wiernik PH, Bortin MM, Horowitz MM. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol 14:572-8, 1996. e-Pub 1996. PMID: 8636773.
Anderlini P, Przepiorka D, Huh Y, Lauppe J, Miller P, Sundberg J, Seong D, Champlin R, Korbling M. Duration of filgrastim mobilization and apheresis yield of CD34+ progenitor cells and lymphoid subsets in normal donors for allogeneic transplantation. Br J Haematol 93:940-2, 1996. e-Pub 1996. PMID: 8703830.
Korbling M, Anderlini P, Durett A, Maadani F, Bojko P, Seong D, Giralt S, Khouri I, Andersson B, Mehra R, vanBesien K, Mirza N, Przepiorka D, Champlin R. Delayed effects of rhG-CSF mobilization treatment and apheresis on circulating CD34+ and CD34+ Thy-1dim CD38- progenitor cells, and lymphoid subsets in normal stem cell donors for allogeneic transplantation. Bone Marrow Transplant 18:1073-9, 1996. e-Pub 1996. PMID: 8971375.
Talpaz, M, Kantarjian H, Liang J, Calvert L, Hamer J, Tibbits P, Durett A, Claxton D, Giralt, Khouri I, Przepiorka D, van Besien K, Andersson B, Mehra R, Gajewski J, Seong D, Hester J, Estey E, Körbling M, Pollicardo N, Berenson R, Heimfeld S, Champlin RE, Deisseroth AB. Percent Ph-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia (CML) depends on percent of diploid cells induced by conventional dose chemotherapy before collection of autologous cells. Blood 85:3257-3263, 1995. e-Pub 1995.
Bayouth JE, Macey DJ, Kasi LP, Garlich JR, McMillan K, Dimopoulos MA, Champlin RE. Pharmacokinetics, dosimetry and toxicity of holmium-166-DOTMP for bone marrow ablation in multiple myeloma. J Nucl Med 36:730-7, 1995. e-Pub 1995. PMID: 7738641.
Przepiorka, D, Nath R, Ippoliti C, Mehra R, Hagemeister F, Diener K, Dimopoulos M, Giralt S, Khouri I, Samuels B, van Besien K, Andersson B, Deisseroth A, Luna M, Cabanillas F, Champlin RE. A phase I-II study of high dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma. Leukemia Lymphoma 17:427-433, 1995. e-Pub 1995.
Przepiorka D, Chan KW, Champlin RE, Culbert SJ, Petropoulos D, Ippoliti C, Khouri I, Huh YO, Vreisendorp H, Deisseroth AB, et al. Prevention of graft-versus-host disease with anti-CD5 ricin A chain immunotoxin after CD3-depleted HLA-nonidentical marrow transplantation in pediatric leukemia patients. Bone Marrow Transplant 16:737-41, 1995. e-Pub 1995. PMID: 8750262.
Hester JP, Rondon G, Huh YO, Lauppe MJ, Champlin RE, Deisseroth AB. Principles of bone marrow processing and progenitor cell/mononuclear cell concentrate collection in a continuous flow blood cell separation system. J Hematother 4:299-306, 1995. e-Pub 1995. PMID: 7489144.
Abu-Farsakh HA, Katz RL, Atkinson N, Champlin RE. Prognostic factors in bronchoalveolar lavage in 77 patients with bone marrow transplants. Acta Cytol 39:1081-8, 1995. e-Pub 1995. PMID: 7483980.
Bayouth JE, Macey DJ, Boyer AL, Champlin RE. Radiation dose distribution within the bone marrow of patients receiving holmium-166-labeled-phosphonate for marrow ablation. Med Phys 22:743-53, 1995. e-Pub 1995. PMID: 7565363.
Korbling M, Huh YO, Durett A, Mirza N, Miller P, Engel H, Anderlini P, van Besien K, Andreeff M, Przepiorka D, Deisseroth AB, Champlin RE. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood 86:2842-8, 1995. e-Pub 1995. PMID: 7545476.
Körbling, M, Przepiorka D, Engel H, Giralt S, van Besien K, Huh YO, Kleine HD, Bellare N, Deisseroth AB, Andreeff M, Champlin RE. Successful allogeneic blood stem cell transplantation for refractory acute myelogenous leukemia: Potential advantage of blood over marrow allografts. Blood 85:1659-1665, 1995. e-Pub 1995.
Besien V, KW, Khouri IF, Giralt SA, McCarthy P, Mehra R, Andersson BA, Przepiorka D, Gajewski JL, Bellare N, Nath R, Romaguera JE, McLaughlin PW, Körbling M, Deisseroth AB, Cabanillas FF, Champlin RE. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management. J. Clin Oncol 13:1096-1102, 1995. e-Pub 1995.
Gluckman E, Auerbach AD, Horowitz MM, Sobocinski KA, Ash RC, Bortin MM, Butturini A, Camitta BM, Champlin RE, Friedrich W, Good RA, Gordon-Smith EC, Harris RE, Klein JP, Ortega JJ, Pasquini R, Ramsay NK, Speck B, Vowels MR, Zhang MJ, Gale RP. Bone marrow transplantation for Fanconi anemia. Blood 86:2856-62, 1995. e-Pub 1995. PMID: 7670120.
Giralt S, Hester J, Huh Y, Hirsch-Ginsberg C, Rondon G, Seong D, Lee M, Gajewski J, Van Besien K, Khouri I, Mehra R, Przepiorka D, Korbling M, Talpaz M, Kantarjian H, Fischer H, Deisseroth A, Champlin R. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 86:4337-43, 1995. e-Pub 1995. PMID: 7492795.
Shaffer L, Giralt S, Champlin R, Chan KW. Treatment of leukemia relapse after bone marrow transplantation with interferon-alpha and interleukin 2. Bone Marrow Transplant 15:317-9, 1995. e-Pub 1995. PMID: 7773225.
Whimbey E, Champlin RE, Englund JA, Mirza NQ, Piedra PA, Goodrich JM, Przepiorka D, Luna MA, Morice RC, Neumann JL, et al. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant 16:393-9, 1995. e-Pub 1995. PMID: 8535312.
Besien V, K, Tabacoff J, Rodriguez M, Andersson B, Mehra R, Przepiorka D, Dimopoulos M, Giralt S, Suki S, Khouri I, Spitzer G, Jagannath S, Dicke K, LeMaistre CF, Deisseroth A, Cabanillas F, Champlin RE. High dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma; durable complete remissions, but a high rate of regime-related toxicity. Bone Marrow Transplant 15::549-555, 1995. e-Pub 1995.
Seong DC, Kantarjian HM, Ro JY, Talpaz M, Xu J, Robinson JR, Deisseroth AB, Champlin RE, Siciliano MJ. Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment. Blood 86:2343-9, 1995. e-Pub 1995. PMID: 7662980.
Paquette RL, Tebyani N, Frane M, Ireland P, Ho WG, Champlin RE, Nimer SD. Long-term outcome of aplastic anemia in adults treated with antithymocyte globulin: comparison with bone marrow transplantation. Blood 85(1):283-90, 1995. e-Pub 1995. PMID: 7803802.
Alexanian R, Dimopoulos MA, Delasalle KB, Hester J, Champlin R. Myeloablative therapy for primary resistant multiple myeloma. Stem Cells 13 Suppl 2:118-21, 1995. e-Pub 1995. PMID: 8520499.
Seymour JF, Khouri IF, Champlin RE, Keating MJ. Refractory chronic lymphocytic leukemia complicated by hypercalcemia treated with allogeneic bone marrow transplantation. Case report and review. Am J Clin Oncol 17:360-8, 1994. e-Pub 1994. PMID: 8048400.
Schiller G, Feig SA, Territo M, Wolin M, Lill M, Belin T, Hunt L, Nimer S, Champlin R, Gajewski J. Treatment of advanced acute leukaemia with allogeneic bone marrow transplantation from unrelated donors. Br J Haematol 88:72-8, 1994. e-Pub 1994. PMID: 7803259.
Przepiorka D, Dimopoulos M, Smith T, Ippoliti C, Diener K, Luna M, Champlin RE. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for marrow transplantation: risk factors for early regimen-related toxicity. Ann Hematol 68:183-8, 1994. e-Pub 1994. PMID: 8003559.
Nimer, SD, Giorgi J, Ku N, Lee K, Gajewski JL, Schiller GJ, Territo M, Ho WG, Feig S, Selch M, Reichert T, Champlin RE. Selective depletion of CD8-positive cells for prevention of graft-versus-host disease following bone marrow transplantation: A randomized controlled trial. Transplantation 57:82-87, 1994. e-Pub 1994.
Przepiorka, D, Dimopoulos M, Smith T, Ippoliti C, Diener K, Luna M, Alexanian R, Champlin RE. A Phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation. Bone Marrow Transplant 14:449, 1994. e-Pub 1994.
Alexanian R, Dimopoulos M, Smith T, Delasalle K, Barlogie B, Champlin R. Limited value of myeloablative therapy for late multiple myeloma. Blood 83:512-6, 1994. e-Pub 1994. PMID: 7904486.
Korbling M, Drach J, Champlin RE, Engel H, Huynh L, Kleine HD, Berenson R, Deisseroth AB, Andreeff M. Large-scale preparation of highly purified, frozen/thawed CD34+, HLA-DR- hematopoietic progenitor cells by sequential immunoadsorption (CEPRATE SC) and fluorescence-activated cell sorting: implications for gene transduction and/or transplantation. Bone Marrow Transplant 13:649-54, 1994. e-Pub 1994. PMID: 7519938.
Przepiorka, D, Ippoliti C, Koberda J, K-W C, Khouri I, Fischer HE, Huh YO, Escudier S, Seong D, Davis M, Gajewski J, Vriesendorp H, Champlin RE. Interleukin-2 for prevention of graft-vs-host disease after haploidentical marrow transplantation. Transplantation 58:858-860, 1994. e-Pub 1994.
Dimopoulos MA, Hester J, Huh Y, Champlin R, Alexanian R. Intensive chemotherapy with blood progenitor transplantation for primary resistant multiple myeloma. Br J Haematol 87:730-4, 1994. e-Pub 1994. PMID: 7986714.
Whimbey E, Elting LS, Couch RB, Lo W, Williams L, Champlin RE, Bodey GP. Influenza A virus infections among hospitalized adult bone marrow transplant recipients. Bone Marrow Transplant 13:437-40, 1994. e-Pub 1994. PMID: 8019468.
Gale RP, Horowitz MM, Ash RC, Champlin RE, Goldman JM, Rimm AA, Ringden O, Stone JA, Bortin MM. Identical-twin bone marrow transplants for leukemia. Ann Intern Med 120:646-52, 1994. e-Pub 1994. PMID: 8135448.
Kantarjian HM, Talpaz M, Andersson B, Khouri I, Giralt S, Rios MB, Champlin R, Hester J, Deisseroth AB. High doses of cyclophosphamide, etoposide and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemia. Bone Marrow Transplant 14:57-61, 1994. e-Pub 1994. PMID: 7951120.
Deisseroth, AB, Zu Z, Claxton D, Hanania EG, Fu S, Ellerson D, Goldberg L, Thomas M, Janicek K, Anderson WF, Hester J, Körbling M, Durett A, Moen R, Berenson R, Heimfeld S, Hamer J, Calvert L, Tibbets P, Talpaz M, Kantarjian H, Champlin RE, Reading C. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia contribute to relapse after autologous bone marrow in CML. Blood 83:3068 3076, 1994. e-Pub 1994.
Meyers CA, Weitzner M, Byrne K, Valentine A, Champlin RE, Przepiorka D. Evaluation of the neurobehavioral functioning of patients before, during, and after bone marrow transplantation. J Clin Oncol 12:820-6, 1994. e-Pub 1994. PMID: 8151324.
Przepiorka D, LeMaistre CF, Huh YO, Luna M, Saria EA, Brown CT, Champlin RE. Evaluation of anti-CD5 ricin A chain immunoconjugate for prevention of acute graft-vs.-host disease after HLA-identical marrow transplantation. Ther Immunol 1:77-82, 1994. e-Pub 1994. PMID: 7584486.
Giralt, S, LeMaistre CF, Vriesendorp H, Andersson B, Van Besien K, Dimopoulos M, Mehra R, Przepiorka D, Khouri I, Yau J, Kantarjian H, Deisseroth A, Champlin RE. Etoposide, cyclophosphamide, total body irradiation and allogeneic bone marrow transplantation: an effective treatment for hematologic malignancies. J. Clin. Oncol 12:1923-1930, 1994. e-Pub 1994.
Alexanian R, Dimopoulos MA, Hester J, Delasalle K, Champlin R. Early myeloablative therapy for multiple myeloma. Blood 84:4278-82, 1994. e-Pub 1994. PMID: 7994043.
Schiller G, Gajewski J, Lee M, Ho W, Territo M, Champlin R. Benefit of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. Leuk Lymphoma 15:85-90, 1994. e-Pub 1994. PMID: 7858506.
Guo JQ, Lian JY, Xian YM, Lee MS, Deisseroth AB, Stass SA, Champlin RE, Talpaz M, Wang JY, Arlinghaus RB. BCR-ABL protein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy. Blood 83:3629-37, 1994. e-Pub 1994. PMID: 8204887.
Storek J, Hultin LE, Ferrara S, Ku N, Giorgi JV, Champlin RE, Saxon A. B cell dysfunction after bone marrow transplantation is associated with decreased Ca2+ flux upon membrane Ig crosslinking. Clin Immunol Immunopathol 72:210-6, 1994. e-Pub 1994. PMID: 8050196.
Khouri, IF, Keating MJ, Reading CL, Przepiorka D, Giralt S, Ippoliti C, Huh YO, Marshall M, Thomas M, Deisseroth AB, Champlin RE. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J. Clin. Oncol 12:748-758, 1994. e-Pub 1994.
Seong DC, Song MY, Henske EP, Zimmerman SO, Champlin RE, Deisseroth AB, Siciliano MJ. Analysis of interphase cells for the Philadelphia translocation using painting probe made by inter-Alu-polymerase chain reaction from a radiation hybrid. Blood 83:2268-73, 1994. e-Pub 1994. PMID: 8161793.
Kernan, NA, Bartsch G, Ash RC, Beatty PG, Champlin RE, Filopovich A, Gajewski J, Hansen J, Henslee-Downey J, McCullough J, McGlave P, Mickelson E, Perkins HA, Phillips GL, Sanders J, Stroncek D, Thomas ED, Blume K. Retrospective analysis of 462 unrelated marrow transplants facilitated by The National Marrow Donor Program (NMDP) for treatment of acquired and congenital disorders of the lymphohematopoietic system and congenital metabolic disorders. N. Engl. J. Med 328:593-602, 1993. e-Pub 1993.
Ringden O, Horowitz MM, Sondel P, Gale RP, Biggs JC, Champlin RE, Deeg HJ, Dicke K, Masaoka T, Powles RL, et al. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia?. Blood 81:1094-101, 1993. e-Pub 1993. PMID: 8427991.
Whimbey E, Vartivarian SE, Champlin RE, Elting LS, Luna M, Bodey GP. Parainfluenza virus infection in adult bone marrow transplant recipients. Eur J Clin Microbiol Infect Dis 12:699-701, 1993. e-Pub 1993. PMID: 8243487.
Weyman C, Graham-Pole J, Emerson S, August C, Champlin R, Coccia P, Fay J, Harris R, Koch P, Johnson L, et al. Use of cytosine arabinoside and total body irradiation as conditioning for allogeneic marrow transplantation in patients with acute lymphoblastic leukemia: a multicenter survey. Bone Marrow Transplant 11(1):43-50, 1993. e-Pub 1993. PMID: 8431710.
Dimopoulos, MA, Alexanian R, Przepiorka D, Hester JAndersson B, Giralt S, Mehra R, Van Besien K, Delasalle KB, Reading CR, Deisseroth AB, Champlin RE. Thiotepa, Busulfan and cyclophosphamide with G-CSF: a new preparative regimen for autologous marrow or blood stem cell transplantation in multiple myeloma. Blood 82:2324-2328, 1993. e-Pub 1993.
Guo JQ, Hirsch-Ginsberg CF, Xian YM, Stass SA, Champlin RE, Giralt SA, McCredie KB, Campbell ML, Arlinghaus RB. Acute lymphoid leukemia molecular phenotype in a patient with benign-phase chronic myelogenous leukemia. Hematol Pathol 7(2):91-106, 1993. e-Pub 1993. PMID: 8340287.
Ippoliti C, Przepiorka D, Smith T, Maiese S, Giralt S, Andersson BS, Deisseroth AB, Champlin RE. Adverse effects of molgramostim in marrow transplant recipients. Clin Pharm 12:520-5, 1993. e-Pub 1993. PMID: 8354039.
Champlin R. Allogeneic, syngeneic and autologous bone marrow transplantation for chronic myelogenous leukemia. Leukemia 7:1084-6, 1993. e-Pub 1993. PMID: 8321030.
Storek J, Ferrara S, Ku N, Giorgi JV, Champlin RE, Saxon A. B cell reconstitution after human bone marrow transplantation: recapitulation of ontogeny?. Bone Marrow Transplant 12:387-98, 1993. e-Pub 1993. PMID: 8275039.
Parks, NJ, Kawakami TG, Avila MJ, White R, Cain GR, Raaka SD, Hornoff W, Fisher P, Moore P, Seibert JA, Garlich J, Simon J, Champlin RE. Bone marrow transplantation in dogs after radio-ablation with a Ho-166 amino phosphoric acid bone-seeking agent. Blood 82:318-325, 1993. e-Pub 1993.
Dimopoulos MA, Delasalle KB, Champlin R, Alexanian R. Cyclophosphamide and etoposide therapy with GM-CSF for VAD-resistant multiple myeloma. Br J Haematol 83:240-4, 1993. e-Pub 1993. PMID: 8457473.
Winston DJ, Ho WG, Bartoni K, Champlin RE. Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients. Bone Marrow Transplant 12:283-8, 1993. e-Pub 1993. PMID: 8241988.
Seong DC, Liu P, Siciliano J, Zhao Y, Cork A, Henske E, Warburton D, Yu MT, Champlin R, Trujillo JM, et al. Detection of variant Ph-positive chronic myelogenous leukemia involving chromosomes 1, 9, and 22 by fluorescence in situ hybridization. Cancer Genet Cytogenet 65:100-3, 1993. e-Pub 1993. PMID: 8453592.
Giralt, S, Escudier S, Kantarjian H, Deisseroth A, Freireich EJ, Andersson BS, O'Brien S, Andreeff M, Fisher H, Cork A, Hirsch Ginsberg C, Trujillo J, Stass S, Champlin RE. Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N. Engl. J. Med 329:757 761, 1993. e-Pub 1993.
Schiller G, Nimer S, Gajewski J, Lee M, Ho W, Territo M, Champlin R. Effect of induction cytarabine dose intensity on long-term survival in acute myelogenous leukemia: results of a randomized, controlled study. Leuk Lymphoma 11:69-77, 1993. e-Pub 1993. PMID: 8220156.
Giralt SA, Kantarjian HM, Talpaz M, Rios MB, Del Giglio A, Andersson BS, Przepiorka D, Deisseroth AB, Champlin RE. Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia. J Clin Oncol 11:1055-61, 1993. e-Pub 1993. PMID: 8501491.
Anaissie EJ, Kontoyiannis DP, Vartivarian S, Kantarjian HM, O'Brien S, Giralt SA, Andersson BS, Karl C, Champlin RE, Bodey GP. Effectiveness of an oral triazole for opportunistic mold infections in patients with cancer: experience with SCH 39304. Clin Infect Dis 17:1022-31, 1993. e-Pub 1993. PMID: 8110925.
Winston DJ, Ho WG, Bartoni K, Du Mond C, Ebeling DF, Buhles WC, Champlin RE. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med 118:179-84, 1993. e-Pub 1993. PMID: 8380243.
Przepiorka, D, Ippoliti C, Panina A, Goodrich J, Giralt S, Van Besien K, Mehra R, Deisseroth AB, Andersson B, Luna M, Tarrand JJ, Champlin RE. Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after t cell depleted marrow transplantation. Bone Marrow Transplant 13:461-464, 1993. e-Pub 1993.
Ippoliti C, Przepiorka D, Giralt S, Andersson BS, Wallerstein RO, Gutterman J, Deisseroth AB, Champlin RE. Low-dose non-glycosylated rhGM-CSF is effective for the treatment of delayed hematopoietic recovery after autologous marrow or peripheral blood stem cell transplantation. Bone Marrow Transplant 11(1):55-9, 1993. e-Pub 1993. PMID: 8094309.
Lotzova E, Savary CA, Champlin RE. Genesis of human oncolytic natural killer cells from primitive CD34+CD33- bone marrow progenitors. J Immunol 150:5263-5269, 1993. e-Pub 1993.
Anaissie EJ, Kontoyiannis DP, Vartivarian S, Kantarjian HM O'Brien S, Giralt SA, Andersson BS, Karl C, Champlin RE, Bodey GP. Effectiveness of an oral triazole for opportunistic mold infections in patients with cancer; expereince with SCH 39304. Clin Infect Dis 17:1022-1031, 1993. e-Pub 1993.
Horowitz MM, Przepiorka D, Champlin RE, Gale RP, Gratwohl A, Herzig RH, Prentice HG, Rimm AA, Ringden O, Bortin MM. Should HLA-identical sibling bone marrow transplants for leukemia be restricted to large centers?. Blood 79:2771-4, 1992. e-Pub 1992. PMID: 1586723.
Schiller GJ, Nimer SD, Territo MC, Ho WG, Champlin RE, Gajewski JL. Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission. J Clin Oncol 10(1):41-6, 1992. e-Pub 1992. PMID: 1727924.
Schiller G, Gajewski J, Nimer S, Territo M, Ho W, Lee M, Champlin R. A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukaemia. Br J Haematol 81:170-7, 1992. e-Pub 1992. PMID: 1643014.
Mrsic M, Horowitz MM, Atkinson K, Biggs JC, Champlin RE, Ehninger G, Gajewski JL, Gale RP, Herzig RH, Prentice HG, et al. Second HLA-identical sibling transplants for leukemia recurrence. Bone Marrow Transplant 9:269-75, 1992. e-Pub 1992. PMID: 1600415.
Gluckman E, Horowitz MM, Champlin RE, Hows JM, Bacigalupo A, Biggs JC, Camitta BM, Gale RP, Gordon-Smith EC, Marmont AM, et al. Bone marrow transplantation for severe aplastic anemia: influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome. Blood 79(1):269-75, 1992. e-Pub 1992. PMID: 1728315.
Schiller G, Gajewski J, Territo M, Nimer S, Lee M, Belin T, Champlin R. Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. Blood 80:2977-82, 1992. e-Pub 1992. PMID: 1467513.
Bortin MM, Horowitz MM, Gale RP, Barrett AJ, Champlin RE, Dicke KA, Gluckman E, Kolb HJ, Marmont AM, Mrsic M, et al. Changing trends in allogeneic bone marrow transplantation for leukemia in the 1980s. Jama 268:607-12, 1992. e-Pub 1992. PMID: 1321298.
Lee M, Khouri I, Champlin R, Kantarjian H, Talpaz M, Trujillo J, Freireich E, Deisseroth A, Stass S. Detection of minimal residual disease by polymerase chain reaction of bcr/abl transcripts in chronic myelogenous leukaemia following allogeneic bone marrow transplantation. Br J Haematol 82:708-14, 1992. e-Pub 1992. PMID: 1482658.
Gajewski JL, Petz LD, Calhoun L, O'Rourke S, Landaw EM, Lyddane NR, Hunt LA, Schiller GJ, Ho WG, Champlin RE. Hemolysis of transfused group O red blood cells in minor ABO-incompatible unrelated-donor bone marrow transplants in patients receiving cyclosporine without posttransplant methotrexate. Blood 79:3076-85, 1992. e-Pub 1992. PMID: 1586749.
Ugozzoli L, Yam P, Petz LD, Ferrara GB, Champlin RE, Forman SJ, Koyal D, Wallace RB. Amplification by the polymerase chain reaction of hypervariable regions of the human genome for evaluation of chimerism after bone marrow transplantation. Blood 77:1607-15, 1991. e-Pub 1991. PMID: 1672615.
Winston DJ, Ho WG, Bruckner DA, Champlin RE. Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med 115:849-59, 1991. e-Pub 1991. PMID: 1952471.
Kato Y, Mitsuishi Y, Cecka M, Hopfield J, Hunt L, Champlin R, Terasaki PI, Gajewski JL. HLA-DP incompatibilities and severe graft-versus-host disease in unrelated bone marrow transplants. Transplantation 52:374-6, 1991. e-Pub 1991. PMID: 1871811.
Nimer SD, Golde DW, Kwan K, Lee K, Clark S, Champlin R. In vitro production of granulocyte-macrophage colony-stimulating factor in aplastic anemia: possible mechanisms of action of antithymocyte globulin. Blood 78:163-8, 1991. e-Pub 1991. PMID: 2070050.
Marmont AM, Horowitz MM, Gale RP, Sobocinski K, Ash RC, van Bekkum DW, Champlin RE, Dicke KA, Goldman JM, Good RA, et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 78:2120-30, 1991. e-Pub 1991. PMID: 1912589.
Hershman JM, Eriksen E, Kaufman N, Champlin RE. Thyroid function tests in patients undergoing bone marrow transplantation. Bone Marrow Transplant 6:49-51, 1990. e-Pub 1990. PMID: 2390632.
Nimer SD, Milewicz AL, Champlin RE, Busuttil RW. Successful treatment of hepatic venoocclusive disease in a bone marrow transplant patient with orthotopic liver transplantation. Transplantation 49:819-21, 1990. e-Pub 1990. PMID: 2326879.
Champlin R, Ho W, Gajewski J, Feig S, Burnison M, Holley G, Greenberg P, Lee K, Schmid I, Giorgi J, et al. Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Blood 76:418-23, 1990. e-Pub 1990. PMID: 2142440.
Champlin R, Gajewski J, Nimer S, Vollset S, Landaw E, Winston D, Schiller G, Ho W. Postremission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment. J Clin Oncol 8:1199-206, 1990. e-Pub 1990. PMID: 1694236.
Winston DJ, Ho WG, Bruckner DA, Gale RP, Champlin RE. Ofloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. Am J Med 88(1):36-42, 1990. e-Pub 1990. PMID: 2153006.
Champlin RE, Ho WG, Nimer SD, Gajewski JG, Selch M, Burnison M, Holley G, Yam P, Petz L, Winston DJ, et al. Bone marrow transplantation for severe aplastic anemia. Effect of a preparative regimen of cyclophosphamide-low-dose total-lymphoid irradiation and posttransplant cyclosporine-methotrexate therapy. Transplantation 49:720-4, 1990. e-Pub 1990. PMID: 2326866.
Sun GX, Sparkes RS, Wormsley S, Naeim F, Champlin R, Gale RP. Are some cases of acute leukemia with t(8;21) hybrid leukemias?. Cancer Genet Cytogenet 49:177-84, 1990. e-Pub 1990. PMID: 2170002.
Faisal M, Cumberland W, Champlin R, Fahey JL. Effect of recombinant human granulocyte-macrophage colony-stimulating factor administration on the lymphocyte subsets of patients with refractory aplastic anemia. Blood 76:1580-5, 1990. e-Pub 1990. PMID: 2207331.
Gajewski JL, Ho WG, Feig SA, Hunt L, Kaufman N, Champlin RE. Bone marrow transplantation using unrelated donors for patients with advanced leukemia or bone marrow failure. Transplantation 50:244-9, 1990. e-Pub 1990. PMID: 2143325.
Naeim F, Champlin R, Nimer S. Bone marrow changes in patients with refractory aplastic anemia treated by recombinant GM-CSF. Hematol Pathol 4(2):79-85, 1990. e-Pub 1990. PMID: 2197266.
Sawyers CL, Timson L, Kawasaki ES, Clark SS, Witte ON, Champlin R. Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction. Proc Natl Acad Sci U S A 87(2):563-7, 1990. e-Pub 1990. PMID: 2405384.
Champlin RE, Nimer SD, Ireland P, Oette DH, Golde DW. Treatment of refractory aplastic anemia with recombinant human granulocyte-macrophage-colony-stimulating factor. Blood 73:694-9, 1989. e-Pub 1989. PMID: 2644986.
Cain GR, Champlin RE. Long-term complete chimerism and stable hematopoiesis in beagles after fetal liver hematopoietic stem cell transplantation. Am J Vet Res 50:1282-4, 1989. e-Pub 1989. PMID: 2571318.
Cain GR, Champlin R, Jain N. Immune thrombocytopenia in dogs after fetal liver hematopoietic cell transplantation. Exp Hematol 17:287-91, 1989. e-Pub 1989. PMID: 2563691.
Gale, RP, Gluckman E, Horowitz M, Champlin RE, Bortin MM. Graft failure following transplants for aplastic anemia: evidence for an immune mechanism. Bone Marrow Transplant 4:115, 1989. e-Pub 1989.
Champlin RE, Horowitz MM, van Bekkum DW, Camitta BM, Elfenbein GE, Gale RP, Gluckman E, Good RA, Rimm AA, Rozman C, et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood 73:606-13, 1989. e-Pub 1989. PMID: 2644980.
Gajewski JL, Ho WG, Nimer SD, Hirji KF, Gekelman L, Jacobs AD, Champlin RE. Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome. J Clin Oncol 7:1637-45, 1989. e-Pub 1989. PMID: 2809680.
Baranov A, Gale RP, Guskova A, Piatkin E, Selidovkin G, Muravyova L, Champlin RE, Danilova N, Yevseeva L, Petrosyan L. Bone marrow transplantation after the Chernobyl nuclear accident. N Engl J Med 321:205-12, 1989. e-Pub 1989. PMID: 2664512.
Schiller GJ, Naeim F, Champlin RE. Bone marrow aplasia associated with proliferation of large granular lymphocytes and subsequent transformation to acute lymphoblastic leukemia. Am J Hematol 32:153-4, 1989. e-Pub 1989. PMID: 2757012.
Kagan JM, Champlin RE, Saxon A. B-cell dysfunction following human bone marrow transplantation: functional-phenotypic dissociation in the early posttransplant period. Blood 74:777-85, 1989. e-Pub 1989. PMID: 2665854.
Macy E, Bulpitt K, Champlin RE, Saxon A. Anaphylaxis to infusion of autologous bone marrow: an apparent reaction to self, mediated by IgE antibody to bovine serum albumin. J Allergy Clin Immunol 83:871-5, 1989. e-Pub 1989. PMID: 2654255.
Kedar E, Rezai AR, Giorgi JV, Gale RP, Champlin RE, Mitsuyasu RT, Fahey JL. Immunomodulating effects in vitro of interleukin-2 and interferon-gamma on human blood and bone marrow mononuclear cells. Nat Immun Cell Growth Regul 7(1):13-30, 1988. e-Pub 1988. PMID: 2896298.
Winston DJ, Eron LJ, Ho M, Pazin G, Kessler H, Pottage JC, Jr, Gallagher J, Sartiano G, Ho WG, Champlin RE, et al. Recombinant interferon alpha-2a for treatment of herpes zoster in immunosuppressed patients with cancer. Am J Med 85:147-51, 1988. e-Pub 1988. PMID: 3041829.
Champlin R. Treatment for victims of nuclear accidents: the role of bone marrow transplantation. Radiat Res 113:205-10, 1988. e-Pub 1988. PMID: 3277219.
Nimer SD, Champlin RE, Golde DW. Serum cholesterol-lowering activity of granulocyte-macrophage colony-stimulating factor. Jama 260:3297-300, 1988. e-Pub 1988. PMID: 3054191.
Apperley, JF, Mauro FR, Goldman JM, Gregory W, Arthur CK, Hows J, Arcese W, Papa G, Mandelli F, Wardle, Gravett P, Franklin IM, Bandini G, Ricci P, Tura S, Iacone A, Torlontano G, Heit W, Champlin RE, Gale RP. Bone marrow transplantation for chronic myeloid leukemia in first chronic phase: importance of a graft versus leukemia effect. Brit. J. Hematol 69:239 245, 1988. e-Pub 1988.
Kawasaki ES, Clark SS, Coyne MY, Smith SD, Champlin R, Witte ON, McCormick FP. Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. Proc Natl Acad Sci U S A 85:5698-702, 1988. e-Pub 1988. PMID: 3165197.
Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E, Hoffmann RG, Jacobsen SJ, Marmont AM, McGlave PB, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 108:806-14, 1988. e-Pub 1988. PMID: 3285744.
Winson DJ, Eron LJ, Ho M, Pazin G, Kessler H, Pottage JC, Gallagher J, Sartiano G, Ho WG, Champlin RE, Bernahrdt L, Bigley J, Kantira L, Nadler PI. Recombinant interferon alpha-2a for treatment of herpes zoster in immunosuppressed patients with cancer. Am J Med 85:147-151, 1988. e-Pub 1988.
Winston DJ, Ho WG, Lin CH, Bartoni K, Budinger MD, Gale RP, Champlin RE. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med 106(1):12-8, 1987. e-Pub 1987. PMID: 3024542.
Ho WG, Champlin RE, Winston DJ, Feig SA, Gale RP. Bone marrow transplantation in patients with leukaemia previously transfused with blood products from family members. Br J Haematol 67:67-70, 1987. e-Pub 1987. PMID: 3311126.
Clark SS, McLaughlin J, Crist WM, Champlin R, Witte ON. Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL. Science 235:85-8, 1987. e-Pub 1987. PMID: 3541203.
Decker RW, Ho WG, Champlin RE. Phase II study of amsacrine and high-dose cytarabine for resistant acute myelogenous leukemia. Cancer Treat Rep 71:881-2, 1987. e-Pub 1987. PMID: 3476204.
Cain G, Stitzel K, Gale R, Champlin R. Transplantation of DLA-compatible and incompatible fetal liver hematopoietic cells in dogs. Transplantation 44:742-7, 1987. e-Pub 1987. PMID: 2892290.
Hocking W, Champlin R, Mitsuyasu R. Transient response of pure red cell aplasia to anti-thymocyte globulin in a patient with T-cell chronic lymphocytic leukemia. Am J Hematol 24:285-91, 1987. e-Pub 1987. PMID: 3103427.
Champlin RE, Cain G, Stitzel K, Gale RP. Sustained recovery of hematopoiesis and immunity following transplantation of fetal liver cells in dogs. Thymus 10(1-2):13-8, 1987. e-Pub 1987. PMID: 3324401.
Hocking W, Champlin RE, Mitsuyasu R. Transient response of pure red cell aplasia to antithymocyte gloublin in a patient with T-cell chronic lymphocytic leukemia. Am J Jematol 24:285-291, 1987. e-Pub 1987.
Holland GN, Sidikaro Y, Kreiger AE, Hardy D, Sakamoto MJ, Frenkel LM, Winston DJ, Cottlieb MS, Bryson YJ, Champlin RE, Ho WG, Winters RE, Wolfe PE, Cherry JD. Treatment of cytomegalovirus retinopathy with ganciclovir. Ophthamology 94:815-823, 1987. e-Pub 1987.
Mitsuyasu RT, Champlin RE, Gale RP, Ho WG, Lenarsky C, Winston D, Selch M, Elashoff R, Giorgi JV, Wells J, et al. Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial. Ann Intern Med 105:20-6, 1986. e-Pub 1986. PMID: 3521427.
Mitsuyasu RT, Li SN, Champlin RE, Gale RP. Abnormal T-lymphocyte colonies (CFU-TL) following bone marrow transplantation. Exp Hematol 14:1049-55, 1986. e-Pub 1986. PMID: 3536545.
Saxon A, Mitsuyasu R, Stevens R, Champlin RE, Kimata H, Gale RP. Designed transfer of specific immune responses with bone marrow transplantation. J Clin Invest 78:959-67, 1986. e-Pub 1986. PMID: 3531239.
Cain GR, Cardinet GH, rd, Cuddon PA, Gale RP, Champlin R. Myasthenia gravis and polymyositis in a dog following fetal hematopoietic cell transplantation. Transplantation 41(1):21-5, 1986. e-Pub 1986. PMID: 2867626.
Winston DJ, Ho WG, Nakao SL, Gale RP, Champlin RE. Norfloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. Am J Med 80:884-90, 1986. e-Pub 1986. PMID: 3010716.
Li S, Champlin R, Fitchen JH, Gale RP. Abnormalities of myeloid progenitor cells after "successful" bone marrow transplantation. J Clin Invest 75:234-41, 1985. e-Pub 1985. PMID: 3880774.
Champlin RE, Ho WG, Feig SA, Winston DJ, Lenarsky C, Gale RP. Do androgens enhance the response to antithymocyte globulin in patients with aplastic anemia? A prospective randomized trial. Blood 66:184-8, 1985. e-Pub 1985. PMID: 4005428.
Winston DJ, Huang ES, Miller MJ, Lin CH, Ho WG, Gale RP, Champlin RE. Molecular epidemiology of cytomegalovirus infections associated with bone marrow transplantation. Ann Intern Med 102(1):16-20, 1985. e-Pub 1985. PMID: 2981496.
Jacobs AD, Champlin RE, Golde DW. Pure red cell aplasia characterized by erythropoietic maturation arrest. Response to anti-thymocyte globulin. Am J Med 78:515-7, 1985. e-Pub 1985. PMID: 3919580.
Jacobs AD, Champlin RE, Golde DW. Recombinant alpha-2-interferon for hairy cell leukemia. Blood 65:1017-20, 1985. e-Pub 1985. PMID: 3884059.
Champlin RE, Ho WG, Gale RP, Winston D, Selch M, Mitsuyasu R, Lenarsky C, Elashoff R, Zighelboim J, Feig SA. Treatment of acute myelogenous leukemia. A prospective controlled trial of bone marrow transplantation versus consolidation chemotherapy. Ann Intern Med 102:285-91, 1985. e-Pub 1985. PMID: 3882039.
Winston DJ, Ho WG, Lin GH, Bartoni K, Budinger MD, Gale RP, Champlin RE. [Use of a polyvalent intravenous immunoglobulin or specific cytomegalovirus hyperimmunoglobulin for modification of cytomegalovirus infections and prevention of interstitial pneumonias following bone marrow transplantation]. Immun Infekt 13:296-301, 1985. e-Pub 1985. PMID: 3000923.
Seto B, Kim M, Wolinsky L, Mito RS, Champlin RE. Oral mucositis in patients undergoing bone marrow transplantation. Oral Surg Oral Med Pathol 60:493-497, 1985. e-Pub 1985.
Speck B, Bortin MM, Champlin R, Goldman JM, Herzig RH, McGlave PB, Messner HA, Weiner RS, Rimm AA. Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet 1:665-8, 1984. e-Pub 1984. PMID: 6142357.
Ho WG, Champlin RE, Feig SA, Gale RP. Transplantation of ABH incompatible bone marrow: gravity sedimentation of donor marrow. Br J Haematol 57:155-62, 1984. e-Pub 1984. PMID: 6372850.
Champlin RE, Gale RP. Role of bone marrow transplantation in the treatment of hematologic malignancies and solid tumors: critical review of syngeneic, autologous, and allogeneic transplants. Cancer Treat Rep 68(1):145-61, 1984. e-Pub 1984. PMID: 6362862.
Champlin R, Jacobs A, Gale RP, Boccia R, Elashoff R, Foon K, Zighelboim J. Prolonged survival in acute myelogenous leukaemia without maintenance chemotherapy. Lancet 1:894-6, 1984. e-Pub 1984. PMID: 6200742.
Winston DJ, Barnes RL, Ho WG, Young LS, Champlin RE, Gale RP. Moxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patients. Am J Med 77:442-50, 1984. e-Pub 1984. PMID: 6475984.
Winston DJ, Ho WG, Lin CH, Budinger MD, Champlin RE, Gale RP. Intravenous immunoglobulin for modification of cytomegalovirus infections associated with bone marrow transplantation. Preliminary results of a controlled trial. Am J Med 76:128-33, 1984. e-Pub 1984. PMID: 6324586.
Foon KA, Mitsuyasu RT, Schroff RW, McIntyre RE, Champlin RE, Gale RP. Immunologic defects in young male patients with hepatitis-associated aplastic anemia. Ann Intern Med 100:657-62, 1984. e-Pub 1984. PMID: 6608893.
Gale RP, Champlin RE. How does bone-marrow transplantation cure leukaemia?. Lancet 2:28-30, 1984. e-Pub 1984. PMID: 6145942.
Bayever E, Champlin R, Ho W, Lenarsky C, Storch S, Ladisch S, Gale RP, Feig SA. Comparison between bone marrow transplantation and antithymocyte globulin in treatment of young patients with severe aplastic anemia. J Pediatr 105:920-5, 1984. e-Pub 1984. PMID: 6389812.
Champlin RE, Feig SA, Gale RP. Case problems in bone marrow transplantation. I. Graft failure in aplastic anemia: its biology and treatment. Exp Hematol 12:728-33, 1984. e-Pub 1984. PMID: 6386510.
Champlin RE, Feig SA, Sparkes RS, Peter R, Galen RP. Bone marrow transplantation from identical twins in the treatment of aplastic anaemia: implication for the pathogenesis of the disease. Br J Haematol 56:455-63, 1984. e-Pub 1984. PMID: 6365155.
Boccia, R, Zighelboim J, Champlin RE, Kim CC, Gale RP. AMSA: a phase II trial in resistant and recurrent acute myelogenous leukemia. Med Ped Oncol 12:178 179, 1984. e-Pub 1984.
Feig SA, Champlin R, Arenson E, Yale C, Ho W, Tesler A, Gale RP. Improved survival following bone marrow transplantation for aplastic anaemia. Br J Haematol 54:509-17, 1983. e-Pub 1983. PMID: 6347239.
Winston DJ, Ho WG, Schroff RW, Champlin RE, Gale RP. Safety and tolerance of recombinant leukocyte A interferon in bone marrow transplant recipients. Antimicrob Agents Chemother 23:846-51, 1983. e-Pub 1983. PMID: 6311088.
Champlin, RE, Ho WG, Gale RP. A randomized controlled trial of antithymocyte globulin in patients with aplastic anemia. N Engl J Med 308:113 118, 1983. e-Pub 1983.
Winston DJ, Ho WG, Schiffman G, Champlin RE, Feig SA, Gale RP. Pneumococcal vaccination of recipients of bone marrow transplants. Arch Intern Med 143:1735-7, 1983. e-Pub 1983. PMID: 6351777.
Camitta B, O'Reilly RJ, Sensenbrenner L, Rappeport J, Champlin R, Doney K, August C, Hoffmann RG, Kirkpatrick D, Stuart R, Santos G, Parkman R, Gale RP, Storb R, Nathan D. Antithoracic duct lymphocyte globulin therapy of severe aplastic anemia. Blood 62:883-8, 1983. e-Pub 1983. PMID: 6349719.
Niskanen E, Champlin R, Oki A, Golde DW, Gale RP, Cline MJ. Humoral stimulation of hemopoietic progenitors from human fetal liver. Stem Cells 2:246-52, 1982. e-Pub 1982. PMID: 6132450.
Sarna GP, Champlin R, Wells J, Gale RP. A phase-one study of high-dose mitomycin C with autologous bone marrow support. Cancer Treat Rep 66:277-82, 1982. e-Pub 1982. PMID: 7034933.
Champlin R, Ho W, Arenson E, Gale RP. Allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic or accelerated phase. Blood 60:1038-41, 1982. e-Pub 1982. PMID: 7052161.
Gale RP, Ho W, Feig S, Champlin R, Tesler A, Arenson E, Ladish S, Young L, Winston D, Sparkes R, Fitchen J, Territo M, Sarna G, Wong L, Paik Y, Bryson Y, Golde D, Fahey J, Cline M. Prevention of graft rejection following bone marrow transplantation. Blood 57:9-12, 1981. e-Pub 1981. PMID: 7004532.
Douer D, Champlin RE, Ho WG, Sarna GP, Wells JH, Graze PR, Cline MJ, Gale RP. High-dose combined-modality therapy and autologous bone marrow transplantation in resistant cancer. Am J Med 81:973-6, 1981. e-Pub 1981. PMID: 7032290.
Champlin R, Hunter RL. Studies on the composition of adjuvants which selectively enhance delayed-type hypersensitivity to lipid conjugated protein antigens. J Immunol 114:76-80, 1975. e-Pub 1975. PMID: 1089714.

Invited Articles

Andersson BS, de Lima M, Thall PF, Madden T, Russell JA, Champlin RE. Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia. Curr Opin Oncol 21(Suppl 1):S11-S15, 2009. e-Pub 2009. PMID: 19561406.
Champlin RE. Graft biology: marrow versus peripheral blood versus cord blood. Biol Blood Marrow Transplant 13(Suppl 1):76, 2007. e-Pub 2007.
Youssef S, Rodriguez G, Rolston KV, Champlin RE, Raad II, Safdar A. Streptococcus pneumoniae infections in 47 hematopoietic stem cell transplantation recipients: clinical characteristics of infections and vaccine-breakthrough infections, 1989 - 2005. Medicine 86(2):69-77, 2007. e-Pub 2007.
Wagner J, Champlin R, Petz LD. Symposium Summary - 4th Annual International Umbilical Cord Blood Transplantation. Biol Blood Marrow Transplant 12:1206-1217, 2006. e-Pub 2006.
Wagner J, Champlin R, Petz LD. Symposium Summary. Biol Blood Marrow Transplant 11:921-927, 2005. e-Pub 2005.
Ueno NT, Shpall EJ, Champlin RE, Jones RB. Graft--versus--breast cancer effect by allogeneic hematopoietic stem-cell transplantation: a possible new frontier. J Clin Oncol 22(19):3846-7, 2004. e-Pub 2004. PMID: 15314060.
Qazilbash MH, Giralt SA, Champlin RE. Nonmyeloablative stem cell transplantation for chronic myeloid leukemia. Hematol Oncol Clin North Am 18(3):703-13, xi, 2004. e-Pub 2004. PMID: 15271401.
Khouri IF, Champlin RE. Nonmyeloablative stem cell transplantation for lymphoma. Semin Oncol 31(1):22-6, 2004. e-Pub 2004. PMID: 14970933.
Komanduri, K, Champlin RE. GVHD Therapy: the best laid schemes. Blood 104:1240-1241, 2004. e-Pub 2004.
Korbling M, Estrov Z, Champlin R. Adult stem cells and tissue repair. Bone Marrow Transplant 32 Suppl 1:S23-4, 2003. e-Pub 2003. PMID: 12931235.
Giralt S, Anagnostopoulos A, Shahjahan M, Champlin R, Anagnastopoulos A, Shahjahanan M. Nonablative stem cell transplantation for older patients with acute leukemias and myelodysplastic syndromes. Semin Hematol 39(1):57-62, 2002. e-Pub 2002. PMID: 11799530.
Champlin RE. Non-myeloablative hematopoietic transplantation for treatment of malignant diseases. Current Opinion in Organ Transplantation 7:275-278, 2002. e-Pub 2002.
Champlin RE. Stem Cell Transplantation for lymphoma. Cytotherapy 4:203, 2002. e-Pub 2002.
Champlin RE. Adenovirus infections following allogeneic hematopoietic transplantation. Blood 100:1523, 2002. e-Pub 2002.
Khouri I, Giralt S, Champlin R. Non-myeloablative allogeneic hematopoietic transplantation and induction of graft-versus-malignancy. Cancer Treat Res 110:137-47, 2002. e-Pub 2002. PMID: 11908196.
Anderlini P, Champlin R. Use of filgrastim for stem cell mobilisation and transplantation in high-dose cancer chemotherapy. Drugs 62 Suppl 1:79-88, 2002. e-Pub 2002. PMID: 12479596.
de Lima M, Champlin R. Unrelated donor hematopoietic transplantation. Rev Clin Exp Hematol 5(2):100-34, 2001. e-Pub 2001. PMID: 11486651.
Champlin R, Khouri I, Anderlini P, Gajewski J, Kornblau S, Molldrem J, Shimoni A, Ueno N, Giralt S. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Bone Marrow Transplant 27 Suppl 2:S13-22, 2001. e-Pub 2001. PMID: 11436116.
Champlin RE. Community repiratory virus infections in the bone marrow transplant population. Biology of Blood and Marrow Transplantation 7(Introduction):1S, 2001. e-Pub 2001.
Khouri, IF, Champlin RE. Non-myeloablative allogeneic stem cell transplantation for lymphoid malignancies. Current and Emerging Research in Lymphoma:15-21, 2001. e-Pub 2001.
Storb, R, Champlin RE, Ridell SR, Murata M, Bryant S, Warren EH. Non-myeloablative transplant for malignant disease, . Hematology American Society of Hematology Education Program:237-253, 2001. e-Pub 2001.
Claxton DF, McMannis J, Champlin R, Choudhury A. Therapeutic potential of leukemia-derived dendritic cells: preclinical and clinical progress. Crit Rev Immunol 21(1-3):147-55, 2001. e-Pub 2001. PMID: 11642601.
Champlin RE, Whimbey E. Community respiratory virus infections in bone marrow transplant recipients: the M.D. Anderson Cancer Center experience. Biol Blood Marrow Transplant 7 Suppl:8S-10S, 2001. e-Pub 2001. PMID: 11777103.
Couriel DR, Hicks K, Giralt S, Champlin RE. Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation. Curr Opin Oncol 12(6):582-7, 2000. e-Pub 2000. PMID: 11085458.
Andersson BS, Gajewski J, Donato M, Giralt S, Gian V, Wingard J, Tarantolo S, Fernandez H, Hu WW, Blume K, Kashyap A, Forman SJ, Champlin RE. Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy). Bone Marrow Transplant 25 Suppl 2:S35-8, 2000. e-Pub 2000. PMID: 10933185.
Shimoni A, Giralt S, Khouri I, Champlin R. Allogeneic hematopoietic transplantation for acute and chronic myeloid leukemia: non-myeloablative preparative regimens and induction of the graft-versus-leukemia effect. Curr Oncol Rep 2(2):132-9, 2000. e-Pub 2000. PMID: 11122834.
Champlin R, van Besien K, Giralt S, Khouri I. Allogeneic hematopoietic transplantation for chronic lymphocytic leukemia and lymphoma: potential for nonablative preparative regimens. Curr Oncol Rep 2(2):182-91, 2000. e-Pub 2000. PMID: 11122842.
Donato M, Champlin R. Granulocyte colony-stimulating factor--primed allogeneic bone marrow transplants: capturing the advantages of blood stem cell transplants without increased risk of chronic graft-versus-host disease. Biol Blood Marrow Transplant 6(4A):419-21, 2000. e-Pub 2000. PMID: 10975509.
Cabanillas F, Horning S, Kaminski M, Champlin R. Managing Indolent Lymphomas in Relapse: Working Our Way Through a Plethora of Options. Hematology Am Soc Hematol Educ Program:166-179, 2000. e-Pub 2000. PMID: 11701541.
Besien V, K, Champlin RE. Non-Hodgkin’s lymphoma: Allogeneic and autologous blood and marrow transplantation. Advances in Oncology 16:3-16, 2000. e-Pub 2000.
Champlin R, Khouri I, Kornblau S, Marini F, Anderlini P, Ueno NT, Molldrem J, Giralt S. Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy. Hematol Oncol Clin North Am 13(5):1041-57, vii-viii, 1999. e-Pub 1999. PMID: 10553260.
Champlin R, Khouri I, Komblau S, Molidrem J, Giralt S. Reinventing bone marrow transplantation. Nonmyeloablative preparative regimens and induction of graft-vs-malignancy effect. Oncology (Williston Park) 13(5):621-8; discussion 631, 635-8, 641, 1999. e-Pub 1999. PMID: 10356683.
Champlin R, Khouri I, Kornblau S, Molldrem J, Giralt S. Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy. Curr Opin Oncol 11(2):87-95, 1999. e-Pub 1999. PMID: 10188072.
Ueno NT, Hortobagyi GN, Champlin RE. Allogeneic peripheral blood progenitor cell transplantation in solid tumors. Cancer Treat Res 101:133-56, 1999. e-Pub 1999. PMID: 10800648.
Champlin R, Khouri I, Giralt S. Graft-vs.-malignancy with allogeneic blood stem cell transplantation: a potential primary treatment modality. Pediatr Transplant 3 Suppl 1:52-8, 1999. e-Pub 1999. PMID: 10587972.
Giralt, S, Khouri I, Champlin R. Non myeloablative "mini transplants. Cancer Treat Res 101:97-108, 1999. e-Pub 1999.
Champlin R, Khouri I, Giralt S. Use of nonmyeloablative preparative regimens for allogeneic blood stem cell transplantation: induction of graft-vs.-malignancy as treatment for malignant diseases. J Clin Apher 14(1):45-9, 1999. e-Pub 1999. PMID: 10355664.
Rahman ZU, Hortobagyi GN, Buzdar AU, Champlin R. High-dose chemotherapy with autologous stem cell support in patients with breast cancer. Cancer Treat Rev 24(4):249-63, 1998. e-Pub 1998. PMID: 9805506.
Anderlini P, Przepiorka D, Korbling M, Champlin R. Blood stem cell procurement: donor safety issues. Bone Marrow Transplant 21 Suppl 3:S35-9, 1998. e-Pub 1998. PMID: 9712491.
Choudhury A, Toubert A, Sutaria S, Charron D, Champlin RE, Claxton DF. Human leukemia-derived dendritic cells: ex-vivo development of specific antileukemic cytotoxicity. Crit Rev Immunol 18(1-2):121-31, 1998. e-Pub 1998. PMID: 9419454.
Jones DV, Jr, Ashby M, Vadhan-Raj S, Somlo G, Champlin R, Gajewski J, Hellmann S, Fyfe G. Recombinant human thrombopoietin clinical development. Stem Cells 16 Suppl 2:199-206, 1998. e-Pub 1998. PMID: 11012192.
Khouri IF, Keating MJ, Champlin R. Hematopoietic stem cell transplantation for chronic lymphocytic leukemia. Curr Opin Hematol 5:454-459, 1998. e-Pub 1998.
van Besien K, Margolin K, Champlin R, Forman S. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells. Cancer J Sci Am 3 Suppl 1:S54-8, 1997. e-Pub 1997. PMID: 9457395.
Rahman Z, Champlin R, Rondon G, Frye D, Valero V, Mehra R, Hortobagyi G. Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer. Semin Oncol 24(5 Suppl 17):S17-77-S17-80, 1997. e-Pub 1997. PMID: 9374100.
Giralt S, Davis M, O'Brien S, van Besien K, Champlin R, de Vos D, Kantarjian H. Studies of decitabine with allogeneic progenitor cell transplantation. Leukemia 11 Suppl 1:S32-4, 1997. e-Pub 1997. PMID: 9130690.
Champlin, RE, Khouri I, Giralt S. Induction of graft-vs-leukemia as a new therapeutic modality. American Society of Clinical Oncology Education Book:p 88-92, 1997. e-Pub 1997.
Hortobagyi, GN, Holmes FA, Ibrahim N, Champlin RE, Buzdar AU. The University of Texas, MD Anderson Cancer Center experience with paclitaxel in breast cancer. Semin Oncol 24((suppl 3):):30-33, 1997. e-Pub 1997.
Champlin R. Improving the Results of Bone Marrow Transplants. Cancer J Sci Am 2(6):309, 1996. e-Pub 1996. PMID: 9166550.
Gajewski J, Champlin R. Bone marrow transplantation from unrelated donors. Curr Opin Oncol 8(2):84-8, 1996. e-Pub 1996. PMID: 8727299.
Champlin R. Purging: elimination of malignant cells from autologous blood or marrow transplants. Curr Opin Oncol 8(2):79-83, 1996. e-Pub 1996. PMID: 8727298.
Korbling M, Champlin R. Peripheral blood progenitor cell transplantation: a replacement for marrow auto- or allografts. Stem Cells 14(2):185-95, 1996. e-Pub 1996. PMID: 8991538.
Champlin, RE, Figlin RA. Evolving clinical applications of hematopoietic growth factors - Introduction. . Semin. Oncol 23((Suppl. 4)):1, 1996. e-Pub 1996.
Champlin RE. Peripheral Blood Progenitor Cells: a Replacement for Marrow Transplantation?. Semin Oncol 23:15-21, 1996. e-Pub 1996.
Champlin, RE, Giralt S, Gajewski J. T-cells, graft-versus-host disease and graft-versus-leukemia: new approaches for blood and marrow transplantation. Acta Haematologica 95:157-163, 1996. e-Pub 1996.
Champlin RE. Transplantation. Curr Opin Oncol 8:79-102, 1996. e-Pub 1996.
Alexanian R, Dimopoulos MA, Delasalle KB, Hester J, Champlin R. Myeloablative therapy for primary resistant multiple myeloma. Stem Cells 13 Suppl 2:118-21, 1995. e-Pub 1995. PMID: 8520499.
Champlin R. Optimizing the composition of bone marrow for allogenic transplantation. J Hematother 4(1):53-60, 1995. e-Pub 1995. PMID: 7757401.
Champlin RE. T-cell depletion for allogeneic marrow transplantation: innovations to enhance engraftment and graft vs. leukemia. Bone Marrow Transplant 15:104-111, 1995. e-Pub 1995.
Champlin, RE, Gale RP. Advances and Controversies in Bone Marrow Transplantation. Bone Marrow Transplant (Supplement 1),, 1995. e-Pub 1995.
Gajewski, JL, Mehra R, Warkentin DI, Champlin RE. Outpatient autologous bone marrow transplantation. Cancer Bulletin 47((4)):298-300, 1995. e-Pub 1995.
Dimopoulos MA, Weber DM, Hester J, Delasalle K, Champlin R, Alexanian R. Intensive sequential therapy for VAD-resistant multiple myeloma. Leuk Lymphoma 13(5-6):479-84, 1994. e-Pub 1994. PMID: 7915163.
Vriesendorp HM, Chu H, Ochran TG, Besa PC, Champlin RE. Radiobiology of total body radiation. Bone Marrow Transplant 14 Suppl 4:S4-8, 1994. e-Pub 1994. PMID: 7728124.
Gajewski, JL, Champlin RE. How to manage severe aplastic anemia. Contemporary Oncology 4:69-82, 1994. e-Pub 1994.
Hughes, P, Jr SF, Hagemeister F, Cabanillas F, Samuels B, Champlin RE, Andersson BS. High dose intercalator based therapy with marrow support is effective for refractory Hodgkin's disease (HD). Proceedings of the Sixth International Symposium on Autologous Bone Marrow Transplantation, Houston, Texas:104-110, 1993. e-Pub 1993.
Deisseroth AB, Kantarjian H, Talpaz M, Champlin R, Reading C, Hanania EG, Fu S, Randhawa GS, Cha Y, Fang X, et al. Molecular approaches to the diagnosis and treatment of cancer. Stem Cells 11 Suppl 3:129-30, 1993. e-Pub 1993. PMID: 7905320.
Bleyer WA, Champlin RE, Chan KW, Deisseroth AB. Bone marrow transplantation for leukemia. J Pediatr 123(3):492-3, 1993. e-Pub 1993. PMID: 8257507.
Champlin R. Preparative regimens for autologous bone marrow transplantation. Blood 81(2):277-80, 1993. e-Pub 1993. PMID: 8422454.
Champlin R. Bone marrow transplantation for leukemia utilizing HLA-matched unrelated donors. Bone Marrow Transplant 11 Suppl 1:74-7, 1993. e-Pub 1993. PMID: 8448555.
Champlin RE. Potential of gene therapy for allogeneic marrow transplantation. Cancer Bull 45:159-163, 1993. e-Pub 1993.
Champlin R, Coppo P, Howe C. National Marrow Donor Program: progress and challenges. Bone Marrow Transplant 11 Suppl 1:41-4, 1993. e-Pub 1993. PMID: 8448545.
Champlin RE. Dose intensive therapy with autologous bone marrow transplantation for treatment of breast cancer. Cancer Bull 45:532-537, 1993. e-Pub 1993.
Champlin R. Bone marrow transplantation for Hodgkin's disease--recent advances and current issues. Leuk Lymphoma 10 Suppl:103-8, 1993. e-Pub 1993. PMID: 8481659.
Champlin R. Allogeneic bone marrow transplantation using unrelated donors. Leuk Lymphoma 11 Suppl 2:149-52, 1993. e-Pub 1993. PMID: 8124226.
Przepiorka D, Giralt S, Huh YO, Andreeff M, Luna M, Reading C, Thomas M, Champlin RE. T-cell-depleted autologous marrow fails to prevent acute graft-versus-host disease after allogeneic marrow transplantation for lymphoblastic lymphoma. Transplant Proc 24(6):2906-7, 1992. e-Pub 1992. PMID: 1465994.
Champlin R. Graft-versus-leukemia without graft-versus-host disease: an elusive goal of bone marrow transplantation. Semin Hematol 29(3 Suppl 2):46-52, 1992. e-Pub 1992. PMID: 1509294.
Gluckman E, Auerbach A, Ash RC, Biggs JC, Bortin MM, Camitta BM, Champlin RE, Friedrich W, Gale RP, Good RA, et al. Allogeneic bone marrow transplants for Fanconi anemia. A preliminary report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 10 Suppl 1:53-7, 1992. e-Pub 1992. PMID: 1521091.
Deisseroth, AB, Zhang W, Cha Y, Yuan T, Chen H, Sims S, Wedrychowski A, P-Q G, Huston L, Filaccio M, Claxton D, Kornblau S, Johnson E, Howard OMZ, Andersson B, Del Giglio A, Gresso L, Kantarjian H, Talpaz M, Khouri I, Champlin RE, Andreeff M, Gaozza E, Seong D. New directions in the biology and therapy of chronic myeloid leukemia. Leuk Lymphoma 6:89, 1992. e-Pub 1992.
Champlin R, Giralt S, Przepiorka D, Ho W, Lee K, Gajewski J, Nimer S, Andersson B, Wallerstein R, Ippolito C, et al. Selective depletion of CD8-positive T-lymphocytes for allogeneic bone marrow transplantation: engraftment, graft-versus-host disease and graft-versus leukemia. Prog Clin Biol Res 377:385-94; discussion 395-8, 1992. e-Pub 1992. PMID: 1438435.
Champlin R. Immunobiology of bone marrow transplantation as treatment for hematologic malignancies. Transplant Proc 23(4):2123-7, 1991. e-Pub 1991. PMID: 1871828.
Champlin R, Jansen J, Ho W, Gajewski J, Nimer S, Lee K, Territo M, Winston D, Tricot G, Reichert T. Retention of graft-versus-leukemia using selective depletion of CD8-positive T lymphocytes for prevention of graft-versus-host disease following bone marrow transplantation for chronic myelogenous leukemia. Transplant Proc 23(1 Pt 2):1695-6, 1991. e-Pub 1991. PMID: 1899162.
Champlin RE. Therapeutic use of hematopoietic growth factors in bone marrow transplantation. Cancer Bull 43:197-207, 1991. e-Pub 1991.
Visani G, Gamberi B, Greenberg P, Advani R, Gulati S, Champlin R, Hoglund M, Karanes C, Williams S, Keating A, et al. The use of GM-CSF as an adjunct to autologous/syngeneic bone marrow transplantation: a prospective randomized controlled trial. Bone Marrow Transplant 7 Suppl 2:81, 1991. e-Pub 1991. PMID: 1878732.
Champlin RE. Commentary: Who should receive an unrelated donor bone marrow transplant? . Marrow Transplant Rev 1:7, 1991. e-Pub 1991.
Winston DJ, Ho WG, Champlin RE. Cytomegalovirus infections after allogeneic bone marrow transplantation. Rev Infect Dis 12 Suppl 7:S776-92, 1990. e-Pub 1990. PMID: 2173107.
Champlin R. T-cell depletion to prevent graft-versus-host disease after bone marrow transplantation. Hematol Oncol Clin North Am 4(3):687-98, 1990. e-Pub 1990. PMID: 2193019.
Gajewski J, Cecka M, Champlin R. Bone marrow transplantation utilizing HLA-matched unrelated marrow donors. Blood Rev 4(2):132-8, 1990. e-Pub 1990. PMID: 2194597.
Champlin RE, Nimer SD, Oette D, Golde DW. Effects of recombinant human granulocyte-macrophage colony-stimulating factor as treatment for aplastic anemia and agranulocytosis. Prog Clin Biol Res 338:143-50, 1990. e-Pub 1990. PMID: 2189137.
Gajewski J, Champlin RE. Bone marrow transplantation from unrelated donors. Blood Rev 4:132-138, 1990. e-Pub 1990.
Champlin RE. Role of bone marrow transplantation for victims of nuclear accidents. Proceedings of the Armed Forces Radiobiology Research Institute Consensus Conference, 1990. e-Pub 1990.
Ho WG, Winston DJ, Champlin RE. Tolerance and efficacy of ganciclovir in the treatment of cytomegalovirus infections in immunosuppressed patients. Transplant Proc 21(1 Pt 3):3103-6, 1989. e-Pub 1989. PMID: 2539690.
Champlin R, Gajewski J, Feig S, Giorgi J, Lyddane N, Lee K, Schmidt I, Winston D, Ho W, Reichert T. Selective depletion of CD8 positive T-lymphocytes for prevention of graft-versus-host disease following allogeneic bone marrow transplantation. Transplant Proc 21(1 Pt 3):2947-8, 1989. e-Pub 1989. PMID: 2495694.
Champlin RE, Gajewski JL, Golde DW. Treatment of acute myelogenous leukemia in the elderly. Semin Oncol 16(1):51-6, 1989. e-Pub 1989. PMID: 2645650.
Champlin R. Bone marrow aplasia due to radiation accidents: pathophysiology, assessment and treatment. Baillieres Clin Haematol 2(1):69-82, 1989. e-Pub 1989. PMID: 2645964.
Champlin RE, Gajewski J, Feig SA, Giorgi J< Lyddane N, Lee K, Schmidt I, Winston DJ, Ho WG, Reighert T. Selective depletion of CD8 positive T lymphocytes for prevention of graft-versus-host disease following allogeneic bone marrow transplantation. Transplant Proc 21:2947-2948, 1989. e-Pub 1989.
Winston DJ, Ho WG, Champlin RE. Current approaches to management of infections in bone marrow transplants. Eur J Cancer Clin Oncol 25 Suppl 2:S25-35, 1989. e-Pub 1989. PMID: 2693107.
Champlin RE, Ho WG, Winston DJ. Acute graft-vs.-host disease and interstitial pneumonitis interrelated problems following allogeneic bone marrow transplantation: effects of intravenous immune globulin and other interventions. J Hosp Infect 12 Suppl D:29-33, 1988. e-Pub 1988. PMID: 2902126.
Champlin RE. Treating multiple sclerosis with monoclonal antibodies: the cons. Neurology 38(7 Suppl 2):47-9, 1988. e-Pub 1988. PMID: 3260357.
Winston DJ, Ho WG, Bartoni K, Holland GN, Mitsuyasu RT, Gale RP, Busuttil RW, Champlin RE. Ganciclovir therapy for cytomegalovirus infections in recipients of bone marrow transplants and other immunosuppressed patients. Rev Infect Dis 10 Suppl 3:S547-53, 1988. e-Pub 1988. PMID: 2847292.
Winston DJ, Ho WG, Bruckner DA, Gale RP, Champlin RE. Controlled trials of double beta-lactam therapy with cefoperazone plus piperacillin in febrile granulocytopenic patients. Am J Med 85(1A):21-30, 1988. e-Pub 1988. PMID: 3041815.
Winston DJ, Ho WG, Bruckner DA, Gale RP, Champlin RE. Controlled trials of double beta-lactam therapy with cefoperazone plus piperacillin in febrile granulocytopenic patients. Am J Med 85(Suppl A):21-30, 1988. e-Pub 1988.
Champlin RE, Goldman JM, Gale RP. Bone marrow transplantation in chronic myelogenous leukemia. Semin Hematol 25(1):74-80, 1988. e-Pub 1988. PMID: 3279516.
Winston DJ, Ho WG, Gale RP, Champlin RE. Prophylaxis of infection in bone marrow transplants. Eur J Cancer Clin Oncol 24 Suppl 1:S15-23, 1988. e-Pub 1988. PMID: 3127217.
Champlin R. The role of bone marrow transplantation for nuclear accidents: implications of the Chernobyl disaster. Semin Hematol 24(3 Suppl 2):1-4, 1987. e-Pub 1987. PMID: 3310243.
Winston DJ, Ho WG, Champlin RE, Karp J, Bartlett J, Finley RS, Joshi JH, Talbot G, Levitt L, Deresinski S, et al. Norfloxacin for prevention of bacterial infections in granulocytopenic patients. Am J Med 82(6B):40-6, 1987. e-Pub 1987. PMID: 3037899.
Champlin R, Ho W, Winston D, Decker R, Greenberg P, Burnison M, Holly FE, Gale RP. Treatment of adults with acute myelogenous leukemia: prospective evaluation of high-dose cytarabine in consolidation chemotherapy and with bone marrow transplantation. Semin Oncol 14(2 Suppl 1):1-6, 1987. e-Pub 1987. PMID: 2438775.
Champlin RE, Ho WG, Mitsuyasu R, Burnison M, Greenberg P, Holly G, Winston DW, Feig SA, Gale RP. Graft failure and leukemia relapse following T lymphocyte-depleted bone marrow transplants: effect of intensification of immunosuppressive conditioning. Transplant Proc 19(1 Pt 3):2616-9, 1987. e-Pub 1987. PMID: 3547943.
Cain GR, Champlin RE, Gale RP. Survival and immune recovery in dogs following fetal liver transplantation. Transplant Proc 19(1 Pt 3):2695-7, 1987. e-Pub 1987. PMID: 3079092.
Champlin R. Bone marrow transplantation for leukemia: effects of T lymphocyte depletion of donor bone marrow. Transplant Proc 19(1 Pt 1):157-9, 1987. e-Pub 1987. PMID: 3274769.
Champlin R. Bone marrow transplantation for acute leukemia: a preliminary report from the International Bone Marrow Transplant Registry. Transplant Proc 19(1 Pt 3):2626-8, 1987. e-Pub 1987. PMID: 3274570.
Champlin, RE, Gale RP. Aplastic anemia. Medicine International 2:1748 1751, 1987. e-Pub 1987.
Champlin RE. Bone marrow transplantation for leukemia: effects of lymphocyte depletion of donor bone marrow. Transplant Proc 21:157-159, 1987. e-Pub 1987.
Champlin R, Gale RP. Bone marrow transplantation: its biology and role as treatment for acute and chronic leukemias. Ann N Y Acad Sci 511:447-58, 1987. e-Pub 1987. PMID: 2830829.
Champlin R, Gale RP. Bone marrow transplantation for acute leukemia: recent advances and comparison with alternative therapies. Semin Hematol 24(1):55-67, 1987. e-Pub 1987. PMID: 3547673.
Golde DW, Jacobs AD, Glaspy JA, Champlin RE. Hairy-cell leukemia: biology and treatment. Semin Hematol 23(3 Suppl 1):3-9, 1986. e-Pub 1986. PMID: 3526560.
Winston DJ, Ho WG, Champlin RE, Gale RP, Busuttil RW. Ureidopenicillins, astronam, and thienamycin: efficacy as single-drug therapy of severe infections and potential as components of combined therapy. J Antimicrob Chemother 17(Suppl A):55-56, 1986. e-Pub 1986.
Champlin RE. With the Chernobyl Victims. Los Angeles Times Magazine. (syndicated, 1986. e-Pub 1986.
Ho WG, Winston DJ, Champlin RE, Gale RP. Prophylactic use of immunoglobulin in bone marrow transplantation. Int J Cell Cloning 4 Suppl 1:174-80, 1986. e-Pub 1986. PMID: 3018101.
Gale RP, Champlin RE. Bone marrow transplantation for acute leukemia. Clin Hematol 15(3):851-872, 1986. e-Pub 1986.
Gale RP, Champlin RE, Jacobs A. Treatment of acute leukemia. Educatin Program of the American Society of Hematology, 1985. e-Pub 1985.
Champlin RE, Jacobs A, Gale RP, Ho W, Selch M, Lenarsky C, Feig SA. High-dose cytarabine in consolidation chemotherapy or with bone marrow transplantation for patients with acute leukemia: preliminary results. Sem Oncol 12:190-195, 1985. e-Pub 1985.
Mitsuyasu, RT, Champlin RE, Ho WG, Winston D, Feig S, Wells J, Terasaki P, Billing R, Weaver M, Gale RP. Prospective randomized controlled trial of ex vivo treatment of donor bone marrow with monoclonal anti T cell antibody and complement for prevention of graft versus host disease: a preliminary report. Transplant Proc 17:482 485, 1985. e-Pub 1985.
Champlin, RE, Ho WG, Lenarsky C, Winston D, Mitsuyasu R, Feig SA, Gale RP. Successful second bone marrow transplants for treatment of acute myelogenous leukemia or acute lymphoblastic leukemia. Transplant Proc 17:496 499, 1985. e-Pub 1985.
Jacobs AD, Naiem F, Champlin RE, Golde DW. Toxicity and bone marrow response of patients with hairy cell leukemia treated with biosynthetic (recombinant) alpha-2-interferon. Blut 50(1):33-4, 1985. e-Pub 1985. PMID: 3967099.
Winston DJ, Ho WG, Lin CH, Bartoni KB, Budinger MD, Gale RP, Champlin RE. Use of polyvalent intravenous immune globulin or cytomegalovirus-specific hyperimmune globulin for modication of cytomegalovirus unfection and prevention of interstitial pneumonia after bone marrow transplantation. Immunitat und Infektion 6:296-301, 1985. e-Pub 1985.
Winston DJ, Ho WG, Lin CH, Budinger MD, Champlin RE, Gale RP. Intravenous immunoglobulin for modification of cytomegalovirus infections associated with bone marrow transplantation: preliminary results of a controlled trial. Am J Med 76(3A):128-133, 1984. e-Pub 1984.
Champlin RE. The early complications of bone marrow transplantation. Sem Hematol 21:101-104, 1984. e-Pub 1984.
Champlin, RE, Ho WG, Winston DJ, Feig SA, Gale RP. Allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic or accelerated phase. Transplant Proc 15:1401 1404, 1983. e-Pub 1983.

Review Articles

Bazinet A, Kantarjian H, Arani N, Popat U, Bataller A, Sasaki K, DiNardo CD, Daver N, Yilmaz M, Abbas HA, Short NJ, Issa G, Jabbour E, Pierce SA, Chen J, Garcia R, Konopleva M, Garcia-Manero G, Alousi A, Shpall EJ, Champlin RE, Borthakur G, Ravandi F, Kadia T. Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation. Am J Hematol 98(9):1383-1393, 2023. e-Pub 2023. PMID: 37334870.
Ragoonanan D, Khazal SJ, Mejia R, Ewing L, Durand JB, Bashoura L, Tayar J, Dailey Garnes N, Petropoulos D, Tewari P, Bhatti M, Ahmad AH, Cortes J, Razvi S, McBeth K, Swinford R, Shoberu B, Waseemuddin W, Chi L, Gill JB, Zaky W, Daw N, Gutierrez C, Tereffe W, Kebriaei P, Rezvani K, Shpall EJ, Champlin RE, Mahadeo KM. Case Discussion and Literature Review: Cancer Immunotherapy, Severe Immune-Related Adverse Events, Multi-Inflammatory Syndrome, and Severe Acute Respiratory Syndrome Coronavirus 2. Front Oncol 11:625707, 2021. e-Pub 2021. PMID: 33614514.
Al Malki MM, Jones R, Ma Q, Lee D, Reisner Y, Miller JS, Lang P, Hongeng S, Hari P, Strober S, Yu J, Maziarz R, Mavilio D, Roy DC, Bonini C, Champlin RE, Fuchs EJ, Ciurea SO. Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016. Biol Blood Marrow Transplant 24(5):895-908, 2018. e-Pub 2018. PMID: 29339270.
Myers AL, Kawedia JD, Champlin RE, Kramer MA, Nieto Y, Ghose R, Andersson BS. Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review. Expert Opin Drug Metab Toxicol 13(9):901-923, 2017. e-Pub 2017. PMID: 28766962.
Kongtim P, Lee DA, Cooper LJ, Kebriaei P, Champlin RE, Ciurea SO. Haploidentical Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular Therapy. Biol Blood Marrow Transplant 21(10):1714-20, 2015. e-Pub 2015. PMID: 26172479.
Pingali SR, Champlin RE. Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation. Bone Marrow Transplant 50(9):1157-67, 2015. e-Pub 2015. PMID: 25985053.
Duong HK, Savani BN, Copelan E, Devine S, Costa LJ, Wingard JR, Shaughnessy P, Majhail N, Perales MA, Cutler CS, Bensinger W, Litzow MR, Mohty M, Champlin RE, Leather H, Giralt S, Carpenter PA. Peripheral Blood Progenitor Cell Mobilization for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 20(9):1262-1273, 2014. e-Pub 2014. PMID: 24816581.
Safdar A, Ma J, Saliba F, Dupont B, Wingard JR, Hachem RY, Mattiuzzi GN, Chandrasekar PH, Kontoyiannis DP, Rolston KV, Walsh TJ, Champlin RE, Raad II. Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis. Medicine (Baltimore) 89(4):236-44, 2010. e-Pub 2010. PMID: 20616663.
Champlin R, de Lima M, Kebriaei P, Rondon G, Fisher T, Jabbour E, Cortés JE, Kantarjian H, Anderlini P, Alousi A, Hosing C, Shpall E, Popat U, Qazilbash M, Andersson B, Giralt S. Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. Clin Lymphoma Myeloma 9 Suppl 3:S261-5, 2009. e-Pub 2009. PMID: 19778850.
Koca E, Champlin RE. Peripheral blood progenitor cell or bone marrow transplantation: controversy remains. Curr Opin Oncol 20(2):220-6, 2008. e-Pub 2008. PMID: 18300773.
Anderlini P, Champlin RE. Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges. Blood 111(4):1767-72, 2008. e-Pub 2008. PMID: 18057230.
Nakayama K, Milbourne A, Schover LR, Champlin RE, Ueno NT. Gonadal failure after treatment of hematologic malignancies: from recognition to management for health-care providers. Nat Clin Pract Oncol 5(2):78-89, 2008. e-Pub 2008. PMID: 18235440.
Hymes SR, Turner ML, Champlin RE, Couriel DR. Cutaneous manifestations of chronic graft-versus-host disease. Biol Blood Marrow Transplant 12:1101-13, 2006. e-Pub 2006. PMID: 17085303.
Komanduri KV, Couriel D, Champlin RE. Graft-versus-host disease after allogeneic stem cell transplantation: evolving concepts and novel therapies including photopheresis. Biol Blood Marrow Transplant 12:1-6, 2006. e-Pub 2006. PMID: 16399595.
Couriel D, Caldera H, Champlin R, Komanduri K. Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer 101(9):1936-46, 2004. e-Pub 2004. PMID: 15372473.
Jabbour E, Keating MJ, Champlin RE, Khouri IF. Stem cell transplantation for chronic lymphocytic leukemia: should not more patients get a transplant?. Bone Marrow Transplant 34(4):289-97, 2004. e-Pub 2004. PMID: 15220957.
Gajewski JL, Foote M, Tietjen J, Melson B, Simmons A, Champlin RE. Blood and marrow transplantation compensation: perspective in payer and provider relations. Biol Blood Marrow Transplant 10(7):427-32, 2004. e-Pub 2004. PMID: 15205664.
Hong DS, Jacobson KL, Raad, II, de Lima M, Anderlini P, Fuller GN, Ippoliti C, Cool RM, Leeds NE, Narvios A, Han XY, Padula A, Champlin RE, Hosing C. West Nile encephalitis in 2 hematopoietic stem cell transplant recipients: case series and literature review. Clin Infect Dis 37(8):1044-9, 2003. e-Pub 2003. PMID: 14523768.
Champlin R, Khouri I, Anderlini P, De Lima M, Hosing C, McMannis J, Molldrem J, Ueno N, Giralt S. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Biology and current indications. Oncology (Williston Park) 17(1):94-100; discussion 103-7, 2003. e-Pub 2003. PMID: 12599934.
Ueno NT, Anagnostopoulos A, Rondón G, Champlin RE, Mikhailova N, Pankratova OS, Zoubarovskaya LS, Semenova EV, Afanasyev BV, O'Brien S, Andreeff M, Zaritskey AY. Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. Br J Haematol 119(1):131-4, 2002. e-Pub 2002. PMID: 12358917.
Couriel DR, Beguelin GZ, Giralt S, De Lima M, Hosing C, Kharfan-Dabaja MA, Anagnostopoulos A, Champlin R. Chronic graft-versus-host disease manifesting as polymyositis: an uncommon presentation. Bone Marrow Transplant 30(8):543-6, 2002. e-Pub 2002. PMID: 12379897.
Champlin R, Hesdorffer C, Lowenberg B, Martelli MF, Mertelsmann RH, Reisner Y, Schmitz N. Haploidentical 'megadose' stem cell transplantation in acute leukemia: recommendations for a protocol agreed upon at the Perugia and Chicago meetings. Leukemia 16(3):427-8, 2002. e-Pub 2002. PMID: 11896552.
De La Rosa GR, Champlin RE, Kontoyiannis DP. Risk factors for the development of invasive fungal infections in allogeneic blood and marrow transplant recipients. Transpl Infect Dis 4(1):3-9, 2002. e-Pub 2002. PMID: 12123420.
Champlin R, Khouri I, Shimoni A, Gajewski J, Kornblau S, Molldrem J, Ueno N, Giralt S, Anderlini P. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 111:18-29, 2000. e-Pub 2000. PMID: 11091179.
Montemurro F, Ueno NT, Rondon G, Aglietta M, Champlin RE. High-dose chemotherapy with hematopoietic stem-cell transplantation for breast cancer: current status, future trends. Clin Breast Cancer 1:197-209; discussion 210, 2000. e-Pub 2000. PMID: 11899644.
Carella AM, Champlin R, Slavin S, McSweeney P, Storb R. Mini-allografts: ongoing trials in humans. Bone Marrow Transplant 25:345-50, 2000. e-Pub 2000. PMID: 10723575.
Kornblau S, Benson AB, Catalano R, Champlin RE, Engelking C, Field M, Ippoliti C, Lazarus HM, Mitchell E, Rubin J, Stiff PJ, Vokes E, Wadler S. Management of cancer treatment-related diarrhea. Issues and therapeutic strategies. J Pain Symptom Manage 19:118-29, 2000. e-Pub 2000. PMID: 10699539.
Nieto Y, Champlin RE, Wingard JR, Vredenburgh JF, Elias AD, Richardson P, Glaspy J, Jones RB, Stiff PJ, Bearman SI, Cagnoni PJ, McSweeney PA, LeMaistre CF, Pecora AL, Shpall EF. Status of high-dose chemotherapy for breast cancer: a review. Biol Blood Marrow Transplant 6(5):476-95, 2000. e-Pub 2000. PMID: 11063377.
Khouri IF, Keating MJ, Champlin R. Hematopoietic stem cell transplantation for chronic lymphocytic leukemia. Curr Opin Hematol 5:454-9, 1998. e-Pub 1998. PMID: 9814655.
Przepiorka D, Giralt S, Khouri I, Champlin R, Bueso-Ramos C. Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases. Am J Hematol 57(1):24-8, 1998. e-Pub 1998. PMID: 9423812.
Shpall EJ, Champlin R, Glaspy JA. Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant 4(2):84-92, 1998. e-Pub 1998. PMID: 9763111.
van Besien K, Forman A, Champlin R. Central nervous system relapse of lymphoid malignancies in adults: the role of high-dose chemotherapy. Ann Oncol 8:515-24, 1997. e-Pub 1997. PMID: 9261519.
Piamsomboon S, Kudelka AP, Termrungruanglert W, Van Besien K, Edwards CL, Lifshitz S, Schomer DF, Champlin R, Mante RP, Kavanagh JJ, Verschraegen CF. Remission of refractory gestational trophoblastic disease in the brain with ifosfamide, carboplatin, and etoposide (ICE): first report and review of literature. Eur J Gynaecol Oncol 18(6):453-6, 1997. e-Pub 1997. PMID: 9443008.
Champlin R. Purging: the separation of normal from malignant cells for autologous transplantation. Transfusion 36:910-8, 1996. e-Pub 1996. PMID: 8863780.
Anderlini P, Przepiorka D, Champlin R, Korbling M. Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals. Blood 88:2819-25, 1996. e-Pub 1996. PMID: 8874177.
Hester J, Bojko P, Rondon G, Champlin R. Integration of biological, procedural, apheresis principles of peripheral blood stem cell transplantation programs. Transfus Sci 17:585-90, 1996. e-Pub 1996. PMID: 10168556.
Hanania EG, Kavanagh J, Hortobagyi G, Giles RE, Champlin R, Deisseroth AB. Recent advances in the application of gene therapy to human disease. Am J Med 99:537-52, 1995. e-Pub 1995. PMID: 7485213.
Champlin R. Separation of graft-vs.-host disease and graft-vs.-leukemia effect against chronic myelogenous leukemia. Exp Hematol 23:1148-51, 1995. e-Pub 1995. PMID: 7556522.
Champlin R. Technology of blood and marrow transplantation. Exp Hematol 23:273-6, 1995. e-Pub 1995. PMID: 7875244.
Scerpella EG, Whimbey EE, Champlin RE, Bodey GP. Pericarditis associated with Legionnaires' disease in a bone marrow transplant recipient. Clin Infect Dis 19:1168-70, 1994. e-Pub 1994. PMID: 7888562.
Giralt SA, Champlin RE. Leukemia relapse after allogeneic bone marrow transplantation: a review. Blood 84:3603-12, 1994. e-Pub 1994. PMID: 7949117.
Seong DC, Przepiorka D, Bruner JM, Van Tassel P, Lo WK, Champlin RE. Leptomeningeal toxoplasmosis after allogeneic marrow transplantation. Case report and review of the literature. Am J Clin Oncol 16:105-8, 1993. e-Pub 1993. PMID: 8452099.
Storb R, Champlin RE. Bone marrow transplantation for severe aplastic anemia. Bone Marrow Transplant 8:69-72, 1991. e-Pub 1991. PMID: 1933061.
Champlin R, Gale RP. Acute lymphoblastic leukemia: recent advances in biology and therapy. Blood 73:2051-66, 1989. e-Pub 1989. PMID: 2659098.
Champlin RE, Kastenberg WE, Gale RP. Radiation accidents and nuclear energy: medical consequences and therapy. Ann Intern Med 109:730-44, 1988. e-Pub 1988. PMID: 3056171.
Champlin R, Gale RP. Acute myelogenous leukemia: recent advances in therapy. Blood 69:1551-62, 1987. e-Pub 1987. PMID: 3555647.
Winston DJ, Ho WG, Champlin RE, Gale RP, Busuttil RW. Ureidopenicillins, aztreonam, and thienamycin: efficacy as single-drug therapy of severe infections and potential as components of combined therapy. J Antimicrob Chemother 17 Suppl A:55-66, 1986. e-Pub 1986. PMID: 3086277.
Gale RP, Champlin RE. Bone marrow transplantation in acute leukaemia. Clin Haematol 15:851-72, 1986. e-Pub 1986. PMID: 3536244.
Champlin R, Gale RP, Foon KA, Golde DW. Chronic leukemias: oncogenes, chromosomes, and advances in therapy. Ann Intern Med 104:671-88, 1986. e-Pub 1986. PMID: 3008618.
Champlin RE, Golde DW. Chronic myelogenous leukemia: recent advances. Blood 65:1039-47, 1985. e-Pub 1985. PMID: 2581632.
Winston DJ, Ho WG, Champlin RE, Gale RP. Infectious complications of bone marrow transplantation. Exp Hematol 12:205-15, 1984. e-Pub 1984. PMID: 6368256.
Champlin RE, Gale RP. The early complications of bone marrow transplantation. Semin Hematol 21:101-8, 1984. e-Pub 1984. PMID: 6377500.
Gale RP, Champlin RE, Feig SA, Fitchen JH. Aplastic anemia: biology and treatment. Ann Intern Med 95:477-94, 1981. e-Pub 1981. PMID: 6116472.

Editorials

Champlin RE. Busulfan or TBI: answer to an age-old question. Blood 122(24):3856-7, 2013. PMID: 24311716.
Champlin R. Reduced Intensity Allogeneic Hematopoietic Transplantation Should Be Considered a Standard of Care for Older Patients with Acute Myeloid Leukemia. Biol Blood Marrow Transplant 17(12):1723-4, 2011. PMID: 22005650.
Champlin R. Now everyone has a donor for HSCT. Blood 118(2):218, 2011. PMID: 21757626.
Komanduri KV, Champlin RE. Can Treg therapy prevent GVHD?. Blood 117(3):751-2, 2011. PMID: 21252098.
Champlin RE, Couriel D. Biology of blood and marrow transplantation. Blood 12:1-40, 2006.
Komanduri K, Champlin RE. GVHD therapy: the best laid schemes. Blood 104:1240-1241, 2004.
Ueno N, Shpall E, Re C, Jones R. Graft-versus-breast cancer effect by allogeneic hematopoietic stem cell transplantation: a possible new frontier. J Clin Onc 22:3846-3847, 2004.
Champlin RE. Adenovirus infections following allogeneic hematopoietic transplantation. Blood 100:1523, 2002.
Champlin RE. Stem cell transplantation for lymphoma. Cytotherapy 4:203, 2002.

Abstracts

Song, G, Valdez B, Li Y, Liu Y, Champlin R, Andersson B. Synergistic Cytotoxicity of the Multikinase Inhibitor Sorafenib with the DNA Alkylating Agent Busulfan, and Nucleoside Analogs in Human FLT3-ITD-Positive Acute Myeloid Leukemia Cell Lines. Biology of Blood and Marrow Transplant 20(2):S158, 2014. e-Pub 2014.
Pingali, S R, Milton D, Stasi A, Patel R, Kebriaei P, Popat U, Alousi A, Anderlini P, Qazilbash M, Hosing C, Rezvani K, Bashir Q, Oran B, Shpall E, Khouri I, Champlin R, Ciurea S. Haploidentical Transplantation for Advanced Hematologic Malignancies Using Melphalan-Based Conditioning – Mature Results from a Single Center. Biology of Blood and Marrow Transplant 20(2):S40-S41, 2014. e-Pub 2014.
Qazilbash, M H, Thall P, Fox P, Shah N, Bashir Q, Shah J, Parmar S, Kebriaei P, Nieto Y, Dinh Y, Popat U, Hosing C, Lin P, Shpall E, Orlowski R, Champlin R. Phase I/II Trial of Lenalidomide and High-Dose Melphalan As Preparative Regimen for Relapsed Myeloma. Biology of Blood and Marrow Transplant 20(2):S47, 2014. e-Pub 2014.
Sarvaria, A, Khoder A, Alsuliman A, Chew C, Sekine T, Cooper N, Lavallade H, Muftuoglu M, Yvon E, Hamdi A, Alousi A, John L, Marin D, Stringaris K, Liu E, Molldrem J, Shah N, Parmar S, McNiece I, Champlin R, Shpall E, Rezvani K. Immunoregulatory B Cells Are Enriched within Transitional and IgM Memory B Cell Subsets in Healthy Donors but Are Reduced and Functionally Impaired in Patients with Chronic Graft-Versus-Host Disease. Biology of Blood and Marrow Transplant 20(2):S55, 2014. e-Pub 2014.
Saunders, I M, Gulbis A, Champlin R, Qazilbash M. A Lower Dose of Melphalan (140 mg/m2) As Preparative Regimen for Multiple Myeloma in Patients >65 or with Renal Dysfunction. Biology of Blood and Marrow Transplant 20(2):S293-S294, 2014. e-Pub 2014.
Tewari, P, Kumaresan P, Figliola M, Huls H, Longin K, Ruhnke K, Champlin R, Cooper L. Automated Production of Clinical-Grade CMV-Specific T Cells to Implement Immunotherapy at the Bedside. Biology of Blood and Marrow Transplant 20(2):S136-S137, 2014. e-Pub 2014.
Valdez, B C, Zander A, Song G, Murray D, Nieto Y, Li Y, Champlin R, Andersson B. Synergistic Cytotoxicity of Gemcitabine, Clofarabine and Edelfosine (± DNA alkylating agent) in Lymphoma Cell Lines. Biology of Blood and Marrow Transplant 20(2):S164, 2014. e-Pub 2014.
Ma, Q, Li D, Alousi A, Champlin R, Sale G, Afshar-Kharghan V. Complement Component C3 Mediates Th1/Th17 Polarization in Human T Cell Activation and Cutaneous Graft-Versus-Host Disease. Biology of Blood and Marrow Transplant 20(2):S274, 2014. e-Pub 2014.
Chu, D, Valdez B, Fox P, Thall P, Worth L, Popat U, Jones R, Shpall E, Hosing C, Alousi A, Rondon G, Kebriaei P, Champlin R, Andersson B. Clofarabine ± Fludarabine with IV Busulfan and Allogeneic Stem Cell Transplantation for Advanced Myeloid Leukemia (ML) and MDS. Biology of Blood and Marrow Transplant 20(2):S152-S153, 2014. e-Pub 2014.
Biritxinaga, L, Jauch S, Popat U, Shafi M, Shah N, Bashir Q, Dinh Y, Hosing C, Champlin R, Qazilbash M. Impact of Hepatitis B Core Antibody (HBcAb) Seropositivity on the Outcome of High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplant 20(2):S46-S47, 2014. e-Pub 2014.
Benjamin, C L, Saliba R, Shpall E, Lima M, John L, Szabolcs P, Champlin R, Komanduri K. Benjamin, C. L., R. Saliba, E. J. Shpall, M. J. G. de Lima, L. St. John, P. Szabolcs, R. E. Champlin and K. V. Komanduri "Baseline Thymopoietic Function and Post-Transplant Immune Recovery after Adult Cord Blood Transplantation. Biology of Blood and Marrow Transplant 20(2):S144-S145, 2014. e-Pub 2014.
Anderlini, P, Saliba R, Ledesma C, Chancoco C, Alexander T, Alousi A, Hosing C, Khouri I, Nieto Y, Popat U, Shpall E, Fanale M, Oki Y, Romaguera J, Neelapu S, Younes A, Champlin R. Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation For Relapsed/Refractory Hodgkin Lymphoma In The Brentuximab Vedotin Era. Biology of Blood and Marrow Transplan 20(2):S72, 2014. e-Pub 2014.
Adekola, K, Stasi A, Ferro R, Ahmed S, Lima M, Oran B, Andersson B, Quintas-Cardama A, Jabbour E, Kantarjian H, Cortes J, Champlin R, Ciurea S. Safety and Efficacy of Haploidentical Stem Cell Transplantation for Advanced Chronic Myeloid Leukemia. Biology of Blood and Marrow Transplant 20(2):S213-S214, 2014. e-Pub 2014.
Poon, L, Ferro R, Milton D, Rondon G, Wang S, Hamdi A, Qazilbash M, Ahmed S, Khouri I, Oran B, Hosing C, Kebriaei P, Alousi A, Popat U, Shpall E, Lee D, Rezvani K, Champlin R, Ciurea S. Transplant Outcomes For Patients With AML/MDS Using Melphalan-Based Conditioning. Blood 122(21):2167, 2013. e-Pub 2013.
Baladandayuthapani, V, Weber D, Thomas S, Alexanian R, Wang M, Qazilbash M, Champlin R, Shah N, Bashir Q, Popat U, Nieto Y, Ahmed S, Parmar S, Orlowski R. Phase II Study Of The Combination Of MLN 9708 With Lenalidomide As Maintenance Therapy Post Autologous Stem Cell Transplant In Patients With Multiple Myeloma. Blood 122(21):1983, 2013. e-Pub 2013.
Bashir, Q, Shah N, Pingali S, Parmar S, Popat U, Hosing C, Champlin R, Qazilbash M. Characteristics Of Multiple Myeloma Patients With 6-Year Or Longer Progression-Free Survival After a Single Autologous Transplant. Blood 122(21):3366, 2013. e-Pub 2013.
Lima D, M J, Lee D, Worth L, Kongtim P, Petropoulos D, McNiece I, Shpall E, Rondon G, Champlin R. Is There An Expiration Date For Cord Blood Units In Storage?. Blood 122(21):299, 2013. e-Pub 2013.
Denai, M, Stasi A, Kebriaei P, Popat U, Alousi A, Anderlini P, Parmar S, Hosing C, Andersson B, Bashir Q, Ahmed S, Oran B, Shpall E, Khouri I, Konopleva M, Alatrash G, Champlin R, Ciurea S. Haploidentical Transplantation For Patients With Advanced Hematologic Malignancies With Melphalan-Based Conditioning – Interim Results From a Phase II Clinical Trial. Blood 122(21):4523, 2013. e-Pub 2013.
Stasi D, A, Shpall E, Khouri I, Alousi A, Ciurea S, Bashir Q, Qazilbash M, Jones R, Nieto Y, Parmar S, Kebriaei P, Shah N, Rezvani K, Hosing C, Oran B, Andreeff M, Anderlini P, Andersson B, Champlin R, Popat U. Development of Donor Cell Derived Leukemia After Allogeneic Stem Cell Transplant. Blood 122(21):2083, 2013. e-Pub 2013.
Huls, H, Singh H, Olivares S, Figliola M, Kumar P, Jena B, Forget M, Ang S, Jackson R, Liu T, Bosque D, McNiece I, Rondon G, Hackett P, Hosing C, Shpall E, Champlin R, Cooper L. First Clinical Trials Employing Sleeping Beauty Gene Transfer System and Artificial Antigen Presenting Cells To Generate and Infuse T Cells Expressing CD19-Specific Chimeric Antigen Receptor. Blood 122(21):166, 2013. e-Pub 2013.
Huls, H, Singh H, Olivares S, Figliola M, Kumar P, Jena B, Jackson R, Liu T, McNiece I, Rondon G, Hackett P, Champlin R, Shpall E, Cooper L. Adoptive Immunotherapy Following Umbilical Cord Blood Transplantation Using The Sleeping Beauty System and Artificial Antigen Presenting Cells To Generate Donor-Derived T Cells Expressing a CD19-Specific Chimeric Antigen Receptor. Blood 122(21):4208, 2013. e-Pub 2013.
Kantarjian, H M, Champlin R, Borthakur G, Badar T, Garcia-Manero G, Andersson B, Oran B, Ciurea S, Konopleva M, Andreeff M, Kornblau S, Wierda W, Pierce S, Ravandi F, Cortes J. Survivorship In AML - Outcomes Of Acute Myelogenous Leukemia (AML) Patients (pts) After Maintaining Complete Remission (CR) For At Least 3 Years. Blood 122(21):3886, 2013. e-Pub 2013.
Kazmi, S M, Cornelison A, Kebriaei P, Nieto Y, Oran B, Orlowski R, Parmar S, Popat U, Shah J, Shah N, Champlin R, Qazilbash M, Bashir Q. Outcomes Among High Risk and Standard Risk Multiple Myeloma Patients Treated With High Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation. Blood 122(21):3358, 2013. e-Pub 2013.
Kongtim, P, Lima M, Popat U, Garcia-Manero G, Jabbour E, Abruzzo L, Chen J, Rondon G, Andersson B, Alousi A, Ciurea S, Shpall E, Champlin R. Prior Hypomethylating Agents Or Chemotherapy Does Not Improve The Outcome Of Allogeneic Hematopoietic Transplantation For High Risk MDS. Blood 122(21):305, 2013. e-Pub 2013.
Lichtiger, B, Alousi A, Ahmed S, Anderlini P, Andersson B, Bashir Q, Ciurea S, Jones R, Kebriaei P, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Khouri I, Shpall E, Champlin R, Popat U. Pure Red Cell Aplasia In Major ABO Mismatched Allogeneic Hematopoietic Cell Transplantation Is Associated With Severe Pancytopenia. Blood 122(21):5449, 2013. e-Pub 2013.
Logan, B R, Horowitz M, Zhong X, Perales M, Lee S, Rocha V, Soiffer R, Weisdorf D, Champlin R. Transplantation Of Peripheral Blood Progenitor Cells (PBPC) As Compared To Bone Marrow (BM) From Unrelated Related Donors For Hematologic Cancers Using Fludarabine-Alkylating Agent Based Reduced Intensity Conditioning Regimens. Blood 122(21):550, 2013. e-Pub 2013.
Mawad, R, Stasi A, Bassett R, Ferro R, Ram R, Rondon G, Champlin R, Sandmaier B, Doney K, Bar M, Kebriaei P. Central Nervous System Relapse In Adults With Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. Blood 122(21):3311, 2013. e-Pub 2013.
Mi, T, Ang S, Gragert L, Maiers M, Maiti S, Switzer K, Huls H, Reik A, Holmes M, Gregory P, Champlin R, Shpall E, Cooper L. ZFN-Driven Gene Editing Prevents HLA-A Expression On Hematopoietic Stem Cells -Improving The Chance Of Finding An HLA-Matched Donor. Blood 122(21):1655, 2013. e-Pub 2013.
Mohite, S, Baladandayuthapani V, Thomas S, Weber D, Wang M, Alexanian R, Qazilbash M, Popat U, Champlin R, Shah N, Bashir Q, Parmar S, Nieto Y, Ahmed S, Orlowski R, Shah J. Circulating Plasma Cells By Routine Complete Blood Count Identify Patients With Similar Outcome As Plasma Cell Leukemia. Blood 122(21):5356, 2013. e-Pub 2013.
Poon, M, Chen J, Rondon G, Ahmed S, Andersson B, Bashir Q, Ciurea S, Hosing C, Parmar S, Qazilbash M, Popat U, Nieto Y, Alousi A, Jones R, Rezvani K, Lima M, Shpall E, Champlin R, Kebriaei P. Comparable Outcomes After Sibling and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantations (HCT) In Adult Acute Lymphoblatic Leukemia (ALL) With First Complete Remission (CR). Blood 122(21):2142, 2013. e-Pub 2013.
Kongtim P, MD, Popat UR, MD, Lima MD, MD, Garcia-Manero G, MD, Jabbour EJ, MD, Chen J, Rondon G, MD, Abruzzo LV, MD, PhD, Ciurea SO, MD, Shpall EJ, MD, Champlin RE, MD, Oran B, MD. MD Anderson Scoring System (MDACC) Predicts Outcomes After Hematopoietic Stem Cell Transplantation (HSCT) Better Than Other Prognostic Classifications In MDS. Blood 122(21):3340, 2013. e-Pub 2013.
Qazilbash, M H, Shah J, Orlowski R, Hamdi A, Shah N, Bashir Q, Wang M, Champlin R, Parmar S. Autologous Stem Cell Transplantation Improves Survival For High Risk Cardiac Amyloidosis. Blood 122(21):3341, 2013. e-Pub 2013.
Saliba, R M, Challagundla P, Ledesma C, Korbling M, Gulbis A, Guillermo-Pacheco M, Ahmed S, Anderlini P, Bashir Q, Oran B, Ciurea S, Hosing C, Kebriaei P, Popat U, Jabbour E, Champlin R, Jorgensen J. Bfr (bendamustine, fludarabine, rituximab) Vs. FCR Nonmyeloablative Allogeneic Conditioning In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Outcome Results Including Minimal Residual Disease Analysis. Blood 122(21):3349, 2013. e-Pub 2013.
Saliba, R M, Ledesma C, Chancoco C, Alexander T, Alousi A, Hosing C, Khouri I, Nieto Y, Popat U, Shpall E, Fanale M, Oki Y, Romaguera J, Neelapu S, Younes A, Champlin R. Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) For Relapsed/Refractory Hodgkin Lymphoma (HL) In The Brentuximab Vedotin Era: Favorable Overall and Progression-Free Survival (OS/PFS) With Low Transplant-Related Mortality (TRM). Blood 122(21):410, 2013. e-Pub 2013.
Saliba, R M, Smith V, APN, Maadani F, Adekola K, Popat U, Qazilbash M, Bashir Q, Khouri I, Kebriaei P, Ciurea S, Anderlini P, Shah N, Nieto Y, Champlin R, Hosing C. Number Of Apheresis Days To Reach Target Stem Cell Dose May Be a Predictor Of Secondary Myelodysplastic Syndrome and Acute Myelogenous Leukemia. Blood 122(21):4515, 2013. e-Pub 2013.
Saliba, R M, Xu-Monette Z, Rondon G, Valverde R, Korbling M, Gulbis A, Anderlini P, Sairah A, Hosing C, Popat U, Kebriaei P, Fayad L, Westin J, Turturro F, Medeiros L, Champlin R, Young K. Outcomes Following Autologous Stem Cell Transplantation (ASCT) In Patients With Germinal Center B (GCB) and Non-GCB Cell-Like Diffuse Large B Cell Lymphomas (DLBCL) According To Conditioning With BEAM-Rituximab (Standard vs. High-Dose) Vs. BEAM/Yttrium-90 Ibritumomab Tiuxetan (90YIT). Blood 122(21):3350, 2013. e-Pub 2013.
Thall, P F, Valdez B, Hosing C, Ahmed S, Jones R, Shah N, Anderlini P, Qazilbash M, Popat U, Bashir Q, Shpall E, Alousi A, Kebriaei P, Fox P, Bassett R, Chancoco C, Oki Y, Fanale M, Fowler N, Hagemeister F, Romaguera J, Champlin R, Andersson B. Vorinostat (SAHA) Combined With High-Dose Gemcitabine/Busulfan/Melphalan (SAHA/Gem/Bu/Mel) With Autologous Stem-Cell Transplant (ASCT) In Patients With Refractory Lymphomas. Blood 122(21):2095, 2013. e-Pub 2013.
Wang, R-y, Ruvolo V, Jacamo R, McQueen T, Borthakur G, Qiu Y, Coombes K, Zhang N, Shpall E, Champlin R, Garzon R, Marcucci G, Croce C, Konopleva M, Andreeff M, Kornblau S. Phosphorylation Of GSK3β Is Associated With Inferior Survival In Acute Myeloid Leukemia and Is An Indicator Of AKT Activation In AML Blasts and Bone Marrow Mesenchymal Stem Cells. Blood 122(21):2551, 2013. e-Pub 2013.
Wei, W, Valverde R, Korbling M, Turturro F, Gulbis A, Guillermo-Pacheco M, Ahmed S, Alousi A, Oran B, Anderlini P, Ciurea S, Hosing C, Popat U, Jabbour E, Champlin R, Bassett R. Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning: A Novel Regimen Inducing Immunosuppression Without Myelosuppression. Blood 122(21):541, 2013. e-Pub 2013.
Williams, L A, Worthing A, Shi Q, Wang X, Johnson V, Mendoza T, Qazilbash M, Champlin R, Giralt S, Cleeland C. Higher Stem Cell Dose Infusion As Rescue After Intensive Chemotherapy Does Not Improve Symptom Burden In Older Patients With Multiple Myeloma and Amyloidosis. Blood 122(21):2161, 2013. e-Pub 2013.
Shah, D, Kantarjian H, Wagner V, Orlowski R, Garcia-Manero G, Ravandi F, Pierce S, Takahashi K, Daver N, Nazha A, Verstovsek S, Jabbour E, Lima M, Champlin R, Cortes J, Qazilbash M. Characteristics and Outcomes Of Patients (pts) With Multiple Myeloma (MM) Who Develop Therapy (t)-Related Myelodysplastic Syndrome (MDS), t-Chronic Myelomonocytic Leukemia (CMML), Or t-Acute Myeloid Leukemia (AML). Blood 122(21):1424, 2013. e-Pub 2013.
Oran, B, Hosing C, Kebriaei P, Rezvani K, Parmar S, Shah N, Bollard C, Molldrem J, Nieto Y, Andersson B, Alousi A, Jones R, Cooper L, Qazilbash M, Bashir Q, Ahmed S, Bosque D, Chen J, McCarty J, Rondon G, Munsell M, McNiece I, Kaur I, Yvon E, Annandale K, Olchesky S, Lima M, Champlin R, Miller L, Paradiso L, Koh L, Zweidler-McKay P, Shpall E. Ex Vivo Fucosylation Of Cord Blood Accelerates Neutrophil and Platelet Engraftment. Blood 122(21):691, 2013. e-Pub 2013.
Shah, D, Kantarjian H, Wagner V, Orlowski R, Garcia-Manero G, Ravandi F, Pierce S, Takahashi K, Daver N, Nazha A, Verstovsek S, Jabbour E, Lima M, Champlin R, Cortes J, Qazilbash M. High-Dose Gemcitabine Combined With Busulfan and Melphalan (Gem/Bu/Mel) With Autologous Stem-Cell Transplant (ASCT) In Refractory and Relapsed Myeloma. Blood 122(21):3346, 2013. e-Pub 2013.
O’Donnell, P, Furlong T, Lima M, Wei W, Medeot M, Mielcarek M, Champlin R, Jones R, Thall P, Andersson B, Luznik L. Post-Transplantation Cyclophosphamide Following Busulfan and Fludarabine Myeloablative Conditioning Prevents Severe Acute and Chronic Graft-Versus-Host Disease and Minimizes Duration Of Immunosuppression: Results Of a Multi-Institutional Trial In Patients With High-Risk Hematologic Malignancies. Blood 122(21):3310, 2013. e-Pub 2013.
Khoder, A, Alsuliman A, Chew C, Sekine T, Cooper N, Lavallade H, Muftuoglu M, Yvon E, Hamdi A, Alousi A, John L, Marin D, Stringaris K, Liu E, Molldrem J, Shah N, Parmar S, McNiece I, Champlin R, Shpall E, Rezvani K. B Cell With Regulatory Function Are Enriched Within Transitional and IgM Memory B Cell Subsets In Healthy Donors But Are Reduced and Functionally Impaired In Patients With Chronic Graft-Versus-Host Disease. Blood 122(21):4478, 2013. e-Pub 2013.
Rozovski, U, Jain P, Wierda W, O'Brien S, Burger J, Ferrajoli A, Faderl S, Shpall E, Hosing C, Khouri I, Champlin R, Keating M, Estrov Z. Outcome Of Chronic Lymphocytic Leukemia (CLL) Patients That Failed Allogeneic Stem Cell Transplantation. Blood 122(21):2880, 2013. e-Pub 2013.
Robinson, S N, Thomas M, Lu J, Yang H, Champlin R, Schober W, Simmons P, Shpall E. Cord Blood CD34+ Stem Cell Sialyl Lewis X Levels and E-Selectin Binding Are Predictive Of Engraftment In Mice: Functional Separation Of Stemness and Homing To Improve Engraftment. Blood 122(21):893, 2013. e-Pub 2013.
Hilden, P, Hamdi A, Goldberg J, Poon M, Ledesma C, Devlin S, Rondon G, Papadopoulos E, Jakubowski A, O'Reilly R, Champlin R, Giralt S, Kebriaei P, Perales M. Outcomes In Patients With Acute Lymphoblastic Leukemia In First Or Second Complete Remission Receiving Ex-Vivo T-Cell Depleted Or Unmodified Allografts: Comparison Of Results At Two Institutions. Blood 122(21):3370, 2013. e-Pub 2013.
Ang, S, Maiti S, McNamara G, Sheppard S, Miller T, Huls H, Champlin R, Wilson H, Cooper L. Immune Reconstitution With Activated T Cells In Companion Canines With Lymphoma. Blood 122(21):5153, 2013. e-Pub 2013.
Dinh, Y, Sharma M, Shah N, Bashir Q, Parmar S, Hosing C, Popat U, Champlin R, Qazilbash M. Bortezomib With High-Dose Melphalan, Arsenic Trioxide, and Ascorbic Acid In a Preparative Regimen For Multiple Myeloma: 5-Year Follow Up. Blood 122(21):5547, 2013. e-Pub 2013.
Gulbis, A M, Champlin R, Qazilbash M. A Lower Dose Of Melphalan (140 mg/m2) As Preparative Regimen For Multiple Myeloma In Patients >65 Or With Renal Dysfunction. Blood 122(21):5536, 2013. e-Pub 2013.
Hamdi, A, Kongtim P, Milton D, Alousi A, Anderlini P, Ciurea S, Oran B, Khouri I, Parmar S, Qazilbash M, Kebriaei P, Popat U, Rezvani K, Chemaly R, Shpall E, Champlin R, Bashir Q. he Effect Of CMV Reactivation On Relapse and Survival In Patients With AML and MDS After Allogeneic Stem Cell Transplant (allo-HCT). Blood 122(21):4531, 2013. e-Pub 2013.
Majhail, N S, Murphy, E A, Denzen, E M, Ferguson, S S, Anasetti, C, Bracey, A, Burns, L, Champlin, R, Hubbard, N, Markowitz, M, Maziarz, R T, Medoff, E, Neumann, J, Schmit-Pokorny, K, Weisdorf, D J, Raley Y, D S, Chell, J, Snyder, E L. The National Marrow Donor Program’s Symposium on Hematopoietic Cell Transplantation in 2020: A Health Care Resource and Infrastructure Assessment. Biol Blood Marrow Transplant 18(2 Suppl):172-82, 2012. e-Pub 2012.
Maewal, I, Gulbis A, Champlin R, Qazilbash M. Reduced-Dose Melphalan vs. Standard Dose Melphalan for Autologous Stem Cell Transplantation: Is There a Difference in Outcome?. Biol Blood Marrow Transplant 18(suppl 2):S376-S377, 2012. e-Pub 2012.
Singh, H, Figliola M, Dawson M, Zhang L, Yang G, Huls H, Kelly S, Kebriaei P, Champlin R, Cooper L. NaïVe Cd19-Specific T Cells Exhibit Superior Proliferation and Potential for Adoptive Immunotherapy. Biol Blood Marrow Transplant 18(Suupl 2):S311, 2012. e-Pub 2012.
Ang, S O, Maiti, S N, Hartline, C, Olivares, S, Huls, H, Champlin, R, Cooper, L J N. Avoiding the Need for Clinical-Grade OKT3: Ex Vivo Expansion of T Cells Using Artificial Antigen Presenting Cells Genetically Modified to Cross-Link CD3. Biol Blood Marrow Transplant 18(2 Suppl):S258, 2012. e-Pub 2012.
Thokala, R, Olivares S, Singh H, Champlin R, Cooper L. Targeting Leukemia by CD123 Specific Chimeric Antigen Receptor. Biol Blood Marrow Transplant 18(Suppl 2):S291, 2012. e-Pub 2012.
Ang, S O, Maiti, S N, Moriarity, B, Andrews, K, Ossowski, M, Tzeng, K, Talbot, R, Kellar, D, Huls, H, Kebriaei, P, Kelly, S, Shpall, E, Largaespada, D A, Champlin, R, Hackett, P B, Cooper, L J N. Assessing Sleeping Beauty Transpositions for T-Cell Immunotherapy by Supercomputer-Based High-Throughput Profiling of Integration Events. Biol Blood Marrow Transplant 18(2 Suppl):S219, 2012. e-Pub 2012.
Ahmed, S, Dinh, Y, Rondon, G, Andersson, B, Jones, R, Bashir, Q, Shah, N, Popat, U, Champlin, R E, Qazilbash, M H, Kebriaei, P. Comparison of Busulfan + Melphalan to Melphalan 200 mg/m2 as Preparative Regimen for Autologous Transplantation in Multiple Myeloma. Biol Blood Marrow Transplant 18(2 Suppl):S251, 2012. e-Pub 2012.
Beitinjaneh, A, Jakob J, Saliba R, Chen J, Rondon G, Giralt S, Cortes J, Champlin R, Lima M. Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia in Third Remission. Biol Blood Marrow Transplant 18(Suppl 2):S328, 2012. e-Pub 2012.
Farhan, S, Lin H, Baladandayuthapani V, Shah N, Bashir Q, Hosing C, Popat U, Parmar S, Dinh Y, Qureshi S, Rondon G, Giralt S, Champlin R, Qazilbash M. Outcome of Patients with Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 18(suppl 2):S248-S249, 2012. e-Pub 2012.
Valdez, B C, Nieto Y, Murray D, Li Y, Wang G, Champlin R, Andersson B. Epigenetic Changes Enhance the Cytotoxicity of Combined Nucleoside Analog-Dna Alkylating Agents in Lymphoma Cells. Biol Blood Marrow Transplant 18(Suppl 2):S296, 2012. e-Pub 2012.
Wilhelm, K, Gulbis A, Maewal I, Cool R, Ferguson J, Westmoreland M, Martinez C, Saliba R, Rondon G, Chemaly R, Champlin R, Kebriaei P. The Impact of Pre-Transplant Valganciclovir on Early Cytomegalovirus Reactivation After Allogeneic Hematopoietic Stem Cell Transplant. Biol Blood Marrow Transplant 18(Suppl 2):S377-S378, 2012. e-Pub 2012.
Worth, L L, Andersson B, Kelly S, Petropoulos D, Lee D, Kebriaei P, Cooper L, Champlin R. Thiotepa (Tt), Busulfan (Bu), and Clofarabine (Clo) as a Conditioning Therapy for Allogeneic Hematopoetic Stem Cell Transplant for Patients with High Risk Malignancies: Updated Response and Engraftment Data. Biol Blood Marrow Transplant 18(Suppl 2):S333, 2012. e-Pub 2012.
Nieto, Y, Jones R, Liu P, Anderlini P, Popat U, Andersson B, Shpall E, Alousi A, Hosing C, Kebriaei P, Qazilbash M, Frazier E, Chancoco C, Bashir Q, Ciurea S, Parmar S, Champlin R. Comparison of Gemcitabine, Busulfan and Melphalan (Gem/Bu/Mel) with Beam and Busulfan/Melphalan (Bu/Mel) in Concurrent Cohorts of Refractory Hodgkin'S Lymphoma (HL) Patients Receiving an Autologous Stem-Cell Transplant. Biol Blood Marrow Transplant 18(suppl 2):S206-S2074, 2012. e-Pub 2012.
Nieto, Y, Jones R, Popat U, Andersson B, Valdez B, Thall P, Shpall E, Chancoco C, Alousi A, Anderlini P, Hosing C, Qazilbash M, Bashir Q, Kebriaei P, Khoui I, Ciurea S, Parmar S, Rondon G, Champlin R. Gemcitabine, Busulfan and Melphalan (Gem/Bu/Mel) Is a New High-Dose Chemotherapy (HDC) Regimen with High Activity in Refractory or Poor-Risk Relapsed Non-Hodgkin'S Lymphoma (NHL) Patients Receiving an Autologous Stem-Cell Transplant (ASCT). Biol Blood Marrow Transpalant 18(Suppl 2):S206, 2012. e-Pub 2012.
Tang X, de Lima M, Wei W, Chiattone A, Thall PF, Medeiros LJ, Rondon G, Shpall EJ, Jones RB, Nieto Y, Alousi A, Champlin RE, Andersson BS. Early Mixed Chimerism Does Not Alter Long-Term Prognosis for Patients Receiving IV Busulfan-Fludarabine (Iv Bu-Flu) With Allogeneic Stem Cell Transplantation for AML/MDS. Biol Blood Marrow Transplant 17(2 Suppl):S304, 2011. e-Pub 2011.
Beitinjaneh A, Shah N, Bashir Q, Parmar S, Hosing C, Popat U, Anderlini P, Dinh Y, Qureshi S, Rondon G, Champlin RE, Giralt SA, Qazilbash MH. Donor-Lymphocyte Infusion in Patients With Persistent or Recurrent Multiple Myeloma After Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 17(2 Suppl):S340, 2011. e-Pub 2011.
Ciurea SO, Saliba RM, Rondon G, Sharma M, Montes N, Bosque D, McMannis J, Fernandez-Vina M, Xie S, Konopleva M, Parmar S, Nieto Y, Kebriaei P, Quazilbash M, Alousi A, Popat U, Hosing CM, Shpall EJ, Khouri IF, de Lima M, Champlin RE. Haploidentical Stem Cell Transplantation for Minorities. Biol Blood Marrow Transplant 17(2 Suppl):S227, 2011. e-Pub 2011.
Lecagoonporn S, Watson M, Popat U, Champlin R, Langford R, Cesario S, Young A. Predictive Effects of Malnutrition Indicators for Morbidity and Mortality Among Blood and Marrow Transplantation Recipients: A Retrospective Chart Review. Biol Blood Marrow Transplant 17(2 Suppl):S193, 2011. e-Pub 2011.
Saliba RM, de Lima M, McMannis J, Robinson S, Shpall E, Champlin RE, Bosque DM, Parmar S, Rondon G, Simmons P, Alousi A. Dynamics of Recovery in Double Umbilical Cord Blood Transplantation With an ex-vivo Mesenchymal Cell Expanded Unit: Faster Recovery With Engraftment of the Expanded Unit. Biol Blood Marrow Transplant 17(2 Suppl):S318, 2011. e-Pub 2011.
Torikai H, Reik A, Yuen C, Zhou Y, Kellar D, Huls H, Warren EH, Tykodi SS, Gregory PD, Holmes MC, Rebar EJ, Lee DA, Champlin RE, Bonini C, Cooper LJN. Genetic Reprogramming and Editing of T Cells Using the Sleeping Beauty System and Designer Zinc Finger Nucleases. Biol Blood Marrow Transplant 17(2 Suppl):S187, 2011. e-Pub 2011.
Valdez BC, Wang G, Li Y, Murray D, Champlin RE, Andersson BS. Synergistic Cytotoxicity of Busulfan and Nucleoside Analogs in Human Lymphoid Cell Lines. Biol Blood Marrow Transplant 17(2 Suppl):S249, 2011. e-Pub 2011.
Wang G, Valdez BC, Li Y, Murray D, Champlin RE, Andersson BS. Purine Nucleoside Analogs Exert Synergistic Cytotoxicity With the DNA-Alkylating Agent Busulfan in Human Myeloid Leukemia. Biol Blood Marrow Transplant 17(2 Suppl):S249-S50, 2011. e-Pub 2011.
Yilmaz M, Han XY, DeLima MJ, Hosing CM, Popat UR, Champlin RE, Qazilbash MH. Incidence and Outcome of Adenovirus infection in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients. Biol Blood Marrow Transplant 17(2 Suppl):S290, 2011. e-Pub 2011.
Andersson BS, Valdez BC, Thall PF, Wang X, Worth LL, Popat U, Alousi A, Hosing C, Jones RB, Shpall EJ, de Lima M, Champlin RE. Clofarabine Â± Fludarabine and IV Busulfan With Allogeneic Stem Cell Transplantation for Advanced Myeloid Leukemia (ML) and MDS. Biol Blood Marrow Transplant 17(2 Suppl):S293, 2011. e-Pub 2011.
Aung FM, Lichtiger B, Alousi A, Hosing C, Qazilbash M, deÂ Lima M, Kebriaei P, Khouri I, Champlin RC, Popat U. The Incidence and Natural History of Pure Red Cell Aplasia inÂ Major ABO Mismatched Hematopoietic Stem Cell Transplantation in Patients Receiving Modern Reduce Intensity and Reduced Toxicity Regimens. Biol Blood Marrow Transplant 17(2 Suppl):S153, 2011. e-Pub 2011.
Bashir Q, Wei W, Chiattone A, Rondon G, Parmar S, Shah N, Booc EH, Dinh Y, Qureshi S, Shah J, Orlowski RZ, Webber D, Champlin RE, Giralt S, Qazilbash MH. Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant 17(2 Suppl):S177, 2011. e-Pub 2011.
Bashir Q, Wei W, Chiattone A, Rondon G, Parmar S, Shah N, Booc EH, Dinh Y, Qureshi S, Shah J, Orlowski RZ, Weber D, Champlin RE, Giralt S, Qazilbash MH. Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Patients Age 70 Years and Older. Biol Blood Marrow Transplant 17(2 Suppl):S178, 2011. e-Pub 2011.
Collins NH, Gee AP, Durett AG, Kan F, M-J Z, Champlin RE, Confer D, Eapen M, Howard A, King R, Laughlin MJ, Plante RJ, Setterholm M, Spellman S, Keever-Taylor C, Wagner JE, Weisdorf DJ. The Effect of the Composition of Unrelated Donor Bone Marrow and Peripheral Blood Progenitor Cell Grafts on Transplantation Outcomes. Biol of Blood and Marrow Transplant 16(2):253-62, 2010. e-Pub 2010.
Andersson BS, de Lima M, Valdez BC, Thall PF, Worth LL, Popat U, Jones RB, Shpall EJ, Madden T, McAdams PL, Alousi AM, Rondon G, Kebriaei P, Champlin RE. Clofarabine ± Fludarabine With IV Busulfan And Allogeneic Stem Cell Transplantation For Relapsed, Refractory Myeloid Leukemia (ML) And MDS. Biol Blood and Marrow Transplant 16(2):S271-S72, 2010. e-Pub 2010.
Anderlini P, Acholonu S, Okoroji G, Popat U, Giralt SA, Shpall EJ, Qazilbash M, de Lima M, Worth L, Champlin RE. Fludarabine, Cyclophosphamide And Antithymocyte Globulin (ATG) As Conditioning Regimen In Matched Related And Unrelated Allogeneic Stem Cell Transplantation For Severe Aplastic Anemia (SAA): The M.D. Anderson Cancer Center Ten-Year Experience. Biol Blood and Marrow Transplant 16(2):S217-S17, 2010. e-Pub 2010.
Worth LL, Andersson BS, Kazerooni R, Petropoulos D, Kelly SS, Lee DA, Du M, Madden TL, deLima MJ, Champlin RE, Cooper LJN. Thiotepa (TT), Busulfan (Bu), And Clofarabine (Clo) As A Conditioning Therapy For Allogeneic Hematopoetic Stem Cell Transplant For Patients With High Risk Malignancies: Early Response And Engraftment Data. Biol of Blood and Marrow Transplant 16(2):S292-S93, 2010. e-Pub 2010.
Valdez BC, Li Y, Murray D, Champlin RE, Andersson BS. Synergistic Cytotoxicity Of Clofarabine, Fludarabine And Busulfan: Relevance To Myeloablative Therapy. Biol of Blood and Marrow Transplant 16(2):S232-S32, 2010. e-Pub 2010.
Sharma M, Qazilbash MH, Hosing CM, Thall PF, Mendoza FL, Han E, Wang M, Shah J, Alousi AM, Anderlini P, Kebriaei P, Khouri IF, Popat UR, de Lima M, Champlin RE, Giralt SA. Addition Of Bortezemib To High Dose Melphalan Does Not Improve Response Rate Or Progression-Free Survival. Biol of Blood and Marrow Transplant 16(2):S200-S01, 2010. e-Pub 2010.
Kellar D, Ang S, Olivares S, Dawson M, Figliola M, Huls H, Lee D, Champlin R, Cooper L. CD56+ T Cells Co-Expressing A CD56-Specific Chimeric Antigen Receptor Can Target CD56+ Malignancies Without Autolysis. Biol of Blood and Marrow Transplant 16(2):S153-S53, 2010. e-Pub 2010.
Kebriaei P, Chiattone A, Saliba R, Jones D, Anderlini P, Andersson B, Khouri I, Worth L, Ravandi F, Thomas D, Kantarjian H, Hamerschlak N, Rodrigues M, de Lima M, Giralt S, Champlin R. Imatinib Maintenance Following Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Philadelphia Chromosome Positive (PH+) Acute Lymphoblastic Leukemia (ALL). Biol of Blood and Marrow Transplant 16(2):S230-S30, 2010. e-Pub 2010.
Ciurea SO, de Lima M, Kebriaei P, Rondon G, Saliba R, McMannis J, Andersson BS, Khouri IF, Giralt S, Champlin RE. Safety Of T-Cell Replete Haploidentical Stem Cell Transplantation Using Fludarabine, Melpahalan And Thiotepa Conditioning And High-Dose Post-Transplant Cyclophosphamide. Biol of Blood and Marrow Transplant 16(2):S218-S18, 2010. e-Pub 2010.
Chu DT, Gulbis AM, Howell JE, de Lima M, Matteo P, Ciurea S, Thall PF, Champlin RE, Andersson BS. Cidofovir Treatment Of BK-virus Related Hemorrhagic Cystitis Early After Allogeneic Stem Cell Transplantation (HSCT) For Malignant Diseases. Biol of Blood and Marrow Transplant 16(2):S256-S56, 2010. e-Pub 2010.
Yuen CH, Saliba RM, Andersson BS, Shpall E, Popat UR, Qazilbash MH, Hosing C, de Lima MJ, Giralt SA, Champlin RE, Kebriaei P. Faster Lymphocyte Recovery After Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts For Decreased Non-Relapse Mortality (NRM) In Adults With Acute Lymphoblastic Leukemia (ALL). Biol of Blood and Marrow Transplantat 16(2):S283-S83, 2010. e-Pub 2010.
Kelly SS, Singh H, Figliola MJ, Dawson MJ, Maiti S, Shpall EJ, Champlin RE, Cooper LJN. Adoptive Immunotherapy After Umbilical Cord Blood (UCB) Transplantation: Manufacturing And Analysis Of CD19-Specific UCB-Derived T-cells From Scant Numbers Of UCB Mononuclear Cells. Biology of Blood and Marrow Transplant 16(2):S182-S83, 2010. e-Pub 2010.
Ciurea SO, Cano P, de Lima M, Thall PF, Rondon G, Kebriaei P, Alousi A, Hosing C, Khouri IF, Champlin RE, Fernandez-Vina M. The Role Of Donor-Specific Anti-HLA Antibodies (DSA) In Hematopoietic Stem Cell Transplantation From Matched Unrelated Donors. Biol of Blood and Marrow Transplant 16(2):S158-S58, 2010. e-Pub 2010.
Alousi AM, Rondon G, G-J O, Popat U, Silva LDP, Hymes S, Neumann J, Brunelle NM, Kebriaei P, Hosing C, Khouri IF, Shpall EJ, Qazilbash MH, Giralt S, Champlin RE, Saliba RM. Co-Morbidity Score at the Time of Transplant Determines Prognosis in Older Patients Who Develop Acute Graft-Vs.-Host Disease (GVHD). Blood 114(22):884-5, 2009. e-Pub 2009.
Bashir Q, Thall P, Hosing C, Mendoza FL, Han E, Wang M, Shah J, Alousi A, Anderlini P, Kebriaei P, Khouri IF, Popat U, de Lima M, Champlin RE, Giralt SA, Qazilbash MH. Salvage Autologous or Allogeneic Stem Cell Transplantation After the Failure of First Autograft in Patients with Multiple Myeloma. Blood 114(22):487, 2009. e-Pub 2009.
Denman CJ, Kopp LM, Senyukov V, Hagemeister S, Johnson J, Da Silva MAL, Singh H, Hurton L, Olivares S, Huls MH, Champlin RE, Cooper LJN, Lee DA. Sustained Ex Vivo Expansion of Human Peripheral Blood NK Cells Using Artificial APCs Bearing Membrane-Bound IL-21. Blood 114(22):1181, 2009. e-Pub 2009.
Khouri IF, Bassett RL, Jr, Cano P, O'Brien S, Hsu Y, Bueso-Ramos CE, Harrell R, G-J O, De Padua Silva L, Ferrajoli A, Wierda W, Kantarjian H, Champlin RE, McMannis J, Fernandez-Vina M. Human-Leukocyte-Histocompatibility Antigens (HLA-A1+, A2-, B44-) and Serum Immunoglobulin (Ig)G with CD4 Levels Predict Response to Graft-Versus-Leukemia (GVL) and Overall Survival, Respectively, After Non-Myeloablative Allogeneic Stem Transplantation (NST) for Chronic Lymphocytic Leukemia (CLL). Blood 114(22):902-3, 2009. e-Pub 2009.
de Lima M, McMannis JD, Hosing C, Kebriaei P, Robinson S, Kelly S, LdP S, Fernandez-Vina M, Chiattone A, Bosque D, Rondon G, Giralt S, Cooper L, Chen JJ, Parmar S, Jones R, Andersson B, Worth L, Alousi A, McNiece IK, Komanduri KV, Simmons PJ, Champlin RE, Shpall EJ. Rapid Engraftment of Neutrophils and Platelets with Mesenchymal Stem Cell Based Cord Blood (CB) Expansion (EXP). Blood 114(22):1318, 2009. e-Pub 2009.
Khouri I, Harrell R, Valverde R, Korbling M, Manshouri T, Samuels B, Maadani F, Okoroji G, Bassett RL, Alousi A, Anderlini P, de Lima M, Giralt S, Hosing C, Kebriaei P, Popat U, Qazilbash M, Ueno N, Stachowiak AM, Erwin B, Fayad L, Pro B, Fowler N, McLaughlin P, Neelapu S, Younes A, Champlin R, Podoloff D. Stem Cell Transplantation with 90yttrium Ibritumomab Tiuxetan(90YIT) in Non-Hodgkin's Lymphoma (NHL): Observations From PET Pre-Treatment Imaging and Responses in Allografted Refractory Follicular Histologies. Blood 114(22):357-8, 2009. e-Pub 2009.
Ravandi F, Kantarjian HM, Thomas DA, Faderl S, Jones D, Koller CA, Dara S, Garris R, Kebriaei P, Champlin RE, Borthakur G, Wierda WG, Burger JA, Cortes J, O'Brien S. Phase II Study of Combination of the Hypercvad Regimen with Dasatinib in the Front Line Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). Blood 114(22):345, 2009. e-Pub 2009.
Shah N, Ahmed KF, Qureshi S, Shah J, Orlowski RZ, Weber DM, Hosing C, Popat U, Alousi A, Champlin RE, Giralt S, Qazilbash M. Durable Remission with Salvage Autotransplants in Patients with Multiple Myeloma. Blood 114(22):506, 2009. e-Pub 2009.
Singh H, Gibbons HN, Olivares S, Figliola MJ, Dawson MJ, Huls MH, Lee DA, Kebriaei P, Champlin RE, Cooper LJN. Third Generation Chimeric Antigen Receptors Containing CD137 or CD134 Signaling Endodomains Augment CD19-Specific T-Cell Effector Function. Blood 114(22):1571-2, 2009. e-Pub 2009.
Kebriaei P, Madden T, Kazerooni R, Shpall E, Wang X, Thall P, Hosing C, Qazilbash M, Popat U, Ledesma C, Khouri I, Champlin RE, Jones R, Andersson BS. Intravenous Busulfan Plus Melphalan Is a Highly Effective, Non-Toxic Preparative Regimen for Autologous Stem Cell Transplantation (ASCT) in Patients with Advanced Lymphoid Malignancies. Blood 114(22):1183, 2009. e-Pub 2009.
Hurton LV, Singh H, Olivares S, Ang SO, Kelly SS, Kebriaei P, Lee DA, Champlin RE, Cooper LJN. IL-7 as a Membrane-Bound Molecule for the Costimulation of Tumor-Specific T Cells. Blood 114(22):1183, 2009. e-Pub 2009.
Leandro DPS, Saliba R, McCormick D, G-J O, Alousi A, Anderlini P, Ciurea S, Hosing C, Kebriaei P, Popat U, Qazilbash M, Ueno N, McMannis J, Champlin RE, Pro B, Khouri IF. Autologous Stem Cell Mobilization with Cytokines and in-Vivo Alemtuzumab in Patients with T-Cell Non-Hodgkin's Lymphoma (T-NHL). Blood 114(22):1245, 2009. e-Pub 2009.
Popat U, Hosing C, Fanale M, Medeiros LJ, Alousi AM, Giralt SA, de Lima MJ, Qazilbash MH, Kebriaei P, Younes A, Khouri I, Andersson B, Champlin RE, Anderlini P. Autologous Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). Blood 114(22):912, 2009. e-Pub 2009.
Popat U, Rondon G, Alousi A, Anderlini P, Andersson B, Hosing C, de Lima M, Ciurea S, Giralt S, Kebriaei P, Nieto Y, Khouri I, Qazilbash MH, Jones R, Champlin RE. Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis. Blood 114(22):900, 2009. e-Pub 2009.
Qureshi S, Sharma M, Hosing C, Mendoza FL, Shah J, Alousi A, Anderlini P, Kebriaei P, Khouri IF, Popat U, Md L, Champlin RE, Giralt S, Qazilbash MH. Outcome of IgD Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Blood 114(22):4354, 2009. e-Pub 2009.
Spencer BP, Kaur I, Fong P, Karandish S, Ponweera N, Baez O, Shpall EJ, Champlin RE, McMannis JD. Enrichment of Mononuclear Cells From Cryopreserved Cord Blood Units Using the Purecell" Select System. Blood 114(22):849, 2009. e-Pub 2009.
Sharma M, Thall P, Wang X, Hosing C, Mendoza FL, Han E, Wang M, Weber D, Shah J, Alousi A, Anderlini P, Kebriaei P, Khouri IF, Popat U, de Lima M, Champlin RE, Giralt S, Qazilbash M. A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma. Blood 114(22):912, 2009. e-Pub 2009.
Kebriaei P, Saliba R, Rondon G, Worth L, Cooper LJN, Thomas DA, Kantarjian H, de Lima M, Champlin RE, Giralt S. Second Allogeneic Transplants for Relapsed Acute Lymphoblastic Leukemia Result in High Response Rates of Short Duration: Further Intervention Is Required to Maintain Response. Blood 114(22):4293, 2009. e-Pub 2009.
Niu, T, Najjar A, Robinson S, Yang H, Decker W, McMannis J, Ng J, Thomas M, Champlin RE, Gelovani J, Shpall EJ. Retroviral Gene Transfer with Triple Genetic Reporter Genes into human Cord Blood CD133+ Cells. Blood 104:400b(5260), 2004. e-Pub 2004.
Safdar, A, Rodriguez G, Omhagari N, Champlin RE. Safety of Recombinant Interferon-gamma (IFN-y) Adjuvant Tehrapy for Invasive Fungal Infectiions (IFI) in the Recipients of Hematopoietic Stem Cell Transplantation (HSCT). 13th International Symposium on Infections in the Immunocompromised Host, 2004. e-Pub 2004.
Champlin, RE, Loberiza F, Eapen M, Rizzo D, Bredeson C, Wagner J, Horowitz M. Prevalence of Microbially Contaminated Hematopoietic Stem Cell Products. Blood 104:612a(2228),, 2004. e-Pub 2004.
Gajewski, J, Saliba R, McMannis J, Shpall EJ, Ippoliti C, Giralt S, Jones R, Khouri I, Hosing C, Korbling M, Donato M, Champlin RE. A Pilot Study of Haploidentical Transplant Using a Chemotherapy Only preparative regimen with T-cell Depleted Haploidentical Transplant and Intensive Antibiotic Prophylaxis to Treat Advanced Leukemia patients. Blood 104:380b(5184),, 2004. e-Pub 2004.
DeJesus, J, Ghosh S, Hsu Y, Neumann J, Cohen A, Champlin RE, Couriel D. Tacrolimus in combination with steroids for the treatment of chronic GvHD. BBMT 10((2)):49, 2004. e-Pub 2004.
Champlin, RE, Booser D, Rondon G, Williams P, Wendt R, Hortobagyi G, Ueno N, Podoloff D. Targeted radiotherapy to the Skeleton Using 166HO-DOTMP with Autologous Stem Cell Transplantation for Patients with Bone-only Metastatic Breast Cancer. Blood:395b(5239), 2004. e-Pub 2004.
Shpall, E, de Lima M, Chan K, Champlin RE, Gee A, Thall P, Komanduri K, Couriel D, Andersson B, Hosing C, Giralt S, Karandish S, Sadeghi E, Muriera B, Peled T, Grynspan F, Nagler A, McMannis J. Transplantation of Cord Blood Expanded Ex Vivo with Copper Chelator. Blood 104:281a(982),, 2004. e-Pub 2004.
Thomas, D, Faderl S, Cortes J, O’Brien S, Giles F, Garcia G, Kornblau S, Andreeff M, Beran M, Verstovsek S, Pierce S, Letvak L, Salvad A, Champlin RE, Kantarjian H. Update of the Hyper CVAD and Imatinib Mesylate Regimen in Philadelphia Positive Acute Lymphocytic Leukemia (ALL). Blood 104:748a(2738), 2004. e-Pub 2004.
Gajewski, JL, Ippoliti C, Giralt S, Jones R, McMannis J, Shpall E, Khouri I, Hosing C, Champlin RE, Donato ML. Use of intensive antibiotic prophylaxis and a chemotherapy only T-cell depleted preparative regimen (prep reg) as a pilot study in haploidentical transplant for treatment of patients with advanced leukemia. JCO 22((14s)):593 (6645), 2004. e-Pub 2004.
Qazilbash, M, Wieder E, Rios R, Lu S, Kant S, Giralt S, Estey E, Thall P, de Lima M, Couriel D, Champlin RE, Komanduri K, Molldrem J. Vaccination with the PR1 Leukemia-Associate Antigen Can induce Complete Remission in Patients with Myeloid Leukemia. Blood 104:77a(259, 2004. e-Pub 2004.
Qazilbash, M, Saliba R, De Lima M, Couriel D, Hosing C, Aleman A, Lei X, Champlin RE, Giralt S. Second Autologous or Allogeneic Transplantation after the Failure of First Autograft in multiple Myeloma. Blood 104:909a(3329), 2004. e-Pub 2004.
Lima D, M, Thall P, Shahjahan M, Xuemei W, Couriel D, Anderlini P, Hosing C, Qazilbash M, McCormick G, Ippoliti C, Donato M, Martin T, Metoryer L, Griffin L, Kebriaei P, Champlin RE, Giralt S. Phase I/II study of Gemtuzumab Oxogamicin (GO), Fludarabine and Melphalan (FM) Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in AML/MDS. Blood 104:505a(1824), 2004. e-Pub 2004.
Yang, H, Eaves C, de Lima M, Lee M, Champlin RE, McMannis J, Robinson S, Niu T, Decker W, Xing D, Thomas M, Ng J, Li S, Eaves A, Jones R, Andersson B, Shpall E. A Novel Triple Purge Strategy for Eliminating Chronic Myelogenous Leukemia Cell for Autografts (CML). . Blood 104:47a (152),, 2004. e-Pub 2004.
Neumann, J, Trevino C, Hosing C, Champlin RE. Multidisciplinary Clinical Initiatives to decrease the risk of ethical dilemmas. BBMT 10((2)):97, 2004. e-Pub 2004.
Ozdemir, E, Saliba R, Champlin RE, Komanduri K. A Model to Predict Risk for Late Cytomegalovirus Reactivation after Allogeneic Stem Cell Transplantation for Hematological Malignancies. Blood 104:616a(2241),, 2004. e-Pub 2004.
Andreeff, M, Studeny M, Dembinski J, Konopleva M, Wang RY, Yang HY, Fueyo J, Champlin RE, Lang F, Marini FC. Mesenchymal stem cells as delivery systems for cancer and leukemia gene therapy. JCO 22((14s)):242 (3194),, 2004. e-Pub 2004.
Wang, R, Fuller G, Champlin RE, Andreeff M. Low Frequency of Donor Derived Neuronal, Glia, And Endothelial Cells in the Cerebellum of Patients undergoing Sex-mismatched Bone Marrow Transplantation. Blood 104:980a(3605), 2004. e-Pub 2004.
Lima D, M, Couriel D, Shahjahan M, Alamo J, Thall P, Russell J, Anderlini P, Giralt S, Shpall E, Jones R, Champlin RE, Andersson B. IV Busulfan with Fludarabine or Cyclophosphamide (Cy) – Comparing Ablative Conditioning Regimens for Allogeneic Transplantation in AML/MDS. Blood 104:31a(97), 2004. e-Pub 2004.
Cheng, C, Rondon G, Couriel DR, DeLima M, Hosing C, Khouri IF, Giralt SA, Gajewski JL, Champlin RE, Ueno NT. Interleukin-2 (IL-2) with high-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (AHST) for poor-risk metastatic breast cancer. JCO 22((14s)):598(6664), 2004. e-Pub 2004.
Loren, A, Bunin G, Boudreau C, Champlin RE, Cnaan A, Horowitz M, Loberiza F, Porter D. Impact of Prior Pregnancy on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation. Blood 104:455a(1638),, 2004. e-Pub 2004.
Safdar, A, Rodriguez G, Ohmagari N, Champlin RE. Impact of Interferon-gamma Adjuvant Therapy on Graft-vs-host disease (GvHD) in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients. 13th International Symposium on Infections in the Immunocompromised Host,, 2004. e-Pub 2004.
Couriel, D, Saliba R, De Lima M, Hosing C, Andersson B, De Jesus J, Mickler K, Hsu Y, Shpall EJ, Ghosh S, Champlin RE. Hyperacute Graft Versus Host Disease: Analysis of Risk Factors, Clinical Manifestations and Outcomes. Blood 104:210a(734),, 2004. e-Pub 2004.
Gajewski, J, Saliba R, Rondon G, Ueno N, Donato M, Anderlini P, Korbling M, McMannis J, Giralt S, Khouri I, Mehra R, Champlin RE. High doses of CD34+ cells chemomoblized with G-CSF PBPC Collection Had Grater CD34+ Cells Collected than G-CSF Along and Trended toward Reduced Progression Rate After Autologous PBPC Transplantation for Breast Cancer in a Phase III Trial. Blood 104:394b(5235), 2004. e-Pub 2004.
Safdar, A, Rodriguez G, Champlin RE. Feasibility of Recombinant Interferon-gamma (rIFN-g) Therapy I Hematopoietic Stem Cell Transplant (HSCT) Recipients Receiving Donor Granulocyte Transfusions (GTX) for Refractory Mycosis. IDS, 2004. e-Pub 2004.
Khouri, I, Saliba R, Couriel D, Okoroji G, Acholonu S, Maadani F, Champlin RE. Effects of Rituximab on the Incidence of GvHD in Lymphoma Patients who received the BEAM-Conditioning and an Allogeneic Stem Cell Transplantation. Blood 104:326b(4980), 2004. e-Pub 2004.
Hosing, C, Saliba R, Korbling M, Acholonu S, Karandish S, Giralt S, Lauppe J, DeLima M, G-J O, Couriel D, Champlin RE, Khouri I, Donato M. Effect of High does Rituximab on Peripheral Blood Stem Cell Mobilization in Intermediate Grade Non-Hodgkin’s Lymphomas. Blood 104:787a(2877),, 2004. e-Pub 2004.
Shahjahan, M, Alamo J, de Lima M, Khouri I, Gajewski J, Andersson B, Champlin RE, Giralt S. Effect of comorbidities on allogeneic hematopoietic stem cell transplant outcomes in AML/MDSA patients win first complete remission. BBMT 10((2)):12, 2004. e-Pub 2004.
Decker, W, Xing D, Li S, Robeinson S, Yang H, Niu T, Thomas M, Segall H, McMannis J, Champlin RE, Shpall EJ. Double Loading of Dendritic Cell MHC Class I and MHC Class II with an AML Antigen Repertoire Enhances Primary and Secondary T-cell Responses In Vitro. Blood 104:693a(2529), 2004. e-Pub 2004.
Richard C. CML: Role of Transplantation 2004 – redefined not gone. ASH, 2004. e-Pub 2004.
Khouri, I, Saliba R, Kebriaei P, Ma C, Ippoliti C, Couriel D, De Lima M, Giralt S, Qazilbash M, Gajewski J, Champlin RE. Allogeneic Transplantation for Adult Acute Lymphoblastic Leukemia with Rituximab or Campath I-H. Blood 104:366b(5132), 2004. e-Pub 2004.
Lima D, M, Shahjahan M, Alamo J, Williams P, vonWolff B, Couriel D, Khouri I, Rondon G, Wheeler B, Estey E, Ueno N, Kebriaei P, Champlin RE, Giralt S. Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged 65 years or Older with AML and MDS. Blood 104:632a(2301),, 2004. e-Pub 2004.
Shahjahan, M, Alamo J, Giralt S, Detry M, Munsell M, Estey E, Champlin RE, de Lima M. Age Does Not Influence Long-term Quality of Lift after Allogeneic Hematopoietic Stem Cell Transplantation for AML/MDS. . Blood 104:602a(2193), 2004. e-Pub 2004.
Xing, D, Decker W, Yang H, Robinson S, Thomas M, Li S, Niu T, Segall H, McMannis J, Champlin RE, Shpall E. Acute Myeloid Leukemia Lysate Loaded Dendritic Cells Exhibit Significant Phagocytic Function and Elicit Antigen-Specific Immune Response. Blood 104:693a(2527), 2004. e-Pub 2004.
Khouri, I, Saliba R, Okoroji G, Acholonu S, Maadani F, Hosing C, Champlin RE. Reduced-Intensity Conditioning Regimen with BEAM/Rituximab for Patients with Refractory Non-Hodgkin’s Lymphomas. Blood 104:637a(2315), 2004. e-Pub 2004.
Giralt, S, Aleman A, Lei X, Davis M, Mickler K, Weber D, Wang M, Champlin, RE. Results of Bortezobib (BTZ) Thearpy for Myeloma (MM) Patients Relapsing After An Allogeneic Transplant. Preliminary Results Show Efficacy Without Induction of GvHD. Blood 104:459a(1651), 2004. e-Pub 2004.
Yang H, Eaves C, de Lima M, Lee M, Champlin RE, McMannis J, Robinson S, Niu T, Decker W, Xing D, Thomas M, Ng J, Li S, Eaves A, Jones R, Andersson B, Shpall E. A novel triple purge strategy for eliminating chronic myelogenous leukemia cell for autografts (CML). Blood 104:47a (152), 2004. e-Pub 2004.
Khouti I, Saliba R, Kebraei P, Ma C, Ippoliti C, Couriel D, de Lima M, Giralt S, Qazilbash M, Gajewski J, Champlin RE. Allogeneic transplantation for adult acute lymphoblastic leukemia with rituximab or campath I-H. Blooed 104:366b:1532, 2004. e-Pub 2004.
Champlin, RE, Ghosh S, McCormick G, Andersson B, de Lima M, Anderlini P, Qazilbash M, Giralt S, Cortes J. Sequential Treatment with Reduced Intensity Allogeneic Stem Cell Transplantation and Imatinib for Chronic Myelogenous Leukemia (CML). . Blood 104:232a (812),, 2004. e-Pub 2004.
Anderlini, P, Saliba R, Donato M, Giralt S, Andersson B, Ueno N, Khouri I, de Lima M, Ippoliti C, Champlin RE. Allogeneic Stem Cell Transplantation with Reduced-Intensity, Fludarabine-Based Conditioning in Relapsed and Refractory Hodgkin’s Disease: Low Transplant-Related Mortality and Impact of Intensity of Conditioning Regimen. Blood 104:587a(2135), 2004. e-Pub 2004.
Anderlini, P, Acholonu S, G-J O, Saliba R, Giralt S, Ueno N, Donato M, Andersson B, Champlin, RE. Immunotherapy with Donor Leukocyte Infusions (DLIs) In Relapsed Hodgkin’s Disease (HD) Following Allogeneic Stem Cell Transplantation (Allo-SCT): CD3+ Cell Dose, GvHD and Disease Response. Blood 104:460a(1654),, 2004. e-Pub 2004.
Lima D, M, Couriel D, Munsell M, Westmoreland M, Shah H, DeJesus J, Hosing C, Ghosh S, Anderlini P, Gajewski J, Andersson B, Kornblau S, Hocking B, Ippoliti C, Giralt S, Shpall E, Champlin RE. Pentostatin, Tacroliums and Mini-methotrexate for Graft Versus Host Disease (GVHD) Prophylaxis: A Phase I/II Controlled Randomized Study. Blood 104:208a(727), 2004. e-Pub 2004.
Cheng, YC, Saliba RM, Rondon G, Giralt SA, Lu KH, Bodurka DC, Gershenson DM, Champlin RE, Ueno NT. Reduced-intensity conditioning regimens result in low prevalence of premature ovarian failure in women underwent hematopoietic stem cell transplantation 10((2)):25, 2004. e-Pub 2004.
Körbling, M, Katz R, Khanna A, Chan K, Champlin RE, Estrov Z. Umbilical Cord Blood Stem Cells Generate Neurotransmitter-Producing Neuronal-Type Cells in Human Brain. Blood 102((11)):152b, 2003. e-Pub 2003.
Blood. Effect of the addition of low-dose alemtuzumab (Campath) in non-myeloablative unrelated hematopoietic transplantation in patients with lymphoid malignancies 102(11):484a, 2003. e-Pub 2003.
Khouri IF, Saliba R, Acholonu S, Okoroji G, Hosing C, Fayed L Couriel D, Pro B, Giralt S, Andersson B, Younes A, McLaughlin P, Champlin RE. Improved outcome with high-dose rituximab (HD-R) with G/GM-CSF and autologous stem cell transplantation (ASCT) for relapsed aggressive B-Cell non hodgkin's lymphomas (NHL): the impact of histologies of follicular (FL) origin. Blood 102(11):735a, 2003. e-Pub 2003.
Thomas, DA, Faderl S, Cortes J, O'Brien S, Giles F J, Garcia-Manero G, Keating M, Kornblau S, Andreeff M, Jeha S, Beran M, Verstovsek S, Pierce S, Salvado L A, Champlin RE, Kantarjian H. Update of the Hyper-CVAD and Imatinib Mesylate Regimen in Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL). Blood 102((11)):225a, 2003. e-Pub 2003.
Wang, R, Fuller GN, Sahin AA, Luna MA, De Lima MJ, Champlin RE, Andreeff M. Transdifferentiation of Bone-Marrow Derived Stem Cells Is Infrequent in Organs and Absent in Tumor Metastases. Blood 102((11)):337a, 2003. e-Pub 2003.
Qazilbash, MH, Saliba R, Aleman A, Lei X, Weber D, Carrasco A, Champlin RE, Giralt S. Risk Factors for Relapse after CR with High Dose Therapy for Multiple Myeloma. Blood 102((11)):982A, 2003. e-Pub 2003.
Lee, B, Andersson B, Cohen MZ, Mendoza T, De Lima MJ, Couriel D, Brown B, Wang XS, Cleeland CS, Giralt S, Champlin RE, Rueben J. Relationship between Plasma Cytokine Levels and Self-Reported Symptoms in AML Patients Pre- and Post- Transplantation with Allogeneic Peripheral Blood Stem Cells. Blood 102((11)):966a, 2003. e-Pub 2003.
Madden, T, Nguyen J, Thapar N, Couriel D, De Lima M, Pierre B, Espinosa L, Champlin RE, Andersson BS. The Pharmacokinetics (PK) of Once Daily Intravenous (IV) Busulfan (Bu) as Part of Pre-transplant Preparative Regimens; a Comparison to Q 6 Hourly Dosing. Blood 102((11)):477a, 2003. e-Pub 2003.
Escalon, MP, Champlin RE, Saliba R, Acholonu S, Hosing C, Fayad L, Ueno N T, Pro B, Giralt S, McLaughlin P, Issa I F. Non-Myeloablative Allogeneic Hematopoietic Transplantation: A Promising Salvage Therapy for Patients with Non-Hodgkin’s Lymphoma (NHL) Whose Disease Has Failed a Prior Autologous Stem Cell Transplantation (ASCT). . Blood 102((11)):75a, 2003. e-Pub 2003.
Lima D, M, Carrasco A, Lee M, Saliba R, Glassman A, Anagnostopoulos A, Couriel D, Caldera H, EI-Zimaity M, Giralt S, Champlin RE. Mixed Chimerism after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Blood 102((11)):707a, 2003. e-Pub 2003.
Andreeff, M, Studeny M, Dembinski J, Cabreira-Hansen M, Zompetta C, Champlin RE, Chada S, Lang FF, Jr, Marini FC. Mesenchymal Progenitor Cells as Gene Delivery Systems for Cancer and Leukemia Therapy. Blood 102((11)):60a, 2003. e-Pub 2003.
Khouri, IF, Maher A, Saliba R, Ippoliti C, Ma YC, Keating MJ, Champlin RE. Low-Dose (50 mg) Alemtuzur. Myeloablative Allogeneic Stem Cell l Aggressive Hematological Malignant Acute Graft-Versus-Host Disease Pharmacokinetics. Blood 102((11)):718a, 2003. e-Pub 2003.
Carrasco, A, Aleman A, De Lima M, Glassman A, Anagnostopoulos A, Champlin RE, Giralt S. International Prognostic Index (IPI) and Others Prognostic Factors in Patients with Multiple Myeloma (MM) Undergoing Reduced Intensity Conditioning (RIC) Regimen Allograft. . Blood 102((11)):728a, 2003. e-Pub 2003.
Khouri, IF, Saliba R, Acholonu S, Okoroji G, Hosing C, Fayad L, Couriel D, Pro B, Giralt S, Andersson B, Younes A, McLaughlin P, Champlin RE. Improved Outcome with High-Dose Rituximab (HD-R) with G/GM-CSF and Autologous Stem Cell Transplantation (ASCT) for Relapsed Aggressive B-Cell Non-Hodgkin’s Lymphomas (NHL): The Impact of Histologies of Follicular (FL) Origin. Blood 102((11)):735a, 2003. e-Pub 2003.
Khouri, IF, Lee M, Saliba R, Körbling M, McMannis JD, Keating MJ, Champlin RE. Impact of Rituximab on Immunomodulation and Survival after Non-Myeloablative Allogeneic Stem Cell Transplantation (NST) for Chronic Lymphocytic Leukemia (CLL). Blood 102((11)):727a, 2003. e-Pub 2003.
Champlin, RE, Perez WS, Passweg J, Klein JP, Camitta BM, Gluckman E, Bredeson C, Horowitz MM. Addition of Antithymocyte Globulin (ATG) to Cyclophosphamide (Cy) for HLA-identical Sibling Allogeneic Bone Marrow Transplantation (BMT) for Severe Aplastic Anemia (SAA): Results of a Randomized Controlled Trial. Blood 102((11)):80a, 2003. e-Pub 2003.
Kloecker, G, Saliba R, Aleman A, Champlin RE, Donato ML. Higher Doses of CD34+ Cells are Associated with Improved Disease-Free and Overall Survival after Autologous PBSC Transplantation for Advanced Ovarian Cancer. Blood 102((11)):482b, 2003. e-Pub 2003.
Alexanian, R, Weber DM, Delasalle KB, Wang M, Champlin RE, Giralt S. Progressively Reduced Sensitivity of Multiple Myeloma to Serial Intensive Therapies. Blood 102((11)):982a, 2003. e-Pub 2003.
Rodriguez, M, Van Besien K, Hagemeister B, Giralt S, McLaughlin P, Gajewski J, Romaguera J, Khouri I, Younes A, Cabanillas FC, Champlin RE. Randomized Comparison of Frontline Alternating Chemotherapy (ATT) Versus Brief Induction Followed by Autologous Stem Cell Transplant (ASCT) for Aggressive Lymphomas. Blood 102((11)):402a, 2003. e-Pub 2003.
Shahjahanan, M, Alamo J, de Lima MJ, Khouri IF, Gajewski J, Andersson BS, Champlin R, Giralt S. Impact of Co-morbidity on the Hematopoietic Stem Cell Transplant. Blood 102((11)):708a, 2003. e-Pub 2003.
EI-Zimaity, M, Saliba R, Chan K, Shahjahanan M, Carrasco A, Khorshid O, Caldera H, Couriel D, Ippoliti C, Hosing C, Champlin R, De Lima M. Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem Cell Transplantation: Donor Type Matters. Blood 102((11)):432b, 2003. e-Pub 2003.
Couriel, D, Carrasco A, Ghosh S, de Lima M J, Hosing C, Khouri I, Andersson B, Champlin R, Cleary K. Graft-versus-Host Disease (GvHD) of the Liver: A Clinicopathological Analysis. Blood 102((11)):712a, 2003. e-Pub 2003.
Khouri, IF, Saliba R, Okoroji G, Ippoliti C, Keating MJ, Champlin RE. Effect of the Addition of Low-Dose Alemtuzumab (Campath) in Non-Myeloablative Unrelated Hematopoietic Transplantation in Patients with Lymphoid Malignancies. Blood 102(11):484a, 2003. e-Pub 2003.
Couriel, D, Saliba R, De Lima MJ, Hosing C, Cohen A, Champlin RE. Early Acute GVHD: Syndrome and Clinical Implications. Blood 102((11)):712a, 2003. e-Pub 2003.
Donato, M, Kurzrock R, Champlin RE, Saliba R, Duvic M. Complete Remission of Late Stage Mycosis Fungoidesl Sezary Syndrome Following Allogeneic Transplantation. Blood 102((11)):731a, 2003. e-Pub 2003.
Laughlin, M, Rubinstein P, Stevens C, Eapen M, Wagner JE, Champlin RE, Horowitz MM. Comparison of Unrelated Cord Blood and Unrelated Bone Marrow Transplants for Leukemia in Adults: A Collaborative Study of the International Bone Marrow Transplant Registry and the New York Blood Center. Blood 102((11)):245a, 2003. e-Pub 2003.
Khouri, I, Saliba R, Hosing C, Ming-Sheng L, Jun G, Fayad L, Donato M, Younes A, Pro B, Couriel D, Rodriguez M, Körbling M, Cabanillas F, Champlin RE, Ruth K. Nonablative Allogeneic Stem Cell Transplantation for Relapsed Mantle Cell lymphoma (MCL): A Promising Strategy for an Aggressive Disease. Blood 100((11)):426a, 2002. e-Pub 2002.
Komanduri, K, Dorsam S, StJohn L, Wieder E, Champlin RE, Molldrem JJ, McCormick F, Haqq C. Genomic Expression Analysis of Activated Cytomegalovirus Specific Human CD4+ T Cells. Blood 100((11)):670a, 2002. e-Pub 2002.
Molldrem, J, Kant S, Lu S, Rios R, Streicher H, Wang C, Giralt S, O’Brien S, Cortes J, Champlin RE, Martin T, Wieder E. Peptide Vaccination with PR1 Elicits Active T cells Immunity That Induces Cytogenetic Remission in Acute Myelogenous Leukemia. Blood 100((11)):6a, 2002. e-Pub 2002.
Wong, R, Shahjahan M, De Lima M, Anagnostopoulos A, Estey E, Champlin RE, Andersson B, Khouri I, Giralt S. Prognostic Factors for allogeneic stem cell transplantation (ASCT) for refractory Acute myeloid leukemia (AML)/Myelodysplastic syndrome (MDS). Blood 100((11)):853a, 2002. e-Pub 2002.
Huen, A, Ippoliti C, Whimbey E, Ghosh S, Augustin K, Champlin RE. Cytomegalovirus Immune Globulin Prophylaxis for the Prevention of Cytomegalovirus Infection and Disease in CMV Seropositive Allogeneic Blood and Marrow Transplantation Recipients. Blood 100((11)):628a, 2002. e-Pub 2002.
Ippoliti, C, Hey D, Donato M, Giralt S, Shaw A, de Lima M, Champlin RE, Gajewski J. Use of Activated Recombinant Factor VII (rFVIIa) for Treatment of Pulmonary Hemorrhage in Stem Cell Recipients. Blood 100((11)):838a, 2002. e-Pub 2002.
Khouri, I, Saliba R, Hosing C, Okoroji G, Donato M, Younes A, Acholonu S, McLaughlin P, Andersson B, Rodriguez M, Körbling M, Cabanillas F, Champlin RE. Concurrent Administration of High-dose Rituximab (HD-R) with G/GM-CSF and Autologous Stem Cell Transplantation (ASCT) for relapsed B-cell lymphomas: Increased Efficacy without Added Toxicity. Blood 100((11)):645a, 2002. e-Pub 2002.
Alexanian, R, Weber D, Delasalle K, Giralt S, Champlin RE. Value of Intensive Therapy Supported by Autologous Stem Cells for Primary Resistant Multiple Myeloma. Blood 100((11)):180a, 2002. e-Pub 2002.
Caldera, H, Carrasco A, Shahjahanan M, Tran H, Lee A, Wilson R, De Lima M, Khouri I, Champlin RE, Andersson B. Allogeneic Progenitor Cell Transplantation (PCT) for High-risk patients with Advanced Hematologic Malignancies Using Fludarabine Plus Non-Myeloablative Doses of Intravenous Busulfan. Results of a Phase I/II Trial. Blood 100((11)):623a, 2002. e-Pub 2002.
Hosing, C, de Lima M, Saliba R, Shahjahan M, Couriel D, Andersson B, Giralt S, Champlin RE. Second allogeneic hematopoietic stem cell transplantation (HSCT) in patients with refractory hematological malignancies. Blood 100((11)):430a, 2002. e-Pub 2002.
Couriel, D, Hicks K, Saliba R, Cohen A, Ippoliti C, Donato M, Anderlini P, Giralt S, Khouri I, Hosing C, de Lima M, Andersson B, Neumann J, Champlin RE. Sirolimus (Rapamycin) for treatment of steroid-refractory chronic graft-vs-host disease. Blood 100((11)):847a, 2002. e-Pub 2002.
lima D, M, Couriel D, Shahjahan M, Madden T, Gajewski J, Giralt S, Russell J, Champlin RE, Andersson B. Allogeneic Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Using a Low-Toxicity Combination of Intravenous (IV) Busulfan (Bu) and Fludarabine (Flu) + ATG. Blood 100((11)):853a, 2002. e-Pub 2002.
Couriel, D, Hicks K, Saliba R, Cohen A, Ippoliti C, Giralt S, de Lima M, Neumann J, Champlin RE. TNF-alpha Inhibition for the Treatment of Chronic GvHD. Blood 100((11)):847A, 2002. e-Pub 2002.
Lima D, M, Wong R, Martin T, Couriel D, Anagnostopoulos A, Shahjahan M, Hosting C, Andersson B, Donato M, Cano P Ippoliti C, Estey E, Gajewski J, Champlin RE, Giralt S. Unrelated Donor Hematopoietic Stem Cell Transplantation for the Treatment of Myeloid Malignancies in Patients with Older Than 55 years of Age. Blood 100((11)):642a, 2002. e-Pub 2002.
Eapen, M, Klein J, Champlin RE, Horowitz M, Wagner J. Increased Chronic Graft Versus Host Disease and Mortality after Peripheral Blood Stem Cell Transplantation in Older Children and Adolescents with Acute Leukemia. Blood 100((11)):145a, 2002. e-Pub 2002.
Giralt, S, Bensinger W, Goodman M, Champlin RE, Eary J, Wendt R, Rajendran J, Ghalie R. Long-term follow-up of 83 patients with multiple myeloma (MM) treated on a phase I-II study of skeletal targeted radiotherapy (STR) using Ho-DOTMP plus melphalan with or without total body irradiation (TBI) and autologous hematopoietic stem cell transplant (AHSCT). Blood 100((11)):179a, 2002. e-Pub 2002.
Sheth, S, Hicks K, Ippoliti C, Giralt S, Champlin RE, Anderlini P. Safety, Tolerability and Drug Interactions of Adjuvant Imatinib Mesylate within the First 100 days Following Stem Cell Transplantation in Patients with Ph+ CML and PH+ ALL at High Risk for Recurrence. Blood 100((11)):635a, 2002. e-Pub 2002.
Lima D, M, Saliba R, Ma C, Shahjahan M, Giralt S, Donato M, Couriel D, Khouri I, de Meis E, Andersson B, Champlin RE, Gajewski J. Analysis of One Antigen Mismatched Related Transplants for Advanced Stage Myeloid Leukemias. Blood 102((11)):982a, 2002. e-Pub 2002.
Anagnostopoulos, A, Aleman A, Ayers D, Williams P, Lei X, Donato M, Alexanian R, Champlin R, Giralt S. Comparison of high dose melphalan and a more intensive regimen of Thiotepa, Busulfan and Cyclophosphamide in Multiple Myeloma. Blood 100((11)):436a, 2002. e-Pub 2002.
Anderlini, P, Acholonu S, Okoroji G, Giralt S, Ueno N, Donato M, Andersson B, Khouri I, Couriel D, Ippoliti C, Valverde R, Champlin RE. Reduced Early Transplant Related Mortality Following Allogeneic Stem Cell Transplantation With Fludarabine-Based, Reduced Intensity Conditioning From Matched Related and Unrelated Donors in Advanced Hodgkin’s Disease. Blood 100((11)):620a, 2002. e-Pub 2002.
Mittal, P, Saliba R, Giralt S, Shahjahan M, Cohen A, Karandish S, Champlin RE, de Lima M. Allogeneic Transplant for myelofibrosis, CMML and Philadelphia (Ph) chromosome negative/BCR-abl negative CML (atypical CML): potential survival advantage with reduced intensity regimens. Blood 100((11)):428a, 2002. e-Pub 2002.
Khouri, I, Keating M, Saliba R, Ippoliti C, Giralt S, Anderlini P, Gajewski J, Albitar M, Champlin RE. Mini-dose Campath-1H in –vivo induces significant Reduction of GvHD Associated with High-dose chemotherapy and allogeneic transplantation (ASCT). Blood 100((11)):423a, 2002. e-Pub 2002.
Anagnostopoulos, A, De Lima M, Munsell M, Shahjahan M, Couriel D, Martin T, Cano P, McMannis J, Gajewski J, Andersson B, Champlin RE, Giralt S. Unrelated Donor Bone Marrow Transplantation for Adults with AML /MDS: Similar Outcomes with Ablative or Reduced Intensity Preparative Regimens. Blood 100((11)):635a, 2002. e-Pub 2002.
Anagnostopoulos, A, El-Zimaity M, Munsell M, Wong R, Shahjahan M, Giralt S, Champlin RE, De Lima M. Unrelated Donor Bone Marrow Transplantation for Adults with AML/MDS: Improved Quality of Life with Reduced Intensity Preparative Regimens. Blood 100((11)):856a, 2002. e-Pub 2002.
Ueno, NT, Konopleva SN, Hoy E, Smith T, Rondon G, Anderlini P, Giralt SA, Gajewski JL, Kau SC, Hortobagyi GN, Donato ML, Champlin RE. High-dose chemotherapy (HDCT) for primary breast cancer refractory to neoadjuvant chemotherapy (NAC). . J Clin Onc 20:16a, 2001. e-Pub 2001.
Gajewski, JL, Saliba R, Körbling M, Rondon G, McMannis J, Ueno N, Donato ML, Anderlini P, Hortobagyi G, Champlin R. High doses of Cd34+ cells and chemomobilization are associated with a reduce progression rate after autologous PBSC transplantation for breast cancer in a phase III trial. J Clin Onc 20:6a, 2001. e-Pub 2001.
Donato, ML, Aleman AS, Gershenson DM, Wharton JT, JrRC B, Burke TW, Bodurka-Bevers D, Bevers MW, Levenback CF, Wolf J, Freedman RS, Cooke S, Ippoliti C, Brewer M, Gajewski JL, Champlin RE. Long term results of 102 patients with advanced ovarian cancer treated with high-dose chemotherapy. J Clin Onc 20:204A, 2001. e-Pub 2001.
Couriel DR, Hicks K, Ippoliti C, Donato ML, Martin T, Anderlini P, Khouri I, Andersson B, Giralt S, Champlin RE. Infliximab for the Treatment of Graft-Versus-Host Disease in Allogeneic Transplant Recipients. J Clin Onc 19:52a, 2000. e-Pub 2000.
Couriel, D, Hicks K, Ippoliti C, de Lima M, Donato M, Martin T, Anderlini P, Khouri I, Andersson B, Giralt S, Champlin R. Infliximab for the treatment of graft-versus-host disease in allogeneic transplant recipients: an update. Blood 96((11)):400a, 2000. e-Pub 2000.
Colares, M, de Lima M, Yazji S, Khouri I, Anderlini P, Donato ML, Couriel D, Giralt S, Martin T, Hosing C, Körbling M, Champlin R. Outcome of autologous hematopoietic stem cell transplant (auto HSCT) for patients (pts) with non-Hodgkin’s lymphoma (NHL) that fail to mobilize autologous peripheral blood stem cells (PBSC). Blood 96((11)):795a, 2000. e-Pub 2000.
Donato, ML, Körbling M, Anderlini P, Lichtiger B, Martin T, Champlin R. Thrombotic thrombocytopenic purpura following allogeneic transplantation: high incidence of infectious cause and high rate of resolution with total plasma exchange. Blood 96((11)):630a, 2000. e-Pub 2000.
Donato, ML, Gershenson DM, Ippoliti C, Wharton JT, Bevers MW, Bodurka-Bevers DC, Levenback CF, Wolf JK, Freedman RS, Bast Jr RC, Burke TW, Champlin RE. Topotecan in Combination with Cyclophosphamide and Melphalan for Stem Cell Transplantation: Results of a Large Phase I Trial in Advanced Ovarian Cancer. J Clin Onc 19:50a, 2000. e-Pub 2000.
Shimon, i A, Khouri I, Donato ML, Anderlini P, Andersson B, Ueno N, Champlin R, Giralt S. Allogeneic transplantation with non-myeloablative or reduced intensity conditioning: the intensity of the conditioning regimen is related to outcome in patients with active disease but not in those in remission at the time of transplantation. Blood 96((11)):199a, 2000. e-Pub 2000.
Gajewski, J, Donato ML, Anderlini P, Körbling M, Ueno N, Saliba R, Rondon G, Ippoliti C, Bast R, Buzdar A, Hortobagyi GN, Champlin R. Intensive Chemotherapy with G-CSF with Mobilization Yields Improved Peripheral Blood Progenitor (PBPC) Collection, Quicker Recovery After High Dose Chemotherapy (HDC) and Reduces Progression Risk Compared to G-CSF Alone for Mobilization. J Clin Onc 19:123a, 2000. e-Pub 2000.
Khouri, I, Munsell M, Yajzi S, O’Brien S, Giralt S, Körbling M, Ippoliti C, Donato ML, Keating M, Champlin R. Comparable survival for nonablative and ablative allogeneic transplantation for chronic lymphocytic leukemia (CLL): the case for early intervention. Blood 96((11)):205a, 2000. e-Pub 2000.
Andersson B, Tran H, Madden T, Esfandiary N, Gajewski J, Couriel D, Giralt S, Donato M, Anderlini P, Korbling M, Khouri I, Kantarjian H, Champlin R. Acute graft vs host disease (aGvHD) and toxicity correlate with busulfan systemic exposure (buse) after the IV BuCy2 regimen and stem cell transplantation (HSCT) for CML. Blood 96(11):393a, 2000. e-Pub 2000.
Ravandi, F, Kantarjian H, Davis M, Anderlini P, Donato ML, Khouri I, Martin, DiMartin J, Champlin R, Giralt S. Decitabine with cyclophosphamide and busulfan as a preparative regimen for allogeneic transplantation: results of a phase I trial. Blood 96((11)):393a, 2000. e-Pub 2000.
Donato, ML, Chu D, Alexanian R, Weber D, Körbling M, Giralt S, Champlin R. Filgrastim alone versus chemotherapy plus filgrastim for peripheral blood stem cell mobilization in multiple myeloma. Blood 96((11)):182a, 2000. e-Pub 2000.
Couriel, D, Giralt S, de Lima M, Esfandiary N, Martin T, Donato M, Hicks K, Andersson B, Champlin R. Graft-versus-host disease (GVHD) after non-myeloablative (NMA) versus myeloablative (MA) conditioning regimens in fully matched sibling donor hematopoietic stem cell transplants. Blood 96((11)):408a, 2000. e-Pub 2000.
Donato, ML, Champlin R, Weber D, Alexanian R, Ippoliti C, Aleman A, Cooke S, Martin T, de Lima M, Giralt S. High-dose topotecan, melphalan and cyclophosphamide (TMC): a new regimen for autologous transplantation in multiple myeloma. Blood 96((11)):798a, 2000. e-Pub 2000.
Aleman, A, Weber D, Andersson B, Donato M, Khouri I, Körbling M, Gajewski J, Alexanian R, Champlin R. IL-2 activated autologous progenitor cell (PC) transplant followed by post transplant treatment with IL-2 dose not seem to increase responses in multiple myeloma (MM) patients treated with thiotepa, busulfan and cyclophosamide (TBC) as a preparative regimen. Blood 96((11)):797a, 2000. e-Pub 2000.
Shimoni, A, Anderlini P, Andersson B, Andreeff M, Braunschweig I, Claxton D, Cohen A, Donato ML, Estey E, Gajewski J, Khouri I, Körbling M, Kornblau S, Molldrem J, Ueno N, Champlin R, Giralt S. Allogeneic transplantation for leukemia in patients older then 60 years: age should not exclude treatment with non-myeloablative regimens. Blood 94((11)):710a, 1999. e-Pub 1999.
Shimoni, A, Anderlini P, Andersson B, Braunschweig I, Claxton D, Donato ML, Gajewski J, Kantarjian H, Khouri I, Körbling M, Kornblau S, Molldrem J, Talpaz M, Ueno N, Champlin R, Giralt S. CD8-Depleted donor lymphocyte infusion (DLI) for the treatment of CML relapse after allogeneic transplant: Long-term follow-up and factors predicting of outcome. Blood 94((11)):163a, 1999. e-Pub 1999.
Körbling, M, Giralt S, Huh YO, Mirza N, Lauppe J, Martin T, Donato ML, Khouri I, Champlin R. Donor lymphocytes (DL) for cellular immunotherapy as compared to CD34+ cell apheresis products. Blood 94((11)):554a, 1999. e-Pub 1999.
Ueno, NT, Rondon G, Donato ML, Mehra RC, Anderlini P, Giralt SA, Gajewski JL, Braunschweig I, Rahman Z, Buzdar AU, Singletary SE, Hortobagyi GN, Champlin RE. High-dose chemotherapy (HDCT)/Autologous peripheral blood progenitor cell transplantation (PBPCT) in primary breast cancer refractory to neoadjuvant chemotherapy (NAC). Official Breast Cancer Symposium Abstract, 1999. e-Pub 1999.
Hicks, K, Ippoliti C, Donato ML, Champlin R, Khouri I, Andersson B, Anderlini P, Gajewski J, Giralt S. Infliximab for the treatment of steroid refractory graft-versus-host disease in allogeneic transplant recipients. Blood 94((11)):155a, 1999. e-Pub 1999.
Gajewski JL, Donato ML, Anderlini P, Körbling M, Saliba R, Khouri I, Rondon G, Giralt S, Ueno N, Andersson B, Molldrem J, Ippoliti C, Buzdar A, Valero V, Bast R, Theriault R, Hortobagyi G, Champlin R. Intensive chemotherapy with G-CSF mobilization yields improved peripheral blood progenitor cell (PBPC) collection, quicker recovery after high dose chemotherapy (HDC) and reduces progression risk compared to G-CSF alone for mobilization. Blood 94((11)):665a, 1999. e-Pub 1999.
Anagnostopoulos, A, Aleman A, Weber D, Andersson B, Braunschweig I, Claxton D, Donato ML, Khouri I, Anderlini P, Körbling M, Gajewski J, Alexanian R, Champlin R, Giralt S. Intravenous busulfan with thiotepa and cyclophosphamide (TBS) as a conditioning regimen for autologous progenitor cell transplantation (PCT) in patients with multiple myeloma (MM). Blood 94((11)):335a, 1999. e-Pub 1999.
Andersson, BS, Fernandez H, Cagnoni P, Jones R, Gian V, Wingard J, Tarantolo S, Kashyap A, Forman S, Hu WW, McWilliams K, Trans H, Cabanillas F, Champlin RE. IV Busulfan, Cyclophospamide and Hemopoietic stem cells for Non-Hodgkin’s Lymphomas. Bio Blood & Marrow Trans 5((2)):98, 1999. e-Pub 1999.
Giralt, S, Khouri I, Braunschweig I, Ippoliti C, Claxton D, Donato ML, Cohen A, Davis M, Andersson B, Anderlini P, Gajewski J, Kornblau S, Andreeff M, Przepiorka D, Ueno N, Molldrem J, Champlin R. Melphalan and purine analog containing preparative regimens. Less Intensive conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation (PCT). . Blood 94((11)):564a, 1999. e-Pub 1999.
Giralt, S, Weber D, Aleman A, Anagnostopoulos A, Anderlini P, Braunschweig I, Ontiniano M, Claxton D, Donato ML, Gajewski J, Alexanian R, Champlin R. Non-Myeloablative conditioning with fludarabine/melphalan (FM) for patients with multiple myeloma (MM). . Blood 94((11)):347a, 1999. e-Pub 1999.
Donato, ML, Gershenson D, Wharton JT, Aleman A, Ippoliti C, Bodurka D, Levenback C, Bevers M, Wolf J, Freedman R, Gajewski J, Bast R, Champlin RE. Phase I study of high-dose topotecan and alkylating agents for advanced ovarian cancer. Bio Blood & Marrow Trans 5((2)):101, 1999. e-Pub 1999.
Ravandi, F, Kantarjian H, Cohen A, Davis M, O’Brien S, Anderlini P, Andersson B, Claxton D, Donato ML, Gajewski J, Khouri I, Körbling M, Ueno N, deVos D, Champlin R, Giralt S. Phase I/II study of decitabine with allogeneic peripheral blood stem cell transplantation (SCT) for treatment of relapse after allogeneic progenitor cell transplantation. Blood 94(11):163a, 1999. e-Pub 1999.
Gajewski, J, Donato ML, Anderlini P, Körbling M, Khouri I, Rondón G, Giralt S, Buzdar A, Ueno N, Andersson B, Durett A, Saliba R, Bruton J, Molldrem J, Ippoliti, Raber M, Bast R, Hortobagyi G, Champlin RE. Preliminary Results of a Randomized Trial Comparing Intensive Chemotherapy with Growth Factor (GF) for Peripheral Blood Progenitor Cell (PBPC) Mobilization to Growth Factor Alone for Hematopoietic rescue after High Dose Chemotherapy (HDC). . J Clin Onc 18:50A, 1999. e-Pub 1999.
Khouri, I, M-S L, Palmer L, Giralt S, McLaughlin P, Körbling M, Romaguera J, Donato ML, Younes A, Ueno N, Gajewski J, Cabanillas F, Champlin R. Transplant-lite using fludarabine-cyclophosphamide (FC) and allogeneic stem cell transplant (AlloSCT) for low-grade lymphoma (LGL). . Blood 94((11)):348a, 1999. e-Pub 1999.
Khouri, I, Romaguera J, Kantarjian H, Körbling M, Younes A, Giralt S, Hagemeister F, Gajewski J, Sarris A, Claxton D, McLaughlin P, Donato ML, Rodriguez M, Ueno N, Champlin R, Cabanillas F. Update of the HCVAD regimen followed by stem cell transplantation (SCT) in mantle cell lymphoma (MCL). Blood 94((11)):610a, 1999. e-Pub 1999.
Giralt, S, Weber D, Cohen A, Anderlini P, Braunschweig I, Claxton D, Donato ML, Gajewski J, Alexanian R, Champlin RE. Non-Myeloablative Conditioning with Fludarabine (F)/Melphalan (M) for Patients with Multiple Myeloma (MM. J Clin Onc 18:6A, 1999. e-Pub 1999.
Ueno, N, Rondón G, Mehra R, Anderlini P, Donato ML, Giralt S, Gajewski J, Braunschweig I, Körbling M, Rahman Z, Buzdar A, Singletary S, Hortobagyi G, Champlin RE. High-dose Chemotherapy (HDCT) and Autologous Peripheral Blood Progenitor Cell Transplantation (PBPCT) in Primary Breast Cancer Refractory to Neoadjuvant Chemotherapy. J Clin Onc 18:104A, 1999. e-Pub 1999.
Donato, ML, Körbling M, Gajewski J, Anderlini P, Lauppe M, Champlin R. Estimation of stem cell apheresis yield by pre-apheresis blood CD34+ cell count. Blood 94((11)):136a, 1999. e-Pub 1999.

Book Chapters

Champlin, RE, Bashir, Q. Hematopoietic Transplantation, 3-16, 2023.
Wilson, JM, Eaton, EN, Pool, K, Reioux, D, Fontenot, M, Marin, D, Champlin, RE, Rezvani, K, Shpall, E, Hosing, C. Design and Licensure of an American Cord Blood Bank, 301-338, 2021.
Jones R, Shpall EJ, Champlin RE. Hematopoietic Cell Transplantation. In: Holland Frei Cancer Medicine , 6th Edition. John Wiley and Sons, 831-41, 2017.
Stolar K, Alousi A, Neumann J, Champlin R. Hematologic Cancer Survivorship Management: Transplantation. In: Advances in Cancer Survivorship Management. Springer, 167-86, 2014.
Kebriaei P, Lima MD, Estey E, Champlin AR. Management of Acute Leukemias. In: Cancer: Principles & Practice of Oncology. 10th, 1613-1634, 2014.
Ahmed S, Champlin R. Indications for Hematopoietic Transplantation. In: Targeted Therapy of Acute Myeloid Leukemia. Springer, 2014.
Bashir Q, Champlin RE. Hematopoietic Stem Cell Transplantation. In: Abeloff's Clinical Oncology 5th Edition. Elsevier Churchill Livingston, 485-92, 2014.
Hosing C, Champlin RE. Stem Cell Transplantation for Non-Hodgkin's Lymphomas. In: Younes A, Coiffier B, eds. Lymphoma, Curent Clinical Oncology. Springer Science + Business Media, 371-402, 2013.
Hosing C Champin RE. Stem Cell Transplantation for Treatment of Non Hodgkin's Lymphoma. In: LYMPHOMA: DIAGNOSIS AND TREATMENT. Humana Press, 371-402, 2013.
Yuen C, Champlin RE. Autologous Stem Cell Transplantation. In: MD Anderson Manual of Medical Oncology. 2nd. McGraw Hill, 2011.
Jones R, Shpall E, Champlin RE. Hematolpoietic Cell Transplantation. In: Cancer Medicine. Peoples Medical Publishing House, 776-792, 2010.
Champlin RE, Kebriaei P, de Lima M, Estey E. Management of Acute Leukemias. In: Cancer: Principles and Practice of Oncology. Lippincott Williams and Wilkins, 2232-2265, 2008.
Lazo G, Champlin RE. Autologous Stem Cell Transplantation. In: MD Anderson Manual of Medical Oncology. McGraw Hill, 219-230, 2006.
Khouri, I, Champlin R. Allogeneic transplantation for lymphoma and chronic lymphocytic leukemia. In: Thomas' Hematopoietic Cell Transplantation,. Blackwood Science Ltd, Madden, 1105-1115, 2004.
Shimoni, A, Champlin R. Bone marrow and peripheral blood stem cell transplantation. In: Blood Banking and Transfusion Medicine. Chichill Livingstone, 555-591, 2003.
Champlin RE. Hematopoietic Cellular Transplantation . In: Cancer Medicine. BC Decker Inc, 1019-1036, 2003.
Wang RY, Weidner D, McQueen T, McMannis J, Korbling M, Champlin R, Andreeff M. Quantitative determination of Bcl-2 expression in AML cell lines and in normal and leukemic progenitor cell compartments by laser scanning cytometry: Comparison with flow cytometry and Western blot. In: Acute Leukemias IX. Springer, 239-251, 2003.
Gajewski, J, Ippoliti C, Ma Y, Champlin RE. Blood and Marrow Transplantation. In: Rossi’s Principles of Transfusion Medicine. Lippincott Williams and Wilkins, 555-569, 2002.
Ueno, NT, Champlin RE. High dose chemotherapy as treatment for high-risk primary and metastatic breast cancer. In: Breast Cancer. Springer, 342-365, 2001.
Ueno, NT, Champlin RE. High dose chemotherapy as treatment for high-risk primary and metastatic breast cancer. In: Breast Cancer. Springer, 342-365, 2001.
Gajewski, J, Champlin RE. Blood stem cell and bone marrow transplantation. In: Cancer Treatment. WB Saunders, 276-295, 2001.
Champlin RE. Innovative approaches for allogeneic blood and marrow transplantation for treatment of hematological malignancies: graft engineering and non-myeloablative preparative regimens. In: Hematopoietic Stem Cell Transplantation. Marcel Dekker, Inc, 2000.
Champlin RE. Innovative approaches for allogeneic blood and marrow transplantation for treatment of hematological malignancies: graft engineering and non-myeloablative preparative regimens. In: Hematopoietic Stem Cell Transplantation. Marcel Dekker, Inc, 2000.
Khouri, I, Keating MJ, Champlin RE. Hematopoietic stem cell transplantation for chronic lymphocytic leukemia. . In: High-dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells. Third Edition. Lippincott Williams and Wilkins, 733-742, 2000.
. Hematopoietic Stem Cell Transplantation. Marcel Dekker, Inc, 2000.
Ho, AD, Haas R, Champlin RE. . In: Hematopoietic Stem Cell Transplantation. Marcel Dekker, Inc, 2000.
Giralt, S, Champlin RE. T-cell subsets and separation of GVL from GVHD. In: Allogeneic Immunotherapy for Malignant Diseases. Marcel Decker, Inc, 307-315, 2000.
Besien V, KWQ, Khouri I, Champlin RE. Hematopoietic stem cell transplantation for indolent NHL. In: Current Therapy in Cancer. Churchill Livingstone, 423-434, 1999.
Giralt, S, Khouri I, Champlin RE. Allogeneic progenitor transplantation after nonablative conditioning. In: Autologous Blood and Marrow Transplantation. Carden Jennings, 612-620, 1999.
Champlin, RE, Khouri I, van Besien K. Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia and lymphoma. In: Hematopoietic Cell Transplantation, . 892-903, 1999.
Champlin RE. Dose intensive therapy with autologous blood stem cell of bone marrow transplantation for treatment of breast cancer. In: Breast Cancer MD Anderson Cancer Center Solid Tumor Series, 306-320, 1999.
Champlin, RE, Khouri I, Giralt S. Induction of Graft-vs-Malignancy as Treatment for Malignant Diseases . In: Autologous Blood and Marrow Transplantation. Carden Jennings, 697-707, 1999.
Gajewski JL, Champlin RE. Blood and Marrow Transplantation. In: Cancer Treatment. W.B. Saunders, 1999.
Champlin RE. T-Cell Depleted Bone Marrow Transplantation: Innovative Strategies Addressing Engraftment, Graft-Vs-Host Disease and Graft-Vs-Leukemia, 1998.
Deisseroth, AB, Kantarjian H, Andreeff M, Talpaz M, Keating M, Khouri I, Champlin RE. Chronic Leukemias. . In: Cancer, Principles and Practice of Oncology. Lippincott-Raven, 2321-43, 1997.
Deisseroth, AB, Hanania EG, Kantarjian H, Fu S, Talpaz M, Champlin RE. Gene therapy using stem cell modification. In: Biologic Therapy of Cancer: Principles and Practice. JB Lippincott, 738-746, 1995.
Khouri, I, Kantarjian H, Talpaz M, Andreeff M, Lee MS, Champlin RE, Deisseroth AB. Chronic Myeloid Leukemia. In: Clinical Oncology, Abeloff MD, 2035-51, 1995.
Jacobs, CA, Shpall EJ, Ball ED, Champlin RE, LeMaistre CF, Holland HK, Saral R, Berenson R. A prospective randomized phase III study using the Ceprate SC Stem Cell Concentrator to isolate CD34+ hematopoietic progenitors for autologous marrow transplantation after high dose chemotherapy. In: Autologous Marrow and Blood Transplantation, 669-678, 1995.
Champlin, RE, Korbling M. Bone marrow transplantation for severe aplastic anemia. New York Marcel Dekker, 1995.
Champlin RE. Bone Marrow Transplantation. In: Cancer Treatment, 4th Edition, 199-206, 1995.
Champlin, RE, Gale RP, eds. Advances and Controversies in Bone Marrow Transplantation. In: Bone Marrow Transplant, 1995.
Champlin, RE, Khouri I, van Besien K. Allogeneic Blood And Marrow Transplantation For Chronic Lymphocytic Leukemia And Lymphoma. In: Bone Marrow Transplantation. Blackwell Scientific Publications, 595-606, 1994.
Giralt, S, Champlin RE. Leukemia relapse after allogeneic bone marrow transplantation: Mechanism, prevention and treatment. In: Textbook On Bone Marrow Transplantation. Cambridge University Press, 415-422, 1994.
Giralt, S, Champlin RE. Hematopoietic growth factors in bone marrow transplantation: role in purging, graft engineering, stem cell mobilization, and hematologic recovery. In: Hematopoietic Growth Factors. Karger Academic Press, 1994.
Champlin, RE, McGlave, P. Allogeneic bone marrow transplantation for Chronic Myelogenous Leukemia. In: Bone Marrow Transplantation. Blackwell Scientific Publications, . 595-606, 1994.
Champlin RE. Aplastic Anemia. In: Hematology: Clinical and Laboratory Practice. Mosby, 471-484, 1993.
Deisseroth, A, Andreeff M, Champlin RE, Kantarjian H, Keating M, Khouri I, Talpaz M. Chronic Leukemias. In: Principles and Practice of Oncology. J.B. Lippincott, 1965-83, 1993.
Cain, GR, Kawakami T, Taylor N, Champlin RE. Effects of administration of recombinant human interleukin-2 in dogs. In: Comparative Haematology International. Springer-Verlag, 201-207, 1992.
Champlin RE, Lee K. T-cell depletion to prevent graft-versus-host disease following allogeneic bone marrow transplantation. In: Bone Marrow and Stem Cell Processing: A Manual of Current Techniques. F.A. Davis Co, 163-170, 1992.
Champlin RE. Bone Marrow Transplantation. In: Hematology: Clinical and Laboratory Practice. Mosby, 1691, 1991.
Champlin RE. Aplastic Anemia. In: Conn's Current Therapy. The Blood and Spleen. W.B. Saunders Co, 297-299, 1991.
Winston, DJ, Ho WG, Champlin RE. Ganciclovir and intravenous immunoglobulin in bone marrow transplants. In: New Strategies in Bone Marrow Transplantation. Wiley-Liss, 337-348, 1991.
Gajewski, JL, Champlin RE. Enhanced graft versus leukemia effect in patients receiving matched unrelated donor bone marrow transplants. In: New Strategies in Bone Marrow Transplantation. Wiley-Liss, 281-283, 1991.
Champlin RE. Bone marrow transplantation for severe aplastic anemia: Effects of immunosuppressive treatment regimen on graft failure, graft versus host disease, interstitial pneumonitis and survival. In: New Strategies in Bone Marrow Transplantation. Wiley-Liss, 87-92, 1991.
Champlin RE. Bone marrow transplantation as treatment for cancer. In: Cancer Treatment. WB Saunders, 918-930, 1990.
Gajewski J, Champlin RE. Vascular access. In: Cancer Treatment. W.B. Saunders, 866-869, 1990.
Champlin RE. Treatment of Aplastic anemia: bone marrow transplantation, immunomodulatory therapy and hematopoietic growth factors. In: Aplastic Anemia and Other Bone Marrow Failure Syndromes. Springer Verlag, 121-133, 1990.
Nimer, SD, Champlin RE. Therapeutic use of hematopoietic growth factors in bone marrow transplantation. In: Bone Marrow Transplantation. Kluwer Academic Publishers, 141-164, 1990.
Champlin RE. T- cell depletion for bone marrow transplantation: Effects on graft rejection, graft versus host disease, leukemia relapse and survival. In: Bone Marrow Transplantation. Kluwer Academic Publishers, 99-111, 1990.
Champlin RE. Role of bone marrow transplantation as treatment for victims of nuclear accidents. In: Bone Marrow Transplantation. Kluwer Academic Publishers, 299-306, 1990.
Champlin, RE, Golde DW. The Leukemias. In: Harrison’s Principles of Internal Medicine, 12th Edition. McGraw Hill, 1990.
Champlin RE. Granulocyte macrophage colony stimulating factor as treatment for aplastic anemia. In: Hematopoiesis. Wiley-Liss Inc, 263-270, 1990.
Ho, WG, Winston DJ, Champlin RE. Fluconazole for prophylaxis of fungal infections in neutropenic patients. In: Autologous Bone Marrow Transplantation: Proceedings of the Fifth International Symposium. University of Nebraska, 1990.
Winston, DJ, Ho WG, Champlin RE. Cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. In: Bone Marrow Transplantation. Kluwer Academic Publishers, 113-128, 1990.
Champlin RE. Bone Marrow Transplantation: Introduction and overview. In: Bone Marrow Transplantation. Kluwer Academic Publishers, 1-7, 1990.
Champlin RE. Bone Marrow Transplantation for aplastic anemia: Recent advances and comparisons with alternative therapies. In: Bone Marrow Transplantation. Kluwer Academic Publishers, 185-199, 1990.
Foon, KA, Champlin RE, Gale RP. Acute myelogenous leukemia. In: Cancer Treatment. W.B. Saunders, 589-605, 1990.
Winston, DJ, Ho WG, Champlin RE. Use of DHPG (ganciclovir) and intravenous immune globulin in bone marrow transplants. In: Bone Marrow Transplantation: Current Controversies. Alan Liss, Inc, 533-551, 1989.
Gale, RP, (eds) CR. . In: Bone Marrow Transplantation, Current Controversies,. Alan R. Liss Inc, 1989.
Champlin RE. Bone marrow transplantation for acute myelogenous leukemia: recent advances. In: Bone Marrow Transplantation: Current Controversies. Alan Liss, Inc, 95-106, 1989.
Gale, RP, Champlin RE. Bone marrow transplantation for aplastic anemia and thalessemia. In: Bone Marrow Transplantation, 1989.
Clark, SS, Najfeld V, Dow L, Champlin RE, Crist W, Witte O. Molecular pathology of Ph+ leukemias. In: Molecular Diagnostics of Human Cancer: Cancer Cells. Cold Spring Harbor Symposium, 1989.
Champlinm RE. Acute myelogenous leukemia: biology and treatment. In: Mediguide to Oncology, 1-12, 1988.
Champlin RE. Treatment of aplastic anemia: current role of bone marrow transplantation or immunomodulatory therapy. In: Progress in Bone Marrow Transplantation. Alan Liss, Inc, 37-52, 1987.
Champlin RE. Bone marrow transplantation as treatment for acute and chronic leukemias. In: Recent Advances in Leukemia and Lymphoma. Alan Liss, Inc, 481-500, 1987.
Cain, GR, Gale RP, Champlin RE. Fetal liver cell transplantation in dogs: results with compatible and incompatible cells. In: Progress in Bone Marrow Transplantation. Alan Liss, Inc, 689-694, 1987.
Gale, RP, Champlin RE. Progress in Bone Marrow Transplantation. Alan Liss,. Alan Liss, Inc, 1987.
Winston, DJ, Ho WG, Gale RP, Champlin RE. Treatment and prevention of interstitial pneumonia after bone marrow transplantation. . In: Progress in Bone Marrow Transplantation. Alan R. Liss, 525-544, 1987.
Ho, WG, Winston DJ, Champlin RE. Transfusion support therapy in the management of acute leukemia. In: Leukemia Therapy. Blackwell Scientific Publications, Inc, 239-247, 1986.
Champlin, RE, Golde DW. The Leukemias. In: Harrison’s Principles of Internal Medicine,. McGraw Hill, Inc, 1540 – 49, 1986.
Winston, DJ, Ho WG, Gale RP, Champlin RE. Prevention and treatment of infection in leukemia patients. In: Leukemia Therapy. Blackwell, 213-238, 1986.
Winston, DJ, Ho WG, Gale RP, Champlin RE. Treatment of herpes zoster infection in immunosuppressed patients. In: Biology of the Interferon System. Elsevier Science Publisher, 479-484, 1986.
Champlin, RE, Cain G, Gale RP, Stitzel K. Fetal liver cell transplantation in dogs: results with DLA compatible and incompatible grafts. In: Advances in Fetal Liver Transplantation. Alan Liss, Inc, 195-204, 1985.
Champlin, RE, Mitsuyasu R, Gale RP. Transplantation of T lymphocyte depleted bone marrow: implications for fetal liver transplantation. In: Advances in Fetal Liver Transplantation. Alan Liss, Inc, 315-326, 1985.
Champlin RE. Recent advances in chronic myelogenous leukemia. In: Leukemia 1985. Alan R. Liss, Inc, 651-674, 1985.
Winston DJ, Ho WG, Gale RP, Champlin RE. Interstitial pneumonia after bone marrow transplantation. In: Autologous Bone Marrow Transplantation: Proceedings of the First International Symposium. University of Texas, 481-488, 1985.
Champlin RE. Chronic myelogenous leukemia. In: Leukemia Therapy. Blackwell Scientific Publications, 147-163, 1985.
Champlin RE. Chronic myelogenous leukemia. In: Leukemia Therapy. Blackwell Scientific Publications, 147-163, 1985.
Champlin, RE, Golde DW. Aplastic Anemia. In: Current Therapy in Allergy, Immunology and Rheumatology. B.C. Decker Inc, 146-151, 1985.
Champlin RE. Aplastic Anemia. In: Hematopoietic Stem Cells. Marcell Dekker, Inc, 205-277, 1985.
Champlin RE. Chronic myelogenous leukemia. In: Leukemia Therapy. Blackwell Scientific Publications, 147-163, 1985.
Ho, WG, Winston DJ, Champlin RE, Gale RP. CMV infection and its prevention with specific immunoglobulin. In: Transplantation and Blood Transfusion. Martinus Nijhoff Publishers, 73-77, 1984.
Champlin, RE, Ho W, Bayever E, Winston DJ, Lenarsky C, Feig SA, Gale RP. Treatment of aplastic anemia: results with bone marrow transplantation, antithymocyte globulin and a monoclonal anti T cell antibody. In: Aplastic Anemia: Stem Cell Biology and Advances in Treatment. Alan Liss Inc, 227-238, 1984.
Champlin RE. Vascular Access. In: Cancer Treatment. WB Sanders Co, 886-889, 1984.
Mitsuyasu, RT, Champlin RE, Gale RP. Immune reconstitution following bone marrow transplantation: Implications for the treatment of the acquired immunodeficiency syndrome (AIDS). In: Acquired Immune Deficiency Syndrome. UCLA Symposia on Molecular and Cellular Biology, Now Series. Alan R. Liss, Inc, 395-408, 1984.
Ho, WG, Winston DJ, Champlin RE, Feig SA, Gale RP. Allogeneic bone marrow transplantation. In: Transplantation and Blood Transfusion. Martinus Nijhoff Publishers, 191-198, 1984.
Champlin, RE, Gale RP. Aplastic Anemia. In: Current Therapy in Internal Medicine, 250-254, 1984.
Storch, S, Gale RP, Champlin RE, Ho WG, Falk PM, Feig SA. Partially mismatched marrow transplantation for acute leukemia and aplastic anemia. In: Recent Advances in Bone Marrow Transplantation. Alan Liss Inc, 785-795, 1983.
Champlin, RE, Mitsuyasu R, Gale RP. The role of bone marrow transplantation in the treatment of chronic myelogenous leukemia. In: Recent Advances in Bone Marrow Transplantation. Alan Liss Inc,, 141-158, 1983.
Winston, DJ, Ho WG, Champlin RE, Gale RP. Treatment and prevention of interstitial pneumonia associated with bone marrow transplantation. In: Recent Advances in Bone Marrow Transplantation. Alan Liss Inc, 425-444, 1983.
Champlin, RE, Ho WG, Winston DJ, Bayever E, Feig SA, Gale RP. Treatment of severe aplastic anemia: A comparison of antithymocyte globulin versus allogeneic bone marrow transplantation. In: Recent Advances in Bone Marrow Transplantation. Alan Liss Inc, 29-38, 1983.
Mitsuyasu, R, Champlin RE, Ho WG, Wells J, Billing R, Territo MC, Gale RP. Autologous bone marrow transplantation after in vitro marrow treatment with anti CALLA heteroantiserum and complement for adult acute lymphoblastic leukemia. In: Recent Advances in Bone Marrow Transplantation. Alan Liss Inc, 679-687, 1983.
Champlin, RE, Golde DW. Aplastic anemia. In: Current Therapy in Allergy and Immunology. B.C. Decker Inc, pp. 281-287, 1983.
Champlin RE. Acute leukemia. In: Practical Hematology. John Wiley and Sons, 135-158, 1983.
Gale, RP, Champlin RE. Bone marrow transplantation in leukemia: Critical analysis and controlled clinical trials. In: Recent Advances in Bone Marrow Transplantation. Alan Liss Inc, 71-94, 1983.
Gale, RP, Levine A, Champlin RE, Bloomfield C, Foon KA. Chronic Leukemias. In: Hematology 1983. Education Program of the American Society of Hematology, 16-24, 1983.
Stitzel, KA, Champlin RE, Gale RP. Fetal liver cell transplantation in dogs: A possible alternative source of hematopoietic cells for transplantation. In: Recent Advances in Bone Marrow Transplantation. Alan Liss, 831-840, 1983.
Champlin RE. Acute leukemia. In: Practical Hematology. John Wiley and Sons, 135-158, 1983.
Champlin, RE, Gale RP. Aplastic Anemia. In: Current Therapy in Hematology Oncology. BC Decker Inc, 1-16, 1983.
Champlin, RE, Niskanen E, Gale RP. Hematopoiesis and immune reactivity characteristics of human fetal liver cells. In: Fetal Liver Transplantation. Elsevier, 117-125, 1980.
Niskanen, E, Champlin RE, Cline MJ, Golde DW, Gale RP. Effect of humoral factors on hematopoietic cell proliferation from human fetal liver. In: Fetal Liver Transplantation. Elsevier, 37-44, 1980.
Champlin, RE, Feig S, Gale RP. Bone marrow transplantation in aplastic anemia, acute leukemia and solid tumors. In: Fetal Liver Transplantation. Elsevier, 210.244, 1980.
Niskanen, E, Gale RP, Champlin RE, Cline MJ, Golde DW. Culture of myeloid and erythroid colonies from human fetal liver. In: Experimental Hematology Today. S. Karger, 256-270, 1980.

Books (edited and written)

Bashir, Q, Shpall, E, Champlin, RE. Manual of Hematopoietic Cell Transplantation and Cellular Therapies, 2023.
Champlin RE, Ippoliti C. Supportive Care Manual for Blood and Marrow Transplantation. Summit, 2007.
Atkinson K, Champlin R, Ritz J, Fibbe W, Ljungman P, Brenner M. Clinical Bone Marrow and Blood Stem Cell Transplantation. Cambridge University Press, 2004.
Ho, AD, Haas R, Champlin RE. Hematopoietic Stem Cell Transplantation. Marcel Dekker, Inc, 2000.
Ho, AD, Haas R, Champlin RE. Innovative approaches for allogeneic blood and marrow transplantation for treatment of hematological malignancies: graft engineering and nonmyeloablative preparative regimens. Marcel Dekker, Inc, 2000.
Gajewski JL, Champlin RE. Blood and Marrow Transplantation. W.B. Saunders, 1999.
Giralt, SA, Champlin RE. Treatment of relapse after bone marrow transplantation. Cambridge University Press, 1998.
Giralt, S, Champlin RE. Hematopoietic growth factors in bone marrow transplantation: role in purging, graft engineering, stem cell mobilization, and hematologic recovery. Karger Academic Press, 1994.
Champlin, RE, (ed). Bone Marrow Transplantation. Kluwer Academic Publishers, 1990.
Gale, RP, (eds CR. Bone Marrow Transplantation, Current Controversies. Alan R. Liss Inc, 1989.
Gale, RP, Champlin RE, eds. Progress in Bone Marrow Transplantation. Alan Liss, Inc, 1987.

Letters to the Editor

Rafaeli, N, Costa, DM, Ledesma, C, Jain, N, Tewari, P, Khouri, IF, Al-Atrash, G, Short, NJ, Jabbour, EJ, Rezvani, K, Alousi, AM, Popat, UR, Champlin, RE, Shpall, E, Kebriaei, P. Allogeneic Hematopoietic Stem Cell Transplantation Following CAR T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia 25: e374-e377, 2025.
Marcoux, C, Pasyar, S, Milton, D, Khan, HN, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Neupane, N, Lee, HC, Patel, K, Tang, G, Aljawai, YM, Kebriaei, P, Thomas, SK, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH, Pasvolsky, O. Impact of body mass index on outcomes of multiple myeloma patients undergoing upfront autologous stem cell transplant. British Journal of Haematology 206: 763-765, 2025.
Saliba, RM, Lee, SJ, Carpenter, P, Hill, GR, Lee, CJ, Alousi, AM, Daher, M, Chen, GL, Champlin, RE, Rezvani, K, Shpall, E, Mehta, RS. Mycophenolate mofetil is associated with inferior overall survival in cytomegalovirus-seropositive patients with acute myeloid leukemia undergoing hematopoietic cell transplantation. Haematologica 109: 2321-2325, 2024.
Ramdial, JL, Kebriaei, P, Champlin, RE, Popat, UR, Rezvani, K, Shpall, E, Mehta, RS. Improved survival with younger HLA-matched unrelated donors versus older matched sibling donor HCT with PTCy-prophylaxis. Leukemia 38: 1432-1434, 2024.
Malek, A, Al-Juhaishi, T, Milton, D, Ramdial, JL, Daher, M, Olson, AL, Srour, S, Al-Atrash, G, Oran, B, Mehta, RS, Khouri, IF, Bashir, Q, Shah, N, Ciurea, SO, Rondon, G, Maadani, F, Hosing, C, Marin, D, Kebriaei, P, Rezvani, K, Nieto, Y, Anderlini, P, Alousi, AM, Faisal, MS, Qazilbash, MH, Popat, UR, Champlin, RE, Shpall, E, Mulanovich, VE, Ahmed, S. Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis. Bone marrow transplantation 59: 699-704, 2024.
Srour SA, Singh H, McCarty J, de Groot E, Huls H, Rondon G, Qazilbash M, Ciurea S, Bardelli G, Buck J, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Wierda WG, Kantarjian H, Champlin RE, Cooper LJ, Kebriaei P. Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas. Blood 135: 862-865, 2020.

Less

CV information above last modified March 24, 2026

Richard E. Champlin, M.D.

About Dr. Richard E. Champlin

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Intramural Institutional Committee Activities

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Selected Presentations & Talks

Local Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Other Articles

Editorials

Abstracts

Book Chapters

Books (edited and written)

Letters to the Editor

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Richard E. Champlin, M.D.

About Dr. Richard E. Champlin

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Intramural Institutional Committee Activities

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Selected Presentations & Talks

Local Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Other Articles

Editorials

Abstracts

Book Chapters

Books (edited and written)

Letters to the Editor

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop UT MD Anderson